 
Study Title  Evaluation of the Advanced Hybrid Closed Loop (AHCL) System in Type 1 
Adult and Pediatric Subjects Utilizing LyumjevÂ® insulin lispro -aabc   
NCT Number  [STUDY_ID_REMOVED]  
Document Description  CIP335 Clinical Investigation  Plan (Version E) 
Document Date  10-MAR- 2023  
 
 

CIP335 Clinical Investigation Plan 
 Form 
D00409632 Version E Page 1 of 106 
0HGWURQLF%XVLQHVV5HVWULFWHG
CONFIDENTIAL )5HY(&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Form

Clinical Investigation Plan  
Clinical Investigation Plan 
(CIP)/Study Title  (YDOXDWLRQRIWKH$GYDQFHG+\EULG &ORVHG/RRS$+&/6\VWHPLQ
7\SH$GXOWDQG3HGLDWULF 6XEMHFWV8WLOL]LQJ/\XPMHYÂŠLQVXOLQOLVSUR
DDEF
CIP Identifier 
Investigational Device 
Exemption (IDE) Number *
Study Product Names & 
Model Numbers  Investigational Product 
x 0LQL0HGÂŒ*,QVXOLQ3XPS007UHIHUUHGWRDV
WKHVWXG\SXPSWKURXJKRXWWKLVSURWRFRO
x *XDUGLDQÂŒ*OXFRVH6HQVRU007UHIHUUHGWRDV
WKHVHQVRUWKURXJKRXWWKLVSURWRFRO
x *XDUGLDQ7UDQVPLWWHU007
 Non-Investigational Product 
x /\XPMHY
ÂŠLQVXOLQOLVSURÂ±DDEFLQMHFWLRQ
x 0HGWURQLF([WHQGHGLQIXVLRQVHW007007007
007007007007DQG007

x 0HGWURQLF([WHQGHG5HVHUYRLU007
x 2QH3UHVV6HUWHU007UHIHUUHGWRDVWKH6HUWHU
WKURXJKRXWWKLVSURWRFRO
x 7UDQVPLWWHU&KDUJHU007
x 7HVWHU007/
x 0HGWURQLF&DUH/LQNÂŒ3HUVRQ DOVRIWZDUH007
x 0HGWURQLF&DUH/LQNV\VWHPVRIWZDUH007
x )RRG3ULQWÂŒDSSE\1XWULQRÂŒ
x 5RFKH$FFX&KHNÂŒ*XLGH/LQN*OXFRVH0HWHU
UHIHUUHGWRDVWKH$FFX&KHN*XLGH/LQN
VWXG\PHWHUWKURXJKRXWWKLVSURWRFRO
x 0LQL0HG&OLQLFDO$SS007 $QGURLGÂŒDSS007
,26ÂŒDSS
x &DUH/LQN&OLQLFDO$SS007$QGURLGÂŒDSS007
,26ÂŒDSS
x %OXH%OXHWRRWKÂŠ/RZ(QHUJ\$GDSWHU$&&
UHIHUUHGWRDVWKH%OXH$G DSWHULQWKLVSURWRFRO
x .HWRQHPHWHUWREHXVHGIRUEORRGNHWRQHPHDVXUHPHQWV
RQO\
x $FFX&KHN*XLGHWHVWVWULSV
x 6SRQVRUSURYLGHGVPDUW SKRQHXSRQUHTXHVW
Description of CIP 7KLVVWXG\ZLOOHYDOXDWHWKHVDIHW \DQGHIIHFWLYHQHVVRIXWLOL] LQJ
LQVXOLQOLVSURDDEFLQWKH0LQL0H GÂŒ*6\VWHPWRVXSSRUWSURG XFW
DQGV\VWHPODEHOLQ J
Sponsor 0HGWURQLF0LQL0HG
Â³0HGWURQLFÂ´'HYRQVKLUH6W

CIP335 Clinical Investigation Plan 
 Form 
D00409632 Version E Page 2 of 106 
0HGWURQLF%XVLQHVV5HVWULFWHG
CONFIDENTIAL )5HY(&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Form
$GPHORJÂŠLVDUHJLVWHUHGWUDGHPDUNRI6DQRIL$YHQWLV86//& 
$QGURLGÂŒLVDWUDGHPDUNRI*RRJOH//&
$FFX&KHNÂŒLVDUHJLVWHUHGWUDGHPDUNRI5RFKH'LDEHWHV&DUH,Q FÂ³5RFKHÂ´
'UHD0HG'LDEHWHVLVDWUDGHPDUNRI'UHD0HG'LDEHWHV/WG7KH0 LQL0HGÂŒ*V\VWHPDOJRULWKP
LQFOXGHVWHFKQRORJ\GHYHORSHGE\'UHD0HG'LDEHWHV
)RRG3ULQWÂŒLVDWUDGHPDUNRI1XWULQR+HDOWK/WGÂ³1XWULQRÂ´
+XPDORJ
ÂŠLVDUHJLVWHUHGWUDGHPDUNRI(OL/LOO\DQG&RPSDQ\
,26ÂŒLVDWUDGHPDUNRUUHJLV WHUHGWUDGHPDUNRI&LVFR
1RYR/RJÂŠLVDUHJLVWHUHGWUDGHPDUNRI1RYR1RUGLVN$6
7KH%OXHWRRWKÂŠZRUGPDUNDQGORJRVDUHUHJLVWHUHGWUDGHPDUNVRZQHGE\%OXHWRR WK6,*,QFDQGDQ\XVHRIVXFK
PDUNVE\0HGWURQLFLVXQGHUOLFHQVH2WKHUWUDGHPDUNVDQGWUDGH QDPHVDUHWKRVHRIWKHLUUHVSHFWLYHRZQHUV
Â‹0HGWURQLF$OOULJKWVUHVHUYHG0HGWURQLF0HGWURQLFORJ RDQG(QJLQHHULQJWKHH[WUDRUGLQDU\DUHWUDGHPDUNV
RI0HGWURQLF7KLUGSDUW\EUDQGVDUHWUDGHPDUNVRIWKHLUUHVSHF WLYHRZQHUV$OORWKHUEUDQGVDUHWUDGHPDUNVRID
0HGWURQLFFRPSDQ\
1RUWKULGJH&$

Document Version ((TXLYDOHQWWR)'$9HUVLRQ(
Version Date 0DU
Document Reference 
Number '
Confidentiality Statement 
7KHLQIRUPDWLRQFRQWDLQHGLQW KLVGRFXPHQWLVFRQILGHQWLDODQG WKHSURSULHWDU\SURSHUW\RI0HGWURQLF
$Q\GLVWULEXWLRQFRS\LQJRUG LVFORVXUHZLWKRXW WKHSULRUZULW WHQDXWKRUL]DWLRQRI0HGWURQLFLVVWULFWO\
SURKLELWHG3HUVRQVWRZKRPWKH LQIRUPDWLRQLVGLVFORVHGPXVWN QRZWKDWLWLVFRQILGH QWLDODQGWKDWLW
PD\QRWEHIXUWKHUGLVFORVHGE\WKHP
CIP335 Clinical Investigation Plan 
 Form 
D00409632 Version E Page 3 of 106 
0HGWURQLF%XVLQHVV5HVWULFWHG
CONFIDENTIAL )5HY(&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Form
Table of Contents 
Table of Contents .............................................. ............................................................... ......... 3
1. Glossary ............................................................... ...............................................................  6 
2. Synopsis ...................................................... ............................................................... ........ 8  
3. Introduction .................................................. ............................................................... .... 27  
 %DFNJURXQG   
 3XUSRVH   
4. Objectives and Endpoints ............................................................... .................................. 27  
 2EMHFWLYHV   
 (QGSRLQWV   
5. Study Design .................................................. ............................................................... ... 29  
 'XUDWLRQ   
 5DWLRQDOH   
6. Product Description............................................ .............................................................. 36 
 ,QWHQGHG8VH   
 *HQHUDO2YHUYLHZRI0LQL0HG*,QVXOLQ3XPS6\VWHP&RPSRQHQWV DQG&RQVXPDEOHV  
 ,QYHVWLJDWLRQDO3URGXFW   
 1RQ,QYHVWLJDWLRQDO3URGXFWV    
 &RQVXPDEOH'HYLFHV  
 $QWLFLSDWHG3URGXFW&KDQJHV   
 3URGXFW$FFRXQWDELOLW\   
7. Study Site Requirements ....................................... .......................................................... 46  
 ,QYHVWLJDWRU,QYHVWLJDWLRQDO&HQWHU6HOHFWLRQ   
 6WXG\6LWH$FWLYDWLRQ   
8. Selection of Subjects ............................................................... ......................................... 47  
 6WXG\3RSXODWLRQ    
 6XEMHFW(QUROOPHQW   
 ,QFOXVLRQ&ULWHULD   
 ([FOXVLRQ&ULWHULD   
9. Study Procedures .............................................. ...............................................................  49 
 6FKHGXOHRI(YHQWV    
 'DWD&ROOHFWLRQ   
CIP335 Clinical Investigation Plan 
 Form 
D00409632 Version E Page 4 of 106 
0HGWURQLF%XVLQHVV5HVWULFWHG
CONFIDENTIAL )5HY(&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Form
 6XEMHFW&RQVHQW    
 6DIHW\0RQLWRULQJ5LVN$QDO\VLV    
 *OXFRVHDQG*O\FHPLD0HDVXUHPHQWV   
 5HFRUGLQJ'DWD   
 'HYLDWLRQ+DQGOLQJ   
 6XEMHFW([LW:LWKGUDZDORU'LVFRQWLQXDWLRQ   
 6WXG\6WRSSLQJ5XOHV   
10. Risks and Benefits ............................................ ............................................................ 73  
  3RWHQWLDO5LVNV   
  5LVN0LQLPL]DWLRQ   
  3RWHQWLDO%HQHILWV   
  5LVN%HQHILW5DWLRQDOH   
  5LVN'HWHUPLQDWLRQ    
11. Adverse Events ................................................ ............................................................. 8 0 
  $GYHUVH(YHQWV   
  'HILQLWLRQVDQG&ODVVLILFDWLR QRI$GYHUVH(YHQWV   
  5HFRUGLQJRI$GYHUVH(YHQWV   
  1RWLILFDWLRQRI$GYHUVH(YHQWV   
  ([SHGLWHG6DIHW\5HSRUWLQJ5HTXLUHPHQWV   
  &DXVDOLW\$VVHVVPHQW   
  $QWLFLSDWHGRU8QDQWLFLSDWHG   
12. Data Review Committees ........................................ ..................................................... 85  
  &OLQLFDO(YHQWV&RPPLWWHH    
  'DWD0RQLWRULQJ&RPPLWWHH   
13. Device Deficiencies and Troubleshooting ....................... .............................................. 90  
14. Statistical Design and Methods ................................ .................................................... 90  
  *HQHUDO$VSHFWVRI$QDO\VLV   
  6XEMHFW'LVSRVLWLRQ    
  6XEMHFW'HPRJUDSKLFVDQG% DVHOLQH&KDUDFWHULVWLFV   
  (QGSRLQWVDQG+\SRWKHVHV   
  6DPSOH6L]H&RQVLGHUDWLRQV6DPSOH6L]H-XVWLILFDWLRQ   
  +DQGOLQJ0LVVLQJ'DWD   
CIP335 Clinical Investigation Plan 
 Form 
D00409632 Version E Page 5 of 106 
0HGWURQLF%XVLQHVV5HVWULFWHG
CONFIDENTIAL )5HY(&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Form
  )LQDO5HSRUWV   
15. Ethics ........................................................ ............................................................... ..... 95  
  6WDWHPHQWVRI&RPSOLDQFH   
  ,5%$SSURYDO   
  5ROHRIWKH6SRQVRUÂ¶V5HSUHVHQWDWLYHV   
  ,QYHVWLJDWRUÂ¶V5HVSR QVLELOLWLHV   
16. Study Administration .......................................... .......................................................... 98  
  7UDLQLQJRI&OLQLFDO6WDII   
  0RQLWRULQJ   
  'DWD0DQDJHPHQW    
  'LUHFW$FFHVVWR6RXUFH'DWD'RFXPHQWV   
  &RQILGHQWLDOLW\    
  /LDELOLW\DQG6XEMHFW&RPSHQVDWLRQ   
  &,3$PHQGPHQWV    
  5HFRUGVDQG5HSRUWV    
  5HFRUG5HWHQWLRQ    
  6XVSHQVLRQRU(DUO\7HUPLQDWLRQ    
  6WXG\&ORVH2XW   
  3XEOLFDWLRQDQG8VHRI,QIRUPDWLRQ   
17. References .................................................... .............................................................. 103  
18. Appendices .................................................... ............................................................. 1 04 
  1DPHVDQGDGGUHVVHV   
  /DEHOLQJRI'HYLFHV    
  6DPSOH&RQVHQW0DWHULDOV    
19. Version History ............................................... ............................................................ 10 5 
CIP335 Clinical Investigation Plan 
 Form 
D00409632 Version E Page 6 of 106 
0HGWURQLF%XVLQHVV5HVWULFWHG
CONFIDENTIAL )5HY(&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Form
1. Glossary 
Abbreviations 
$'( $GYHUVH'HYLFH(IIHFW
$( $GYHUVH(YHQW
$+&/ $GYDQFHG+\EULG&ORVHG/RRS
$8& $UHD8QGHU&XUYH
%* %ORRG*OXFRVH
%0, %RG\0DVV,QGH[
&(& &OLQLFDO(YHQWV&RPPLWWHH
&)5 &RGHRI)HGHUDO5H JXODWLRQV
&*0 &RQWLQXRXV*OXFRVH0RQLWRULQ J
&,3 &OLQLFDO,QYHVWL JDWLRQ3ODQ
&5) &DVH5HSRUW)RUP
&6,, &RQWLQXRXV6XEFXWDQHRXV,QVXOLQ,QIXVLRQ
&7$ &OLQLFDO7ULDO$ JUHHPHQW
&9 &XUULFXOXP9LWDH
'' 'HYLFH'HILFLHQF\
'.$ 'LDEHWLF.HWRDFLGRVLV
'0& 'DWD0RQLWRULQ J&RPPLWWHH
'R+ 'HFODUDWLRQRI+HOVLQNL
H&5) (OHFWURQLF&DVH5HSRUW)RUP
('& (OHFWURQLF'DWD&DSWXUH
(26 (QGRI6WXG\
(5 (PHU JHQF\5RRP
)'$ )RRGDQG'UX J$GPLQLVWUDWLRQ
*&3 *RRG&OLQLFDO3UDFWLFH
+E$F *O\FRV\ODWHGKHPR JORELQ
+,3$$ +HDOWK,QVXUDQFH3RUWDE LOLW\DQG$FFRXQWDELOLW\$FW
,% ,QYHVWL JDWRUÂ¶V%URFKXUH
,&) ,QIRUPHG&RQVHQW)RUP
,&0-( ,QWHUQDWLRQDO&RPPLWWHH RI0HGLFDO-RXUQDO(GLWRUV
,GHQWLILFDWLRQ
,' ,GHQWLILFDWLRQ
,'( ,QYHVWL JDWLRQDO'HYLFH([HPSWLRQ
,(& ,QGHSHQGHQW(WKLF&RPPLWWHH
,)8 ,QVWUXFWLRQVIRU8VH
,5% ,QVWLWXWLRQDO5HYLHZ%RDUG
,62 ,QWHUQDWLRQDO2U JDQL]DWLRQIRU6WDQGDUGL]DWLRQ
,9 ,QWUDYHQRXV
0& 0HGWURQLF&RUH&OLQLFDO6ROXWLRQV
1*63 1DWLRQDO*O\FRKHPR JORELQ6WDQGDUGL]DWLRQ3UR JUDP
3& 3HUVRQDO&RPSXWHU
3, 3ULQFLSDO,QYHVWL JDWRU
33 3HU3URWRFRO
4& 4XDOLW\&RQWURO
6$'( 6HULRXV$GYHUVH'HYLFH(IIHFW
6$( 6HULRXV$GYHUVH(YHQW
CIP335 Clinical Investigation Plan 
 Form 
D00409632 Version E Page 7 of 106 
0HGWURQLF%XVLQHVV5HVWULFWHG
CONFIDENTIAL )5HY(&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Form
Abbreviations 
6$3 6HQVRU$X JPHQWHG3XPS
6* 6HQVRU*OXFRVH
6, 6HQVRU,QWH JULW\
60%* 6HOI0RQLWRULQ JRI%ORRG*OXFRVH
623 6WDQGDUG2SHUDWLQ J3URFHGXUH
65 6L JQLILFDQW5LVN
7'' 7RWDO'DLO\'RVH
7,5 7LPHLQ5DQ JH
7/6 7UDQVSRUW/D\HU6HFXULW\
76+ 7K\URLGVWLPXODWLQ JKRUPRQH
8$'( 8QDQWLFLSDWHG$GYHUVH'HYLFH(IIHFW

CIP335 Clinical Investigation Plan 
 Form 
D00409632 Version E Page 8 of 106 
0HGWURQLF%XVLQHVV5HVWULFWHG
CONFIDENTIAL )5HY(&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Form
2. Synopsis 
Title  (YDOXDWLRQRIWKH$GYDQFHG+\EULG&ORVHG/RRS$+&/6\VWHPLQ 7\SH$GXOWDQG
3HGLDWULF6XE MHFWV8WLOL]LQJ/\XPMHYÂŠLQVXOLQOLVSURDDEF 
Clinical Study 
Type 6DIHW\DQG(IIHFWLYHQHVV(YDOXDWLRQ
Sponsor 0HGWURQLF0LQL0HG,QF
Â³0HGWURQLFÂ´
'HYRQVKLUH6W1RUWKULGJH&$

Indication Under 
Investi gation /DEHOLQJIRUWKH XVHRI/\XPMHYÂŠLQVXOLQOLVSURDDEFLQW KH0LQL0HGÂŒ*V\VWHP
Study Product 
Names & Model 
Numbers Investigational Product 
x 0LQL0HGÂŒ*,QVXOLQ3XPS007UHIHUUHGWRDVWKHVWXG \SXPS
WKURXJKRXWWKLVSURWRFRO
x *XDUGLDQÂŒ*OXFRVH6HQVRU007UHIHUUHGWRDVWKHVHQV RU
WKURXJKRXWWKLVSURWRFRO
x *XDUGLDQ7UDQVPLWWHU007
 
Non-Investigational Product 
x /\XPMHY
ÂŠLQVXOLQOLVSURÂ±DDEFLQMHFWLRQ
x 0HGWURQLF([WHQGHGLQIXVLRQVHW007007007007 
007007007DQG007
x 0HGWURQLF([WHQGHG5HVHUYRLU007
x 2QH3UHVV6HUWHU007UHI HUUHGWRDVWKH6HUWHUWKURXJK RXWWKLV
SURWRFRO
x 7UDQVPLWWHU&KDUJHU007
x 7HVWHU007/
x 0HGWURQLF&DUH/LQNÂŒ3HUVRQ DOVRIWZDUH007
x 0HGWURQLF&DUH/LQNV\VWH PVRIWZDUH007
x )RRG3ULQWÂŒDSSE\1XWULQRÂŒ
x 5RFKH$FFX&KHNÂŒ*XLGH/LQN*OXFRVH0HWHUÂ±UHIH UUHGWR
DVWKH$FFX&KHN*XLGH/LQNVWXG\PHWHUWKURXJKRXWWKLVSURWRFR O
x 0LQL0HG&OLQLFDO$SS007$Q GURLGÂŒDSS007,26ÂŒDSS 
x &DUH/LQN&OLQLFDO$SS007$QGURLGÂŒDSS007,26ÂŒDSS 
x %OXH%OXHWRRWKÂŠ/RZ(QHUJ\$GDSWHU$&&UHIHUUHGWRDVWKH
%OXH$GDSWHULQWKLVSURWRFRO
x .HWRQHPHWHUWREHXVHGIRUEO RRGNHWRQHPHDVXUHPHQWVRQO\
x $FFX&KHN*XLGHWHVWVWULSV
x 6SRQVRUSURYLGHGVPDUW SKRQHXSRQUHTXHVW
Purpose 7KHSXUSRVHRIWKLVVWXG\LVWR HYDOXDWHWKHVDIHW\DQGHIIHFWL YHQHVVRI/\XPMHYÂŠ
LQVXOLQOLVSURDDEFXVHLQWKH *V\VWHPLQW\SHGLDEHWHVD GXOWDQGSHGLDWULF
VXEMHFWVLQDKRPHVHWWLQ J
Objective(s) 7KHREMHFWLYHRIWKLVVWXG\LVW RHYDOXDWHWKHVDIHW\DQGHIIHF WLYHQHVVRIXWLOL]LQJ
/\XPMHYÂŠLQVXOLQOLVSURDDEFLQWKH0LQL0H GÂŒ*V\VWHPWRVXSSRUWSUR GXFWDQG
V\VWHPODEHOLQ J
Study Design  7KLVVWXG\LVDPXOWLFHQWHUVLQJO HDUPVWXG\LQLQVXOLQUHTXL ULQJDGXOWDQGSHGLDWULF
VXEMHFWVZLWKW\SHGLDEHWHVRQW KH0LQL0HGÂŒ*V\VWHPXVLQ J/\XPMHYÂŠ
CIP335 Clinical Investigation Plan 
 Form 
D00409632 Version E Page 9 of 106 
0HGWURQLF%XVLQHVV5HVWULFWHG
CONFIDENTIAL )5HY(&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Form
LQVXOLQOLVSURDDEFDQG0HGWURQLF([WHQGHGLQIXVLRQVHWDQGUHV HUYRLU7KHUXQLQ
SHULRGDQGVWXG\SHULRGZLOOEH DSSUR[LPDWHO\GD\VORQJ

7KHSHULRGIURP9LVLWFRQVHQ WDQGVFUHHQLQJWKURXJK9LVLW VKRXOGEH
FRPSOHWHGZLWKLQGD\V
 
Run-in Period (Visits 2-6):  
7KHUXQLQSHULRGEHJLQVDW9LVLW DQGHQGVRQFHYLVLWRFFXU V
 
7KHLQWHQWRIWKHUXQLQSHULR GZLOOEHWRDOORZVXEMHFWVWREH FRPHIDPLOLDUZLWKQHZ
VWXG\GHYLFHVZKLOHXVL QJWKHLURZQLQVXOLQHLWKHU+XPDORJÂŒL QVXOLQOLVSUR
LQMHFWLRQ1RYR/RJ
ÂŠLQVXOLQDVSDUWVROXWLRQIRULQM HFWLRQRU$GPHORJLQVXOLQOL VSUR
LQMHFWLRQ'XULQJWKHUXQLQSH ULRGVWXG\VXEMHFWVZLOOEHXV LQJWKHVWXG\SXPS
ZLWKRQO\WKH6HQVRU$XJPHQWHG3XPS6$3IXQFWLRQDFWLYDWHGL H6PDUW*XDUGÂŒ
IHDWXUHLVWXUQHG2))DQG0HGWU RQLF([WHQGHGLQIXVLRQVHWDQG UHVHUYRLU

'XULQJWKHUXQLQSHULRGWKHXVHRI6PDUW*XDUGÂŒZLWKWKHH[FH SWLRQRI$XWR
&RUUHFWLRQZLOOEHSHUPLWWHGIRU VWXG\VXEMHFWVZKRZHUHXVLQJ WKH$XWR0RGH
IHDWXUHLQD0HGWURQLFSXPSSULR UWRVFUHHQLQJ,QWKH0LQL0HG *SXPSWKH
WHUPÂ³$XWR0RGHÂ´KDVEHHQUHSODFH GZLWKÂ³6PDUW*XDUGÂŒÂ´)RUWKRV HVXEMHFWVD
PJG/$XWR%DVDOWDUJHWVKRX OGEHVHW,WLVUHFRPPHQGHGWK DW$FWLYH,QVXOLQ
7LPHLVVHWWRKRXUV$OORWKHU VDUHWRXVHWKHV\VWHPLQ0DQ XDO0RGHGXULQJWKH
UXQLQSHULRG
Note:7KH$XWR%DVDOWDUJHWVHWWLQJDQG$FWLYH,QVXOLQ7LPHVKRXOGE HVHWDV
UHFRPPHQGHGDERYHXQOHVVWKHUH LVDGRFXPHQWHGVDIHW\UHDVRQW KDWZRXOGQRW
SHUPLWWKHVHVHWWLQJVWREHXVHG


Therapy at Screening Pump Setting During Run-in Period 
&RQWLQXRXV6XEFXWDQHRXV,QVXOLQ,QIXVLRQ
&6,,0DQXDO0RGH
6$3QRFORVHGORR S0 D Q X D O  0 R G H 
6$3ZLWKFORVHGORRSLQQRQ0HGWURQLF
SXPS0DQXDO0RGH
6$3ZLWKFORVHGORRSLQ0HGWURQLFSXPS
DV$XWR0RGH6PDUW*XDUGZLWK$XWR&RUUHFWLRQ2))

$OOVXEMHFWVFRPSDQLRQVDQGSDUHQ WVFDUHJLYHUVLIDSSOLFDEOH ZLOOEHWUDLQHGRQ
GLDEHWHVPDQDJHPHQWSULQFLSOHV VXFKDVWKHWUHD WPHQWRIK\SHUJ O\FHPLDDQG
K\SRJO\FHPLD,QDGGLWLRQWKHU HZLOOEHWUDLQLQJE\WKHLQYHVW LJDWLRQDOFHQWHUVWDII
UHJDUGLQJWKHQHHGWRKDYHDFFHVVWRDQGKRZWRXVHJOXFRVHDQG JOXFDJRQLQFDVH
RIK\SRJO\FHPLD

3DUHQWVFDUHJLYHUVLIDSSOLFDE OHDQGFRPSDQLRQVZLOOEHLQVWU XFWHGWKDWWKH\
VKRXOGEHZLWKWKHVXEMHFWLQWK HVDPHUHVLGHQFHRUEXLOGLQJRY HUQLJKW

CIP335 Clinical Investigation Plan 
 Form 
D00409632 Version E Page 10 of 106 
0HGWURQLF%XVLQHVV5HVWULFWHG
CONFIDENTIAL )5HY(&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Form
,IWKH0LQL0HG&OLQLFDODSSDQGWKH&DUH/LQN&OLQLFDODSSDUHE HLQJXVHG
SDUHQWVFDUHJLYHUVLIDSSOLFDE OHZLOOEHLQVWUX FWHGWKDWVXEM HFWVVKRXOGEH
FRQQHFWHGWR&DUH/LQNYLDWKHD SSURSULDWH6PDUWSKRQHDSSIRUGD WDXSORDGLQJDQG
SXVKQRWLILFDWLRQVIRUORZRUKLJKEORRGVXJDUZKHQWKH\DUHDS DUWHJDWVFKRRO
RWKHUDFWLYLWLHV,QVWUXFWLRQVRQWKHDSSURSULDWHRSHUDWLRQRI WKHDSSVZLOOEH
SURYLGHG

)RUVWXG\SXUSRVHVVXEMHFWVSD UHQWVFDUHJLYHUVLIDSSOLFDEOH DQGFRPSDQLRQVZLOO
EHWUDLQHGDQGRULQVWUXFWHGWR SHUIRUPVHOIPRQLWRULQJRIEORR GJOXFRVH60%*LI
VXEMHFWVDUHH[SHULHQFLQJDVHYHUHK\SRJO\FHPLFHYHQWVHYHUHK \SHUJO\FHPLFHYHQW
RUGLDEHWLFNHWRDFLGRVLV'.$6X EMHFWVDQGWKHLUSDUHQWVFDUH JLYHUVLIDSSOLFDEOH
DVZHOODVFRPSDQLRQVZLOODOVREH LQVWUXFWHGWRFKHFNVXEMHFWÂ¶ VEORRGNHWRQHVXVLQJ
DNHWRQHPHWHULIWKH$FFX&KHN*XLGH/LQNVWXG\PHWHUUHDGLQJ LVJUHDWHUWKDQ
PJG/

$VDSUHFDXWLRQVXEMHF WVDQGWKHLUSDUHQWVFDUHJLYHUVLIDSSO LFDEOHZLOOEHWROG
WKDWWKH\VKRXOGNHHSWKHLURZQLQVXOLQSXPSVXSSOLHVLQDVDIH SODFHDQGWRKDYH
EDFNXSVXSSOLHVRQKDQGVXFKDV LQVXOLQDQGV\ULQJHRULQVXO LQSHQLQWKHHYHQW
WKH\DUHDVNHGWRUHYH UWEDFNWRWKHLURZQW KHUDS\GXULQJWKHV WXG\RUH[SHULHQFH
VWXG\SXPSLVVXHVLHLQIXVLRQVHWRFFOXVLRQZLWKKLJKJOXFR VH

6XEMHFWVDQGWKHLUSDUHQWVFDU HJLYHUVLIDSSOLFDEOHZLOOEHL QVWUXFWHGWRLQVHUWWKH
JOXFRVHVHQVRUVRQO\LQWKHORFDW LRQVWKDWDUHVSHFLILHGLQWKH 8VHU*XLGH
5HPLQGHUVZLOOEHJLYHQWRVXEMHFW VDQGWKHLUSDUHQWVFDUHJLYHU VLIDSSOLFDEOHDW
HDFKRIILFHYLVLW,QIRUPDWLRQ DERXWVHQVRULQVHUWLRQVZLOOEH FROOHFWHGRQDQ
HOHFWURQLFFDVHUHSRUWIRUPH&5 )LQWKHVWXG\GDWDEDVHLH LQVHUWLRQORFDWLRQ

6XEMHFWVDQGWKHLUSDUHQWVFDU HJLYHUVLIDSSOLFDEOHZLOOEHW UDLQHGRQDOOSDUWVRI
WKHGHYLFHV\VWHP&RPSDQLRQVVK RXOGEHWUDLQHGRQPDWWHUVUHJD UGLQJUHVSRQVHV
WRKLJKRUORZJOXFRVHHYHQWV 7KLVZLOOLQYROYHWUDLQLQJFRQGX FWHGE\WKH
LQYHVWLJDWLRQDOFHQWHU VWDII$WUDLQLQJFKHFNOLVWIRUHDFKVXE MHFWVKRXOGEH
FRPSOHWHGE\LQYHVWLJDWLRQDOFHQ WHUEDVHGWUDLQHUV3DUHQWVFDU HJLYHUVLI
DSSOLFDEOHDQGFRPSDQLRQVVKRXO GEHDYDLODEOHIRUUHOHYDQWSDU WVRUDOORIWKLV
WUDLQLQJHLWKHULQSHUVRQRUYLUWXDOO\

$IWHUFRPSOHWLRQRIWUDLQLQJRQWKHVWXG\GHYLFHVVXEMHFWVDQG WKHLU
SDUHQWVFDUHJLYHUVLIDSSOLFDE OHPD\DWWHQGDGGLWLRQDOYLVLWV LQWKHGD\V
LPPHGLDWHO\IROORZLQJWKHVWDUWRIV\VWHPXVHDVQHHGHG7KH\ PD\DOVREHDEOH
WDNHDGYDQWDJHRIKD YLQJDFFHVVWRWKHGLJLWDOOHDUQLQJFRQWHQW SURYLGHGLWLV
DYDLODEOHDWVWXG\VWDUW
 
 
Study Period (Visits 7-15): 
 
7KHVWXG\SHULRGEHJLQVDW9LVLW DQGHQGVDWWKHFRQFOXVLRQR I9LVLW
 
$OOVXEMHFWVZLOOXVH/\XPMHYÂŠLQVXOLQIRUWKHUHPDLQGH URIWKHVWXG\7KH\ZLOO
FRQWLQXHXVLQJWKH0LQ L0HGÂŒ*V\VWHPH[WHQGHGLQIXVLRQVHW DQGH[WHQGHG
UHVHUYRLU$OO6PDUW*XDUGÂŒIHDW XUHVZLOOEHDFWLYDWHGDQGVKRXO GEHXVHGIRUWKH
GXUDWLRQRIWKHVWXG\SHULRG
CIP335 Clinical Investigation Plan 
 Form 
D00409632 Version E Page 11 of 106 
0HGWURQLF%XVLQHVV5HVWULFWHG
CONFIDENTIAL )5HY(&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Form

6XEMHFWVVKRXOGXVHWKHV\VWHPZLWK6PDUW*XDUGÂŒWXUQHGRQZKLO HDOVRXVLQJ
/\XPMHYÂŠLQVXOLQDWDOOWLPHV:KHQSURPSWHGE\WKHSXPSVXEMHFWVVKRX OGWDNH
DSSURSULDWHPHDVXUHVDQGIROORZGLUHFWLRQVRQWKHSXPSWRUHPDL QLQRUUHWXUQWR
6PDUW*XDUGÂŒ'XULQJWLPHVZKHQVXEMHFWVDUHQRWDEOHWRXVH6PD UW*XDUGÂŒWKH\
VKRXOGXVHWKHV\VWHPLQ0DQXDO 0RGHHJZLWK6XVSHQGEHIRUH ORZRU6XVSHQG
RQORZDFWLYDWHG
Therapy at Screening Pump Setting During Study Period 
&6,, 6PDUW*XDUGZLWK$XWR&RUUHFWLRQ21
6$3QRFORVHGORRS 6PDUW*XDUGZLWK$XWR&RUUHFWLRQ21
6$3ZLWKFORVHGORRSLQQRQ0HGWURQLF
SXPS6PDUW*XDUGZLWK$XWR&RUUHFWLRQ21
6$3ZLWKFORVHGORRSLQ0HGWURQLFSXPS
DV$XWR0RGH6PDUW*XDUGZLWK$XWR&RUUHFWLRQ21


'XULQJWKHILUVWZHHNVEHWZ HHQ9LVLWVDQGRIWKHVWXG\ SHULRGDPJG/
$XWR%DVDOWDUJHWVKRXOGEHVH W,WLVUHFRPPHQGHGWKDW$FWLYH ,QVXOLQ7LPHLV
LQLWLDOO\VHWWRKRXUVDQGWKHQ WLWUDWHGWRZDUGVKRXUVRU DWWKHLQYHVWLJDWRUÂ¶V
GLVFUHWLRQ
'XULQJWKHQH[WZHHNVEHWZ HHQ9LVLWVDQGRIWKHVWXG\ SHULRGWKH$XWR
%DVDOWDUJHWVHWWLQJVKRXOGEHVH WWRPJG/$FWLYH,QVXOLQ 7LPHLV
UHFRPPHQGHGWREHVHW WRKRXUVRUDWLQ YHVWLJDWRUÂ¶VGLVFUHW LRQ

'XULQJWKHUHPDLQLQJZ HHNVRIWKHVWXG\DQ\WLPHDIWHU9LVLW RIWKHVWXG\
SHULRGWKH$XWR%DVDOWDUJHW DVZHOODV$FWLYH ,QVXOLQ7LPHVK RXOGEHVHWWRZKDWLV
EHVWIRUWKHLQGLYLGXDOVXEMHFWD WLQYHVWLJDWRUÂ¶VGLVFUHWLRQ

Note: 7KH$XWR%DVDOWDUJHWVHWWLQJDQG$FWLYH,QVXOLQ7LPHVKRXOGEH VHWDV
UHFRPPHQGHGDERYHXQOHVVWKHUH LVDGRFXPHQWHGVDIHW\UHDVRQWK DWZRXOGQRW
SHUPLWWKHVHVHWWLQJVWREHXVHG
$IWHUFRPSOHWLRQRIWUDLQLQJRQ6PDUW*XDUGÂŒIXQFWLRQVVXEMHFWV DQGWKHLU
SDUHQWVFDUHJLYHUVPD\DWWHQG DGGLWLRQDOYLVLWVLQWKHGD\VLPP HGLDWHO\IROORZLQJ
WKHVWDUWRI6PDUW*XDUGXVHDVQHHGHG7KH\PD\DOVRWDNHDGYD QWDJHRIKDYLQJ
DFFHVVWRWKHGLJLWDOOHDUQLQJFRQWHQWSURYLGHGLWLVDYDLODEO HDWVWXG\VWDUW
Staged Enrollment: 
 
7KHHQUROOPHQWRISHGLDWULFVXEMH FWV\HDUVRIDJHLQWRWKH VWXG\PD\QRW
SURFHHGXQWLO1 VXEMHFWV\HDUVRIDJHRUROGHUKDYHFRPSO HWHGGD\VRI
WKHVWXG\SHULRGDQGWKH'DWD0RQLWRULQJ&RPPLWWHH'0&KDVGH WHUPLQHGLWLV
VDIHIRUVXEMHFWV\HDUVRI DJHWREHHQUROOHGLQWKHVWXG\ 

SMBG recommendations for the MiniMed ÂŒ780G system: 
 
&DOLEUDWLRQLVQRWUHTXLUHGZLWKW KH0LQL0HGÂŒ*V\VWHPXVLQJ *XDUGLDQ&*0
+RZHYHUDFDOLEUDWLRQLVRSWLRQD ODQGLWZLOODXWRPDWLFDOO\RF FXUDQ\WLPHDEORRG
CIP335 Clinical Investigation Plan 
 Form 
D00409632 Version E Page 12 of 106 
0HGWURQLF%XVLQHVV5HVWULFWHG
CONFIDENTIAL )5HY(&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Form
JOXFRVH%*LVHQWHUHG2FFDVLR QDOO\VXEMHFWVPD\UHFHLYHDQ RWLILFDWLRQLIWKH
SXPSQHHGVD%*WRHQWHURUVWD\LQWKH6PDUW*XDUGÂŒ6XEMHFWVZ LOOEHLQVWUXFWHG
WRSHUIRUP60%*LIWKHLUV\PSWRP VGRQRWPDWFKWKHVHQVRUJOXFR VH6*YDOXH
LHWKH\GHYHORSV\PSWRPVRIK\SRJO\FHPLDRUK\SHUJO\FHPLD EXWWKH6*YDOXH
GRHVQRWFRUUHODWHZLWKWKHLUV\PSWRPV

Meal and Exercise Challenges:  
6XEMHFWVZLOOEHDVNHGWRSDUWLFL SDWHLQPHDODQGH[HUFLVHFKDO OHQJHVGXULQJWKHUXQ
LQDQGVWXG\SHULRG
x $OOFKDOOHQJHVDUHDWOHDVWKRXU VLQGXUDWLRQEHJLQQLQJDWW KHWLPHZKHQ
WKHFKDOOHQJHPHDOVRUH[HUFLVHDUHVWDUWHG
x 7KHUHVKRXOGEHQRPRUHWKDQRQHPHDOFKDOOHQJHRQDVLQJOHGD\ 
x 0HDODQGH[HUFLVHFKDOOHQJHVVKR XOGQRWEHVFKHGXOHGRQWKHVDP HGD\
GXULQJWKHVSHFLILHGWLPHSHULRGV

)RUH[DPSOH$VWXG\SHULRGUHJXODUVL]HGRUODUJHVL]HGPHDOF KDOOHQJHVKRXOGQRW
WDNHSODFHRQWKHVDPHGD\D VDQH[HUFLVHFKDOOHQJH

6XEMHFWVZLOOEHDVNHGWRFKHFN% *DWWKHVWDUWRIWKHPHDOH[H UFLVHDVZHOODV
KRXUVDQGKRXUVDIWHUWKHVWDUWRIWKHPHDOH[HUFLVHDQGSURY LGHLQVXOLQFRUUHFWLRQ
DVQHFHVVDU\
,WLVLPSRUWDQWIRUVXEMHFWVWRDYRLGDGGLWLRQDOPHDOVQDFNRU H[HUFLVHXSWRKRXUV
DIWHUWKHVWDUWRIHDFKFKDOOHQJ H,IDGGLWLRQDOPHDOVQDFNLV FRQVXPHGRUH[HUFLVH
LVGRQHZLWKLQKRXUVDIWHUWKH VWDUWRIWKHFKDOOHQJHWKHVX EMHFWZLOODFNQRZOHGJH
WKLVRQWKHFKDOOHQJHORJ&RQWHQWDQGWLPLQJRIWKHPHDODQGH [HUFLVHDORQJZLWK
DQVZHUVWRFKDOOHQJHTXHVWLRQV ZLOOEHUHFRUGHGRQDORJSURYL GHGE\WKHVWXG\
WHDP
 
Meal Challenges for all Subjects (Run-in and Study Period):  
 
7KHIROORZLQJPHDOFKDOOHQJHVDUHUHTXLUHGGXULQJWKHUXQLQDQ GVWXG\SHULRGV
x 7ZRPHDOFKDOOHQJHVGXULQJWKH UXQLQSHULRGZL WKVXEMHFWVXVLQ JWKHV\VWHPLQ
Manual Mode 6PDUW*XDUGPXVWEHWXUQHGRIID WOHDVWKRXUVSULRUWRWKH
PHDOFKDOOHQJHIRUVXEMHFWVXVLQJ LWGXULQJWKHUXQLQSHULRG Â±EHWZHHQ9LVLWV
DQG
o2QH5HJXODUVL]HGPHDOZLWK
PLVVHGPHDOEROXVDWOXQFK
o 2QH/DUJHVL]HGPHDODWEUHDNIDVWOXQFKRUGLQQHU

x 7ZRPHDOFKDOOHQJHVGXULQJWKHVW XG\SHULRGZLWKVXEMHFWVXVLQJ WKHV\VWHPLQ
6PDUW*XDUG$XWR%DVDOWDUJHW VHWDWPJG/Â±EHWZHHQ9LVLWV DQGRI
VWXG\SHULRG
o 2QH5HJXODUVL]HGPHDOZLWK PLVVHGPHDOEROXVDWOXQFK
o 2QH/DUJHVL]HGPHDODWEUHDNIDVWOXQFKRUGLQQHU
CIP335 Clinical Investigation Plan 
 Form 
D00409632 Version E Page 13 of 106 
0HGWURQLF%XVLQHVV5HVWULFWHG
CONFIDENTIAL )5HY(&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Form
x 7ZRPHDOFKDOOHQJHVGXULQJWKHVW XG\SHULRGZLWKVXEMHFWVXVLQJ WKHV\VWHPLQ
6PDUW*XDUG$XWR%DVDOWDUJHWVH WDWPJG/Â±EHWZHHQ9LVLWV DQGRI
VWXG\SHULRG
o 2QH5HJXODUVL]HGPHDOZLWK PLVVHGPHDOEROXVDWOXQFK
o 2QH/DUJHVL]HGPHDODWEUH DNIDVWOXQFKRUGLQQHU

x 2QHPHDOFKDOOHQJHGXULQJWKHVWXG\SHULRGZLWKVXEMHFWVXVLQJ WKHV\VWHPLQ
6PDUW*XDUG$XWR%DVDOWDUJHWVHWDWLQYHVWLJDWRUÂ¶VGLVFUHWLRQ Â±DWDQ\WLPH
DIWHU9LVLWRIVWXG\SHULRG
o 2QH/DUJHVL]HGPHDODWEU HDNIDVWOXQFKRUGLQQHU
0HDOFKDOOHQJHVVKRXO GRQO\VWDUWLIWKHIROORZLQJFRQGLWLRQVD UHPHW
o 60%*DWVWDUWRIPHDOLVPJG/
o 6HQVRUJOXFRVHLVDYDLODEOH

Timing Settings/Conditions Meal 
SizeMeal 
TypeNotes
Run-in 
Period 
between 
visits 5 and 
7 0DQXDO0RGHRQO\
Missed meal bolus 5HJXODU
VL]HG
PHDO/XQFK0HDOFRQWHQWPHDO
VL]HDQGWLPHRIPHDO
FRQVXPSWLRQVKRXOG
EHHVWDEOLVKHGVRWKDW
UHJXODUVL]HGPHDO
FKDOOHQJHVGXULQJWKH
VWXG\SHULRG  FDQEH
PDWFKHG
Run-in 
Period 
between 
visits 5 and 
7 0DQXDO0RGHRQO\/DUJH
VL]HG
PHDO%UHDNIDVW
/XQFKRU
'LQQHU0HDOFRQWHQWPHDO
VL]HDQGWLPHRIPHDO
FRQVXPSWLRQVKRXOG
EHHVWDEOLVKHGVRWKDW
ODUJHVL]HGPHDO
FKDOOHQJHVGXULQJWKH
VWXG\SHULRG  FDQEH
PDWFKHG
Study 
Period, 
between 
Visits 9 and 
11 6PDUW*XDUG
PJG/VHWSRLQW
Missed Meal bolus 5HJXODU
VL]HG
PHDO/XQFK0HDOFRQWHQWPHDO
VL]HDQGWLPHRIPHDO
FRQVXPSWLRQVKRXOG
PDWFKUHJXODUPHDO
WDNHQGXULQJUXQLQ
DQGWKHUHJXODUPHDO
WDNHQDWWKH
PJG/VHWSRLQW
Study 
Period, 
between 
Visits 9 and 
11 6PDUW*XDUG
PJG/VHWSRLQW/DUJH
VL]HG
PHDO%UHDNIDVW
/XQFKRU
'LQQHU0HDOFRQWHQWPHDO
VL]HDQGWLPHRIPHDO
FRQVXPSWLRQVKRXOG
PDWFKPHDODW
6HWSRLQWRIPJG/
DQGUXQLQSHULRG
PHDO
Study 
Period, 
between 6PDUW*XDUG
PJG/VHWSRLQW
Missed meal bolus 5HJXODU
VL]HG
PHDO/XQFK0HDOFRQWHQWPHDO
VL]HDQGWLPHRIPHDO
FRQVXPSWLRQVKRXOG
CIP335 Clinical Investigation Plan 
 Form 
D00409632 Version E Page 14 of 106 
0HGWURQLF%XVLQHVV5HVWULFWHG
CONFIDENTIAL )5HY(&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Form
Visits 12 
and 13 PDWFKUHJXODUPHDO
WDNHQGXULQJUXQLQ
DQGWKHUHJXODUPHDO
WDNHQDWWKH
PJG/
Study 
Period,  
between 
Visits 12 
and 13 6PDUW*XDUG
PJG/VHWSRLQW/DUJH
VL]HG
PHDO%UHDNIDVW
/XQFKRU
'LQQHU0HDOFRQWHQWPHDO
VL]HDQGWLPHRIPHDO
FRQVXPSWLRQVKRXOG
PDWFKPHDODW
6HWSRLQWRIPJG/
DQGUXQLQSHULRG
ODUJHVL]HGPHDO   
Study 
Period 
Any time 
after Visit 
13 6PDUW*XDUG
$XWR%DVDOWDUJHWDW
LQYHVWLJDWRUÂ¶V
GLVFUHWLRQ/DUJH
VL]HG
PHDO%UHDNIDVW
/XQFKRU
'LQQHU0HDOFRQWHQWPHDO
VL]HDQGWLPHRIPHDO
FRQVXPSWLRQVKRXOG
PDWFKODUJHPHDODW
6HWSRLQWRIPJG/
PJG/DQGUXQLQ
SHULRGODUJHVL]HG
PHDOV
 
Regular Sized Meal Challenge with Missed Meal Bolus:  
%HWZHHQYLVLWVDQGIRUWKHUXQLQSHULRGZKLOHVXEMHFWVDU HLQ0DQXDO0RGH
ZLWK&*0WKH\ZLOOEHDVNHGWRF RQVXPHDPHDOZLWKRXWDGPLQLVW UDWLRQRID0HDO
%ROXVDWOXQFK7KHVL]HRIWKHP HDOVKRXOGEHHTXLYDOHQWWRZK DWVXEMHFWVZRXOG
QRUPDOO\HDWDW WKLVPHDOWLPH
'XULQJWKHVWXG\SHULRGRQFHDWHDFK$XWR%DVDOVHWSRLQWLH PJG/DQG
PJG/VXEMHFWVZLOOEHDVNHGWR FRQVXPHWKHVDPHUHJXODUVL]H GOXQFKPHDOWKDW
WKH\KDGGXULQJWKHUXQLQSHULRG)RUH[DPSOHLIWKHUHJXODU VL]HGPHDOZDV
FRQVXPHGZLWKRXWDQLQVXOLQER OXVIRUWKHPHDODWSPGXULQ JWKHUXQLQSHULRG
WKDWVDPHUHJXODUVL]HGPHDOVKR XOGEHFRQVXPHGDWDSSUR[LPDWHO \WKHVDPHWLPH
RIGD\DWHDFKVHWSRLQWGXULQJ WKHVWXG\SHULRG6XEMHFWVZLOO EHDVNHGWRFKHFN%*
DWWKHVWDUWRIWKHPHDODVZHO ODVKRXUVDQGKRXUVDIWHU WKHVWDUWRIWKHPHDO
DQGWDNHEROXVFRUUHFWLRQDVQ HFHVVDU\'HWDLOVVKRXOGEHUHFRU GHGRQWKHORJ
 Large Sized Meal Challenges:   
2QODUJHVL]HGPHDOFKDOOHQJHGD \VVXEMHFWVZLOOEHLQVWUXFWHG WRHDWRQHPHDOZLWK
DWOHDVWKLJKHUFDORULFLQWDNHLQFOXGLQJPRUHFDUERK\G UDWHVDQG
KLJKHULQIDW,WLVUHFRPPHQGHG WKDWVXEMHFWVHDWIRRGDWUHVW DXUDQWVRUFRQVXPH
SUHSDUHGPHDOV7KH)RRG3ULQWÂŒ DSSDVZHOODVTXHVWLRQVWKDWZ LOOEHDVNHGE\
LQYHVWLJDWLRQDOFHQW HUVWDIIGXULQJYLVLWVIROORZLQJPHDOFKDOO HQJHVZLOOEHXVHGE\
VXEMHFWVWRFROOHFWLQIRUPDWLRQDERXWWKHIRRGWKDWZDVHDWHQ WKHQDPHRIWKH
UHVWDXUDQWLIDSSOLFDEOHDQGVX EMHFWFRQILUPDWLRQWKDWPHDOV L]HZDVDWOHDVW
PRUHLQWHUPVRIFDORULHVFDUERK\GUDWHVDQGIDW7KHWLPLQJRI WKHPHDOFKDOOHQJHV
ZLOOEHDWWKHLQYHVWLJDWRUÂ¶VGLVF UHWLRQ7KHVXEMHFW
VSDUHQW FDUHJLYHURUFRPSDQLRQ
VKRXOGEHSK\VLFDOO\SUHVHQWLQ WKHVDPHEXLOGLQJKRPHRUORFD WLRQLIQRWDWKRPH
GXULQ
JWKHPHDOFKDOOHQ JHDQGIRUKRXUVIROORZLQ JWKHVWDUWRIWKHPHDO7KH\
CIP335 Clinical Investigation Plan 
 Form 
D00409632 Version E Page 15 of 106 
0HGWURQLF%XVLQHVV5HVWULFWHG
CONFIDENTIAL )5HY(&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Form
PXVWEHDEOHWRFKHFN60%*LQ FDVHLWLVQHHGHGDQGJLYHJOXF RVHDGPLQLVWHU
JOXFDJRQLIUHTXLUHG
 
Exercise Challenge for all Subjects (during Study Period only):    

7KHIROORZLQJH[HUFLVHFKDOOHQJHVDUHUHTXLUHGGXULQJWKHVWXG\ SHULRG

x H[HUFLVHFKDOOHQJHVDWVHWSRL QWRIPJG/EHWZHHQ9LVLWV DQGRIWKH
VWXG\SHULRG
x H[HUFLVHFKDOOHQJHVDWVHWSRL QWRIPJG/EHWZHHQ9LVLWV DQGRIWKH
VWXG\SHULRG
x H[HUFLVHFKDOOHQJHDWVHWSRLQW RILQYHVWLJDWRUÂ¶VGLVFUHWLRQ DWDQ\WLPHDIWHU
9LVLWRIWKHVWXG\SHULRG

&RQGLWLRQVDWVWDUWRIW KHH[HUFLVHFKDOOHQJHV
x 6*VKRXOGEHSUHVHQWDWWKHVWDUWRIHDFKH[HUFLVHFKDOOHQJH
x 7KHLQYHVWLJDWRURUKLVKHUVWDI IZLOOGHWHUPLQHWKHPLQLPXP%* IRUHDFK
VXEMHFWDWWKHVWDUWRIHDFKH[ HUFLVHFKDOOHQJH,WZLOOEHQRW HGRQWKHVXEMHFWÂ¶V
H[HUFLVHORJ

Timing Settings/Conditions Exercise 
durationNotes
Study 
Period, 
between 
Visits 9 and 
11 6PDUW*XDUG
PJG/VHWSRLQW  0LQ
PLQXWHVXS
WR
KRXUV&KDOOHQJHPXVWWDNHSODFHRQ
GD\VZLWKRXWPHDOFKDOOHQJH
Study 
Period, 
between 
Visits 9 and 
11 6PDUW*XDUG
PJG/VHWSRLQW0LQ
PLQXWHVXS
WR
KRXUV&KDOOHQJHPXVWWDNHSODFHRQ
GD\VZLWKRXWPHDOFKDOOHQJH
Study 
Period, 
between 
Visits 12 and 
13 6PDUW*XDUG
PJG/VHWSRLQW0LQ
PLQXWHVXS
WR
KRXUV&KDOOHQJHPXVWWDNHSODFHRQ
GD\VZLWKRXWPHDOFKDOOHQJH
Study 
Period, 
between 
Visits 12 and 
13 6PDUW*XDUG
PJG/VHWSRLQW  0LQ
PLQXWHVXS
WR
KRXUV&KDOOHQJHPXVWWDNHSODFHRQ
GD\VZLWKRXWPHDOFKDOOHQJH
Study Period 
Any time 
after Visit 13 6PDUW*XDUG
$XWR%DVDOWDUJHW
VHWSRLQWDW
LQYHVWLJDWRUÂ¶V
GLVFUHWLRQ0LQ
PLQXWHVXS
WR
KRXUV&KDOOHQJHPXVWWDNHSODFHRQ
GD\VZLWKRXWPHDOFKDOOHQJH
 
Exercise Challenges Details: 
7RIXOILOOWKHH[HUFLV HFKDOOHQJHUHTXLUHP HQWVXEMHFWVZLOOEH DVNHGWRHQJDJHLQ
XSWRKRXUVRISK\ VLFDOH[HUFLVH'XULQ JWKLVWLPHVXE MHFWVVKRXOGXVHHLWKHUWKH
CIP335 Clinical Investigation Plan 
 Form 
D00409632 Version E Page 16 of 106 
0HGWURQLF%XVLQHVV5HVWULFWHG
CONFIDENTIAL )5HY(&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Form
$XWR%DVDOVHWSRLQWWDUJHWRIPJG/RUPJG/GHSHQGLQJ RQZKDWLV
UHTXLUHGDWWKDWWLPHRIWKHVWXG\SHULRGXQOHVVDVXEMHFWSUH IHUVWRXVHWKH
PJG/WHPSWDUJHWEHIRUHGXULQJ DQGLPPHGLDWHO\ DIWHUWKHH[HU FLVHFKDOOHQJHV
7KH)RRG3ULQWÂŒDSSDVZHOODVTXH VWLRQVWKDWZLOOEHDVNHGE\ VLWHVWDIIGXULQJ
YLVLWVIROORZLQJH[HUF LVHFKDOOHQJHVZLOOEHXVHGE\VXEMHFWV WRFROOHFWLQIRUPDWLRQ
DERXWH[HUFLVHW\SHGDWHWLPHVWDUWDQGILQLVKRIH[HUFLVH DQGGXUDWLRQ7KH
WLPLQJRIWKHH[HUFLVHFKDOOHQ JHZLOOEHDWWKHLQ YHVWLJDWRUÂ¶VGLVFUHWLRQ$
SKRWRJUDSKVKRXOGEHWDNHQRQHDFKGD\RIWKHH[HUFLVHFKDOOHQJ HVWRLQGLFDWH
ZKHUHWKHH[HUFLVHWRRNSODFH7 KHVXEMHFW
VSDUH QWVFDUHJLYHUV LIDSSOLFDEOHRU
FRPSDQLRQPXVWEHSK\VLFDOO\SUH VHQWLQWKHVDPHEXLOGLQJKRPH RUORFDWLRQLIQRW
DWKRPHGXULQJWKHH[HUFLVHFKDOOHQJHPXVWEHDEOHWRFKHFN6 0%*LQFDVHLWLV
QHHGHGDQGJLYHJOXFRVHDGPLQLV WHUJOXFDJRQDVQHHGHG([DPSOH VRIW\SHVRI
H[HUFLVHLQFOXGHEXWDUHQRWOLPLWHGWR

Âƒ 5XQQLQJ
Âƒ &\FOLQJ
Âƒ 6ZLPPLQJ
Âƒ +LNLQJ
Âƒ :DONLQJ
Âƒ *DPHVHJ:LLLQWHUDFWLYHYLGHRJDPHV
Âƒ ,QGRRURXWGRRUSOD\JURXQG3HGLDWULFVXEMHFWV
Âƒ <RJDVWUHWFKLQJ
Âƒ $Q\VSRUWDFWLYLW\WKDWLQYROYH VRQJRLQJSK\VLFDOPRYHPHQWHJ 
WHQQLVJROIEDVNHWEDOO YROOH\EDOOVRFFHU
Âƒ 'DQFLQJ
Âƒ =XPED
Âƒ $HURELFV
Âƒ 6SLQQLQJ
 
Companions: 
6XEMHFWVZLOOEHUHTXLUHGWRKDYH DFRPSDQLRQZKRUHVLGHVRUZ LOOOLYHLQWKHVDPH
EXLOGLQJRUKRPHGXULQJWKHVWX G\DWQLJKWDQGDOVRWREHSK \VLFDOO\SUHVHQWLQ
WKHVDPHEXLOGLQJKRP HRUORFDWLRQLIQRWDWKRPHGXULQJWKH H[HUFLVHDQGPHDO
FKDOOHQJHV$FRPSDQLRQVKRXOGEHSUHVHQWGXULQJPHDOFKDOOHQJH VDQGIRUKRXUV
IROORZLQJWKHVWDUWRIWKHPHDO& RPSDQLRQVVKRXOGEHDEOHWRF KHFN60%*JLYH
JOXFRVHDQGRUDGPLQLVWHUJOXFDJRQ
Safety Considerations with the Use of Lyumjev
ÂŠ insulin: 
6LWHVZLOOVHQGRXWDQHP DLOWRHDFKVXEMHFW GXULQJZHHNVZKHUH QRYLVLWLV
VFKHGXOHGWRLQTXLUHDERXWLQVXOLQLQIXVLRQZLWK/\XPMHYÂŠLQVXOLQ7KHHPDLOZLOODVN
VXEMHFWVZKHWKHURUQRWWKH\KDYHH[SHULHQFHGDQ\LQVXOLQLQIXV LRQUHDFWLRQVZLWK
WKHXVHRIWKH/\XPMHYÂŠLQVXOLQ7KHHPDLOZLOODOVRUHP LQGVXEMHFWVWKDWVLWHV
VKRXOGEHFDOOHGLIDQ\ LVVXHVZLWK/\XPMHYÂŠLQVXOLQLQIXVLRQRFFXU'XULQJVXFK
FDOOVSKRWRVDQGYLGHRVKRXOGEHXVHGLISRVVLEOH

Sample Size and 
Investigational 
Centers  $WRWDORIXSWRVXEMHFWVZLW KLQVXOLQUHTXLULQJW\SHGLD EHWHVDJHZLOOEH
HQUROOHGDWXSWRLQYHVWLJDW LRQDOFHQWHUVDFURVVWKH8QLWHG 6WDWHVLQRUGHUWR
KDYHDWOHDVWVXEMHFWVHQWHU WKHVWXG\SHULRG8SWRVX EMHFWVZLOOEH
HQUROOHGLQWKHSHGLDWULFDJHJUR XS\HDUVRIDJHDQGXS WRLQWKHDGXOW
DJHJURXS\HDUVRUROGHU 
CIP335 Clinical Investigation Plan 
 Form 
D00409632 Version E Page 17 of 106 
0HGWURQLF%XVLQHVV5HVWULFWHG
CONFIDENTIAL )5HY(&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Form

Subject Age Group Sub-groups Enrollment Goal (N) 
3HGLDWULF
$JHÂ±\HDUV$OO3HGLDWULF 0LQLPXP6XE MHFWV
$JH\HDUV 0LQLPXP6XE MHFWV
$JH\HDUV 0LQLPXP6XE MHFWV
$GXOW
$JH\HDUV1$ 0LQLPXP6XEMHFWV

$PLQLPXPRIVXEMHFWVDQGD PD[LPXPRIVX EMHFWVLVWDUJHW HGIRUHQUROOPHQW
DWHDFKLQYHVWLJDWLRQDOFHQWHUWR HQVXUHWKDWWKHUHVXOWVIURP WKHLQGLYLGXDO
LQYHVWLJDWLRQDOFH QWHUVPD\EHSRROHGIRUDQDO\VLV

,QYHVWLJDWLRQDOFHQWH UVZLOOEHHQFRXUDJHG WRHQUROODVWXG\SR SXODWLRQWKDW
UHSUHVHQWVDZLGHYDULHW\RIEDFNJURXQGV 
Duration 7KHVWXG\LVDQWLFLSDWHGWRODVW DSSUR[LPDWHO\PRQWKVIURPI LUVWLQYHVWLJDWLRQDO
FHQWHULQLWLDWLRQWRVWXG\FRPSOH WLRQ,QGLYLGXDOVXEMHFWSDUWL FLSDWLRQLVH[SHFWHGWR
EHDSSUR[LPDWHO\GD\V
Inclusion Criteria  $JH\HDUVDWWLPHRIVFUHHQLQJ
 +DVDFOLQLFDOGLDJQRVLVRIW\SHGLDEHWHV
D Â±\HDUVRIDJH$FOLQLFDOG LDJQRVLVRIW\SHGLDEHWHVIRU \HDUV
RUPRUHDVGHWHUPLQHGYLDPHGLFDOUHFRUGRUVRXUFHGRFXPHQWDWLR QE\
DQLQGLYLGXDOTXDOLILHGWRPDNHDPHGLFDOGLDJQRVLV
E Â±\HDUVRIDJH$FOLQLFDOGLD JQRVLVRIW\SHGLDEHWHVIRU \HDURU
PRUHDVGHWHUPLQHGYLDPHGLFDOU HFRUGRUVRXUFHGRFXPHQWDWLRQE \DQ
LQGLYLGXDOTXDOLILHGWRPDNHDPHGLFDOGLDJQRVLV
 'RHVQRWUHTXLUHDOHJDOO\DXWKRUL ]HGUHSUHVHQWDWLYHWRFRQVHQW RQWKHLUEHKDOI
GXHWRPHQWDORULQWHOOHFWXDOGLVDELOLW\
 6XEMHFWRUSDUHQWFDUHJLYHULV OLWHUDWHDQGDEOHWRUHDGWKHOD QJXDJHRIIHUHGLQ
WKHSXPSRUSXPSPDWHULDOV
 6XEMHFWDQGRUOHJDOO\DXWKRUL ]HGUHSUHVHQWDWLYHLVZLOOLQJWR SURYLGHLQIRUPHG
FRQVHQWIRUSDUWLFLSDWLRQ
 ,VZLOOLQJWRSHUIRUPILQJHUVWLFNE ORRGJOXFRVHPHDVXUHPHQWVDV QHHGHG
 ,VZLOOLQJWRZHDUWKHV\VWHPFRQ WLQXRXVO\WKURXJKRXWWKHVWXG\ 
 0XVWKDYHDPLQLPXPGDLO\LQVXOL QUHTXLUHPHQW7RWDO'DLO\'RVH RIJUHDWHU
WKDQRUHTXDOWRXQLWVDQGDP D[LPXPWRWDOGDLO\GRVHRI XQLWVRUOHVV
 +DVD*O\FRV\ODWHGKHPRJORELQ +E$FOHVVWKDQDVSURFHVV HGE\
&HQWUDO/DEDWWLPHRIVFUHHQLQJYLVLW
Note: $OO+E$FEORRGVSHFLPHQVZLOOEH VHQWWRDQGWHVWHGE\D1DWLR QDO
*O\FRKHPRJORELQ6WDQGDUGL]DWLRQ 3URJUDP1*63FHUWLILHG&HQWUD O
/DERUDWRU\+E$FWHVWLQJ PXVWIROORZ1*63VWDQGDUGV   
 +DVWK\URLGVWLPXODWLQJKRUPRQH7 6+LQWKHQRUPDOUDQJH25LI WKH76+LV
RXWRIQRUPDOUHIHUHQFHUDQJH WKH)UHH7LVEHORZRUZLWKLQW KHODEÂ¶V
UHIHUHQFHUDQJHDQG)UHH7LVZLWKLQWKHQRUPDOUHIHUHQFHUDQJ H
 8VHVSXPSWKHUDS\IRUJUHDWHUWKDQPRQWKVZLWKRUZLWKRXW&* 0
H[SHULHQFHSULRUWRVFUHHQLQJ
 ,VZLOOLQJWRXSORDGGDWDIURPWK HVWXG\SXPSPXVWKDYH,QWHUQ HWDFFHVVDQG
DFRPSXWHUV\VWHPRUFRPSDWLEOH VPDUWSKRQHWKDWPHHWVWKHUHTX LUHPHQWVIRU
XSORDGLQJWKHVWXG\SXPS
CIP335 Clinical Investigation Plan 
 Form 
D00409632 Version E Page 18 of 106 
0HGWURQLF%XVLQHVV5HVWULFWHG
CONFIDENTIAL )5HY(&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Form
 ,VZLOOLQJWRWDNHRQHRIWKHIR OORZLQJLQVXOLQVDQGFDQILQDQF LDOO\VXSSRUWWKH
XVHRILQVXOLQSUHSDUDWLRQVDVU HTXLUHGGXULQJWKHUXQLQSHULR G
D +XPDORJLQVXOLQOLVSURLQMHFWLRQ
E 1RYR/RJLQVXOLQDVSDUWLQMHFWLRQ
F $GPHORJLQVXOLQOLVSURLQMHFWLRQ
 ,VZLOOLQJWRWDNH/\XPMHYLQVXOLQ GXULQJWKHVWXG\SHULRGVXS SOLHGYLD
6SRQVRU
Exclusion Criteria  +DVK\SHUVHQVLWLYLW\WRLQVXOLQ OLVSURRURQHRIWKHH[FLSLHQWV LQ/\XPMHYÂŠ
 +DVDKLVWRU\RIRUPRUHHSLVRGH VRIVHYHUHK\SRJO\FHPLDZKL FKUHVXOWHGLQ
DQ\WKHIROORZLQJGXULQJWKHPRQWKVSULRUWRVFUHHQLQJ
D 0HGLFDODVVLVWDQFHLH3DUDPH GLFV(PHUJHQF\5RRP>(5@RU
+RVSLWDOL]DWLRQ
E &RPD
F 6HL]XUHV
 +DVEHHQKRVSLWDOL]HGRUKDVYLVLW HGWKH(5LQWKHPRQWKVSUL RUWRVFUHHQLQJ
UHVXOWLQJLQDSULPDU\GLDJQRVLVRIXQFRQWUROOHGGLDEHWHV
 +DVKDG'.$LQWKHODVWPRQWKVSULRUWRVFUHHQLQJYLVLW
 :LOOQRWWROHUDWHWDSHDGKHVLYHLQ WKHDUHDRIVHQVRUSODFHPHQW DVDVVHVVHGE\
DTXDOLILHGLQGLYLGXDO
 +DVDQ\XQUHVROYHGDGYHUVHVNLQFRQGLWLRQLQWKHDUHDRIVHQVRU SODFHPHQW
HJSVRULDVLVGHUPDWLWLVKHUSH WLIRUPLVUDVK6WDSK\ORFRFFX VLQIHFWLRQ
 ,VIHPDOHRIFKLOGEHDULQJSRWHQWL DODQGUHVXOWRISUHJQDQF\WH VWLVSRVLWLYHDW
VFUHHQLQJ
 ,VVH[XDOO\DFWLYHIHPDOHRIFK LOGEHDULQJSRWHQWLDODQGLVQRW XVLQJDIRUPRI
FRQWUDFHSWLRQGHHPHGUHOLDEOHE\WKHLQYHVWLJDWRU
 ,VIHPDOHDQGSODQVWREHFRPHSUHJQDQWGXULQJWKHFRXUVHRIWKH VWXG\
 ,VEHLQJWUHDWHGIRUK\SHUWK\URL GLVPDWWLPHRIVFUHHQLQJ
 +DVGLDJQRVLVRIDGUHQDOLQVXIILFLHQF\
 +DVWDNHQDQ\RUDOLQMHFWDEOH RULQWUDYHQRXV,9JOXFRFRUWLF RLGVZLWKLQ
ZHHNVIURPWLPHRIVFU HHQLQJYLVLWRUSODQVWRWDNHDQ\RUDO LQMHFWDEOHRU,9
JOXFRFRUWLFRLGGXULQJWKHFRXUVHRIWKHVWXG\  
 ,VXVLQJK\GUR[\XUHDDWWLPHRIVF UHHQLQJRUSODQVWRXVHLWGX ULQJWKHVWXG\
 ,VDFWLYHO\SDUWLFLSDWLQJLQDQ LQYHVWLJDWLRQDOVWXG\GUXJRU GHYLFHZKHUHLQ
KHVKHKDVUHFHLYHGWUHDWPHQWIURPDQLQYHVWLJDWLRQDOVWXG\GUX JRU
LQYHVWLJDWLRQDOVWXG\GHYL FHLQWKHODVWZHHNV
 ,VFXUUHQWO\DEXVLQJLOOLFLWGUXJV
 ,VFXUUHQWO\DEXVLQJPDULMXDQD
 ,VFXUUHQWO\DEXVLQJSUHVFULSWLRQGUXJV
 ,VFXUUHQWO\DEXVLQJDOFRKRO
 8VLQJSUDPOLQWLGH6\ POLQ'33LQKLELWRUOLUDJOXWLGH9LFWR ]DRURWKHU*/3
DJRQLVWVPHWIRUPLQFDQDJOLIOR ]LQ,QYRNDQDRURWKHU6*/7LQ KLELWRUVDWWLPH
RIVFUHHQLQJ
 +DVDKLVWRU\RIYLVXDOLPSDLUPH QWZKLFKZRXOGQ RWDOORZVXEMHF WWRSDUWLFLSDWH
LQWKHVWXG\DQGSHUIRUPDOOVWX G\SURFHGXUHVVDIHO\DVGHWHUP LQHGE\WKH
LQYHVWLJDWRU
 +DVHOHFWLYHVXUJHU\SODQQHGWK DWUHTXLUHVJHQHUDODQHVWKHVLDG XULQJWKHFRXUVH
RIWKHVWXG\
 +DVVLFNOHFHOOGLVHDVHKHPRJORELQRSDWK\RUKDVUHFHLYHGUHG EORRGFHOO
WUDQVIXVLRQRUHU\WKURSRLHWLQZLWKLQPRQWKVSULRUWRWLPHRI VFUHHQLQJ
CIP335 Clinical Investigation Plan 
 Form 
D00409632 Version E Page 19 of 106 
0HGWURQLF%XVLQHVV5HVWULFWHG
CONFIDENTIAL )5HY(&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Form
 3ODQVWRUHFHLYHUHGEORRGFHOO WUDQVIXVLRQRUHU\WKURSRLHWLQR YHUWKHFRXUVHRI
VWXG\SDUWLFLSDWLRQ
 ,VGLDJQRVHGZLWKFXUUHQWHDWLQJGLVRUGHUVXFKDVDQRUH[LDRUE XOLPLD
 +DVEHHQGLDJQRVHGZLWKFKURQLF NLGQH\GLVHDVHWKDWUHVXOWVLQ FKURQLFDQHPLD
 +DVDKHPDWRFULWWKDWLVEHORZWKHQRUPDOUHIHUHQFHUDQJHRIOD EXVHG
 ,VRQGLDO\VLV
 +DVVHUXPFUHDWLQLQHRI!PJG/
 +DVFHOLDFGLVHDVHWKDWLVQRWDG HTXDWHO\WUHDWHGDVGHWHUPLQHG E\WKH
LQYHVWLJDWRU
 +DVKDGDQ\RIWKHIROORZLQJFDUG LRYDVFXODUHYHQWVZLWKLQ\HD URIVFUHHQLQJ
P\RFDUGLDOLQIDUFWLRQXQVWDEOHDQJLQDFRURQDU\DUWHU\E\SDVV VXUJHU\
FRURQDU\DUWHU\VWHQWLQJWUDQ VLHQWLVFKHPLFDWWDFNFHUHEURYDV FXODUDFFLGHQW
DQJLQDFRQJHVWLYHKHDUWIDLOXUHRUYHQWULFXODUUK\WKPGLVWXUE DQFHV
 +DVKDGKLVWRU\RIFDUGLRYDVFXODUHYHQW\HDURUPRUHIURPWKH WLPHRI
VFUHHQLQJZLWKRXW
D DQRUPDO(.*DQGVWUHVVWHVWZLW KLQPRQWKVSULRUWRVFUHHQLQJ RU
GXULQJVFUHHQLQJRU
E FOHDUDQFHIURPDTXDOLILHGSK\VLF LDQSULRUWRUHFHLYLQJWKHVWX G\GHYLFHV
LIWKHUHLVDQDEQRUPD O(.*RUVWUHVVWHVW
 +DVRUPRUHFDUGLRYDVFXODUU LVNIDFWRUVOLVWHGEHORZZLWKRXW DQRUPDO(.*
ZLWKLQPRQWKVSULRU WRVFUHHQLQJRUGXULQJVFUHHQLQJRUFOHDU DQFHIURPD
TXDOLILHGSK\VLFLDQLIWKH UHLVDQDEQRUPDO(.*
x $JH!\HDUV
x 7\SHGLDEHWHVRI! \HDUVÂ¶GXUDWLRQ
x 3UHVHQFHRIDQ\DGGLWLRQDOULVNIDFWRUIRUFRURQDU\DUWHU\GLVH DVH
x 3UHVHQFHRIPLFURYDVFXODUGLVHDV HSUROLIHUDWLYHUHWLQRSDWK\RU 
QHSKURSDWK\LQFOXGLQJPLFURDOEXPLQXULD
x 3UHVHQFHRISHULSKHUDOYDVFXODUGLVHDVH
x 3UHVHQFHRIDXWRQRPLFQHXURSDWK\
 ,VDPHPEHURIWKHUHVHDUFKVWDI ILQYROYHGZLWKWKHVWXG\
 +DVXVHGD0LQL0HG*SXPSSULRUWRVFUHHQLQJ


Study Visit 
Schedule  6XEMHFWVPD\SDUWLFLSDWHLQXSW RSODQQHGVWXG\YLVLWVIRU DSSUR[LPDWHO\
GD\VRIGHYLFHZHDU$YLUWXDO RIILFHYLVLWDXGLRYLVXDOPD\ EHSHUIRUPHGIRURIILFH
YLVLWVLQFDVHVZKHUH DQRIILFHYLVLWLVQRWSRVVLEOH)RUGHWD LOHGLQIRUPDWLRQVHH
Section 9.1.1.
 
Visit 1 to Visit 6 should be completed within 30 days. 
 
x 9LVLW2IILFH&RQ VHQWDQGVFUHHQLQJ
o +E$FDQGRWKHUODEVIRUDOOVXEMHFWV
 
Run-In Period:  
x 9LVLW2IILFH9LUWXDO2IILFH6WDUW5XQ,Q
o (OLJLELOLW\KDVEHHQFRQILUPHG
o 6WDUWVWXG\SXPSDQG&*0
o 5HJLVWHUDQGXSORDGVWXG\SXPSLQ&DUH/LQN3HUVRQDODQG&DUH/LQ N
V\VWHP
CIP335 Clinical Investigation Plan 
 Form 
D00409632 Version E Page 20 of 106 
0HGWURQLF%XVLQHVV5HVWULFWHG
CONFIDENTIAL )5HY(&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Form
x 9LVLW3KRQH'D\DIWHU9LVLW 5HTXLUHGIRUVXEMHFWVZLW KRXW&*0RU
FORVHGORRSH[SHULHQFHDVQHHGHGIRUDOORWKHUV
o $VNVXEMHFWVWKHLUSDUHQWVFD UHJLYHUVLIDSSOLFDEOHDQG
FRPSDQLRQVLIWKH\UHTXLUHDVVLVW DQFHHJDGGLWLRQDOWUDLQLQ J
o $VNVXEMHFWVDQGSDUHQWVFDUHJLY HUVLIDSSOLFDEOHDERXWDGYHU VH
HYHQWVGHYLFHSHUIRUPDQFHDQ GXQH[SODLQHGK\SHUJO\FHPLD
o 5HYLHZ&DUH/LQNUHSRUWV
x 9LVLW3KRQH'D\DIWHU9LVL W5HTXLUHGIRUVXEMHFWVZL WKRXW&*0RU
FORVHGORRSH[SHULHQFHDVQHHGHGIRUDOORWKHUV
o $VNVXEMHFWVWKHLUSDUHQWVFD UHJLYHUVLIDSSOLFDEOHDQG
FRPSDQLRQVLIWKH\UHTXLUHDVVLVW DQFHHJDGGLWLRQDOWUDLQL QJ
o $VNVXEMHFWVDQGWKHLUSDUHQWVF DUHJLYHUVLIDSSOLFDEOHDERXW 
DGYHUVHHYHQWVGHYLFHSHUIRUPDQFHDQGXQH[SODLQHG
K\SHUJO\FHPLD
o 5HYLHZ&DUH/LQNUHSRUWV
x 9LVLW3KRQH'D\Â“GD\VDIWHU9LVLW
o $VNVXEMHFWVWKHLUSDUHQWVFD UHJLYHUVLIDSSOLFDEOHDQG
FRPSDQLRQVLIWKH\UHTXLUHDVVLVW DQFHHJDGGLWLRQDOWUDLQLQ J
o $VNVXEMHFWVDQGWKHLUSDUHQWVF DUHJLYHUVLIDSSOLFDEOHDERXW 
DGYHUVHHYHQWVGHYLFHSHUIRUPDQFHDQGXQH[SODLQHG
K\SHUJO\FHPLD
o 5HYLHZ&DUH/LQNUHSRUWV
o ,QVWUXFWVXEMHFWVDERXWUX QLQSHULRGPHDOFKDOOHQJH
x 9LVLW2IILFH9LUWXD O2IILFH'D\Â“GD\VDIWHU9LVLW 
o $VNVXEMHFWVWKHLUSDUHQWVFDUHJ LYHUVLIDSSOLFDEOHDERXWDGY HUVH
HYHQWVGHYLFHSHUIRUPDQFHDQ GXQH[SODLQHGK\SHUJO\FHPLD
o 5HYLHZ&DUH/LQNUHSRUWV
o 5HPLQGVXEMHFWVDERXWUXQ LQSHULRGPHDOFKDOOHQJH
o 9LVLWDQG9LVLWPD\EHFRPELQHG

Study Period:  
x 9LVLW2IILFH9LUWXD O2IILFH6WDUW6WXG \3HULRGZLWK/\XPMH YLQVXOLQ
'D\GD\VDIWHU9LVLW
o $VNVXEMHFWVDQGWKHLUSDUHQWVF DUHJLYHUVLIDSSOLFDEOHDERXW 
DGYHUVHHYHQWVGHYLFHSHUIRUPDQFHXQH[SODLQHGK\SHUJO\FHPLD
DQGLQVXOLQLQIXVLRQUHODWHG LVVXHVZLWK/\ XPMHYLQVXOLQ
o +E$FIRUVXEMHFWVDQGROGHU
o 5HYLHZ&DUH/LQNUHSRUWV
o 6WDUW$XWR%DVDOWDUJHWDWP JG/VHWSRLQWZLWK$FWLYH,QVXO LQ
7LPHVHWWRKRXUVW LWUDWHWRZDUGVKRXUVRUDWLQYHVWLJDW RUÂ¶V
GLVFUHWLRQ
o 7XUQRQ6PDUW*XDUGZLWK$XWR&RUUHFWLRQVÂ³21Â´
o ,QVWUXFWVXEMHFWVDERXWWKHUHT XLUHGPHDODQGH [HUFLVHFKDOOHQJ HV
IRUERWKWKHPJG/DQG PGG/VHWSRLQWEHWZHHQ9LVLWV
DQGRIWKHVWXG\SHULRG
x 9LVLW3KRQH'D\DIWHU9LVLW 5HTXLUHGIRUVXEMHFWVZL WKRXW&*0RU
FORVHGORRSH[SHULHQFHDVQHHGHGIRUDOORWKHUV
o $GMXVWSXPSVHWWLQJVDVQHHGHG
o $VNVXEMHFWVWKHLUSDUHQWVFD UHJLYHUVLIDSSOLFDEOHDQG
FRPSDQLRQVLIWKH\UHTXLUHDVVLVWDQFHH JDGGLWLRQDOWUDLQLQ J
CIP335 Clinical Investigation Plan 
 Form 
D00409632 Version E Page 21 of 106 
0HGWURQLF%XVLQHVV5HVWULFWHG
CONFIDENTIAL )5HY(&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Form
o $VNVXEMHFWVDQGWKHLUSDUHQWVF DUHJLYHUVLIDSSOLFDEOHDERXW 
DGYHUVHHYHQWVGHYLFHSHUIRUPDQ FHXQH[SODLQHGK\SHUJO\FHPLD
DQGLQVXOLQLQIXVLRQUHODWHG LVVXHVZLWK/\XPMHYLQVXOLQ
o 5HYLHZ&DUH/LQNUHSRUWV
o 5HPLQGVXEMHFWVDERXWPHDOH[HU FLVHFKDOOHQJHVIRUPJG/
VHWSRLQW
x 9LVLW3KRQH'D\Â“GD\VDIWHU9LVLW
o $GMXVWSXPSVHWWLQJVDVQHHGHG
o $VNVXEMHFWVDQGWKHLUSDUHQWVF DUHJLYHUVLIDSSOLFDEOHDERXW 
DGYHUVHHYHQWVGHYLFHSHUIRUPDQ FHXQH[SODLQHGK\SHUJO\FHPLD
DQGLQVXOLQLQIXVLRQUHODWHG LVVXHVZLWK/\XPMHYLQVXOLQ
o 5HYLHZ&DUH/LQNUHSRUWV
o 5HPLQGVXEMHFWVDERXWPHDOH[HU FLVHFKDOOHQJHVIRUPJG/
VHWSRLQW
x 9LVLW3KRQH'D\Â“GD\VDIWHU9LVLW
o $GMXVWSXPSVHWWLQJVDVQHHGHG
o $VNVXEMHFWVDQGWKHLUSDUHQWVF DUHJLYHUVLIDSSOLFDEOHDERXW 
DGYHUVHHYHQWVGHYLFHSHUIRUPDQ FHXQH[SODLQHGK\SHUJO\FHPLD
DQGLQVXOLQLQIXVLRQUHODWHG LVVXHVZLWK/\XPMHYLQVXOLQ
o 5HYLHZ&DUH/LQNUHSRUWV
o 5HPLQGVXEMHFWVDERXWPHDOH[HU FLVHFKDOOHQJHVIRUPJG/
VHWSRLQW
x 9LVLW3KRQH'D\Â“GD\VDIWHU9LVLW
o $GMXVWSXPSVHWWLQJVDVQHHGHG
o $VNVXEMHFWVDQGWKHLUSDUHQWVF DUHJLYHUVLIDSSOLFDEOHDERXW 
DGYHUVHHYHQWVGHYLFHSHUIRUPDQ FHXQH[SODLQHGK\SHUJO\FHPLD
DQGLQVXOLQLQIXVLRQUHODWHG LVVXHVZLWK/\XPMHYLQVXOLQ
o 5HYLHZ&DUH/LQNUHSRUWV
o &KDQJH$XWR%DVDOWDUJHWWRPJG/VHWSRLQWZLWK$FWLYH
,QVXOLQ7LPHVHWWRKRXUVR UDWLQYHVWLJDWRUÂ¶VGLVFUHWLRQ
o 5HPLQGVXEMHFWVDERXWPHDOH[HU FLVHFKDOOHQJHVIRUPJG/
VHWSRLQW
x 9LVLW2IILFH9LUWXDO2IILFH 'D\GD\VDIWHU9LVLW 
o $GMXVWSXPSVHWWLQJVDVQHHGHG
o $VNVXEMHFWVDQGWKHLUSDUHQWVF DUHJLYHUVLIDSSOLFDEOHDERXW 
DGYHUVHHYHQWVGHYLFHSHUIRUPDQ FHXQH[SODLQHGK\SHUJO\FHPLD
DQGLQVXOLQLQIXVLRQUHODWHG LVVXHVZLWK/\ XPMHYLQVXOLQ
o +E$FIRUVXEMHFWVDQGROGHU
o 5HYLHZ&DUH/LQNUHSRUWV
x 9LVLW2IILFH9LUWXDO2IILFH 'D\Â“GD\VDIWHU9LVLW 
o $GMXVW$XWR%DVDOWDUJHWZLWK$FW LYH,QVXOLQ7LPHDWLQYHVWLJDW RUÂ¶V
GLVFUHWLRQ
o $GMXVWSXPSVHWWLQJVDVQHHGHG
o $VNVXEMHFWVDQGWKHLUSDUHQWVF DUHJLYHUVLIDSSOLFDEOHDERXW 
DGYHUVHHYHQWVGHYLFHSHUIRUPDQ FHXQH[SODLQHGK\SHUJO\FHPLD
DQGLQVXOLQLQIXVLRQUHODWHG LVVXHVZLWK/\XPMHYLQVXOLQ
o 5HYLHZ&DUH/LQNUHSRUWV
o 5HPLQGVXEMHFWVDERXWPHDOH[HUFLVHFKDOOHQJHV
x 9LVLW2IILFH9LUWXDO2IILFH 'D\GD\VDIWHU9LVLW 
CIP335 Clinical Investigation Plan 
 Form 
D00409632 Version E Page 22 of 106 
0HGWURQLF%XVLQHVV5HVWULFWHG
CONFIDENTIAL )5HY(&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Form
o $GMXVWSXPSVHWWLQJVDVQHHGHG
o $VNVXEMHFWVDQGWKHLUSDUHQWVF DUHJLYHUVLIDSSOLFDEOHDERXW 
DGYHUVHHYHQWVGHYLFHSHUIRUPDQ FHXQH[SODLQHGK\SHUJO\FHPLD
DQGLQVXOLQLQIXVLRQUHODWHG LVVXHVZLWK/\XPMHYLQVXOLQ
o +E$FIRUVXEMHFWVDQGROGHU
o 5HYLHZ&DUH/LQNUHSRUWV
x 9LVLW2IILFH9LUWXDO2IILFH'D\GD\VDIWHU9LVLW 
o $VNVXEMHFWVDQGWKHLUSDUHQWVF DUHJLYHUVLIDSSOLFDEOHDERXW 
DGYHUVHHYHQWVGHYLFHSHUIRUPDQ FHXQH[SODLQHGK\SHUJO\FHPLD
DQGLQVXOLQLQIXVLRQUHODWHG LVVXHVZLWK/\XPMHYLQVXOLQ
o 5HYLHZ&DUH/LQNUHSRUWV
o 5HWXUQVWXG\GHYLFHV
o +E$FIRUDOOVXEMHFWV
o(QGRI6WXG\(26
CIP335 Clinical Investigation Plan 
 Form 
D00409632 Version E Page 23 of 106 
0HGWURQLF%XVLQHVV5HVWULFWHG
CONFIDENTIAL )5HY(&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Form
Synopsis Figure 1. Study Visit Schedule 
 
Run-in Period
Office
Visit 1
Consent & 
ScreeningOffice/Virtual 
Office
Visit 2
Start Study 
Pump& CGMVisit Schedule
Study Period
Phone 
Visit 11
Day 21 
(Â±3 days) 
after Visit 7Phone 
Visit 10
Day 14
 (Â±3 days) 
after Visit 7Phone
Visit 9
Day 7 (Â±2 
days) after 
Visit 7Visit 1 to Visit 6 should be completed within 30 days.Phone 
Visit 5
Day 7 (Â±2 
days) after 
Visit 2Office/Virtual 
Office
Visit 6
Day 14 (Â±3 days) 
after Visit 2Phone 
Visit 3
Day 1 after 
Visit 2Phone 
Visit 4
Day 3 after 
Visit 2
Phone
Visit 8
Day 2 after 
Visit 7Office/Virtual 
Office
Visit 7
Day 7 (-7 days) 
after Visit 6Office/Virtual 
Office
Visit 12
Day 28 (+7 days) 
after Visit 7Office/Virtual 
Office
Visit 13
Day 44 (Â±3 days) 
after Visit 7Office/Virtual 
Office
Visit 14
Day 60 (+7 days) 
after Visit 7Office/Virtual 
Office
Visit 15
Day 90 (+7 days) 
after Visit 7 EOS
 
 
 
CIP335 Clinical Investigation Plan 
 Form 
D00409632 Version E Page 24 of 106 
0HGWURQLF%XVLQHVV5HVWULFWHG
CONFIDENTIAL )5HY(&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Form
Safety and 
Monitoring/Risk 
Analysis  6DIHW\PRQLWRULQJDQGULVND QDO\VLVGHWDLOVDUHGHVFULEHGLQ Section 9.
Device 
Deficiencies  6XEMHFWDQGLQYHVWLJDWLRQDOFHQW HUUHSRUWVRIGHYLFHGHILFLHQFL HV''V
ZLOOEHFROOHFWHGE\VXEMHFWVDQG RULQYHVWLJDWLRQDOFHQWHUVFD OOLQJWKH
+RXU7HFKQLFDO6XSSRUW76IRUGHYLFHWURXEOHVKRRWLQJDQGG HYLFH
FRPSODLQWV)RUDGGLWLRQDOLQIRUPDWLRQVHH Section 13
Statistical 
Analysis for 
Endpoints and 
Hypothesis During Study Period  
 
6DIHW\DQGHIIHF WLYHQHVVHQGSRLQWVZLOO EHHYDOXDWHGLQGHSHQGHQ WO\IRU
DJHVDQGDJHV  
 
Primary Safety Endpoint 
x $JH7KHRYHUDOOPHDQFKDQJHLQ+E$FIURPEDVHOLQH
WRHQGRIPRQWKVWXG\SHULRG7KHPHDQFKDQJHZLOOEH
HVWLPDWHGDQGFRPSDUHGWRD WKUHVKROGRIZLWKD
PDUJLQRI
x $JH7KHRYHUDOOPHDQFKDQJHLQ+E$FIURPEDVHOLQHWR
HQGRIPRQWKVWXG\SHULRG 7KHPHDQFKDQJHZLOOEH
HVWLPDWHGDQGFRPSDUHGWRD WKUHVKROGRIZLWKD
PDUJLQRI
 
Primary Effectiveness Endpoint 
x $JH7KHPHDQRIWLPHLQUDQJH7,5PJG/
ZLOOEHHVWLPDWHGDQGFRPSDUHG WRDWKUHVKROGRIZLWK
DPDUJLQRIDQGDVLJQLILFDQFHOHYHORIRQHVLGHG
x $JH7KHPHDQRIWLPHLQUDQJH7,5PJG/
ZLOOEHHVWLPDWHGDQGFRPSDUHG WRDWKUHVKROGRIZLWK
DPDUJLQRIDQGDVLJQLILFDQFHOHYHORIRQH
VLGHG
 Secondary Effectiveness Endpoints 
x $JH7KHPHDQRIWLPHLQK\SRJO\FHPLD
PJG/ZLOOEHHVWLPDWHGDQG FRPSDUHGWRDWKUHVKROGRI
ZLWKDPDUJLQRIDQG DVLJQLILFDQFHOHYHORI
RQHVLGHG
x $JH7KHPHDQRIWLPHLQUDQJH7,5PJG/
ZLOOEHHVWLPDWHGDQGFRPSDUHG WRDWKUHVKROGRIDQG
DVLJQLILFDQFHOHYHORIRQHVLGHG
x $JH7KHPHDQRIWLPHLQK\SRJO\FHPLD
PJG/ZLOOEHHVWLPDWHGDQG FRPSDUHGWRDWKUHVKROGRI
ZLWKDPDUJLQRIDQGDVLJQLILFDQFHOHYHORI
RQHVLGHG
x $JH7KHPHDQRIWLPHLQUDQJH7,5PJG/
ZLOOEHHVWLPDWHGDQGFRPSDUHG WRDWKUHVKROGRIDQG
DVLJQLILFDQFHOHYHORIRQHVLGHG


Descriptive Endpoints 
CIP335 Clinical Investigation Plan 
 Form 
D00409632 Version E Page 25 of 106 
0HGWURQLF%XVLQHVV5HVWULFWHG
CONFIDENTIAL )5HY(&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Form
x 7LPHVSHQWLQWKH6PDUW*XDUGIH DWXUHYHUVXVWLPHVSHQWLQ
0DQXDO0RGH
x &KDQJHLQPHDQJOXFRVHYDOXHIURPEDVHOLQHWR(26
x 7LPHLQGLIIHUHQWUDQJHVRI6*6*PJG/6*
PJG/PJG/Â”6*Â”PJG/6*!PJG/
PJG/PJG/DQGPJG/
x 1XPEHURI(YHQWV$UHD8QGHU&XUYH$8&DQG7LPHLQWKH
K\SHUJO\FHPLFUDQJH6*!PJG/PJG/
PJG/DQGPJG/
x 1XPEHURI(YHQWV$8&DQG7LPH LQWKHK\SRJO\FHPLFUDQJH
6*DQGPJG/
x &KDQJHLQ%*YDOXHVGXULQJPHDO H[HUFLVHFKDOOHQJH%*SULRU
DQG%*KRXUVDIWHUPHDOH[HUFLVH
x &KDQJHLQRIWLPHLQHXJO\FHPLDPJG/GXULQJ
PHDOH[HUFLVHFKDOOHQJHSULRUDQGKRXUVDIWHU
PHDOH[HUFLVH
x 'LIIHUHQFHLQ$8&GXULQJPHDOFKDOOHQJHSULRUDQGKRXUV
DIWHUPHDOH[HUFLVH
x &KDQJHRI7RWDO'DLO\'RVH7''RILQVXOLQIURPEDVHOLQHWR
(263HULRG
x &KDQJHRIZHLJKWIURPED VHOLQHWR(263HULRG
x 6XEJURXSDQDO\VLVZLOOEHSHUIRUPHGIRU
o 6HWSRLQW
x PJG/
x PJG/
x PJG/
x PJG/7HPS7DUJHW8VDJH 

Safety Data Summarized 
x 6HULRXV$GYHUVH(YHQWV6$(
x 6HULRXV$GYHUVH'HYLFH(IIHFWV6$'(
x 8QDQWLFLSDWHG$GYHUVH'HYLFH(IIHFWV
x ,QFLGHQFHRI6HYHUH+\SRJO\FHPLD
x ,QFLGHQFHRI6HYHUH+\SHUJO\FHPLD
x ,QFLGHQFHRI'.$
 Device Deficiencies 
'HVFULSWLYHVXPPDU\ZLOOEHXVHGWRFKDUDFWHUL]H''V
x $OOUHSRUWVRIGHYLFHLVVXHV
 
Subject Feedback 
'HVFULSWLYHVXPPDU\ZLOOEHXVHG WRFKDUDFWHUL]HVWXG\TXHVWLRQ QDLUH
UHVXOWV5HIHUWR&,3/\XPM HY4XHVWLRQQDLUH*XLGHIRU
DGPLQLVWUDWLRQGHWDLOV
Simulation Data 
&RPSXWHUVLPXODWHGGDWDPD\EHFRPSDUHGWRVWXG\GDWD

Final Report  7KHVWXG\UHVXOWVZLOOEHVXPPDUL]H GDQGSUHVHQWHGLQWKHILQDO UHSRUW
CIP335 Clinical Investigation Plan 
 Form 
D00409632 Version E Page 26 of 106 
0HGWURQLF%XVLQHVV5HVWULFWHG
CONFIDENTIAL )5HY(&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Form
 
CIP335 Clinical Investigation Plan 
 Form 
D00409632 Version E Page 27 of 106 
0HGWURQLF%XVLQHVV5HVWULFWHG
CONFIDENTIAL )5HY(&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Form
3. Introduction 
3.1 Background 
,QSDWLHQWVZLWKLQVXOLQGHSHQGH QWGLDEHWHVPHOOLW XVJO\FHPLF FRQWUROLVLQIOXHQFHGE\QXPHURXVIDFWRUV
VXFKDVLQVXOLQGRVDJHLQVXOLQDEVRUSWLRQWLPLQJSK\VLRORJLF DOOLIHVW\OHIDFWRUVV XFKDVH[HUFLVHIRRG
LQWDNHKRUPRQHVDQGLOOQHVV7KH VHIDFWRUVPD\FRQWULEXWHWRV LJQLILFDQWYDULDELOLW\LQLQVXOLQ
UHTXLUHPHQWVZKLFKPDNHVVHOIPDQDJHPHQWRIW\SHGLDEHWHVFK DOOHQJLQJ
3DWLHQWVZKRDUHXVLQJFRQWLQXRXVJOXFRVHPRQLWRULQJ&*0LQF OXGLQJVHQVRUDXJPHQWHGSXPSWKHUDS\
H[SHULHQFHLPSURYHPHQWVLQJO\FH PLFFRQWURO$GYDQFHGVHQVRUDX JPHQWHGLQVXOLQSXPSVDUHQRZEHLQJ
XVHGLQFOLQLFDOSUDFWLFHLQFOXGLQJFORVHGORRSV\VWHPVWKDWDX WRPDWLFDOO\DGMXVWWKHDPRXQWRILQVXOLQ
GHOLYHUHGWRPDLQWDLQJOXFRVHOH YHOVQHDUWKHWDUJHWYDOXHVHW E\WKHXVHU

7KH0LQL0HG*V\VWHPLVDFORVHGORRSLQVXOLQV\VWHP,QDGG LWLRQWRDXWRPDWLFDOO\DGMXVWLQJWKH
DPRXQWRILQVXOLQGHOLYHUHGEDVHG RQVHQVRUJOXFRVH6*UHDGLQ JVZKLOHRSHUDWLQJ ZLWK6PDUW*XDUG
IHDWXUHDFWLYDWHGWKH0LQL0HG *LQVXOLQSXPSFDQDOVRDXWRP DWLFDOO\GHOLYHUFRU UHFWLRQEROXVHVZKHQ
WKHV\VWHPKDVEHHQGH OLYHULQJDWWKHPD[LPXPDOORZDEOHEDVDOU DWHDQG6*UHPDLQVHOHYDWHG7KLV
SXPSLVFXUUHQWO\LQFRPPHUFLDOGLVWULEXWLRQLQ(XURSHDQGLVX QGHUUHYLHZE\WKH8QLWHG6WDWHV)RRGDQG
'UXJ$GPLQLVWUDWLRQ)'$3UHYL RXVFOLQLFDOLQYHVWLJDWLRQVLQY ROYHGWKH*9HUVLRQSXPSFRQWDLQV
WKH*$+&/DOJRULWKPXVHGLQFRPELQDWLRQZLWKWKH*XDUGLDQ 6HQVRUJOXFR VHVHQVRUDQG
*XDUGLDQ/LQNWUDQVPLWWHU+XPDORJDQG1RYRORJLQVXOLQ7KLV LQYHVWLJDWLRQLVLQWHQGHGWRFRQILUPVDIHW\
RIWKH*LQVXOLQSXPSXVHGLQ FRPELQDWLRQZLWKLQVXOLQOLVSU RDDEF/\XPMHY
3.2 Purpose 
7KHSXUSRVHRIWKLVVWXG\LVWR HYDOXDWHWKHVDIHW\DQGHIIHFWL YHQHVVRI/\XPMHYLQVX OLQOLVSURDDEFXVHLQ
WKH0LQL0HG*6\VWHPLQW\SH GLDEHWHVDGXOWDQGSHGLDWULF VXEMHFWVLQDKRPHVHWWLQJ
4. Objectives and Endpoints
4.1 Objectives 
7KHREMHFWLYHRIWKLVVWXG\LVW RHYDOXDWHWKHVDIHW\DQGHIIHF WLYHQHVVRIXWLOL]LQJ/\ XPMHYLQVXOLQOLVSUR
DDEFLQWKH0LQL0HG*6\VWHP WRVXSSRUWSURGXFWDQGV\VWHPO DEHOLQJ
4.2 Endpoints 
6DIHW\DQGHIIHF WLYHQHVVHQGSRLQWVZLOO EHHYDOXDWHGLQGHSHQGHQ WO\IRUDJHVDQGDJHV  
4.2.1  Primary Safety Endpoint 
x $JH7KHRYHUDOOPHDQFKDQJHLQ+E$FIURPEDVHOLQHWRHQ GRIPRQWKVWXG\SHULRG
7KHPHDQFKDQJHZLOOEHHVWLPDWHG DQGFRPSDUHGWRDWKUHVKROGR IZLWKDPDUJLQRI

x $JH7KHRYHUDOOPHDQFKDQJ HLQ+E$FIURPEDVHOLQHWRHQG RIPRQWKVWXG\SHULRG7KH
PHDQFKDQJHZLOOEHHVWLPDWHGDQG FRPSDUHGWRDWKUHVKROGRI ZLWKDPDUJLQRI
4.2.2  Primary Effectiveness Endpoint 
x $JH7KHPHDQRIWLPHLQUDQJH7,5PJG/ZLOO EHHVWLPDWHGDQGFRPSDUHG
WRDWKUHVKROGRIZLWKDPD UJLQRIDQGDVLJQLILFDQ FHOHYHORIRQHVLGHG
CIP335 Clinical Investigation Plan 
 Form 
D00409632 Version E Page 28 of 106 
0HGWURQLF%XVLQHVV5HVWULFWHG
CONFIDENTIAL )5HY(&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Form
x $JH7KHPHDQRIWLPHLQUDQJH7,5PJG/ZLOOE HHVWLPDWHGDQGFRPSDUHGWR
DWKUHVKROGRIZLWKDPDUJLQRIDQGDVLJQLILFDQFH OHYHORIRQHVLGHG
4.2.3  Secondary Effectiveness Endpoint 
x $JH7KHPHDQRIWLPHLQK\SRJO\FHPLDPJG/ZLOO EHHVWLPDWHGDQGFRPSDUHG
WRDWKUHVKROGRIZLWKDPDUJLQRIDQGDVLJQLILFDQFH OHYHORIRQHVLGHG
x $JH7KHPHDQRIWLPHLQUDQJH7,5PJG/ZLOO EHHVWLPDWHGDQG FRPSDUHGWR
DWKUHVKROGRIDQGDVLJQLILFDQFHOHYHORIRQHVLG HG
x $JH7KHPHDQRIWLPHLQ K\SRJO\FHPLDPJG/ZLOO EHHVWLPDWHGDQG FRPSDUHGWR
DWKUHVKROGRIZLWKDPDUJ LQRIDQGDVLJQLILFDQFHOHY HORIRQHVLGHG
x $JH7KHPHDQRIWLPHLQUDQJH7,5PJG/ZLOOE HHVWLPDWHGDQGFRPSDUHGWR
DWKUHVKROGRIDQGDVLJQLILFDQFHOHYHORIRQHVLG HG
4.2.4  Descriptive Endpoints 
x 7LPHVSHQWLQWKH6PDUW*XDUGIHD WXUHYHUVXVWLPHVSHQWLQ0DQXD O0RGH
x &KDQJHLQPHDQJOX FRVHYDOXHIURP EDVHOLQHWR(26
x 7LPHLQGLIIHUHQWUDQJHVRI 6*6*PJG/6*PJG /PJG/Â”6*Â”
PJG/6*!PJG/PJG/PJG/DQGPJG/
x 1XPEHURI(YHQWV$UHD8QGHU&XU YH$8&DQG7LP HLQWKHK\SHUJ O\FHPLFUDQJH6*!
PJG/PJG/PJG/DQGPJG/
x 1XPEHURI(YHQWV$8&DQG7LPHL QWKHK\SRJO\FHPLFUDQJH6* DQGPJG/
x &KDQJHLQ%*YDOXHVGXULQJPHDO H[HUFLVHFKDOOHQJH%*SULRUDQ G%*KRXUVDIWHU
PHDOH[HUFLVH
x &KDQJHLQRIWLPHLQHXJO\FHPLDPJG/GXULQJPHDOH[HU FLVHFKDOOHQJHSULRUDQG
KRXUVDIWHUPHDOH[HUFLVH
x 'LIIHUHQFHLQ$8&GXULQJPHDOFKDOOHQJHSULRUDQGKRXUVDIWHU PHDOH[HUFLVH
x &KDQJHRI7RWDO'DLO\'RVH7''RILQVXOLQIURPEDVHOLQHWR(2 63HULRG
x &KDQJHRIZHLJKWIURPED VHOLQHWR(263HULRG
x 6XEJURXSDQDO\VLVZLOOEHSHUIRUPHGIRU
o 6HWSRLQW
Âƒ PJG/
Âƒ PJG/
Âƒ PJG/
Âƒ PJG/7HPS7DUJHW8VDJH 
4.2.5  Safety Data Summarized 
Â‡ 6HULRXV$GYHUVH(YHQWV6$(
Â‡ 6HULRXV$GYHUVH'HYLFH(IIHFWV6$'(
Â‡ 8QDQWLFLSDWHG$GYHUVH'HYLFH(IIHFWV
Â‡ ,QFLGHQFHRI6HYHUH+\SRJO\FHPLD
Â‡ ,QFLGHQFHRI6HYHUH+\SHUJO\FHPLD
Â‡ ,QFLGHQFHRI'.$ 
4.2.6  Device Deficiencies  
CIP335 Clinical Investigation Plan 
 Form 
D00409632 Version E Page 29 of 106 
0HGWURQLF%XVLQHVV5HVWULFWHG
CONFIDENTIAL )5HY(&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Form
'HVFULSWLYHVXPPDU\ZLOOEHXVHGWRFKDUDFWHUL]H''V
x $OOUHSRUWVRIGHYLFHLVVXHV
4.2.7  Subject Feedback 
'HVFULSWLYHVXPPDU\ZLOOEHXVHG WRFKDUDFWHUL]HVWXG\TXHVWLRQ QDLUHUHVXOWV5HIHUWR&,3/\XPMHY
4XHVWLRQQDLUH*XLGHIRUDGPLQLVWUDWLRQGHWDLOV 
4.2.8  Simulation Data 
&RPSXWHUVLPXODWHGGDWDPD\ EHFRPSDUHGWRVWXG\GDWD
5. Study Design 
7KLVVWXG\LVDPXOWLFHQWHUVLQJO HDUPVWXG\LQLQVXOLQUHTXL ULQJDGXOWDQGSHGLDWULF VXEMHFWVZLWKW\SH
GLDEHWHVRQWKH0LQL0HG *V\VWHPXVLQJ/\XPMHY LQVXOLQOLVSURDDEFDQG0HGWURQLF([WHQGHGLQIXVLRQ
VHWDQGUHVHUYRLU7KHUXQLQSH ULRGDQGVWXG\SHULRGZLOOEHD SSUR[LPDWHO\GD\VORQJ

7KHSHULRGIURP9LVLWFRQVHQ WDQGVFUHHQLQJWKURXJK9LVLW VKRXOGEHFRPSOHWHGZLWKLQGD\V


Run-in Period (Visits 2-6):  
7KHUXQLQSHULRGEHJLQVDW9 LVLWDQGHQGVRQFH9LVLWRFFXU V
 
7KHLQWHQWRIWKHUXQLQSHULR GZLOOEHWRDOORZVXEMHFWVWREH FRPHIDPLOLDUZLWKQHZ VWXG\GHYLFHVZKLOH
XVLQJWKHLURZQLQVXOLQHLWKH U+XPDORJLQVXOLQOLVSURLQMHFWL RQRU1RYR/RJLQVXOLQDVSDUWVROXWLRQIRU
LQMHFWLRQRU$GPHORJLQVXOLQ OLVSURLQMHFWLRQ'XULQJWKHUX QLQSHULRGVWXG\VXEMHFWVZLOOEHXVLQJWKH
VWXG\SXPSZLWKRQO\WKH6HQVRU$XJPHQWHG3XPS6$3IXQFWLRQD FWLYDWHGLH6PDUW*XDUGIHDWXUHLV
WXUQHG2))DQG0HGWURQLF([WHQGHGLQIXVLRQVHWDQGUHVHUYRLU 

'XULQJWKHUXQLQSHULRGWKHXVHRI6PDUW*XDUGZLWKWKHH[FHS WLRQRI$XWR&RUUHFWLRQZLOOEHSHUPLWWHG
IRUVWXG\VXEMHFWVZKRZHUHXVLQJWKH$XWR0RGHIHDWXUHLQD0H GWURQLFSXPSSULRUWRVFUHHQLQJ,QWKH
0LQL0HG*SXPSWKHWHUPÂ³$XWR0RGHÂ´KDVEHHQUHSODFHGZLWK Â³6PDUW*XDUGÂ´)RUWKRVHVXEMHFWVD
PJG/$XWR%DVDOWDUJHWVK RXOGEHVHW,WLVUHFRPPHQGHGWK DW$FWLYH,QVXOLQ7LPHLVVHWWRKRXUV
$OORWKHUVDUHWRXVHWKHV\VWHP LQ0DQXDO0RGHGXULQJWKHUXQ LQSHULRG$OORWKHUVDUHWRXVHWKH
V\VWHPLQ0DQXDO0RGHGXULQJWKHUXQLQSHULRG

Note:7KH$XWR%DVDOWDUJHWVHWWLQJDQG$FWLYH,QVXOLQ7LPHVKRXOGE HVHWDVUHFRPPHQGHGDERYH
XQOHVVWKHUHLVDGRFXPHQ WHGVDIHW\UHDVRQWK DWZRXOGQRWSHUPL WWKHVHVHWWLQJVWREHXVHG


Therapy at Screening Pump Setting During Run-in Period 
&6,, 0DQXDO0RGH
6$3QRFORVHGORR S0 D Q X D O  0 R G H 
6$3ZLWKFORVHGORRSLQQRQ0HGWURQLF
SXPS0DQXDO0RGH
CIP335 Clinical Investigation Plan 
 Form 
D00409632 Version E Page 30 of 106 
0HGWURQLF%XVLQHVV5HVWULFWHG
CONFIDENTIAL )5HY(&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Form
6$3ZLWKFORVHGORRSLQ0HGWURQLFSXPS
DV$XWR0RGH6PDUW*XDUGZLWK$XWR&RUUHFWLRQ2))
$OOVXEMHFWVFRPSDQLRQVDQGWK HLUSDUHQWVFDUHJLYHUVLIDSSO LFDEOHZLOOEHWUDLQHGRQGLDEHWHV
PDQDJHPHQWSULQFLSOHVVXFKDVWKHWUHDWPHQWRIK\SHUJO\FHPLDD QGK\SRJO\FHPLD,QDGGLWLRQWKHUHZLOO
EHWUDLQLQJE\WKHLQYH VWLJDWLRQDOFHQWHUVWDIIUHJDUGLQJWKHQ HHGWRKDYHDFFHVVWRDQGKRZWRXVH
JOXFRVHDQGJOXFDJRQLQFDVHRIK\SRJO\FHPLD

3DUHQWVFDUHJLYHUVLIDSSOLFDEOH DQGFRPSDQLRQVZLOOEHLQVWU XFWHGWKDWWKH\VKRXOG EHZLWKWKHVXEMHFW
LQWKHVDPHUHVLGHQFHRUEXLOGLQJRYHUQLJKW

,IWKH0LQL0HG&OLQLFDODSSDQGWKH&DUH/LQN&OLQLFDODSSDUHE HLQJXVHGSDUHQWVFDU HJLYHUVLIDSSOLFDEOH
ZLOOEHLQVWUXFWHGWKDWVXEMHFW VVKRXOGEHFRQQHFWHGWR&DUH/LQ NYLDWKHDSSURSULDWH6PDUWSKRQHDSSIRU
GDWDXSORDGLQJD QGSXVKQRWLILFDWLRQVIRUORZRUKLJKEORRGVXJ DUZKHQWKH\DUHDSDUWHJDWVFKRRO
RWKHUDFWLYLWLHV,QVWUXFWLRQVRQWKHDSSURSULDWHRSHUDWLRQRI WKHDSSVZLOOEHSURYLGHG
)RUVWXG\SXUSRVHVVXEMHFWVSD UHQWVFDUHJLYHU VLIDSSOLFDEOH DQGFRPSDQLRQVZLOOEHWUDLQHGDQGRU
LQVWUXFWHGWRSHUIRUPVHOIPRQLW RULQJRIEORRGJOXFRVH60%*L IVXEMHFWVDUHH[SHU LHQFLQJDVHYHUH
K\SRJO\FHPLFHYHQWVHYHUHK\SHUJO\FHPLFHYHQWRUGLDEHWLFNHWR DFLGRVLV'.$6XEMHFWVDQGWKHLU
SDUHQWVFDUHJLYHUVLIDSSOLF DEOHDVZHOODVFRPSDQLRQVZLOOD OVREHLQVWUXFWHGWRFKHFNVXEMHFWÂ¶VEORRG
NHWRQHVXVLQJDNHWRQHPHWHULIWKH$FFX&KHN*XLGH/LQNVWXG\ PHWHUUHDGLQJLVJUHDWHUWKDQ
PJG/

$VDSUHFDXWLRQVXEMHF WVDQGWKHLUSDUHQWVFDUHJLYHUVLIDSSO LFDEOHZLOOEHWROGWKDWWKH\VKRXOGNHHS
WKHLURZQLQVXOLQSXPSVXSSOLH VLQDVDIHSODFHD QGWRKDYHEDF NXSVXSSOLHVRQKDQGVXFKDVLQVXOLQDQG
V\ULQJHRULQVXOLQSHQLQWKHHYHQWWKH\DUHDVNHGWRUHYHUW EDFNWRWKHLURZQWKHUDS\GXULQJWKHVWXG\
RUH[SHULHQFHVWXG\SX PSLVVXHVLHLQIXVLRQVHWRFFOXVLRQZ LWKKLJKJOXFRVH
6XEMHFWVDQGWKHLUSDUHQWVFDU HJLYHUVLIDSSOLFDEOHZLOOEHL QVWUXFWHGWRLQVHUWWKHJ OXFRVHVHQVRUVRQO\LQ
WKHORFDWLRQVWKDWDUHVSHFLILHG LQWKH8VHU*XLGH5HPLQGHUVZ LOOEHJLYHQWRVXEMHFWVDQGWKHLU
SDUHQWVFDUHJLYHUVLIDSSOLFDEOH DWHDFKRIILFHYLVLW,QIRU PDWLRQDERXWVHQVRULQVHUWLRQVZLOOEHFROOHFWHG
RQDQHOHFWURQLFFDVHUHSRUWIRU PH&5)LQWKHVWXG\GDWDEDVH LHLQVHUWLRQORFDWLRQ
6XEMHFWVDQGWKHLUSDUHQWVFDU HJLYHUVLIDSSOLFDEOHZLOOEHW UDLQHGRQDOOSDUWVRIWKHGHYLFHV\VWHP
&RPSDQLRQVVKRXOGEHWUDLQHGRQP DWWHUVUHJDUGLQJUHVSRQVHVWR KLJKRUORZJOXFRVHHYHQWV7KLVZLOO
LQYROYHWUDLQLQJFRQGXFWHGE\WK HLQYHVWLJDWLRQD OFHQWHUVWDII $WUDLQLQJFKHFNOLVWIRUHDFKVXEMHFWVKRXOG
EHFRPSOHWHGE\LQYHVWLJDWLRQDOFHQWHUEDVHGWUDLQHUV3DUHQWV FDUHJLYHUVLIDSSOLFDEOHDQGFRPSDQLRQV
VKRXOGEHDYDLODEOHIRUUHOHYDQWSDUWVRUDOORIWKLVWUDLQLQJ HLWKHULQSHUVRQRUYLUWXDOO\

$IWHUFRPSOHWLRQRIWUDLQLQJRQ WKHVWXG\GHYLFHVVXEMHFWVDQG WKHLUSDUHQWVFDUHJLYHUVLIDSSOLFDEOH
PD\DWWHQGDGGLWLRQDOYLVLWVLQW KHGD\VLPPHGLDWHO\IROORZLQJ WKHVWDUWRIV\VWHPXVHDVQHHGHG7KH\
PD\DOVRWDNHDGYDQWDJHRIKDY LQJDFFHVVWRWKHGLJLWDOOHDUQLQ JFRQWHQWSURYLGHGLWLVDYDLODEOHDWVWXG\
VWDUW  
 
7KHSHULRGIURP9LVLWFRQVHQ WDQGVFUHHQLQJWKURXJK9LVLW VKRXOGEHFRPSOHWHGZLWKLQGD\V
 
CIP335 Clinical Investigation Plan 
 Form 
D00409632 Version E Page 31 of 106 
0HGWURQLF%XVLQHVV5HVWULFWHG
CONFIDENTIAL )5HY(&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Form
Study Period (Visits 7-15): 
7KHVWXG\SHULRGEHJLQVDW9LVLW DQGHQGVDWWKHFRQFOXVLRQR I9LVLW

$OOVXEMHFWVZLOOXVH/\XPMHYLQVX OLQIRUWKHUHPDLQGHURIWKH VWXG\7KH\ZLOOFRQWLQXHXVLQJWKH0LQL0HG
*V\VWHPH[WHQGHGLQIXVLRQVHWDQGH[WHQGHGUHVHUYRLU$OO 6PDUW*XDUGIHDWXUHVZLOOEHDFWLYDWHG
DQGVKRXOGEHXVHGIRUWKHGXUDWLRQRIWKHVWXG\SHULRG

6XEMHFWVVKRXOGXVHWKHV\VWHPZLWK6PDUW*XDUGWXUQHGRQZKLOH DOVRXVLQJ/\XPMHYLQVXOLQDWDOOWLPHV
:KHQSURPSWHGE\WKHSXPSVXEMH FWVVKRXOGWDNHDSSURSULDWHPHD VXUHVDQGIROORZGLUHFWLRQVRQWKH
SXPSWRUHPDLQLQRUUHWXUQWR6 PDUW*XDUG'XULQJWLPHVZKHQVX EMHFWVDUHQRWDEOHWRXVH6PDUW*XDUG
WKH\VKRXOGXVHWKHV\VWHPLQ0D QXDO0RGHHJZLWK6XVSHQGE HIRUHORZRU6XVSHQGRQORZDFWLYDWHG

Therapy at Screening Pump Setting During Study Period 
&6,, 6PDUW*XDUGZLWK$XWR&RUUHFWLRQ21
6$3QRFORVHGORRS 6PDUW*XDUGZLWK$XWR&RUUHFWLRQ21
6$3ZLWKFORVHGORRSLQQRQ0HGWURQLF
SXPS6PDUW*XDUGZLWK$XWR&RUUHFWLRQ21
6$3ZLWKFORVHGORRSLQ0HGWURQLF
SXPSDV$XWR0RGH6PDUW*XDUGZLWK$XWR&RUUHFWLRQ21
'XULQJWKHILUVWZHHNVEHWZ HHQ9LVLWVDQGRIWKHVWXG\ SHULRGDPJG/ $XWR%DVDO7DUJHW
VKRXOGEHVHW,WLVUHFRPPHQGHGW KDW$FWLYH,QVXOLQ7LPHLVLQ LWLDOO\VHWWRKRXUVDQGWKHQWLWUDWHG
WRZDUGVKRXUVDWLQYHVWLJDWRUÂ¶VGLVFUHWLRQ
'XULQJWKHQH[WZHHNVEHWZH HQ9LVLWVDQGRIWKHVWXG\ SHULRGWKH$XWR%DVDO7DUJHWVHWWLQJ
VKRXOGEHVHWWRPJG/$FW LYH,QVXOLQWLPHLVUHFRPPHQGHG WREHVHWWRKRXUVRUDWLQYHVWLJDWRU
GLVFUHWLRQ
'XULQJWKHUHPDLQLQJZHHNVRIW KHVWXG\DQ\WLPHDIWHU9LVLW RIWKHVWXG\SHULRGWKHDXWREDVDO
WDUJHWDVZHOODV$FWLYHLQVXOLQW LPHVKRXOGEHVHWWRZKDWLV EHVWIRUWKHLQGLYLGXDOVX EMHFWDWLQYHVWLJDWRU
GLVFUHWLRQ

Note: 7KH$XWR%DVDOWDUJHWVHWWLQJDQG$FWLYH,QVXOLQ7LPHVKRXOGEH VHWDVUHFRPPHQGHGDERYHXQOHVV
WKHUHLVDGRFXPHQWHGVDIHW\UHDVR QWKDWZRXOGQRWSHUPLWWKHVH VHWWLQJVWREHXVHG

$IWHUFRPSOHWLRQRIWUDLQLQJRQ6PDUW*XDUGIXQFWLRQVVXEMHFWV DQGWKHLUSDUHQWVFDUHJL YHUVLIDSSOLFDEOH
PD\DWWHQGDGGLWLRQDOYLVLWVLQW KHGD\VLPPHGLDWHO\IROORZLQJ WKHVWDUWRI6PDUW*X DUGXVHDVQHHGHG
7KH\PD\DOVRWDNHDGYDQWDJHRIKDYLQJDFFHVVWRWKHGLJLWDOOH DUQLQJFRQWHQWSURYLGHGLWLVDYDLODEOHDW
VWXG\VWDUW
Staged Enrollment:

7KHHQUROOPHQWRISHGLDWULFVXEM HFWV\HDUVRIDJHLQWRWKH VWXG\PD\QRWSURFHHGXQWLO1 
VXEMHFWV\HDUVRIDJHRUROGH UKDYHFRPSOHWHGGD\VRIWKH VWXG\SHULRGDQGWK H'DWD0RQLWRULQJ
&RPPLWWHH'0&KDVGHWHUPLQHG LWLVVDIHIRUVXE MHFWV\HD UVRIDJHWREHHQUROOHGLQWKHVWXG\

SMBG recommendations for the MiniMed 780G system: 
 
CIP335 Clinical Investigation Plan 
 Form 
D00409632 Version E Page 32 of 106 
0HGWURQLF%XVLQHVV5HVWULFWHG
CONFIDENTIAL )5HY(&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Form
&DOLEUDWLRQLVQRWUHTXLUHGZLWKW KH0LQL0HGÂŒ*V\VWHPXVLQJ *XDUGLDQ&*0+RZHYHUDFDOLEUDWLRQ
LVRSWLRQDODQGLWZLOODXWRPDWLFD OO\RFFXUDQ\WLPHDEORRGJO XFRVH%*LVHQWHUHG2FFDVLRQDOO\VXEMHFWV
PD\UHFHLYHDQRWLILFDWLRQLIWKHSXPSQHHGVD%*WRHQWHURUV WD\LQWKH6PDUW*XDUGÂŒ6XEMHFWVZLOOEH
LQVWUXFWHGWRSHUIRUP60%*LIWKHLUV\PSWRPVGRQRWPDWFKWKHV HQVRUJOXFRVH6*YDOXHLHWKH\
GHYHORSV\PSWRPVRIK\SRJO\FHPLDRUK\SHUJO\FHPLDEXWWKH6*Y DOXHGRHVQRWFRUUHODWHZLWKWKHLU
V\PSWRPV

Meal and Exercise Challenges: 
 
6XEMHFWVZLOOEHDVNHGWRSDUWLFL SDWHLQPHDODQGH[HUFLVHFKDO OHQJHVGXULQJWKHUXQLQDQGVWXG\SHULRG
x $OOFKDOOHQJHVDUHDWOHDVWKRXUVLQGXUDWLRQEHJLQQLQJDWW KHWLPHZKHQWKHFKDOOHQJHPHDOVRU
H[HUFLVHDUHVWDUWHG
x 7KHUHVKRXOGEHQRPRUHWKDQRQH PHDOFKDOOHQJHRQDVLQJOHGD\ 
x 0HDODQGH[HUFLVHFKDOOHQJHVVKR XOGQRWEHVFKHGXOHGRQWKHVDP HGD\GXULQJWKHVSHFLILHGWLPH
SHULRGV
)RUH[DPSOH$VWXG\SHULRGUHJXODUVL]HGRUODUJHVL]HGPHDOF KDOOHQJHVKRXOGQRWWDNHSODFHRQWKH
VDPHGD\DVDQH[HUFLVHFKDOOHQJH6XEMHFWVZLOOEHDVNHGWRFKHFN% *DWWKHVWDUWRIWKHPHDOH[H UFLVHDVZHOODVKRXU VDQGKRXUVDIWHU
WKHVWDUWRIWKHPHDOH[HUFLVHD QGSURYLGHLQVXOLQFRUUHFWLRQD VQHFHVVDU\
,WLVLPSRUWDQWIRUVXEMHFWVWRDYRLGDGGLWLRQDOPHDOVQDFNRU H[HUFLVHXSWRKRXUVDIWHUWKHVWDUWRI
HDFKFKDOOHQJH,IDGGLWLRQDOPHD OVQDFNLVFRQVXPHGRUH[HUFLV HLVGRQHZLWKLQKRXUVDIWHUWKHVWDUWRI
WKHFKDOOHQJHWKHVXEMHFWZLOOD FNQRZOHGJHWKLVRQWKHFKDOOHQ JHORJ&RQWHQWDQGWLPLQJRIWKHPHDODQG
H[HUFLVHDORQJZLWKDQVZHUVWR FKDOOHQJHTXHVWLRQVZLOOEHUH FRUGHGRQDORJSURYLGHGE\WKHVWXG\
WHDP
Meal Challenges for all Subjects (Run-in and Study Period):  
7KHIROORZLQJPHDOFKDOOHQJHVDUHUHTXLUHGGXULQJWKHUXQLQDQ GVWXG\SHULRGV
x 7ZRPHDOFKDOOHQJHVGXULQJWKH UXQLQSHULRGZL WKVXEMHFWVXVLQ JWKHV\VWHPLQ Manual Mode 
6PDUW*XDUGPXVWEHWXUQHGRIID WOHDVWKRXUVSULRUWRWKHPH DOFKDOOHQJHIRUVXEMHFWVXVLQJLW
GXULQJWKHUXQLQSHULRG Â±EHWZHHQ9LVLWVDQG
o 2QH5HJXODUVL]HGPHDOZLWK
PLVVHGPHDOEROXVDWOXQFK
o 2QH/DUJHVL]HGPHDODWEU HDNIDVWOXQFKRUGLQQHU
x 7ZRPHDOFKDOOHQJHVGXULQJWKHV WXG\SHULRGZLWKVXEMHFWVXVLQJ WKHV\VWHPLQ6PDUW*XDUG$XWR
%DVDOWDUJHWVHWDWPJG/Â± EHWZHHQ9LVLWVDQGRIVWXG \SHULRG
o 2QH5HJXODUVL]HGPHDOZLWK PLVVHGPHDOEROXVDWOXQFK
o 2QH/DUJHVL]HGPHDODWEU HDNIDVWOXQFKRUGLQQHU
x 7ZRPHDOFKDOOHQJHVGXULQJWKHV WXG\SHULRGZLWKVXEMHFWVXVLQJ WKHV\VWHPLQ6PDUW*XDUG$XWR
%DVDOWDUJHWVHWDWPJG/Â± EHWZHHQ9LVLWVDQGRIVWX G\SHULRG
o 2QH5HJXODUVL]HGPHDOZLWK PLVVHGPHDOEROXVDWOXQFK
o 2QH/DUJHVL]HGPHDODWEU HDNIDVWOXQFKRUGLQQHU
CIP335 Clinical Investigation Plan 
 Form 
D00409632 Version E Page 33 of 106 
0HGWURQLF%XVLQHVV5HVWULFWHG
CONFIDENTIAL )5HY(&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Form
x 2QHPHDOFKDOOHQJHGXULQJWKHVWXG\SHULRGZLWKVXEMHFWVXVLQJ WKHV\VWHPLQ6PDUW*XDUG$XWR
%DVDOWDUJHWVHWDWLQYHVWLJDWRUÂ¶VGLVFUHWLRQÂ±DWDQ\WLPHDIW HU9LVLWRIVWXG\SHULRG
o 2QH/DUJHVL]HGPHDODWEU HDNIDVWOXQFKRUGLQQHU
0HDOFKDOOHQJHVVKRXO GRQO\VWDUWLIWKHIROORZLQJFRQGLWLRQVD UHPHW
o 60%*DWVWDUWRIPHDOLVPJG/
o 6HQVRUJOXFRVHLVDYDLODEOH

 Timing Settings/Conditions Meal Size Meal Type Notes
Run-in 
Period 
between 
visits 5 and 7 0DQXDO0RGHRQO\
Missed meal bolus 5HJXODUVL]HG
PHDO/XQFK0HDOFRQWHQWPHDOVL]HDQG
WLPHRIPHDOFRQVXPSWLRQ
VKRXOGEHHVWDEOLVKHGVRWKDW
UHJXODUVL]HGPHDOFKDOOHQJHV
GXULQJWKHVWXG\SHULRG  FDQEH
PDWFKHG
Run-in 
Period 
between 
visits 5 and 7 0DQXDO0RGHRQO\/DUJHVL]HG
PHDO%UHDNIDVW
/XQFKRU
'LQQHU0HDOFRQWHQWPHDOVL]HDQG
WLPHRIPHDOFRQVXPSWLRQ
VKRXOGEHHVWDEOLVKHGVRWKDW
ODUJHVL]HGPHDOFKDOOHQJHV
GXULQJWKHVWXG\SHULRG  FDQEH
PDWFKHG
Study Period, 
between 
Visits 9 and 
11 6PDUW*XDUG
PJG/VHWSRLQW
Missed Meal bolus 5HJXODUVL]HG
PHDO/XQFK0HDOFRQWHQWPHDOVL]HDQG
WLPHRIPHDOFRQVXPSWLRQ
VKRXOGPDWFKUHJXODUPHDO
WDNHQGXULQJUXQLQDQGWKH
UHJXODUPHDOWDNHQDWWKH
PJG/VHWSRLQW
Study Period,  
between 
Visits 9 and 
11 6PDUW*XDUG
PJG/VHWSRLQW  /DUJHVL]HG
PHDO%UHDNIDVW
/XQFKRU
'LQQHU0HDOFRQWHQWPHDOVL]HDQG
WLPHRIPHDOFRQVXPSWLRQ
VKRXOGPDWFKPHDODW6HWSRLQW
RIPJG/DQGUXQLQSHULRG
PHDO
Study Period,  
between 
Visits 12 and 
13 6PDUW*XDUG
PJG/VHWSRLQW
Missed meal bolus 5HJXODUVL]HG
PHDO/XQFK0HDOFRQWHQWPHDOVL]HDQG
WLPHRIPHDOFRQVXPSWLRQ
VKRXOGPDWFKUHJXODUPHDO
WDNHQGXULQJUXQLQDQGWKH
UHJXODUPHDOWDNHQDWWKH
PJG/
Study Period,  
between 
Visits 12 and 
13 6PDUW*XDUG
PJG/VHWSRLQW/DUJHVL]HG
PHDO%UHDNIDVW
/XQFKRU
'LQQHU0HDOFRQWHQWPHDOVL]HDQG
WLPHRIPHDOFRQVXPSWLRQ
VKRXOGPDWFKPHDODW6HWSRLQW
RIPJG/DQGUXQLQSHULRG
ODUJHVL]HGPHDO
Study Period 
Any time 
after Visit 13 6PDUW*XDUG
$XWR%DVDOWDUJHWDW
LQYHVWLJDWRUÂ¶VGLVFUHWLRQ/DUJHVL]HG
PHDO%UHDNIDVW
/XQFKRU
'LQQHU0HDOFRQWHQWPHDOVL]HDQG
WLPHRIPHDOFRQVXPSWLRQ
VKRXOGPDWFKODUJHPHDODW
6HWSRLQWRIPJG/
PJG/DQGUXQLQSHULRG
ODUJHVL]HGPHDOV
CIP335 Clinical Investigation Plan 
 Form 
D00409632 Version E Page 34 of 106 
0HGWURQLF%XVLQHVV5HVWULFWHG
CONFIDENTIAL )5HY(&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Form
Regular Sized Meal Challenge with Missed Meal Bolus:  
%HWZHHQYLVLWVDQGIRUWKHUXQLQSHULRGZKLOHVXEMHFWVDU HLQ0DQXDO0RGHZLW K&*0WKH\ZLOOEH
DVNHGWRFRQVXPHDPHD OZLWKRXWDGPLQLVWUDWLRQRID0HDO%ROXV DWOXQFK7KHVL]HRIWKHPHDOVKRXOGEH
HTXLYDOHQWWRZKDWVXEMHFWVZRXO GQRUPDOO\HDWDWWKLVPHDOWLPH 
'XULQJWKHVWXG\SHUL RGRQFHDWHDFK$XWR%DVDOVHWSRLQWLH PJG/DQGPJG/VXEMHFWVZLOO
EHDVNHGWRFRQVXPHWKHVDPHUHJXODUVL]HGOXQFKPHDOWKDWWKH\ KDGGXULQJWKHUX QLQSHULRG)RU
H[DPSOHLIWKHUHJXODUVL]HGP HDOZDVFRQVXPHGZLWKRXWDQLQVX OLQEROXVIRUWKHPHDODWSPGXULQJ
WKHUXQLQSHULRGWKDWVDPHUHJXODUVL]HGPHDOVKRXOGEHFRQVX PHGDWDSSUR[LPDWHO\WKHVDPHWLPHRI
GD\DWHDFKVHWSRLQWGXULQJWK HVWXG\SHULRG6XEMHFWVZLOOEH DVNHGWRFKHFN%*DWW KHVWDUWRIWKHPHDO
DVZHOODVKRXUVDQGKRXUVD IWHUWKHVWDUWRIWKHPHDODQG WDNHEROXVFRUUHFWLRQDVQHFHVVDU\'HWDLOV
VKRXOGEHUHFRUGHGRQWKHORJ
Large Sized Meal Challenges:   
2QODUJHVL]HGPHDOFKDOOHQJHGD \VVXEMHFWVZLOOEHLQVWUXFWHG WRHDWRQHPHDOZLWKDWOHDVWKLJKHU
FDORULFLQWDNHLQFOXGLQJPRUHFDUERK\GUDWHVDQGKLJKHU LQIDW,WLVUHFRPPHQGHGWKDWVXEMHFWV
HDWIRRGDWUHVWDXUDQWVRUFRQVX PHSUHSDUHGPHDOV7KH)RRG3ULQ WÂŒDSSDVZHOODVTXH VWLRQVWKDWZLOO
EHDVNHGE\LQYHVWLJDW LRQDOFHQWHUVWDIIGXULQJYLVLWVIROORZLQ JPHDOFKDOOHQJHVZLOOEHXVHGE\VXEMHFWV
WRFROOHFWLQIRUPDWLRQDERXWWKHIRRGWKDWZDVHDWHQWKHQDPH RIWKHUHVWDXUDQWLIDSSOLFDEOHDQG
VXEMHFWFRQILUPDWLRQWKDWPHD OVL]HZDVDWOHDVWPRUHLQWH UPVRIFDORULHVFDUERK\GUDWHVDQGIDW
7KHWLPLQJRIWKHPHDOFKDOOHQ JHVZLOOEHDWWKHLQYHVWLJDWRUÂ¶V GLVFUHWLRQ7KHVXEMHF W
VSDUHQWFDUHJLYHU
RUFRPSDQLRQVKRXOGEHSK\VLFDOO\ SUHVHQWLQWKHVDPHEXLOGLQJ KRPHRUORFDWLRQLIQRWDWKRPHGXULQJ
WKHPHDOFKDOOHQJHDQGIRUKRXUVIROORZLQJWKHVWDUWRIWKH PHDO7KH\PXVWEHDEOHWRFKHFN60%*
LQFDVHLWLVQHHGHGDQGJLYHJOX FRVHDGPLQLVWHUJOXFDJRQLI UHTXLUHG
Exercise Challenge for all Subjects (during Study Period only):    
7KHIROORZLQJH[HUFLVHFKDOOHQJHVDUHUHTXLUHGGXULQJWKHVWXG\ SHULRG
x H[HUFLVHFKDOOHQJHVDWVHWSRL QWRIPJG/EHWZHHQ9LVLWV DQGRIWKHVWXG\SHULRG
x H[HUFLVHFKDOOHQJHVDWVHWSRL QWRIPJG/EHWZHHQ9LVLWV DQGRIWKHVWXG\SHULRG
x H[HUFLVHFKDOOHQJHDWVHWSRLQW LQYHVWLJDWRUÂ¶VGLVFUHWLRQDW DQ\WLPHDIWHU9LVLWRIWKHVWXG\
SHULRG
&RQGLWLRQVDWVWDUWRIW KHH[HUFLVHFKDOOHQJHV
x 6*VKRXOGEHSUHVHQWDWWKHVWDUWRIHDFKH[HUFLVHFKDOOHQJH
x 7KHLQYHVWLJDWRURUKLVKHUVWDI IZLOOGHWHUPLQHWKHPLQLPXP%* IRUHDFKVXEMHFWDWWKHVWDUWRIHDFK
H[HUFLVHFKDOOHQJH,WZLOOEHQR WHGRQWKHVXEMHFWÂ¶VH[HUFLVH ORJ

Timing Settings/Conditions Exercise 
durationNotes
Study Period, 
between Visits 9 
and 11 6PDUW*XDUG
PJG/VHWSRLQW  0LQ
PLQXWHVXSWR
KRXUV&KDOOHQJHPXVWWDNHSODFHRQGD\V
ZLWKRXWPHDOFKDOOHQJH
CIP335 Clinical Investigation Plan 
 Form 
D00409632 Version E Page 35 of 106 
0HGWURQLF%XVLQHVV5HVWULFWHG
CONFIDENTIAL )5HY(&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Form
Study Period, 
between Visits 9 
and 11 6PDUW*XDUG
PJG/VHWSRLQW0LQ
PLQXWHVXSWR
KRXUV&KDOOHQJHPXVWWDNHSODFHRQGD\V
ZLWKRXWPHDOFKDOOHQJH
Study Period, 
between Visits 
12 and 13 6PDUW*XDUG
PJG/VHWSRLQW0LQ
PLQXWHVXSWR
KRXUV&KDOOHQJHPXVWWDNHSODFHRQGD\V
ZLWKRXWPHDOFKDOOHQJH
Study Period, 
between Visits 
12 and 13 6PDUW*XDUG
PJG/VHWSRLQW  0LQ
PLQXWHVXSWR
KRXUV&KDOOHQJHPXVWWDNHSODFHRQGD\V
ZLWKRXWPHDOFKDOOHQJH
Study Period 
Any time after  
Visit 13 6PDUW*XDUG
$XWR%DVDOWDUJHWDW
LQYHVWLJDWRUÂ¶VGLVFUHWLRQ0LQ
PLQXWHVXSWR
KRXUV&KDOOHQJHPXVWWDNHSODFHRQGD\V
ZLWKRXWPHDOFKDOOHQJH
Exercise Challenges Details: 
7RIXOILOOWKHH[HUFLV HFKDOOHQJHUHTXLUHP HQWVXEMHFWVZLOOEH DVNHGWRHQJDJHLQXSWRKRXUVRI
SK\VLFDOH[HUFLVH'XULQJWKLVW LPHVXEMHFWVVKRXOGXVHHLWKHU WKH$XWR%DVDOVHWSRLQWWDUJHWRI
PJG/RUPJG/GHSHQGLQJRQZKDWLVUHTXLUHGDWWKDWWLPH RIWKHVWXG\SHULRGXQOHVVDVXEMHFW
SUHIHUVWRXVHWKHPJG/WHP SWDUJHWEHIRUHGXULQJDQGLPP HGLDWHO\DIWHUWKHH[HUFLVHFKDOOHQJHV
7KH)RRG3ULQWÂŒDSSDVZHOODVTXH VWLRQVWKDWZLOOEHDVNHGE\ VLWHVWDIIGXULQJYLVLW VIROORZLQJH[HUFLVH
FKDOOHQJHVZLOOEHXVHGE\VXEM HFWVWRFROOHFWLQIRUPDWLRQDER XWH[HUFLVHW\SHGDWH WLPHVWDUWDQGILQLVK
RIH[HUFLVHDQGGXUDWLRQ7KH WLPLQJRIWKHH[HUFLVHFKDOOHQJ HZLOOEHDWWKHLQYHVWLJDWRUÂ¶VGLVFUHWLRQ$
SKRWRJUDSKVKRXOGEHWDNHQRQHDFKGD\RIWKHH[HUFLVHFKDOOHQJ HVWRLQGLFDWHZKHUH WKHH[HUFLVHWRRN
SODFH7KHVXEMHFW
VSDU HQWVFDUHJLYHUVLIDSSOLFDEOHRUFRPS DQLRQPXVWEHSK\VLFDOO\SUHVHQWLQWKH
VDPHEXLOGLQJKRPHRUORFDWLRQ LIQRWDWKRPHGXULQJWKHH[H UFLVHFKDOOHQJHPXVWEHDEOHWRFKHFN
60%*LQFDVHLWLVQHHGHGDQGJL YHJOXFRVHDGPLQLVWHUJOXFDJR QDVQHHGHG([DPSOHVRIW\SHVRI
H[HUFLVHLQFOXGHEXWDUHQRWOLPLWHGWR
Âƒ 5XQQLQJ
Âƒ &\FOLQJ
Âƒ 6ZLPPLQJ
Âƒ +LNLQJ
Âƒ :DONLQJ
Âƒ *DPHVHJ:LLLQWHUDFWLYHYLGHRJDPHV
Âƒ ,QGRRURXWGRRUSOD\JURXQG3HGLDWULFVXEMHFWV
Âƒ <RJDVWUHWFKLQJ
Âƒ $Q\VSRUWDFWLYLW\WKDWLQYROYHVRQJRLQJSK\VLFDOPRYHPHQWHJ WHQQLVJROIEDVNHWEDOO
YROOH\EDOOVRFFHU
Âƒ 'DQFLQJ
Âƒ =XPED
Âƒ $HURELFV
Âƒ 6SLQQLQJ
 
Companions: 
6XEMHFWVZLOOEHUHTXLUHGWRKDYH DFRPSDQLRQZKRUHVLGHVRUZ LOOOLYHLQWKHVDPHEXLOGLQJRUKRPH
GXULQJWKHVWXG\DWQLJKWDQGD OVRWREHSK\VLFDOO\SUHVHQWLQ WKHVDPHEXLOGLQJKRPHRUORFDWLRQLIQRW
DWKRPHGXULQJWKHH[HUFLVHDQGPHDOFKDOOHQJHV$FRPSDQLRQV KRXOGEHSUHVHQWGXULQJPHDO
FKDOOHQJHVDQGIRUKRXUVIROOR ZLQJWKHVWDUWRIWKHPHDO&RP SDQLRQVVKRXOGEHDEOHWRFKHFN60%*
JLYHJOXFRVHDQGRUDGPLQLVWHUJOXFDJRQ
CIP335 Clinical Investigation Plan 
 Form 
D00409632 Version E Page 36 of 106 
0HGWURQLF%XVLQHVV5HVWULFWHG
CONFIDENTIAL )5HY(&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Form
Safety Considerations with the Use of Lyumjev insulin: 
6LWHVZLOOVHQGRXWDQHP DLOWRHDFKVXEMHFW GXULQJZHHNVZKHUH QRYLVLWLVVFKHGXOHGWRLQTXLUHDERXW
LQVXOLQLQIXVLRQZLWK/\XPMHY LQVXOLQ7KHHPDLOZLOODVNVXEMH FWVZKHWKHURUQRWWK H\KDYHH[SHULHQFHG
DQ\LQVXOLQLQIXVLRQUHDFWLRQVZ LWKWKHXVHRIWKH/\XPMHYLQVX OLQ7KHHPDLOZLOODOVRUHPLQGVXEMHFWVWKDW
VLWHVVKRXOGEHFDOOHGLIDQ\LVVX HVZLWK/\XPMHYLQVXOLQLQIXV LRQRFFXU'XULQJVXFKFDOOVSKRWRVDQG
YLGHRVKRXOGEHXVHGLISRVVLEOH
5.1 Duration 
7KHVWXG\LVDQWLFLSDWHGWRODVW DSSUR[LPDWHO\PRQWKVIURPI LUVWLQYHVWLJDWLRQDOFHQWHULQLWLDWLRQWR
ILQDOL]DWLRQRIDOOGDWDHQWU\DQGPRQLWRULQJSURFHGXUHVIRUGD WDFOHDQLQJ,QGLYLGXD OVXEMHFWSDUWLFLSDWLRQ
LVH[SHFWHGWREHDSSUR[LPDWHO\GD\V
5.2 Rationale 
3UHYLRXVFOLQLFDOLQYHVWLJDWLRQVK DYHFRQILUPHGWKHVDIHW\DQG FOLQLFDOSHUIRUPDQFHRIWKH0LQL0HG*
LQVXOLQSXPSZKHQXVHGWRGHOLYHU+XPDORJRU1RYRORJ8LQVXO LQWRSDWLHQWV\HDUVRIDJH,Q
VLOLFRPRGHOLQJLQGLFDWHVWKDWWKH XVHRI/\XPMHY8LQVXOLQ ZLWKWKH0LQL0HG*SXPSZLOOUHVXOWLQ
VLPLODURXWFRPHV7KLVLQYHVWLJD WLRQLVLQWHQGHGWRSURYLGHDGG LWLRQDOFRQILUPDWLRQRIWKHVDIHW\RIWKH
*LQVXOLQSXPSXVHGLQFRPELQDWLRQZLWK/\XPMHY8LQVXOLQ LQKXPDQV
6. Product Description 
6.1 Intended Use 
,QWKLVVWXG\WKH0LQL0HG*V\ VWHPLVLQWHQGHGIRUXVHE\S DWLHQWVWZR\HDUVDQGROGHUZLWKW\SH
GLDEHWHVZKRUHTXLUHDWOHDV WXQLWVRILQVXOLQSHUGD\
6.2 General Overview of MiniMed 780G Insulin Pump System Components  
and Consumables 
Table 1. MiniMed 780G Insulin Pump: System Components and consu mable materials 
Device name MDT Model number/ 
part number Device Regulatory Status 
0LQL0HG*,QVXOLQ3XPS 007 ,QYHVWL JDWLRQDO
*XDUGLDQ6HQVRU 007 ,QYHVWL JDWLRQDO
*XDUGLDQ7UDQVPLWWHU 007 ,QYHVWL JDWLRQDO
0HGWURQLF([WHQGHG5HVHUYRLU 007 1RQ,QYHVWL JDWLRQDO
0HGWURQLF([WHQGHGLQIXVLRQVHW007007007
007007
007007DQG
0071RQ,QYHVWLJDWLRQDO
2QH3UHVV6HUWHU 007 1RQ,QYHVWL JDWLRQDO
&KDUJHU 007 1RQ,QYHVWL JDWLRQDO
7HVWHU 007/ 1RQ,QYHVWL JDWLRQDO
0HGWURQLF&DUH/LQN3HUVRQDO
VRIWZDUH007 1RQ,QYHVWLJDWLRQDO

CIP335 Clinical Investigation Plan 
 Form 
D00409632 Version E Page 37 of 106 
0HGWURQLF%XVLQHVV5HVWULFWHG
CONFIDENTIAL )5HY(&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Form
Device name MDT Model number/ 
part number Device Regulatory Status 
0HGWURQLF&DUH/LQNV\V WHPVRIWZDUH 007 1RQ,QYHVWLJDWLRQDO

5RFKH$FFX&KHN*XLGH/LQN*OXFRVH
0HWHU 1RQ,QYHVWLJDWLRQDO
0LQL0HG&OLQLFDO$SS007$QGURLG007
,261RQ,QYHVWLJDWLRQDO


&DUH/LQN&OLQLFDO$SS007$QGURLG007
,261RQ,QYHVWLJDWLRQDO


%OXH$GDSWHU $&& 1RQ,QYHVWLJDWLRQDO
.HWRQH0HWHU  1RQ,QYHVWL JDWLRQDO
Drug name MDT Model number/ 
part number Drug Status 
/\XPMHYLQVXOLQOLVSURDDEF ***  $SSURYHG

&ODVV,H[HPSW


&ODVV,,H[HPSW



)RUGHWDLOHGLQIRUPDWLRQRQWKHFKDUDFWHULVWLFVRIWKH/\XPM HYLQVXOLQVHHGHYLFHLQVWUXFWLRQVIRUXVH,)8 
6.3 Investigational Product 
6.3.1  MiniMed 780G Insulin Pump 
7KH0LQL0HG*,QVXOLQ3XPSKRXVHVHOHFWURQLFVDSXPSLQJPHF KDQLVPDXVHULQWHUIDFHDQGD
PHGLFDWLRQUHVHUYRLUZLWKLQWKH VDPHSK\VLFDOGHYLFH7KHSXPS FRPPXQLFDWHVYLD%OXHWRRWKÂŠ/RZ
(QHUJ\ZLUHOHVVFRPPXQLFDWLRQSUR WRFROZLWKWKHFRPSDWLEOHGHYL FHVLQWKH0LQL0HG*6\VWHP
,QWKLVVWXG\WKH0 LQL0HG*3XPSZLOOEHXVHGLQFRPELQDWLR QZLWKWKHIROORZLQJGHYLFHV
x 7KH0LQL0HG*3XPSUHFHLYHVWK H6*YDOXHVDQGVHQVRULQWHJUL W\FKHFNIURPWKH
*XDUGLDQ7UDQVPLWWHUZKLFKLVFRQQHFWHGWRWKH*XDUGLDQVH QVRU
x 7KH0LQL0HG*3XPSUHFHLYHV%*YDOXHVIURPWKH5RFKHÂ¶V$FFX &KHN*XLGH/LQN%*
PHWHU
x 7KH0LQL0HG*3XPSWUDQVPLWV GDWDWRDFRPSDWLEOHFRQVXPHUH OHFWURQLFGHYLFHZLWKWKH
0LQL0HG&OLQLFDODSSWRSURYLGH DVHFRQGDU\GLVSOD\IRUSDVVLY HPRQLWRULQJRI&*0DQGSXPS
GDWDIRUWKHXVHU
x 7KH0LQL0HG*3XPSDOVRWUDQVPL WVGDWDWR&DUH/LQN3HUVRQDO &DUH/LQNV\VWHPVRIWZDUH
WKURXJKWKH%OXH$GDSWHU0LQL0HG&OLQLFDODSS
CIP335 Clinical Investigation Plan 
 Form 
D00409632 Version E Page 38 of 106 
0HGWURQLF%XVLQHVV5HVWULFWHG
CONFIDENTIAL )5HY(&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Form
Figure 1. 780G System and Components 

6.3.2  Guardian 4 Sensor 
7KH*XDUGLDQVHQVRUUHIHUUHGWRDVWKHVHQVRULQWKLVSURWR FROLVDVHQVRUWKDWFRQWDLQVRQH
PLFURHOHFWURGHZLWKDWKLQFRDWLQJRIJOXFRVHR[LGDVHEHQHDWKV HYHUDOOD\HUVRIELRFRPSDWLEOHPHPEUDQH
7KH*XDUGLDQVHQVRUZLOOEHXVH GZLWKWKH*V\VWHP7KHVH QVRULVWKHODWHVWJHQ HUDWLRQRIJOXFRVH
VHQVRUZLWKGHVLJQFKDQJHVIRUV XSSRUWLQJLPSURYHGDFFXUDF\,W LVLQWHQGHGWRSHQHWUDWHWKHVNLQDWD
GHJUHHDQJOH7KHVHQVRULVWXEHOHVV$QLQWURGXFHUQHHGOHS HQHWUDWHVWKHVNLQVXUIDFHDQGSURYLGHV
VXSSRUWIRUWKHVHQVRUPLFURHOHFW URGHGXULQJLQVHUWLRQ7KHVHQ VRUFRQWLQXRXVO\FRQ YHUWVVPDOODPRXQWV
RIJOXFRVHIURPWKHVXEMHFWÂ¶VLQ WHUVWLWLDOIOXLG LQWRDQHOHFWU RQLFVLJQDOWKDWLVUHFHLYHGE\DWUDQVPLWWHURU
UHFRUGHUWKHVWUHQJWKRIZKLFKLVSURSRUWLRQDOWRWKHDPRXQWR IJOXFRVHSUHVHQWLQWKHEORRG7KH
HOHFWURGHLVFRPSRVHGRIHPEHGGL QJVLJQDOFRQGXFWLQJDQGLQVXO DWLQJOD\HUV  
6.3.3  Guardian 4 Transmitter 
7KH*XDUGLDQ7UDQVPLWWHULVD SRUWDEOHHOHFWULFDOFXUUHQWPH WHULQWHQGHGWRSURFHVVVWRUHDQG
WUDQVPLWJOXFRVHVHQVRUYDOXHVWR WKHFRPSDWLEOHLQVXOLQSXPS 7KHWUDQVPLWWHUVHQGV6*YDOXHVDQG
VHQVRULQWHJULW\6,GDWDIURPWKHVHQVRUWRFRPSDWLEOHLQVXOL QSXPSVYLDD%OXHWRRWK/RZ(QHUJ\
ZLUHOHVVFRPPXQLFDWLRQSURWRFRO
g
CIP335 Clinical Investigation Plan 
 Form 
D00409632 Version E Page 39 of 106 
0HGWURQLF%XVLQHVV5HVWULFWHG
CONFIDENTIAL )5HY(&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Form
6.4 Non-Investigational Product(s) 
6.4.1  Insulin  
/\XPMHYLQVXOLQOLVSURDDEFLQMHFWLRQLVDIDVWDFWLQJLQVXOL QZLWKWKHVDPHDFWLYHLQJUHGLHQWDV+XPDORJ
XVHGWRWUHDWFKLOGUHQDQGDGXOWVZLWKGLDEHWHVIRUWKHFRQWURO RIKLJKEORRGVXJDU ./\XPMHYLVDQ
DSSURYHGLQVXOLQIRUDGPLQLVWUDWLRQYLDFRQWLQXRXVVXEFXWDQHRXV LQVXOLQLQIXVLRQ&6,,LQFKLOGUHQDQG
DGXOWV  
6XEMHFWVZLOOXVHUDSLGDFWLQJDQD ORJXHLQVXOLQ1RYRORJ+XPDO RJRU$GPHORJGXULQJWKHUXQLQSHULRG
'XULQJWKHVWXG\SHULRGVXEMHF WVZLOOEHSURYLGHGZLWK/\XPMHY IRUXVH
6.4.2  Medtronic Extended Infusion Set  
,QIXVLRQVHWVDUHVLQJOHXVHE\S DWLHQWVZLWKGL DEHWHVPHOOLWXV UHTXLULQJVXEFXWDQHRXVDGPLQLVWHUHG
LQVXOLQWRPDLQWDLQDFFHSWDEOH% *OHYHOV7KH0H GWURQLF([WHQGH GLQIXVLRQVHWLVDQ LQIXVLRQVHWZLWKD
SUHORDGHGLQVHUWHULQ VHUWHGLQWRWKHVXEFXWDQHRXVWLVVXHRID XVHUDQGLVFRQQHFWHGWRD0HGWURQLF
0LQL0HG([WHQGHG5HVHUYRLUIRU XVHZLWKD0HGWURQLF0LQL0HGLQ VXOLQSXPS7KHUHDUHWKUHHEDVLF
FRPSRQHQWVRIWKHLQIXVLRQVHW
 &DWKHWHUKXEZLWKFDQQXODDQGDGKHVLYHSDWFK
 7XELQJ
 7XELQJFRQQHFWRU

7KHFDQQXODFRQQHFWHGWRWKHFDWKHWHUKXELVLQWURGXFHGLQWR VXEFXWDQHRXVWLVVXHLHLQIXVLRQVLWH
7KHWXELQJFRQQHFWVWKHFDWKHWHUKXEDQGWKHWXELQJFRQQHFWRUW RSURYLGHWKHIOXLGIURPWKHPHGLFDWLRQ
UHVHUYRLUKRXVHGZLWKL QWKHLQVXOLQSXPS
7KHGHYLFHXWLOL]HVDQHZKLJKSH UIRUPDQFHWXELQJFRQQHFWRU+ &DSWRUHSODFHWKH FXUUHQWSURSULHWDU\
3DUDGLJPFRQQHFWRU3&DSDQH [WHQGHGZHDUWXELQJWRUHSODFH WKHFXUUHQWWXELQJ DQGDQH[WHQGHG
ZHDUDGKHVLYHSDWFK  Figure 2DQG Figure 3LOOXVWUDWHVWKHGHYLFHDQG WKHWXELQJFRQQHFWRUV
7KH0HGWURQLF([WHQGHGLQIXVLRQVHWHQKDQFHVSDWLHQWZHDUWLPH WRGD\V7KLVLVG RQHE\PDLQWDLQLQJ
LQVXOLQIRUPXODWLRQVWDELOLW\LQF OXGLQJSK\VLFDOFKHPLFDODQ GPLFURELRORJLFDOVWDELOLW\GXULQJLQIXVLRQ
WKURXJKWKHSXPSLQIXVLRQVHWV\VWHPRYHUH[WHQGHGWLPHXSWR GD\V

CIP335 Clinical Investigation Plan 
 Form 
D00409632 Version E Page 40 of 106 
0HGWURQLF%XVLQHVV5HVWULFWHG
CONFIDENTIAL )5HY(&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Form
Figure 2. Medtronic Extended infusion set 
Figure 3. Connector, P-Cap (Left); High-Performance Connector, H-Cap (Right) 
 


CIP335 Clinical Investigation Plan 
 Form 
D00409632 Version E Page 41 of 106 
0HGWURQLF%XVLQHVV5HVWULFWHG
CONFIDENTIAL )5HY(&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Form
6.4.3  Medtronic Extended Reservoir  
7KH0HGWURQLF([WHQGHG5HVHUYR LULVLQGLFDWHGIRUWKHVXEFXWDQH RXVLQIXVLRQRILQVXOLQIURPFRPSDWLEOH
0HGWURQLFLQVXOLQSXPSVDQG0HGWURQLF([WHQGHGLQIXVLRQVHWV
6.4.4  One-Press Serter  
7KH2QH3UHVV6HUWHUUHIHUUHGWR DVWKH6HUWHULQWKLVSURWRFR OLVDQLQVHUWLRQGH YLFHWKDWLVXVHGWR
HQVXUHFRUUHFWSODFHPH QWRIWKHVHQVRULQWR WKHXVHUÂ¶VVXEFXWDQ HRXVWLVVXH,QVHUWLRQLVWULJJHUHGZKHQ
WKHWZRVSULQJORDGHGEXWWRQVRQ WKHVLGHVRIWKH6HUWHUDUHSU HVVHGVLPXOWDQHRXVO \7KH6HUWHULV
LQWHQGHGDVDVLQJOHSDWLHQWQRQ VWHULOHPXOWLXVHGHYLFH
6.4.5  Charger  
7KH&KDUJHULVXVHGWRUHFKDUJHW KHWUDQVPLWWHUDVQHHGHG$IX OO\FKDUJHGEDWWHU\SURYLGHVXSWRGD\V
RIWUDQVPLWWHUXVH7KHV\VWHPLQ FOXGHVDEDWWHU\ FKDUJHUWKDW ZLOOUHFKDUJHWKHGHYLF HDFFRUGLQJWRWKH
XVHUJXLGH
6.4.6  Tester  
7KH7HVWHURSHUDWHVDVDVHQVRUVLP XODWRUFUHDWLQJVLJQDOFXUUH QWDWDOHYHOWKDWLVZL WKLQWKHUDQJHRIDQ
LQYLYRVHQVRUGXULQJQRUPDORSHUDWLRQ . 
6.4.7  CareLink Personal Software  
0HGWURQLF&DUH/LQN3HUVRQDOVRIW ZDUHLVDQLQWHUQHWEDVHGVRIWZ DUHV\VWHPZKLFKDOORZVWKHGHYLFHGDWD
WREHXSORDGHGDQGUHYLHZHGE\W KHVXEMHFW7KH &DUH/LQN3HUVRQ DOVRIWZDUHDOORZVVXEMHFWVWRXSORDG
GDWDIURP0HGWURQLF0LQL0HGLQVX OLQSXPSVDQGDUDQJHRIV\VWHP VXSSRUWHGWKLUGSDUW\%*PHWHUV7KH
GDWDFRQWDLQHGLQ&DUH/LQN3HUV RQDOVRIWZDUHLVDFFHVVLEOHWRX VHUVXVLQJDVWDQGDUGEURZVHULH
0LFURVRIWÂŠ,QWHUQHW([SORUHURU*RRJOH&KURPHRQDQ,QWHUQHWHQDEOHGSHU VRQDOFRPSXWHU3&

7KH&DUH/LQN3HUVRQDOVRIWZDUHXVHVVWDQGDUG7UDQVSRUW/D\HU6H FXULW\7/6WHFKQRORJ\7/6
WUDQVPLVVLRQSURWRFROLQYRNHVHQFU\SWLRQRQERWKHQGVRIWKHWU DQVPLVVLRQVDQGLVWKHVWDQGDUGIRUDOO
VHFXULW\EDVHGV\VWHPV 7KHHQFU\SWLRQUHPDLQVLQHIIHFWZKHWKH UWKHGDWDLVPRYLQJWRDQGIURPWKH
FOLHQWDQGVHUYHULQW KH8QLWHG6WDWHVRU WRDQGIURPDFOLHQW LQDQRWKHUFRXQWU\WRWKH8QLWHG6WDWHV7KH
GDWDLVVHFXUHEHKLQGDWKUHHWLHULQGXVWU\VWDQGDUGDUFKLWHFWX UHZKLFKSODFHVWKHGDWDEDVHEHKLQGWKUHH
GLIIHUHQWILUHZDOOVZKHUHHDF KILUHZDOOVHSDUDWHVDWLHU
x 7KHLQWHUQHWWRWKHZHEVHUYHU
x :HEVHUYHUWRWKHDSSOLFDWLRQVHUYHU
x $SSOLFDWLRQVHUYHUWRWKHGDWDEDVHVHUYHU

6.4.8  CareLink System Software  
0HGWURQLF&DUH/LQNV\VWHPVRIWZ DUHLVDQLQWHUQHWEDVHGVRIWZDU HV\VWHPZKLFKDOOR ZVWKHGHYLFHGDWD
WREHXSORDGHGYLHZHGDQGHDVLO\HYDOXDWHGE\WKHSK\VLFLDQ7 KH&DUH/LQNV\VWHPVRIWZDUHDOORZV
UHWURVSHFWLYHUHYLHZRIGHYLFHG DWDDQGZDVGHYHORSHGIRUXVHE \WKHLQYHVWLJDWLRQDOFHQWHUVWDII7KH
&DUH/LQNV\VWHPVRIWZDUHDOORZ VWKHLQYHVWLJDWLR QDOFHQWHUVWDI IWRPDQDJHFUHDWHDQGUHTXHVWIRU
DSSURYDOWROLQNWKHVXEMHFWÂ¶VD FFRXQW7KHGDWDFRQWDLQHGLQ& DUH/LQNV\VWHPVRIW ZDUHLVDFFHVVLEOHWR
XVHUVXVLQJDVWDQGDUGEURZVHULH0LFURVRIWÂŠ,QWHUQHW([SORUHURU*RRJOH&KURPHRQDQ,QWHUQHW
HQDEOHG3&
7KH&DUH/LQNV\VWHPVRIWZDUHXVH VWDQGDUG7/6WHFKQRORJ\7/6W UDQVPLVVLRQSURWRFROLQYRNHV
HQFU\SWLRQRQERWKHQGVRIWKH WUDQVPLVVLRQVDQGLVWKHVWDQGDU GIRUDOOVHFXULW\EDVHGV\VWHPV7KH
HQFU\SWLRQUHPDLQVLQHIIHFWZKHWKHUWKHGDWDLVPRYLQJWRDQG IURPWKHFOLHQWDQGVHUYHULQWKH8QLWHG
6WDWHVRUWRDQGIURPDFOLHQW LQDQRWKHUFRXQWU\WRWKH8QLWH G6WDWHV7KHGDWDLVVHFXUHEHKLQGDWKUHH
CIP335 Clinical Investigation Plan 
 Form 
D00409632 Version E Page 42 of 106 
0HGWURQLF%XVLQHVV5HVWULFWHG
CONFIDENTIAL )5HY(&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Form
WLHULQGXVWU\VWDQGDUGDUFKLWHFWXUHZKLFKSODFHVWKHGDWDEDVH EHKLQGWKUHHGLIIHUHQWILUHZDOOVZKHUH
HDFKILUHZDOOVHSDUDWHVDWLHU
x 7KHLQWHUQHWWRWKHZHEVHUYHU
x :HEVHUYHUWRWKHDSSOLFDWLRQVHUYHU
x $SSOLFDWLRQVHUYHUWR WKHGDWDEDVHVHUYHU

6.4.9  FoodPrint App by Nutrino 
7KH)RRG3ULQWDSSE\1XWULQRLVDPHDOORJJLQJDSS)RRG3ULQWF DQDOVREHXVHGWRORJZRUNRXWVVOHHS
PHGLFDWLRQVEORRGJOXFRVHDQGLQVXOLQ 
6.4.10  Roche Accu-Chek Guide Glucose Meter 
7KH5RFKH
V$FFX&KHN*XLGH/LQN PHWHULVDKRPH%*PHWHUGHVLJ QHGWRPHDVXUHD QGWUDQVPLW%*
YDOXHVWRWKHFRPSDWLEOHLQVXOLQS XPSVYLDD%OXHWRRWK/RZ(QHU J\ZLUHOHVVFRPPXQLFDWLRQSURWRFRO7KH
LQVXOLQSXPSWKHQVHQGVWKH%*YD OXHVWRWKHWUDQVPLWWHU7KHW UDQVPLVVLRQRI%*YDOXHVIURPD
FRPSDWLEOHPHWHULVDQRSWLRQDO IHDWXUHSURYLGHGDVDFRQYHQLHQ FHWRWKHXVHULWHOLPLQDWHVWKHQHHGWR
PDQXDOO\HQWHU%*YDOXHVLQWRWKHSXPS7KH$FFX&KHN*XLGH/LQ N%*PHWHULVFRPSDWLEOHZLWK5RFKH
V
$FFX&KHN*XLGHWHVWVWULSV
6.4.11  Accessory Applications â€“ MiniMed 780G system 
7KH0LQL0HG&OLQLFDODSSLVDQRSWLRQDODFFHVVRU\ZKLFKUHFHLY HVSXPSGDWDYLD%OXHWRRWK/RZ(QHUJ\
ZLUHOHVVFRPPXQLFDWLRQIURPWKH SXPS7KH0LQL0HG&OLQLFDODSS SURYLGHVXVHUVZLWKWKHFRQYHQLHQFHWR
ZLUHOHVVO\WUDQVIHUSXPSGDWDWR& DUH/LQN3HUVRQDO&DUH/LQNV\V WHPVRIWZDUHDQGDOVRSURYLGHVD
PLUURULQJGLVSOD\RIWKHSXPS VFUHHQ7KH0LQL0HG&OLQLFDODSS LVQRWGHVLJQHGWRFRQWURORUPRQLWRUWKH
SHUIRUPDQFHRIWKHLQVXOLQSXPSQR UIRUGLUHFWPRQLWRULQJRISX PSGDWD$VDPLUURULQJGLVSOD\WKHDSS
FDQSURYLGHDOHUWVWRWKHVXEMHF WYLDWKHXVHULQWHUIDFH$OOD OHUWVPXVWEHDGGUHVVHG RQWKHLQVXOLQSXPS

7KH&DUH/LQN&OLQLFDODSSLVDQRSWLRQDODFFHVVRU\ZKLFKUHFHLY HVSXPSGDWDZLUHOHVVO\ IURPWKH&DUH/LQN
VHUYHU7KH&DUH/LQN&OLQLFDOD SSSURYLGHVDPLUURULQJGLVSOD\ RIWKH0LQL0HG&OLQLFDODSSVFUHHQIRU
UHPRWHPRQLWRULQJE\D FDUHSDUWQHUHJFDUHJLYHU7KH&DUH /LQN&OLQLFDODSSLVQRWGHVLJQHGWR
PRQLWRUWKHSHUIRUPDQFHRIWKHL QVXOLQSXPSQRUIRUGLUHFWPRQL WRULQJRISXPSGDWD$VDPLUURULQJ
GLVSOD\WKHDSSFDQSURYLGHQRW LILFDWLRQVWRWKHFDUHSDUWQHU YLDWKHXVHULQWHUIDFH

6.4.12 Blue Adapter 
7KH%OXH$GDSWHULVDQRSWLRQDOD FFHVVRU\ZLWK%OXHWRRWKWHFKQR ORJ\WKDWIDFLOLWDWHVWKHFRPPXQLFDWLRQ
EHWZHHQD3&DQGWKHLQ VXOLQSXPSYLDD%OXHWRRWK/RZ(QHUJ\Z LUHOHVVFRPPXQLFDWLRQSURWRFRO7KH
%OXH$GDSWHULVDQRIIWKHVKHOI QRQPHGLFDOGHYLFHLQWHQGHGWR WUDQVIHUGDWDWR&DUH/LQNVHUYHU7KH%OXH
$GDSWHUGRHVQRWKDYHDQ\FRPSXW DWLRQGLDJQRVWLFPRQLWRULQJR UWKHUDSHXWLFIXQFWLRQEHQHILW
0HGWURQLFZLOOSURYLGHWKH%OXH$G DSWHUDVDFRQYHQLHQFHWRVXE MHFWVDVDQDOWHUQDWLYHIRUVXEMHFWVZKHQ
DXWRPDWLFXSORDGVYLDWKH0LQL0H G&OLQLFDODSSDUHQRWSRVVLEOH 
6.4.13  Ketone Meter 
7KHNHWRQHPHWHUFDQPHDVXUHERW K%*VXJDUDQGEORRGÂ‰.HWRQH ,QWKLVVWXG\KRZHYHUWKHPHWHU
ZLOORQO\EHXVHGWRPHDVXUHÂ‰.HW RQHOHYHOVZKLFKZLOOEHFRO OHFWHGIRUUHSRUWLQJDQGUHYLHZVHH
,QYHVWLJDWRU&RRUGLQDWRUELQGH UIRUGHWDLOVDQGDVGHVFULEHGL QWKHERG\RIWKLVVWXG\SURWRFRO7KLV
PHWHUDOORZVTXDQWLILFDWLRQRIE ORRGÂ‰.HWRQHOHYHOVDQGLVWKH SUHIHUUHGSDWLHQWPHW KRGRIWHVWLQJRYHU
XULQHWHVWLQJ
CIP335 Clinical Investigation Plan 
 Form 
D00409632 Version E Page 43 of 106 
0HGWURQLF%XVLQHVV5HVWULFWHG
CONFIDENTIAL )5HY(&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Form
6.4.14   Smartphone  
6SRQVRUPD\SURYLGHDVPDUWSKRQHXSRQUHTXHVW
6.5 Consumable Devices 
*OXFRVHPHWHUDFFHVVRULHVDQG RWKHUFRQVXPDE OHPDWHULDOVZLOOE HSURYLGHGWRVXEMHFWVIRUXVHLQWKH
VWXG\
6.6 Anticipated Pr oduct Changes 
7KHUHDUHQRFKDQJHVDQWLFLSDWHGIRUDQ\RIWKHSURGXFWVGHYLFH VGXULQJWKHFRXUVHRIWKHVWXG\
6.7 Product Accountability 
*RRGFOLQLFDOUHVHDUFKSUDFWLFHUHTXLUHVWKDWLQYHVWLJDWRUVDQG UHVHDUFKWHDPVHQVXUHDFFXUDWH
DFFRXQWDELOLW\IRUDQ\LQYHVWLJDWLRQDOGHYLFHVXVHGLQDUHVHDU FKWULDO,WLVH[SHFWHG WKDWDOOLQYHVWLJDWLRQDO
GHYLFHVZLOOEHXVHGLQ WKHPDQQHULQWHQGHGGXULQJWKHVWXG\DQ GWKDWWKH\ZLOOEHXVHGRQO\E\RQ
VXEMHFWVZKRKDYHFRQVHQWHGWRSDUWLFLSDWHLQWKHUHVHDUFKVWXG \DQGE\LQYHVWLJDWL RQDOFHQWHUVWDII
WUDLQHGRQWKHVWXG\

$Q\LQYHVWLJDWLRQDOGHYLFHDQGLQVXOLQEHLQJXVHGLQFOLQLFDOU HVHDUFKPXVWEHVWULFWO\DFFRXQWHGIRUDQG
ZLOOQRWEHVKLSSHGWRDQ\LQYHV WLJDWLRQDOFHQWHUXQOHVVDOORI WKHQHFHVVDU\DSSURYDOVHJUHJXODWRU\
DXWKRULW\DQG,5%KDYHEHHQUHFHLYHG
7KHSULQFLSDOLQYHVWLJDWRU3,R UDQDXWKRUL]HGGHVLJQHHVKDOO NHHSUHFRUGVGRFXPHQWLQJWKHUHFHLSWXVH
UHWXUQDQGGLVSRVDORIWKHLQYH VWLJDWLRQDOGHYLFHVDQGLQVXOLQ $GGLWLRQDOGHWDLOVUHJDUGLQJSURGXFW
DFFRXQWDELOLW\DQGSURGXFWGLVSRVLWLRQUHTXLUHPHQWVDUHSURYLGH GLQTable 2


CIP335 Clinical Investigation Plan 
 Form 
D00409632 Version E Page 44 of 106 
0HGWURQLF%XVLQHVV5HVWULFWHG
CONFIDENTIAL )5HY(&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Form
Table 2. Product Accountability Requirements 
Device/Drug Record on 
Site 
Received 
eCRFRecord 
Disbursement, 
Returned or Not 
Returned from 
Subject on 
Subject Device 
Identification 
eCRFSubject Return 
Device to 
Investigational 
Center Record 
Returned or 
Not Returned 
to Sponsor on 
Site Returned 
eCRF Investigational 
Center Return 
Device to 
Sponsor at 
Conclusion of 
Study
0LQL0HG*
,QVXOLQ3XPS
007<HV <HV <HV <HV <HV
*XDUGLDQ
6HQVRU007
<HV <HV<HV8QXVHG
DQGXVHGZLWK
FRPSODLQW
1R8VHG<HV<HV
8QXVHGDQG
XVHGZLWK
FRPSODLQW
1R8VHG
*XDUGLDQ
7UDQVPLWWHU007<HV <HV <HV <HV <HV
0HGWURQLF
([WHQGHG
,QIXVLRQ6HW
007007
007
007007
007
007DQG
0071R 1R<HV
&RPSODLQW
1R
8VHG1R<HV&RPSODLQW  
1R
8VHG
0HGWURQLF
([WHQGHG
5HVHUYRLU007
<HV <HV<HV
&RPSODLQW
1R
8VHG<HV<HV&RPSODLQW
1R
8VHG
5RFKH$FFX&KHN
*XLGH/LQN6WXG\
0HWHU
<HV <HV <HV <HV 1R

.HWRQH0HWHU 1R 1R <HV 1R 1R

/\XPMHYLQVXOLQ <HV <HV
<HV8QRSHQHG
YLDOV<HV 1R


6PDUWSKRQHDV
DSSURYHGIRU
GLVWULEXWLRQ<HV <HV <HV <HV <HV

,IVXEMHFWLVXQDEOHWRGLVSRVHUHWXUQSURGXFWVWRLQYHVWLJDW LRQDOFHQWHUIRUGLVSRVDO,ILQYHVWLJDWLRQDOFHQWHULVXQDEOH WRGLVSRVH
UHWXUQSURGXFWVWRVSRQVRUIRUGLVSRVDO


,QVXOLQOHIWRYHUVVKRXOGEHGHVWUR\HGDWLQYHVWLJDWLRQDOFHQW HU
CIP335 Clinical Investigation Plan 
 Form 
D00409632 Version E Page 45 of 106 
0HGWURQLF%XVLQHVV5HVWULFWHG
CONFIDENTIAL )5HY(&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Form
7KHLQYHVWLJDWLRQDOFHQWHUZLOOS URPSWO\QRWLI\WKHVSRQVRURI DQ\GHYLFHDQGLQVXOLQKDQGOLQJYLRODWLRQ
WKDWPLJKWLPSDFWHLWKHUWKHVDI HW\DQGRUZHOIDUHRIVXEMHFWV RUGDWDLQWHJULW\
6.7.1  Receipt and Inventory of Study D evices/Insulin by Investigation al Center 
x 8SRQUHFHLSWRIWKHVWXG\SURGXF WLQYHVWLJDWLRQDOFHQWHUVWDII ZLOOWDNHLQYHQWRU\ RIWKHVKLSPHQW
PDNLQJVXUHWKDWLQIRUPDWLRQRQ WKHSDFNLQJVOLSVLQYRLFHVPDWF KHVH[DFWO\WKHFRQWHQWVRIWKH
FRQWDLQHUVDVDSSOLFDEOHLQFOXGLQJ
o 6KLSWRDGGUHVV
o 5HIHUHQFHQXPEHU
o 'HYLFHW\SH
o 4XDQWLW\
o 4XDQWLW\SHUSDFNDJH
o /RWQXPEHUZKHUHDSSOLFDEOH
o 6HULDOQXPEHUZKHUHDSSOLFDEOH
x (QVXUHWKDWGHYLFHVLQVXOLQDQGVXSSOLHVUHFHLYHGKDYHQRWUH DFKHGRUH[FHHGHGWKHLUH[SLUDWLRQ
GDWH
x 6LJQDQGGDWHWKHSDFNLQJVOLSV LQYRLFHVQRWLQJDQ\GLVFUHSDQF LHVDQGILOHLQD SSURSULDWHVWXG\
ELQGHU
x 1RWLI\WKHVWXG\PRQLWRURIDQ\GLVFUHSDQFLHV
(QWHURUDFNQRZOHGJHWKHVWXG\GHYLFHDQGLQVXOLQLQIRUPDWLRQR QWKHDSSURSULDWHH&5)LQWKHVWXG\
GDWDEDVHLIDSSOLFDEOHDVGHVFULEHGLQ Table 2. 
6.7.2  Storage of Study Devices/Insulin at Investigational Center 
6WXG\GHYLFHVDQGLQVXOLQDUHWREHVWRUHGLQDVHFXUHHQYLURQP HQWZLWKDFFHVVOLPLWHGWRDXWKRUL]HG
UHVHDUFKSHUVRQQHO6WXG\GHYLFHVDQGLQVXOLQDUHVWRUHGLQWKH DSSURSULDWHHQYLURQPHQWDOFRQGLWLRQVDV
LGHQWLILHGLQWKH,)8XVHUJXLGHODEHOLQJ
6.7.3  Dispensing of Study Devices/Insulin 
(DFKWLPHDVWXG\GHYLFHDQGLQV XOLQLVGLVSHQVHGWRDVXEMHFW E\WKHLQYHVWLJDWRURUDXWKRUL]HGPHPEHU
RIWKHUHVHDUFKWHDPH&5)DQGRUVRXUFHGRFXPHQWDWLRQZLOOEH FRPSOHWHGDVUHTXLUHG'RFXPHQWDWLRQ
PD\LQFOXGH
x 'LVSHQVLQJGDWH
x 6XEMHFWLGHQWLILFDWLRQ,'
x /RWQXPEHUZKHUHDSSOLFDEOH
x 6HULDOQXPEHUZKHUHDSSOLFDEOH
x 'HYLFHW\SH
x $PRXQWGLVSHQVHG
6.7.4  Return or Disposal of Study Devices/Insulin 
$IWHUXVHE\WKHVXEMHFWWKHLQ YHVWLJDWLRQDOFHQWHULVH[SHFWH GWRDFFHSWDQGUHWDLQD OOGHYLFHVDQGLQVXOLQ
DVGHVFULEHGLQ Table 2DQGVWRUHWKHPLQDVHFXUHHQYL URQPHQW,IFRQWDLQHUVXQLWVGH YLFHVDUHPLVVLQJ
WKHUHDVRQVVKRXOGEHGRFXPHQWHG LQWKHDSSOLFDEOHH&5)DQGRU VRXUFHGRFXPHQW,IGLVFUHSDQFLHV
EHWZHHQWKHDPRXQWVXVHGE\VXEMHFWVDQGWKHDPRXQWVH[SHFWHGW REHUHWXUQHGH[LVWWKHUHDVRQV
VKRXOGEHGRFXPHQWHGLQWKHDSS OLFDEOHH&5)DQGRUVRXUFHGRFXP HQW

5HTXLUHPHQWVIRUUHWXUQRIGHYLF HVDQGLQVXOLQE\VXEMHFWVWRW KHLQYHVWLJDWLRQDOFH QWHUDQGUHWXUQRI
GHYLFHDQGLQVXOLQE\WKHLQYHVW LJDWLRQDOFHQWHUWRWKHVSRQVRU DUHOLVWHGLQ Table 27KHGHYLFHVDQG
LQVXOLQWKDWDUHEHLQJUHWXUQHGWRWKHLQYHVWLJDWLRQDOFHQWHUP D\EHUHWXUQHGWRWKHVSRQVRUDVVXEMHFWV
FRPSOHWHWKHVWXG\DWWKHVWXG\ FORVXUHRUXSRQVSRQVRUUHTXHV W

CIP335 Clinical Investigation Plan 
 Form 
D00409632 Version E Page 46 of 106 
0HGWURQLF%XVLQHVV5HVWULFWHG
CONFIDENTIAL )5HY(&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Form
2WKHUFRQVXPDEOHGHYLFHVHJ DOFRKROZLSHVVWXG\PHWHUVXSS OLHVDQGWDSHDQGDFFHVVRULHVVKLSSHG
LQNLWVVXSSOLHVRUPDWHULDOVPD\ EHUHWXUQHGWRWKHVSRQVRU WKH\PD\EHUHWDLQHGE\LQYHVWLJDWLRQDO
FHQWHUVIRUHGXFDWLRQDOSXUSRVHVR QO\RUWKH\PD\EHGLVSRVHG RIDSSURSULDWHO\E\WKHLQYHVWLJDWLRQDO
FHQWHUVWDII
'LVSRVDEOHDQGFRQVXPDEOHGHYLFHVWKDWKDYHEHHQ usedE\DVXEMHFWZLOOEHGLVSRVHGRIDSSURSULDWHO\
E\WKHVXEMHFWRUWKHLQYHVWLJDWLRQDOFHQWHUVWDIIGXULQJWKHF RQGXFWRIWKHVWXG\


$OOVWXG\GHYLFHVDQGL QVXOLQWKDWDUHUHTXLUHGWREHHQWHUHGL QWRWKHVWXG\GDWDEDVHDQGRUVRXUFH
GRFXPHQWPXVWEHDFFRXQWHGIRUD VGHVFULEHGDERYHEHIRUHWKH\D UHUHWXUQHGWRWKHVSRQVRU
/\XPMHYLQVXOLQZLOOEHDFFRXQWHGIRUDWWKHLQYHVWLJDWLRQDOFH QWHU$Q\LQVXOLQWKD WLVOHIWRYHUZLOOEH
GHVWUR\HGE\SDUWLFLSDWLQJFHQWH UVDQGGHVWUXFWLRQUHFRUGVZLOO EHILOHG
7. Study Site Requirements 
7.1 Investigator/Investigational Center Selection  
,QRUGHUWRFRQGXFWWKHVWXG\ LWLVUHTXLUHGWKDWWKHLQYHVWLJ DWRUDQGLQYHVWLJDWLRQDOF HQWHUVWDIIKDYHWKH
DSSURSULDWHPHGLFDOWUDLQLQJ7KH SULQFLSDOLQYHVWLJDWRUPXVWE HDSK\VLFLDQZKRKD VPDQDJHGSDWLHQWV
RQERWK&*0DQGLQVXOLQSXPSWKHU DS\IRUDWOHDVWRQH\HDUDQG PXVWEHIDPLOLDUZLWKLQVXOLQ
FDUERK\GUDWHUDWLRVLQVXOLQVHQ VLWLYLW\DQGWUHDWLQJGLDEHWLF HPHUJHQFLHV
7.2 Study Site Activation 
'XULQJWKHDFWLYDWLRQSURFHVVSU LRUWRVXEMHFWHQUROOPHQW0H GWURQLFZLOOWUDLQLQYHVW LJDWLRQDOFHQWHUVWDII
ZKRPD\WKHQWUDLQRWKHUVWDIIDW HDFKLQYHVWLJDW LRQDOFHQWHU ,IQHZPHPEHUVMRLQWKHVWXG\
LQYHVWLJDWLRQDOFHQWHU WHDPWKH\ZLOOUHFHL YHWUDLQLQJRQWKH DSSOLFDEOHVWXG\UHTXL UHPHQWVUHOHYDQWWR
WKHLUUROHEHIRUHFRQWULEXWLQJWRWKHVWXG\
3ULRUWRSHUIRUPLQJVWXG\UHODWHGDFWLYLWLHVDOOUHJXODWRU\UH TXLUHPHQWVVKDOOEHIXOILOOHGLQFOXGLQJEXWQRW
OLPLWHGWRWKHIROORZLQJ
x ,5%DSSURYDODQGYRWLQJOLVWD VUHTXLUHGE\ORFDOODZRIWKH FXUUHQWYHUVLRQRIWKH&OLQLFDO
,QYHVWLJDWLRQ3ODQ&,3DQG,QI RUPHG&RQVHQW)RUP,&)DQGU HSRUWRISULRULQYHVWLJDWLRQV
x 5HJXODWRU\DXWKRULW\DSSURYDORUQRWLILFDWLRQDVUHTXLUHGSHU ORFDOODZ
x )XOO\H[HFXWHG&OLQLFDO7ULDO$JUHHPHQW&7$
x )LQDQFLDOGLVFORVXUHLIDSSOLFDEOH
x &XUULFXOXPYLWDH&9RILQYHVWLJDWRUV
x 'RFXPHQWDWLRQRIGHOHJDWHGWDVNV
x 'RFXPHQWDWLRQRIVWXG\WUDLQLQJ

,QDGGLWLRQDOOSDUWLFLSDWLQJLQ YHVWLJDWLRQDOFH QWHUVWDIIPXV WEHWUDLQHGRQWKHFXUUHQWYHUVLRQRIWKH&,3
DVZHOODVRQWKHDSSOLFDEOHVWXG \UHTXLUHPHQWVGHSHQGLQJRQWK HLUUROHDQGPXVWEHGHOHJDWHGE\WKH3,
SULRUWRSHUIRUPLQJGHOHJDWHGVWXG\DFWLYLWLHV

0HGWURQLFZLOOSURYLGH HDFKVWXG\LQYHVWLJDWLRQDOFHQWHUZLWKG RFXPHQWDWLRQRIVWXG\LQYHVWLJDWLRQDO
FHQWHULQYHVWLJDWRUVXEMHFWHQUR OOPHQWUHDGLQHVVWKLVOHWWHUP XVWEHUHFHLYHGSULRU WRVXEMHFWHQUROOPHQW
CIP335 Clinical Investigation Plan 
 Form 
D00409632 Version E Page 47 of 106 
0HGWURQLF%XVLQHVV5HVWULFWHG
CONFIDENTIAL )5HY(&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Form
8. Selection of Subjects 
8.1 Study Population 
$WRWDORIXSWRVXEMHFWVZLW KLQVXOLQUHTXLULQJW\SHGLD EHWHVDJHZLOOEHHQUROOHGDWXSWR
LQYHVWLJDWLRQDOFHQWHUVDFURVVW KH8QLWHG6WDWHVLQRUGHUWRKD YHDWOHDVWVXEMHFWVHQWHUWKHVWXG\
SHULRG8SWRVXEMHFWVZLOOE HHQUROOHGLQWKHSHGLDWULFDJ HJURXS\HDUVRIDJHDQGXSWRLQ
WKHDGXOWDJHJURXS\HDUVRUROGHU

Subject Age Group Sub-groups Enrollment Goal (N) 
3HGLDWULF
$JHÂ±\HDUV$OO3HGLDWULF 0LQLPXP6XEMHFWV
$JH\HDUV 0LQLPXP6XE MHFWV
$JH\HDUV 0LQLPXP6XE MHFWV
$GXOW
$JH\HDUV1$ 0LQLPXP6XEMHFWV
$PLQLPXPRIVXEMHFWVDQGD PD[LPXPRIVX EMHFWVLVWDUJHW HGIRUHQUROOPHQWDWHDFK
LQYHVWLJDWLRQDOFHQWHUWRHQVXUH WKDWWKHUHVXOWVIURPWKHLQGL YLGXDOLQYHVWLJDWLRQDO FHQWHUPD\EHSRROHG
IRUDQDO\VLV
,QYHVWLJDWLRQDOFHQWH UVZLOOEHHQFRXUDJHG WRHQUROODVWXG\SR SXODWLRQWKDWUHSUHVHQWVDZLGHYDULHW\RI
EDFNJURXQGV
8.2 Subject Enrollment 
6XEMHFWVZLOOEHFRQVLGHUHGHQURO OHGLQWKHVWXG\XSRQVLJQLQJ WKH,&)DQGDVVHQWIRUPLIDSSOLFDEOH
$VXEMHFWZLOOEHDVVLJQHGDXQLTX HVWXG\VXEMHFW,'YLDWKHH& 5)ZKLFKLVDGLJLWFRGH;;;;;;
7KHILUVWWKUHHGLJLWVUHIHUWR WKH&,3QXPEHUWKHQH[W WKUHHGLJLWVUHIHUWR WKHLQYHVWLJDWLRQDO
FHQWHUQXPEHUDQGWKHODVWGLJLWVUHIHUWRWKHVXEMHFWQXPEH UDVVLJQHGGXULQJ9LVLWHJ
LVVXEMHFWIURPLQYHVWLJDWLRQDOFHQWHU

7KHLQYHVWLJDWRUZLOOP DLQWDLQDORJRIDOOVXEMHFWVHQUROOHGL QWKHFOLQLFDOVWXG\DVVLJQLQJDVXEMHFW,'
OLQNHGWRWKHLUQDPHVDQG DOWHUQDWLYHVXEMHFW,' 
8.3 Inclusion Criteria 
 $JH\HDUVDWWLPHRIVFUHHQLQJ
 +DVDFOLQLFDOGLDJQRVLVRIW\SHGLDEHWHV
D Â±\HDUVRIDJH$FOLQLFDOGLD JQRVLVRIW\SHGLDEHWHVIRU \HDUVRUPRUHDVGHWHUPLQHG
YLDPHGLFDOUHFRUGRUVRXUFHGRFXPHQWDWLRQE\DQLQGLYLGXDOTXD OLILHGWRPDNHDPHGLFDO
GLDJQRVLV
E Â±\HDUVRIDJH$FOLQLFDOGLD JQRVLVRIW\SHGLDEHWHVIRU \HDURUPRUHDVGHWHUPLQHG
YLDPHGLFDOUHFRUGRUVRXUFHGRFXPHQWDWLRQE\DQLQGLYLGXDOTXD OLILHGWRPDNHDPHGLFDO
GLDJQRVLV
 'RHVQRWUHTXLUHDOHJDOO\DXWKR UL]HGUHSUHVHQWDWLYHWRFRQVHQW RQWKHLUEHKDOIGXHWRPHQWDORU
LQWHOOHFWXDOGLVDELOLW\
 6XEMHFWRUSDUHQWFDUHJLYHULVOLW HUDWHDQGDEOHWRUHDGWKHOD QJXDJHRIIHUHGLQWKHSXPSRUSXPS
PDWHULDOV
CIP335 Clinical Investigation Plan 
 Form 
D00409632 Version E Page 48 of 106 
0HGWURQLF%XVLQHVV5HVWULFWHG
CONFIDENTIAL )5HY(&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Form
 6XEMHFWDQGRUOHJDOO\DXWKRUL ]HGUHSUHVHQWDWLYHLVZLOOLQJWR SURYLGHLQIRUPHGFRQVHQWIRU
SDUWLFLSDWLRQ
 ,VZLOOLQJWRSHUIRUPILQJHUVWLFNE ORRGJOXFRVHPHDVXUHPHQWVDV QHHGHG
 ,VZLOOLQJWRZHDUWKHV\VWHPFRQW LQXRXVO\WKURXJKRXWWKHVWXG\ 
 0XVWKDYHDPLQLPXPGDLO\LQVXOLQUHTXLUHPHQW7RWDO'DLO\'RVH RIJUHDWHUWKDQRU HTXDOWRXQLWV
DQGDPD[LPXPWRWDOGDLO\GRVHRIXQLWVRUOHVV
 +DVD*O\FRV\ODWHGKHPRJORELQ+E$FOHVVWKDQDVSURFHVV HGE\&HQWUDO/DEDWWLPHRI
VFUHHQLQJYLVLW
Note: $OO+E$FEORRGVSHFLPHQVZLOOEHVH QWWRDQGWHVWHGE\D1DWLR QDO*O\FRKHPRJORELQ
6WDQGDUGL]DWLRQ3URJUDP1*63FHUWLILHG&HQWUDO/DERUDWRU\+E $FWHVWLQJPXVWIROORZ1*63
VWDQGDUGV   
 +DVWK\URLGVWLPXODWLQJKRUPRQH76+LQWKHQRUPDOUDQJH25LI WKH76+LVRXWRIQRUPDOUHIHUHQFH
UDQJHWKH)UHH7LVEHORZRUZ LWKLQWKHODEÂ¶VUHIHUHQFHUDQJH DQG)UHH7LVZLWKLQWKHQRUPDO
UHIHUHQFHUDQJH
 8VHVSXPSWKHUDS\IRUJUHDWHUWKDQPRQWKVZLWKRUZLWKRXW&* 0H[SHULHQFHSULRUWRVFUHHQLQJ
 ,VZLOOLQJWRXSORDGGDWDIURPWKH VWXG\SXPSPXVWKDYH,QWHUQ HWDFFHVVDQGDFRPSXWHUV\VWHP
RUFRPSDWLEOHVPDUWSKRQHWKDWPHHWVWKHUHTXLUHPHQWVIRUXSORDG LQJWKHVWXG\SXPS
 ,VZLOOLQJWRWDNHRQHRIWKHIR OORZLQJLQVXOLQVDQGFDQILQDQF LDOO\VXSSRUWWKHXVHRIHLWKHURIWKH
LQVXOLQSUHSDUDWLRQVDVUHTXLUH GGXULQJWKHUXQLQSHULRG
D +XPDORJLQVXOLQOLVSURLQMHFWLRQ
E 1RYR/RJLQVXOLQDVSDUWLQMHFWLRQ
F $GPHORJLQVXOLQOLVSURLQMHFWLRQ
 ,VZLOOLQJWRWDNH/\XPMHYLQVXOLQ GXULQJWKHVWXG\SHULRGVXS SOLHGYLD6SRQVRU
8.4 Exclusion Criteria 
 +DVDK\SHUVHQVLWLYLW\WRLQVXOLQ OLVSURRURQHRIWKHH[FLSLHQ WVLQ/\XPMHY
 +DVDKLVWRU\RIRUPRUHHSLVR GHVRIVHYHUHK\SRJO\FHPLDZKL FKUHVXOWHGLQDQ\WKHIROORZLQJ
GXULQJWKHPRQWKVSULRUWRVFUHHQLQJ
D 0HGLFDODVVLVWDQFHLH3DUDPHGL FV(PHUJHQF\5RRP>(5@RU+R VSLWDOL]DWLRQ
E &RPD
F 6HL]XUHV
 +DVEHHQKRVSLWDOL]HGRUKDVYLVLW HGWKH(5LQWKHPRQWKVSUL RUWRVFUHHQLQJUHVX OWLQJLQDSULPDU\
GLDJQRVLVRIXQFRQWUROOHGGLDEHWHV
 +DVKDG'.$LQWKHODVWPRQWKVSULRUWRVFUHHQLQJYLVLW
 :LOOQRWWROHUDWHWDSHDGKHVLYH LQWKHDUHDRIVH QVRUSODFHPHQW DVDVVHVVHGE\DTXDOLILHGLQGLYLGXDO
 +DVDQ\XQUHVROYHGDGYHUVHVNLQFRQGLWLRQLQWKHDUHDRIVHQVRU SODFHPHQWHJSVRULDVLVGHUPDWLWLV
KHUSHWLIRUPLVUDVK6WD SK\ORFRFFXVLQIHFWLRQ
 ,VIHPDOHRIFKLOGEHDULQJSRWHQWL DODQGUHVXOWRISUHJQDQF\WH VWLVSRVLWLYHDWVFUHHQLQJ
 ,VVH[XDOO\DFWLYHIHPDOHRIFKLOG EHDULQJSRWHQWLDODQGLVQRW XVLQJDIRUPRIFRQWUDFHSWLRQGHHPHG
UHOLDEOHE\WKHLQYHVWLJDWRU
 ,VIHPDOHDQGSODQVWREHFRPHSU HJQDQWGXULQJWKHFRXUVHRIWKH VWXG\
 ,VEHLQJWUHDWHGIRUK\SHUWK\URLGLVPDWWLPHRIVFUHHQLQJ
 +DVGLDJQRVLVRIDGUHQDOLQVXIILFLHQF\
 +DVWDNHQDQ\RUDOLQMHFWDEOH RULQWUDYHQRXV,9JOXFRFRUWLF RLGVZLWKLQZHHNVIURPWLPHRI
VFUHHQLQJYLVLWRUSODQVWRWDNH DQ\RUDOLQMHFWDEOHRU,9J OXFRFRUWLFRLGVGXULQJWKHFRXUVHRIWKH
VWXG\
 ,VXVLQJK\GUR[\XUHDDWWLPHRIVF UHHQLQJRUSODQVWRXVHLWGX ULQJWKHVWXG\
 ,VDFWLYHO\SDUWLFLSDWLQJLQDQLQ YHVWLJDWLRQDOVWXG\GUXJRU GHYLFHZKHUHLQKHVKHKDVUHFHLYHG
WUHDWPHQWIURPDQLQYHVWLJDWLRQD OVWXG\GUXJRULQYHVWLJDWLRQDO VWXG\GHYLFHLQWK HODVWZHHNV
CIP335 Clinical Investigation Plan 
 Form 
D00409632 Version E Page 49 of 106 
0HGWURQLF%XVLQHVV5HVWULFWHG
CONFIDENTIAL )5HY(&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Form
 ,VFXUUHQWO\DEXVLQJLOOLFLWGUXJV
 ,VFXUUHQWO\DEXVLQJPDULMXDQD
 ,VFXUUHQWO\DEXVLQJSUHVFULSWLRQGUXJV
 ,VFXUUHQWO\DEXVLQJDOFRKRO
 ,VXVLQJSUDPOLQWLGH6\POLQ' 33LQKLELWRUOLUDJOXWLGH9L FWR]DRURWKHU*/3DJRQLVWV
PHWIRUPLQFDQDJOLIOR]LQ,QYRNDQ DRURWKHU6*/7LQKLELWRUVD WWLPHRIVFUHHQLQJ
 +DVDKLVWRU\RIYLVXDOLPSDLUPHQW ZKLFKZRXOGQRWDOORZVXEMHF WWRSDUWLFLSDWHLQWKHVWXG\DQG
SHUIRUPDOOVWXG\SURFHGXUHVVDIH O\DVGHWHUPLQHGE\WKHLQYHV WLJDWRU
 +DVHOHFWLYHVXUJHU\SODQQHGWK DWUHTXLUHVJHQHUDODQHVWKHVLDG XULQJWKHFRXUVHRIWKHVWXG\
 +DVVLFNOHFHOOGLVHDVHKHPRJORELQRSDWK\RUKDVUHFHLYHGUHG EORRGFHOOWUDQVIXVLRQRUHU\WKURSRLHWLQ
ZLWKLQPRQWKVSULRUW RWLPHRIVFUHHQLQJ
 3ODQVWRUHFHLYHUHGEORRGFHOOW UDQVIXVLRQRUHU\WKURSRLHWLQR YHUWKHFRXUVHRIVW XG\SDUWLFLSDWLRQ
 ,VGLDJQRVHGZLWKFXUUHQWHDWLQJ GLVRUGHUVXFKDVDQRUH[LDRUE XOLPLD
 +DVEHHQGLDJQRVHGZLWKFKURQLF NLGQH\GLVHDVHWKDWUHVXOWVLQ FKURQLFDQHPLD
 +DVDKHPDWRFULWWKDWLVEHORZWKHQRUPDOUHIHUHQFHUDQJHRIOD EXVHG
 ,VRQGLDO\VLV
 +DVVHUXPFUHDWLQLQHRI!PJG/
 +DVFHOLDFGLVHDVHWKDWLVQRWDG HTXDWHO\WUHDWHGDVGHWHUPLQHG E\WKHLQYHVWLJDWRU
 +DVKDGDQ\RIWKHIROORZLQJFDUG LRYDVFXODUHYHQWVZLWKLQ\HD URIVFUHHQLQJP\RFDUGLDOLQIDUFWLRQ
XQVWDEOHDQJLQDFRURQDU\DUWHU\E\SDVVVXUJHU\FRURQDU\DUWHU \VWHQWLQJWUDQVLHQWLVFKHPLFDWWDFN
FHUHEURYDVFXODUDFFLGHQWDQJLQDFRQJHVWLYHKHDUWIDLOXUHRU YHQWULFXODUUK\WKPGLVWXUEDQFHV
 +DVKDGKLVWRU\RIFDUGLRYDVFXODU HYHQW\HDURUPRUHIURPWKH WLPHRIVFUHHQLQJZLWKRXW
D DQRUPDO(.*DQGVWUHVVWHVWZLWKLQPRQWKVSULRUWRVFUHHQLQJ RUGXULQJVFUHHQLQJRU
E FOHDUDQFHIURPDTXDOLILHGSK\VLF LDQSULRUWRUHFHLYLQJWKHVWX G\GHYLFHVLIWKHUHLVDQ
DEQRUPDO(.*RUVWUHVVWHVW
 +DVRUPRUHFDUGLRYDVFXODUU LVNIDFWRUVOLVWHGEHORZZLWKRXW DQRUPDO(.*ZLWKLQPRQWKVSULRUWR
VFUHHQLQJRUGXULQJVFUHHQLQJRU FOHDUDQFHIURPDTXDOLILHGSK\ VLFLDQLIWKHUHLVDQDEQRUPDO(.*
x $JH!\HDUV
x 7\SHGLDEHWHVRI! \HDUVÂ¶GXUDWLRQ
x 3UHVHQFHRIDQ\DGGLWLRQDOULVNIDFWRUIRUFRURQDU\DUWHU\GLVH DVH
x 3UHVHQFHRIPLFURYDVFXODUGLVHDV HSUROLIHUDWLYHUHWLQRSDWK\RU QHSKURSDWK\LQFOXGLQJ
PLFURDOEXPLQXULD
x 3UHVHQFHRISHULSKHUDOYDVFXODUGLVHDVH
x 3UHVHQFHRIDXWRQRPLFQHXURSDWK\
 ,VDPHPEHURIWKHU HVHDUFKVWDIILQYROYHGZLWKWKHVWXG\
 +DVXVHGD0LQL0HG*SXPSSULRUWRVFUHHQLQJ

9. Study Procedures
9.1 Schedule of Events 
6XEMHFWVPD\SDUWLFLSDWHLQXSWRSODQQHGVWXG\YLVLWVDVSU HVHQWHGLQ Figure 5 (Section 9.1.1) IRU
DSSUR[LPDWHO\GD\VRIGHYLFH ZHDU$YLUWXDORIILFHYLVLW DXGLRYLVXDOPD\EHSHUIRUPHGIRURIILFH
YLVLWVLQFDVHVZKHUH DQRIILFHYLVLWLVQRWSRVVLEOH7KHH[LW YLVLWVKRXOGRFFXUDWWKHRIILFHXQOHVVDQ
HPHUJHQWVLWXDWLRQRFFXUV

CIP335 Clinical Investigation Plan 
 Form 
D00409632 Version E Page 50 of 106 
0HGWURQLF%XVLQHVV5HVWULFWHG
CONFIDENTIAL )5HY(&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Form
,IWKHVXEMHFWYLVLWVW KHLQYHVWLJDWLRQDOFHQ WHURXWVLGHRIWKH VFKHGXOHGVWXG\YLVLW VD9LVLWH&5)ZLOOEH
FRPSOHWHGWRGRFXPHQWWKHUHDV RQIRUWKHXQVFKHGXOHGYLVLW

5HIHUWR Section 9.1.1 Table 3IRUWKH9LVLW'HWDLOV
,IVXEMHFWH[LWVWKHVWXG\HDUO\ LHEHIRUHWKHLUODVWVFKHG XOHGYLVLW+E$FUHTXLUHPHQWVWKDWDSSO\WR
WKHILQDOYLVLWZLOOEHFRPSOHWHG IRUVXEMHFWVZKRKDYHFRPSOHW HG9LVLW5HIHUWR &,3/\XPMHY
4XHVWLRQQDLUH*XLGHIRUFROOHFWLRQRIHDUO\H[LWTXHVWLRQQDLUH UHTXLUHPHQWV
7KH([LWH&5)DQGDOODVVRFLDWHG DFWLYLWLHVVKRXOGEHFRPSOHWHG IRUDOOVXEMHFWVZKR KDYHZLWKGUDZQ
GLVFRQWLQXHGRUFRPSOHWHGWKHVWXG\


 
 
CIP335 Clinical Investigation Plan 
 Form 
D00409632 Version E Page 51 of 106 
0HGWURQLF%XVLQHVV5HVWULFWHG
CONFIDENTIAL )5HY(&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Form
9.1.1  Study Visit Schedule & Scheduled Follow-Up Visit Windows 
Figure 4. Study Visit Schedule 
Run-in Period
Office
Visit 1
Consent & 
ScreeningOffice/Virtual 
Office
Visit 2
Start Study 
Pump& CGMVisit Schedule
Study Period
Phone 
Visit 11
Day 21 
(Â±3 days) 
after Visit 7Phone 
Visit 10
Day 14
 (Â±3 days) 
after Visit 7Phone
Visit 9
Day 7 (Â±2 
days) after 
Visit 7Visit 1 to Visit 6 should be completed within 30 days.Phone 
Visit 5
Day 7 (Â±2 
days) after 
Visit 2Office/Virtual 
Office
Visit 6
Day 14 (Â±3 days) 
after Visit 2Phone 
Visit 3
Day 1 after 
Visit 2Phone 
Visit 4
Day 3 after 
Visit 2
Phone
Visit 8
Day 2 after 
Visit 7Office/Virtual 
Office
Visit 7
Day 7 (-7 days) 
after Visit 6Office/Virtual 
Office
Visit 12
Day 28 (+7 days) 
after Visit 7Office/Virtual 
Office
Visit 13
Day 44 (Â±3 days) 
after Visit 7Office/Virtual 
Office
Visit 14
Day 60 (+7 days) 
after Visit 7Office/Virtual 
Office
Visit 15
Day 90 (+7 days) 
after Visit 7 EOS

CIP335 Clinical Investigation Plan 
 Form 
D00409632 Version E Page 52 of 106 
0HGWURQLF%XVLQHVV5HVWULFWHG
CONFIDENTIAL )5HY(&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Form
Visit 1 to Visit 6 should be completed within 30 days. 
 
x 9LVLW2IILFH&RQ VHQWDQGVFUHHQLQJ
o +E$FDQGRWKHUODEVIRUDOOVXEMHFWV
 
Run-In Period:  
x 9LVLW2IILFH9LUWXDO2IILFH6WDUW5XQ,Q
o (OLJLELOLW\KDVEHHQFRQILUPHG
o 6WDUWVWXG\SXPSDQG&*0
o 5HJLVWHUDQGXSORDGVWXG\SXPSLQ &DUH/LQN3HUVRQDODQG&DUH/LQ NV\VWHP
x 9LVLW3KRQH'D\DIWHU9LVLW 5HTXLUHGIRUVXEMHFWVZL WKRXW&*0RUFORVHGORRS
H[SHULHQFHDVQHHGHGIRUDOORWKHUV
o $VNVXEMHFWVWKHLUSDUHQWVFDUH JLYHUVLIDSSOLFDEOHDQGFRP SDQLRQVLIWKH\UHTXLUH
DVVLVWDQFHHJDGGLWLRQDOWUDLQLQJ
o $VNVXEMHFWVDQGWKHLUSDUHQWVF DUHJLYHUVLIDSSOLFDEOHDERXW DGYHUVHHYHQW VGHYLFH
SHUIRUPDQFHDQGXQH[SODLQHGK\SHUJO\FHPLD
o 5HYLHZ&DUH/LQNUHSRUWV
x 9LVLW3KRQH'D\DIWHU9LVL W5HTXLUHGIRUVXEMHFWVZL WKRXW&*0RUFORVHGORRS
H[SHULHQFHDVQHHGHGIRUDOORWKHUV
o $VNVXEMHFWVWKHLUSDUHQWVFDUH JLYHUVLIDSSOLFDEOHDQGFRP SDQLRQVLIWKH\UHTXLUH
DVVLVWDQFHHJDGGLWLRQDOWUDLQLQJ
o $VNVXEMHFWVDQGWKHLUSDUHQWVF DUHJLYHUVLIDSSOLFDEOHDERXW DGYHUVHHYHQW VGHYLFH
SHUIRUPDQFHDQGXQH[SODLQHGK\SHUJO\FHPLD
o 5HYLHZ&DUH/LQNUHSRUWV
x 9LVLW3KRQH'D\Â“GD\VDIWHU9LVLW
o $VNVXEMHFWVWKHLUSDUHQWVFDUH JLYHUVLIDSSOLFDEOHDQGFRPS DQLRQVLIWKH\UHTXLUH
DVVLVWDQFHHJDGGLWLRQDOWUDLQLQJ
o $VNVXEMHFWVDQGWKHLUSDUHQWVF DUHJLYHUVLIDSSOLFDEOHDERXW DGYHUVHHYHQW VGHYLFH
SHUIRUPDQFHDQGXQH[SODLQHGK\SHUJO\FHPLD
o 5HYLHZ&DUH/LQNUHSRUWV
o ,QVWUXFWVXEMHFWVDERXWUX QLQSHULRGPHDOFKDOOHQJH
x 9LVLW2IILFH9LUWXD O2IILFH'D\Â“GD\VDIWHU9LVLW 
o $VNVXEMHFWVDQGWKHLUSDUHQWVF DUHJLYHUVLIDSSOLFDEOHDERXW DGYHUVHHYHQWVGHYLFH
SHUIRUPDQFHDQGXQH[S ODLQHGK\SHUJO\FHPLD
o 5HYLHZ&DUH/LQNUHSRUWV
o 5HPLQGVXEMHFWVDERXWUXQ LQSHULRGPHDOFKDOOHQJH
o 9LVLWDQG9LVLWPD\EHFRPELQHG

Study Period:  
x 9LVLW2IILFH9LUWXD O2IILFH6WDUW6WXG \3HULRGZLWK/\XPMH YLQVXOLQ
'D\GD\VDIWHU9LVLW
o $VNVXEMHFWVDQGWKHLUSDUHQWVF DUHJLYHUVLIDSSOLFDEOHDERXW DGYHUVHHYHQWVGHYLFH
SHUIRUPDQFHXQH[SODLQHGK\SHUJO\FHPLDDQGLQVXOLQLQIXVLRQUHO DWHGLVVXHVZLWK
/\XPMHYLQVXOLQ
o +E$FIRUVXEMHFWVDQGROGHU
o 5HYLHZ&DUH/LQNUHSRUWV
o 6WDUW$XWR%DVDOWDUJHWDWPJG/VHWSRLQWZLWK$FWLYH,QVXO LQ7LPHVHWWRKRXUV
WLWUDWHWRZDUGVKRXUVRUDWLQYHVWLJDWRUÂ¶VGLVFUHWLRQ
o 7XUQRQ6PDUW*XDUGZLWK$XWR&RUUHFWLRQVÂ³21Â´
CIP335 Clinical Investigation Plan 
 Form 
D00409632 Version E Page 53 of 106 
0HGWURQLF%XVLQHVV5HVWULFWHG
CONFIDENTIAL )5HY(&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Form
o ,QVWUXFWVXEMHFWVDERXWWKHUHTXLUHGPHDODQGH[HUFLVHFKDOOHQJ HVIRUERWKWKH
PJG/DQGPGG/VHWSRLQWEHW ZHHQYLVLWVDQGRIWKHVWX G\SHULRG
x 9LVLW3KRQH'D\DIWHU9LVLW 5HTXLUHGIRUVXEMHFWVZL WKRXW&*0RUFORVHGORRS
H[SHULHQFHDVQHHGHGIRUDOORWKHUV
o $GMXVWSXPSVHWWLQJVDVQHHGHG
o $VNVXEMHFWVWKHLUSDUHQWVFDUH JLYHUVLIDSSOLFDEOHDQGFRP SDQLRQVLIWKH\UHTXLUH
DVVLVWDQFHHJDGGLWLRQDOWUDLQLQJ
o $VNVXEMHFWVDQGWKHLUSDUHQWVF DUHJLYHUVLIDSSOLFDEOHDERXW DGYHUVHHYHQWVGHYLFH
SHUIRUPDQFHXQH[SODLQHGK\SHUJO\FHPLDDQGLQVXOLQLQIXVLRQUHO DWHGLVVXHVZLWK
/\XPMHYLQVXOLQ
o 5HYLHZ&DUH/LQNUHSRUWV
o 5HPLQGVXEMHFWVDERXWPHDOH[HUF LVHFKDOOHQJHVIRUPJG/VH WSRLQW
x 9LVLW3KRQH'D\Â“GD\VDIWHU9LVLW
o $GMXVWSXPSVHWWLQJVDVQHHGHG
o $VNVXEMHFWVDQGWKHLUSDUHQWVF DUHJLYHUVLIDSSOLFDEOHDERXW DGYHUVHHYHQW VGHYLFH
SHUIRUPDQFHXQH[SODLQHGK\SHUJO\FHPLDDQGLQVXOLQLQIXVLRQUHO DWHGLVVXHVZLWK
/\XPMHYLQVXOLQ
o 5HYLHZ&DUH/LQNUHSRUWV
o 5HPLQGVXEMHFWVDERXWPHDOH[HU FLVHFKDOOHQJHVIRUPJG/VH WSRLQW
x 9LVLW3KRQH'D\Â“GD\VDIWHU9LVLW
o $GMXVWSXPSVHWWLQJVDVQHHGHG
o $VNVXEMHFWVDQGWKHLUSDUHQWVF DUHJLYHUVLIDSSOLFDEOHDERXW DGYHUVHHYHQWVGHYLFH
SHUIRUPDQFHXQH[SODLQHGK\SHUJO\FHPLDDQGLQVXOLQLQIXVLRQUHO DWHGLVVXHVZLWK
/\XPMHYLQVXOLQ
o 5HYLHZ&DUH/LQNUHSRUWV
o 5HPLQGVXEMHFWVDERXWPHDOH[HUF LVHFKDOOHQJHVIRUPJG/VH WSRLQW
x 9LVLW3KRQH'D\Â“GD\VDIWHU9LVLW
o $GMXVWSXPSVHWWLQJVDVQHHGHG
o $VNVXEMHFWVDQGWKHLUSDUHQWVF DUHJLYHUVLIDSSOLFDEOHDERXW DGYHUVHHYHQWVGHYLFH
SHUIRUPDQFHXQH[SODLQHGK\SHUJO\FHPLDDQGLQVXOLQLQIXVLRQUHO DWHGLVVXHVZLWK
/\XPMHYLQVXOLQ
o 5HYLHZ&DUH/LQNUHSRUWV
o &KDQJH$XWR%DVDOWDUJHWWR PJG/VHWSRLQWZLWK$FWLYH,QVX OLQ7LPHVHWWR
KRXUVRUDWLQYHVWLJDWRUÂ¶VGLVFUHWLRQ
o 5HPLQGVXEMHFWVDERXWPHDOH[HUF LVHFKDOOHQJHVIRUPJG/VH WSRLQW
x 9LVLW2IILFH9LUWXDO2IILFH 'D\GD\VDIWHU9LVLW 
o $GMXVWSXPSVHWWLQJVDVQHHGHG
o $VNVXEMHFWVDQGWKHLUSDUHQWVF DUHJLYHUVLIDSSOLFDEOHDERXW DGYHUVHHYHQWVGHYLFH
SHUIRUPDQFHXQH[SODLQHGK\SHUJO\FHPLDDQGLQVXOLQLQIXVLRQUHO DWHGLVVXHVZLWK
/\XPMHYLQVXOLQ
o +E$FIRUVXEMHFWVDQGROGHU
o 5HYLHZ&DUH/LQNUHSRUWV
x 9LVLW2IILFH9LUWXDO2IILFH 'D\Â“GD\VDIWHU9LVLW 
o $GMXVW$XWR%DVDOWDUJHWZLWK$FW LYH,QVXOLQ7LPHDWLQYHVWLJDW RUÂ¶VGLVFUHWLRQ
o $VNVXEMHFWVDQGWKHLUSDUHQWVF DUHJLYHUVLIDSSOLFDEOHDERXW DGYHUVHHYHQWVGHYLFH
SHUIRUPDQFHXQH[SODLQHGK\SHUJO \FHPLDDQGLQVXOLQLQIXVLRQUH ODWHGLVVXHVZLWK
/\XPMHYLQVXOLQ
o 5HYLHZ&DUH/LQNUHSRUWV
CIP335 Clinical Investigation Plan 
 Form 
D00409632 Version E Page 54 of 106 
0HGWURQLF%XVLQHVV5HVWULFWHG
CONFIDENTIAL )5HY(&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Form
o 5HPLQGVXEMHFWVDERXWPHDOH[HUFLVHFKDOOHQJHV
x 9LVLW2IILFH9LUWXDO2IILFH 'D\GD\VDIWHU9LVLW 
o $GMXVWSXPSVHWWLQJVDVQHHGHG
o $VNVXEMHFWVDQGWKHLUSDUHQWVF DUHJLYHUVLIDSSOLFDEOHDERXW DGYHUVHHYHQWVGHYLFH
SHUIRUPDQFHXQH[SODLQHGK\SHUJO\FHPLDDQGLQVXOLQLQIXVLRQUHO DWHGLVVXHVZLWK
/\XPMHYLQVXOLQ
o +E$FIRUVXEMHFWVDQGROGHU
o 5HYLHZ&DUH/LQNUHSRUWV
x 9LVLW2IILFH9LUWXDO2IILFH'D\GD\VDIWHU9LVLW 
o $VNVXEMHFWVDQGWKHLUSDUHQWVF DUHJLYHUVLIDSSOLFDEOHDERXW DGYHUVHHYHQWVGHYLFH
SHUIRUPDQFHXQH[SODLQHGK\SHUJO\FHPLDDQGLQVXOLQLQIXVLRQUHO DWHGLVVXHVZLWK
/\XPMHYLQVXOLQ
o 5HYLHZ&DUH/LQNUHSRUWV
o 5HWXUQVWXG\GHYLFHV
o +E$FIRUDOOVXEMHFWV
o (QGRI6WXG\(26
CIP335 Clinical Investigation Plan 
 Form 
D00409632 Version E Page 55 of 106 
0HGWURQLF%XVLQHVV5HVWULFWHG
CONFIDENTIAL )5HY(&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Form
Table 3. Study Visit Details 
  Run-In Period Study Period 
Visit 1 
(Office)Visit 2 
(Office) Visit 3** 
and 4**
(Phone) Visit 5 
(Phone) Visit 6 
(Office or 
Virtual 
Office) Visit 7 
(Office) Visit 
8**
(Phone) Visit 9, 10 
& 11
(Phone) Visit 12 
(Office) Visit 13 
(Office) Visit 14 
(Office) Visit 15* 
(Office) 
Visit Window  Enrollment   Day 1 
and Day 
3 after 
Visit 2  Day 7 
(Â±2 
days) 
after 
Visit 2 Day 14 
(Â±3 
days) 
after 
Visit 2  Day 7  
(-7 
days) 
after 
Visit 6 Day 2 
after 
Visit 7 Day 7 (Â±2 
days),  
Day 14 (Â±3 
days), and 
Day 21 (Â±3 
days) after 
Visit 7 Day 28 
(+7 
days) 
after 
Visit 7 Day 44 
(Â±3 
days) 
after 
Visit 7 Day 60 
(+7 
days) 
after 
Visit 7 Day 90 
(+7 
days) 
after 
Visit 7 
EOS 
Visit Activities and Data Collection 
&ROOHFWFRQVHQWIRUPVHJ,&)
$VVHQWIRUPLIDSSOLFDEOH&DOLIRUQLD
([SHULPHQWDO6XEMHFWÂ¶V%LOORI5LJKWVLIDSSOLFDEOH+,3$$IRUPDQGIRUPV
UHTXLUHGE\ORFDOUHJXODWLRQ;    
    
    
$VVHVVVXEMHFWHOLJLELOLW\WRSDUWLFLSDWH
LQWKHVWXG\;    
    
    
0HDVXUHVXEMHFWKHLJKWDQGZHLJKW
1RWH%RG\PDVVLQGH[%0,ZLOOEH
FDOFXODWHGDXWRPDWLFDOO\LQWKHVWXG\
GDWDEDVHEDVHGRQKHLJKWDQGZHLJKW
PHDVXUHPHQWVHQWHUHG;   

; 
&ROOHFWGHPRJUDSKLFDQGRWKHU
EDVHOLQHFKDUDFWHULVWLFVDFFRUGLQJWRH&5)TXHVWLRQV;         
&ROOHFWXULQHWHVWIRUSUHJQDQF\IURP
IHPDOHVXEMHFWVRIFKLOGEHDULQJDJH
RUFDSDELOLW\3RLQWRI&DUHRUORFDO
ODE;    
     
  
&ROOHFWEORRGVDPSOHIRU+E$FWHVWLQJ
DOOVXEMHFWV$OOFROOHFWHGEORRG
VSHFLPHQVZLOOEHVHQWWRDQGWHVWHG
E\D1*63FHUWLILHG&HQWUDO/DERUDWRU\+E$FWHVWLQJPXVWIROORZ
1*63VWDQGDUGV;    
  
; 
&ROOHFWEORRGVDPSOHIRU+E$FWHVWLQJ
6XEMHFWV\HDUVRIDJHDQGROGHU
$OOFROOHFWHGEORRGVSHFLPHQVZLOOEH    
 ; 
; ;   
CIP335 Clinical Investigation Plan 
 Form 
D00409632 Version E Page 56 of 106 
0HGWURQLF%XVLQHVV5HVWULFWHG
CONFIDENTIAL )5HY(&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Form
  Run-In Period Study Period 
Visit 1 
(Office)Visit 2 
(Office) Visit 3** 
and 4** 
(Phone) Visit 5 
(Phone) Visit 6 
(Office or 
Virtual 
Office) Visit 7 
(Office) Visit 
8** 
(Phone) Visit 9, 10 
& 11 
(Phone) Visit 12 
(Office) Visit 13 
(Office) Visit 14 
(Office) Visit 15* 
(Office) 
Visit Window  Enrollment   Day 1 
and Day 
3 after 
Visit 2  Day 7 
(Â±2 
days) 
after 
Visit 2 Day 14 
(Â±3 
days) 
after 
Visit 2  Day 7  
(-7 
days) 
after 
Visit 6 Day 2 
after 
Visit 7 Day 7 (Â±2 
days),  
Day 14 (Â±3 
days), and 
Day 21 (Â±3 
days) after 
Visit 7 Day 28 
(+7 
days) 
after 
Visit 7 Day 44 
(Â±3 
days) 
after 
Visit 7 Day 60 
(+7 
days) 
after 
Visit 7 Day 90 
(+7 
days) 
after 
Visit 7 
EOS 
VHQWWRDQGWHVWHGE\D1*63FHUWLILHG
&HQWUDO/DERUDWRU\+E$FWHVWLQJ
PXVWIROORZ1*63VWDQGDUGV
&ROOHFWVSHFLPHQVIRUUHTXLUHGODEWHVWLQJ+HPDWRFULW&UHDWLQLQH76+
VHHODELQVWUXFWLRQVIRUDGGLWLRQDO
LQIRUPDWLRQ;    
     
  
&ROOHFWLQIRUPDWLRQDERXWPHGLFDO
KLVWRU\;           
&ROOHFWLQIRUPDWLRQDERXWFRQFRPLWDQW
PHGLFDWLRQV;          
&ROOHFWDQ\FKDQJHVWRGLDEHWHV
PHGLFDWLRQVGXULQJWKHVWXG\;LI
DSSOLFDEO
H;LI
DSSOLFDEOH  ;LI
DSSOLFDEO
H;LI
DSSOLFDEOH  ;LI
DSSOLFDEOH
 ;LI
DSSOLFDEO
H ;LI
DSSOLFDEOH;LI
DSSOLFDEOH;LI
DSSOLFDEOH;LI
DSSOLFDEOH;LI
DSSOLFDEOH
&RQILUPVXEMHFWHOLJLELOLW\UHVXOWVLQFOXGLQJODEVSULRUWRPRYLQJ
IRUZDUGZLWKDQ\VWXG\SURFHGXUHV;  

   
$VVLVWZLWK4XHVWLRQQDLUHV5HIHUWR
&,34XHVWLRQQDLUH*XLGHIRU
DGPLQLVWUDWLRQGHWDLOV;    
 ; 

;
3URYLGHVWXG\VXEMHFWVZLWKWKH$FFX
&KHN*XLGH/LQNVWXG\PHWHUDQG
NHWRQHPHWHULQFOXGLQJQHHGHG
VXSSOLHV;   
$VQHHGHG  $V
QHHGHG    $VQHHGHG $VQHHGHG $VQHHGHG
&RPSOHWH4XDOLW\&RQWURO4&WHVWLQJ
RIWKH$FFX&KHN*XLGH/LQNVWXG\
PHWHUDQGNHWRQHPHWHUSHU
UHVSHFWLYHXVHUJXLGH;   
$VQHHGHG  $V
QHHGHG  $V
QHHGHG  $VQHHGHG $VQHHGHG $VQHHGHG $VQHHGHG
7UDLQVXEMHFWVDQGSDUHQWVFDUHJLYHUV
LIDSSOLFDEOHRQWKHXVHRIWKH$FFX
&KHN*XLGH/LQNVWXG\PHWHUDQG
NHWRQHPHWHUUHIHUWRXVHUJXLGHV;    
      
7UDLQFRPSDQLRQVRQHPHUJHQF\
UHVSRQVHDQGWKHXVHRIWKHNHWRQH
PHWHUUHIHUWRXVHUJXLGHV;    
      
CIP335 Clinical Investigation Plan 
 Form 
D00409632 Version E Page 57 of 106 
0HGWURQLF%XVLQHVV5HVWULFWHG
CONFIDENTIAL )5HY(&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Form
  Run-In Period Study Period 
Visit 1 
(Office)Visit 2 
(Office) Visit 3** 
and 4** 
(Phone) Visit 5 
(Phone) Visit 6 
(Office or 
Virtual 
Office) Visit 7 
(Office) Visit 
8** 
(Phone) Visit 9, 10 
& 11 
(Phone) Visit 12 
(Office) Visit 13 
(Office) Visit 14 
(Office) Visit 15* 
(Office) 
Visit Window  Enrollment   Day 1 
and Day 
3 after 
Visit 2  Day 7 
(Â±2 
days) 
after 
Visit 2 Day 14 
(Â±3 
days) 
after 
Visit 2  Day 7  
(-7 
days) 
after 
Visit 6 Day 2 
after 
Visit 7 Day 7 (Â±2 
days),  
Day 14 (Â±3 
days), and 
Day 21 (Â±3 
days) after 
Visit 7 Day 28 
(+7 
days) 
after 
Visit 7 Day 44 
(Â±3 
days) 
after 
Visit 7 Day 60 
(+7 
days) 
after 
Visit 7 Day 90 
(+7 
days) 
after 
Visit 7 
EOS 
7UDLQVXEMHFWVDQGSDUHQWVFDUHJLYHUV
LIDSSOLFDEOHRQWKHXVHRIWKH*
SXPS;    
    
    
6WDUWVWXG\VXEMHFWVRQWKH*
LQVXOLQSXPSV\VWHP0DQXDO0RGH;            
3URYLGHVWXG\VXEMHFWVWKH0HGWURQLF
([WHQGHGLQIXVLRQVHWVUHVHUYRLUV
VHQVRUVDQGWUDQVPLWWHU;   $VQHHGHG  $V
QHHGHG  $VQHHGHG  $VQHHGHG $VQHHGHG
7UDLQVXEMHFWVDQGSDUHQWVFDUHJLYHUV
LIDSSOLFDEOHRQWKH0HGWURQLF
([WHQGHGLQIXVLRQVHWVUHVHUYRLUV
VHQVRUVDQGWUDQVPLWWHU;    
    
    
6WDUWVWXG\VXEMHFWVRQ&*0
WUDQVPLWWHUDQGVHQVRUDQG
DFFHVVRULHV;    
    
    
,QVWUXFWUHPLQGVXEMHFWVDQG
SDUHQWVFDUHJLYHUVLIDSSOLFDEOHWR
SODFHWKHVHQVRULQDORFDWLRQWKDWLV
DSSURYHGIRUSODFHPHQWSHUWKH8VHU
JXLGHDQGVWXG\GLUHFWLRQVDV
DSSOLFDEOH;  ;  ; ;  ; ;  ; ;  ; ; 
7UDLQVXEMHFWVDQGWKHLU
SDUHQWVFDUHJLYHUVLIDSSOLFDEOHRQ
WKHXVHRI6PDUW*XDUG;
$V
DSSOLFDEOH   ;       
6WDUWVWXG\VXEMHFWVRQ*
6PDUW*XDUG7KHXVHRI6PDUW*XDUG
ZLWKWKHH[FHSWLRQRI$XWR&RUUHFWLRQ
GXULQJUXQLQLVSHUPLWWHGIRUVWXG\
VXEMHFWVZKRDUHXVLQJWKH$XWR0RGH
IHDWXUHSULRUWRVFUHHQLQJLQD
0HGWURQLFSXPS1RWHWKDWWKHGHIDXOWIRU$XWR&RUUHFWLRQLVÂ³21Â´DQGPXVW
EHPDQXDOO\WXUQHGRII

5HFRPPHQGHG6HWWLQJVIRUVXEMHFWV
XVLQJ6PDUW*XDUG;
6XEMHFWV
ZLWK$XWR
0RGH
H[SHULHQFH  
 ;
6XEMHFWV
ZLWKRXW$XWR
0RGH
H[SHULHQFH  
    
CIP335 Clinical Investigation Plan 
 Form 
D00409632 Version E Page 58 of 106 
0HGWURQLF%XVLQHVV5HVWULFWHG
CONFIDENTIAL )5HY(&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Form
  Run-In Period Study Period 
Visit 1 
(Office)Visit 2 
(Office) Visit 3** 
and 4** 
(Phone) Visit 5 
(Phone) Visit 6 
(Office or 
Virtual 
Office) Visit 7 
(Office) Visit 
8** 
(Phone) Visit 9, 10 
& 11 
(Phone) Visit 12 
(Office) Visit 13 
(Office) Visit 14 
(Office) Visit 15* 
(Office) 
Visit Window  Enrollment   Day 1 
and Day 
3 after 
Visit 2  Day 7 
(Â±2 
days) 
after 
Visit 2 Day 14 
(Â±3 
days) 
after 
Visit 2  Day 7  
(-7 
days) 
after 
Visit 6 Day 2 
after 
Visit 7 Day 7 (Â±2 
days),  
Day 14 (Â±3 
days), and 
Day 21 (Â±3 
days) after 
Visit 7 Day 28 
(+7 
days) 
after 
Visit 7 Day 44 
(Â±3 
days) 
after 
Visit 7 Day 60 
(+7 
days) 
after 
Visit 7 Day 90 
(+7 
days) 
after 
Visit 7 
EOS 
x 8VHPJG/$XWR%DVDO
WDUJHWVHWWLQJV

$OORWKHUVDUHWRXVHWKHV\VWHPLQ0DQXDO0RGHGXULQJWKHUXQLQSHULRG

7UDLQVXEMHFWVZKRZHUHDOORZHGWRVWDUW6PDUW*XDUGDW9LVLWRQWKH
$XWR&RUUHFWLRQIHDWXUHDQGWXUQWKH
IHDWXUHRQ   
 ;   
    
,QVWUXFWVXEMHFWVDQG
SDUHQWVFDUHJLYHUVLIDSSOLFDEOHWR
VZLWFKIURPSXPSWKHUDS\WRPDQXDO
LQMHFWLRQVXQWLOLVVXHLVUHVROYHGLI
x +RVSLWDODGPLVVLRQLV
QHHGHGIRUDQ\UHDVRQ
x *OXFRVHLVSHUVLVWHQWO\
HOHYDWHGLHDERYH
PJG/DQGQRWUHVSRQGLQJ
WRFRUUHFWLRQEROXVHVDQGRULQIXVLRQVHW
FKDQJHV
x 7KHUHLVDQRFFOXVLRQ
DODUPZLWKHOHYDWHGJOXFRVHZKHUHWKHVWXG\
VXEMHFWLVQRWDEOHWR
DGGUHVVWKHRFFOXVLRQE\
FKDQJLQJWKHLQIXVLRQVHW;    
 ;   
    
$GMXVWSXPSVHWWLQJV      $V
QHHGHG  $VQHHGHG  $VQHHGHG  $VQHHGHG  $VQHHGHG   
&UHDWHDQLQYHVWLJDWLRQDOFHQWHU
DFFRXQWLQWKH&DUH/LQNV\VWHP
VRIWZDUHVHHVHSDUDWHLQVWUXFWLRQV ;   
        
&UHDWHDQDFFRXQWIRUVWXG\VXEMHFWV
LQ&DUH/LQN3HUVRQDOVHHVHSDUDWHLQVWUXFWLRQV;        
/LQNWKHVWXG\VXEMHFWVDFFRXQWWRWKH
LQYHVWLJDWLRQDOFHQWHUDFFRXQW ;           
CIP335 Clinical Investigation Plan 
 Form 
D00409632 Version E Page 59 of 106 
0HGWURQLF%XVLQHVV5HVWULFWHG
CONFIDENTIAL )5HY(&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Form
  Run-In Period Study Period 
Visit 1 
(Office)Visit 2 
(Office) Visit 3** 
and 4** 
(Phone) Visit 5 
(Phone) Visit 6 
(Office or 
Virtual 
Office) Visit 7 
(Office) Visit 
8** 
(Phone) Visit 9, 10 
& 11 
(Phone) Visit 12 
(Office) Visit 13 
(Office) Visit 14 
(Office) Visit 15* 
(Office) 
Visit Window  Enrollment   Day 1 
and Day 
3 after 
Visit 2  Day 7 
(Â±2 
days) 
after 
Visit 2 Day 14 
(Â±3 
days) 
after 
Visit 2  Day 7  
(-7 
days) 
after 
Visit 6 Day 2 
after 
Visit 7 Day 7 (Â±2 
days),  
Day 14 (Â±3 
days), and 
Day 21 (Â±3 
days) after 
Visit 7 Day 28 
(+7 
days) 
after 
Visit 7 Day 44 
(Â±3 
days) 
after 
Visit 7 Day 60 
(+7 
days) 
after 
Visit 7 Day 90 
(+7 
days) 
after 
Visit 7 
EOS 
7UDLQVXEMHFWVDQGSDUHQWVFDUHJLYHUV
LIDSSOLFDEOHRQWKHXVHRI&DUH/LQN
3HUVRQDOÂ±SURYLGHUHOHYDQWVHWRI
ZULWWHQLQVWUXFWLRQV ;   
        
6HWXS*V\VWHPDSSVLI
DSSOLFDEOH
x 0LQL0HG&OLQLFDODSS
x &DUH/LQN&OLQLFDODSS ;
LI
DSSOLFDEO
H      
,IDSSOLFDEOH
7UDLQVXEMHFWVDQGSDUHQWFDUHJLYHUV
LIDSSOLFDEOHRQWKHXVHRIWKH*
V\VWHPDSSV0LQL0HG&OLQLFDODSSDQG
&DUH/LQN&OLQLFDODSS ;
LI
DSSOLFDEO
H  
    
    
7UDLQVXEMHFWVDQGSDUHQWVFDUHJLYHUV
RQWKHLQVWDOODWLRQDQGXVHRIWKH
)RRG3ULQWDSS ;   
    
    
,QVWUXFW5HPLQGVXEMHFWVDERXWWKH
UHTXLUHPHQWWRSHUIRUPDPHDO
FKDOOHQJHGXULQJWKH run-inSHULRG

,IDSSOLFDEOHIRUVXEMHFWVXVLQJ6PDUW*XDUGGXULQJWKHUXQLQSHULRG
6PDUW*XDUGVKRXOGQRWEHDFWLYDWHG
6PDUW*XDUGPXVWEHWXUQHGRIIDW
OHDVWKRXUVSULRUWRWKHPHDO
FKDOOHQJH;;,I
QHHGHG         
,QVWUXFW5HPLQGVXEMHFWVDERXWWKH
UHTXLUHPHQWWRSHUIRUPPHDODQG
H[HUFLVHFKDOOHQJHVGXULQJWKHVWXG\
SHULRGSURYLGHUHOHYDQWVHWRIZULWWHQ
LQVWUXFWLRQV
x $WPJG/$XWR%DVDO
6HWSRLQWGXULQJ between Visits 
7 and 11RIWKHVWXG\SHULRG
x $WPJG/$XWR%DVDO
6HWSRLQWGXULQJ between Visits 
11 and 13 RIWKHVWXG\SHULRG     ; ; ;  ;   
CIP335 Clinical Investigation Plan 
 Form 
D00409632 Version E Page 60 of 106 
0HGWURQLF%XVLQHVV5HVWULFWHG
CONFIDENTIAL )5HY(&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Form
  Run-In Period Study Period 
Visit 1 
(Office)Visit 2 
(Office) Visit 3** 
and 4** 
(Phone) Visit 5 
(Phone) Visit 6 
(Office or 
Virtual 
Office) Visit 7 
(Office) Visit 
8** 
(Phone) Visit 9, 10 
& 11 
(Phone) Visit 12 
(Office) Visit 13 
(Office) Visit 14 
(Office) Visit 15* 
(Office) 
Visit Window  Enrollment   Day 1 
and Day 
3 after 
Visit 2  Day 7 
(Â±2 
days) 
after 
Visit 2 Day 14 
(Â±3 
days) 
after 
Visit 2  Day 7  
(-7 
days) 
after 
Visit 6 Day 2 
after 
Visit 7 Day 7 (Â±2 
days),  
Day 14 (Â±3 
days), and 
Day 21 (Â±3 
days) after 
Visit 7 Day 28 
(+7 
days) 
after 
Visit 7 Day 44 
(Â±3 
days) 
after 
Visit 7 Day 60 
(+7 
days) 
after 
Visit 7 Day 90 
(+7 
days) 
after 
Visit 7 
EOS 
x $WFXUUHQW$XWR%DVDO6HWSRLQWDW
DQ\WLPHDIWHU Visit 13 RIWKH
VWXG\SHULRG
6WDUW$XWR%DVDOWDUJHWDWPJG/
PPRO/VHWSRLQWZLWK$FWLYH
,QVXOLQ7LPHVHWWRKRXUVWLWUDWHWRZDUGVKRXUVRUDWLQYHVWLJDWRUÂ¶VGLVFUHWLRQ

7XUQRQ6PDUW*XDUGZLWK$XWR&RUUHFWLRQVÂ³21Â´1RWH7KH$XWR%DVDOWDUJHWVHWWLQJDQG$FWLYH,QVXOLQ7LPHVKRXOGEHVHWDVUHFRPPHQGHGDERYHXQOHVVWKHUHLVDGRFXPHQWHGVDIHW\UHDVRQWKDWZRXOGQRWSHUPLWWKHVHVHWWLQJVWREHXVHG
     ;       
&KDQJH$XWR%DVDOWDUJHWWR
PJG/PPRO/VHWSRLQWZLWK
$FWLYH,QVXOLQ7LPHVHWWRKRXUVRUDWLQYHVWLJDWRUÂ¶VGLVFUHWLRQ

1RWH7KH$XWR%DVDOWDUJHWVHWWLQJ
DQG$FWLYH,QVXOLQ7LPHVKRXOGEHVHW
DVUHFRPPHQGHGDERYHXQOHVVWKHUHLVDGRFXPHQWHGVDIHW\UHDVRQWKDW
ZRXOGQRWSHUPLWWKHVHVHWWLQJVWREH
XVHG       ;
9LVLW      
$GMXVWWKH$XWR%DVDOWDUJHWDVZHOODV
$FWLYH,QVXOLQ7LPHVKRXOGEHVHWWR
ZKDWLVEHVWIRUWKHLQGLYLGXDOVXEMHFW
DWLQYHVWLJDWRUÂ¶VGLVFUHWLRQ         ;   
CIP335 Clinical Investigation Plan 
 Form 
D00409632 Version E Page 61 of 106 
0HGWURQLF%XVLQHVV5HVWULFWHG
CONFIDENTIAL )5HY(&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Form
  Run-In Period Study Period 
Visit 1 
(Office)Visit 2 
(Office) Visit 3** 
and 4** 
(Phone) Visit 5 
(Phone) Visit 6 
(Office or 
Virtual 
Office) Visit 7 
(Office) Visit 
8** 
(Phone) Visit 9, 10 
& 11 
(Phone) Visit 12 
(Office) Visit 13 
(Office) Visit 14 
(Office) Visit 15* 
(Office) 
Visit Window  Enrollment   Day 1 
and Day 
3 after 
Visit 2  Day 7 
(Â±2 
days) 
after 
Visit 2 Day 14 
(Â±3 
days) 
after 
Visit 2  Day 7  
(-7 
days) 
after 
Visit 6 Day 2 
after 
Visit 7 Day 7 (Â±2 
days),  
Day 14 (Â±3 
days), and 
Day 21 (Â±3 
days) after 
Visit 7 Day 28 
(+7 
days) 
after 
Visit 7 Day 44 
(Â±3 
days) 
after 
Visit 7 Day 60 
(+7 
days) 
after 
Visit 7 Day 90 
(+7 
days) 
after 
Visit 7 
EOS 

1RWH7KH$XWR%DVDOWDUJHWVHWWLQJ
DQG$FWLYH,QVXOLQ7LPHVKRXOGEHVHW
DVUHFRPPHQGHGDERYHXQOHVVWKHUH
LVDGRFXPHQWHGVDIHW\UHDVRQWKDW
ZRXOGQRWSHUPLWWKHVHVHWWLQJVWREH
XVHG
'LVSHQVH/\XPMHY      ;   $V1HHGHG $V1HHGHG  
'LVSHQVHVWXG\PDWHULDOVHJ
VPDUWSKRQH>XSRQUHTXHVWDQG
DSSURYDO@UHIHUHQFHJXLGHVVXEMHFW
WUDLQLQJPDWHULDOVHWF;    
       
'LVSHQVHRWKHUVWXG\VXSSOLHVDV
QHHGHGHJDOFRKROVZDEVDGKHVLYH
UHPRYHUHWF;   
$VQHHGHG$V
QHHGHG
$VQHHGHG  $VQHHGHG $VQHHGHG 
$WDQ\WLPHLIWKHLQYHVWLJDWLRQDO
FHQWHULVFRQWDFWHGDGMXVWLQVXOLQ
VHWWLQJVDQGLQVXOLQGRVHDVQHHGHG ; $VQHHGHG$V
QHHGHG$VQHHGHG$V
QHHGHG$V
QHHGHG$VQHHGHG $VQHHGHG  $VQHHGHG $VQHHGHG 
&RQILUPWKHVWXG\SXPSXSORDGGDWD
LVDYDLODEOHLQ&DUH/LQNV\VWHP
VRIWZDUHDWRIILFHYLVLWRUGD\SULRULI
SKRQHRUYLUWXDORIILFHYLVLW ; ; ; ; ; ;  ;  ;  ; ; ;
3ULQWDQGUHYLHZ&DUH/LQNV\VWHP
UHSRUWV  ; ; ; ; ; ; ; ; ; ;
5HYLHZVXUYHLOODQFHUHSRUWLQ
0HGWURQLFÂ¶VVHFXUHXSORDGDSSOLFDWLRQ
DQGUHYLHZZLWKVXEMHFWVDVQHFHVVDU\$VQHHGHG$V
QHHGHG$VQHHGHG$V
QHHGHG$V
QHHGHG$VQHHGHG $VQHHGHG $VQHHGHG $VQHHGHG $VQHHGHG
(QWHUGDWDLQWRH&5)VDVUHTXLUHG ; ; ; ; ; ; ; ; ;  ; ; ;
6FKHGXOHQH[WYLVLWGD\DQGWLPH ; ; ; ; ; ; ; ; ;  ; ; 
&ROOHFWDQGGHVWUR\/\XPMHY   ;
&ROOHFWVWXG\GHYLFHVDWVWXG\HQG
VHHGHYLFHGLVSRVLWLRQ Table 2IRU
GHWDLOV
1RWH,IWKHYLVLWPXVWEHFRQGXFWHG
YLD9LUWXDO2IILFHWKHEORRGWHVWVPD\ 


;
CIP335 Clinical Investigation Plan 
 Form 
D00409632 Version E Page 62 of 106 
0HGWURQLF%XVLQHVV5HVWULFWHG
CONFIDENTIAL )5HY(&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Form
  Run-In Period Study Period 
Visit 1 
(Office)Visit 2 
(Office) Visit 3** 
and 4** 
(Phone) Visit 5 
(Phone) Visit 6 
(Office or 
Virtual 
Office) Visit 7 
(Office) Visit 
8** 
(Phone) Visit 9, 10 
& 11 
(Phone) Visit 12 
(Office) Visit 13 
(Office) Visit 14 
(Office) Visit 15* 
(Office) 
Visit Window  Enrollment   Day 1 
and Day 
3 after 
Visit 2  Day 7 
(Â±2 
days) 
after 
Visit 2 Day 14 
(Â±3 
days) 
after 
Visit 2  Day 7  
(-7 
days) 
after 
Visit 6 Day 2 
after 
Visit 7 Day 7 (Â±2 
days),  
Day 14 (Â±3 
days), and 
Day 21 (Â±3 
days) after 
Visit 7 Day 28 
(+7 
days) 
after 
Visit 7 Day 44 
(Â±3 
days) 
after 
Visit 7 Day 60 
(+7 
days) 
after 
Visit 7 Day 90 
(+7 
days) 
after 
Visit 7 
EOS 
EHFROOHFWHGYLDPRELOHSKOHERWRP\
VHUYLFH6XEMHFWVVKRXOGVHQGGHYLFHV
EDFNWRWKHLQYHVWLJDWLRQDOFHQWHU
Questions To Ask at Study Visits 
$VNLIVXEMHFWVKDYHJHQHUDOVWXG\
UHODWHGTXHVWLRQVDQGFRQFHUQV; ; ; ; ; ; ; ; ; ; ; ;
$VNVXEMHFWVDERXWWKHRFFXUUHQFHRI
DGYHUVHHYHQWV
x 5HFRUGWKHHYHQWRQWKH
DSSURSULDWHH&5)LIDVWXG\VXEMHFWUHSRUWVD
FKDQJHLQKHDOWKVWDWXV
WKDWUHVXOWVLQDQHZPHGLFDOFRQGLWLRQRULQD
GHWHULRUDWLRQRIDQH[LVWLQJ
PHGLFDOFRQGLWLRQVXFKDV
LOOQHVVRUJO\FHPLF
SUREOHPV
x ,QVWUXFWVXEMHFWWRFDOOWKH
LQYHVWLJDWLRQDOFHQWHUWR
UHSRUWDQ\FKDQJHVWR
WKHLUKHDOWKVWDWXVVHH
DGYHUVHHYHQWGHILQLWLRQ ; ; ; ; ; ;  ;  ; ; ; ; 
$VNVXEMHFWVDERXWGHYLFH
SHUIRUPDQFHLVVXHVDQGLIWKH\FDOOHG
WKH0HGWURQLF+RXU7HFKQLFDO
6XSSRUW76OLQHWRUHSRUWWKHP

,QVWUXFW5HPLQGVXEMHFWVWRFRQWDFW
WKH0HGWURQLF+RXU76LQWKHHYHQW
WKH\H[SHULHQFHSUREOHPVZLWKWKHLU
VWXG\GHYLFHV ; ; ; ; ; ;  ;  ; ; ; ; 
$VNVXEMHFWVDQGWKHLU
SDUHQWVFDUHJLYHUVDERXWLQVXOLQ
LQIXVLRQUHDFWLRQVZLWK/\XPMHY
LQVXOLQ&RPSOHWHDQ,QVXOLQ,QIXVLRQ
$VVHVVPHQW&5)LIQHHGHG      ; ; ; ; ; ;
CIP335 Clinical Investigation Plan 
 Form 
D00409632 Version E Page 63 of 106 
0HGWURQLF%XVLQHVV5HVWULFWHG
CONFIDENTIAL )5HY(&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Form
  Run-In Period Study Period 
Visit 1 
(Office)Visit 2 
(Office) Visit 3** 
and 4** 
(Phone) Visit 5 
(Phone) Visit 6 
(Office or 
Virtual 
Office) Visit 7 
(Office) Visit 
8** 
(Phone) Visit 9, 10 
& 11 
(Phone) Visit 12 
(Office) Visit 13 
(Office) Visit 14 
(Office) Visit 15* 
(Office) 
Visit Window  Enrollment   Day 1 
and Day 
3 after 
Visit 2  Day 7 
(Â±2 
days) 
after 
Visit 2 Day 14 
(Â±3 
days) 
after 
Visit 2  Day 7  
(-7 
days) 
after 
Visit 6 Day 2 
after 
Visit 7 Day 7 (Â±2 
days),  
Day 14 (Â±3 
days), and 
Day 21 (Â±3 
days) after 
Visit 7 Day 28 
(+7 
days) 
after 
Visit 7 Day 44 
(Â±3 
days) 
after 
Visit 7 Day 60 
(+7 
days) 
after 
Visit 7 Day 90 
(+7 
days) 
after 
Visit 7 
EOS 
$VNVXEMHFWVDQGWKHLU
SDUHQWVFDUHJLYHUVDERXWXQH[SODLQHG
K\SHUJO\FHPLD%*!PJG/!
KRXUVDIWHUDPHDOWKDWGRHVQRW
UHVROYHZLWK,QVXOLQEROXV
HJPJG/UHGXFWLRQLQ%*DIWHU
KRXUDQGOHDGVWRLQIXVLRQVHWUHSODFHPHQW&RPSOHWHDQ,QIXVLRQ
&KDQJHGXHWR8QH[SODLQHG
+\SHUJO\FHPLD&5)LIDSSURSULDWH  ; ; ; ; ; ; ; ; ; ;
$VNVXEMHFWVWKHLUSDUHQWVFDUHJLYHUV
LIDSSOLFDEOHDQGFRPSDQLRQVLIWKH\
UHTXLUHDVVLVWDQFHHJDGGLWLRQDO
WUDLQLQJ  ; ;   ;     
Study Subject General Training and Instructions 
5HPLQGVXEMHFWVDQGWKHLU
SDUHQWVFDUHJLYHUVLIDSSOLFDEOHWKDW
WKHXVHDQGZHDURIVWXG\GHYLFHV
WKURXJKRXWWKHVWXG\LVDUHTXLUHPHQW; ; ; ; ; ; ; ; ; ; 
,QVWUXFWVXEMHFWVRQFDUERK\GUDWH
&+2FRXQWLQJDVQHHGHG
,QYHVWLJDWRUGLVFUHWLRQ; ; ; ; ; ; ; ; ; ; 
,QVWUXFWVXEMHFWVFRPSDQLRQVDQG
WKHLUSDUHQWVFDUHJLYHUVLIDSSOLFDEOH
RQGLDEHWHVVHOIPDQDJHPHQW
SULQFLSOHVLQFOXGLQJUHVSRQVHWR
JO\FHPLFHYHQWVHJXVHRIRUDO
JOXFRVHJOXFDJRQLQFDVHRI
K\SRJO\FHPLDRUFKHFNLQJNHWRQHVLQ
FDVHRIVHYHUHK\SHUJO\FHPLD ;          
,QVWUXFWVXEMHFWVDQGWKHLU
SDUHQWVFDUHJLYHUVLIDSSOLFDEOHWKDWEORRGNHWRQHWHVWLQJLVUHTXLUHGHYHU\
WLPH%*LVJUHDWHUWKDQPJG/DV
PHDVXUHGE\WKH$FFX&KHN*XLGH
/LQNVWXG\PHWHU ; ;  ; ;  ; ; ; ;  ; ; 
CIP335 Clinical Investigation Plan 
 Form 
D00409632 Version E Page 64 of 106 
0HGWURQLF%XVLQHVV5HVWULFWHG
CONFIDENTIAL )5HY(&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Form
  Run-In Period Study Period 
Visit 1 
(Office)Visit 2 
(Office) Visit 3** 
and 4** 
(Phone) Visit 5 
(Phone) Visit 6 
(Office or 
Virtual 
Office) Visit 7 
(Office) Visit 
8** 
(Phone) Visit 9, 10 
& 11 
(Phone) Visit 12 
(Office) Visit 13 
(Office) Visit 14 
(Office) Visit 15* 
(Office) 
Visit Window  Enrollment   Day 1 
and Day 
3 after 
Visit 2  Day 7 
(Â±2 
days) 
after 
Visit 2 Day 14 
(Â±3 
days) 
after 
Visit 2  Day 7  
(-7 
days) 
after 
Visit 6 Day 2 
after 
Visit 7 Day 7 (Â±2 
days),  
Day 14 (Â±3 
days), and 
Day 21 (Â±3 
days) after 
Visit 7 Day 28 
(+7 
days) 
after 
Visit 7 Day 44 
(Â±3 
days) 
after 
Visit 7 Day 60 
(+7 
days) 
after 
Visit 7 Day 90 
(+7 
days) 
after 
Visit 7 
EOS 
,QVWUXFWVXEMHFWVDQGWKHLU
SDUHQWVFDUHJLYHUVWRFDOOWKH
LQYHVWLJDWLRQDOFHQWHULIWKH\
H[SHULHQFHDQLVVXHUHODWHGWRLQVXOLQ
LQIXVLRQZLWK/\XPMHYLQVXOLQ
6XEMHFWVVKRXOGEHSUHSDUHGWR
SURYLGHSKRWRJUDSKLFDQGRUYLGHRHYLGHQFHZKHUHDSSOLFDEOHVRWKDWDQ
DVVHVVPHQWFDQEHPDGHDQG
UHFRUGHG ;  ; ; ; ; ;  
,QVWUXFWVXEMHFWVDQGWKHLU
SDUHQWVFDUHJLYHUVWRFDOOWKH
LQYHVWLJDWLRQDOFHQWHULIWKH\
H[SHULHQFHXQH[SODLQHGK\SHUJO\FHPLD%*!PJG/!KRXUVDIWHUD
PHDOXQUHVSRQVLYHWRLQVXOLQEROXVWR
UHGXFH%*DSSUR[LPDWHO\PJG/LQ
KRXUDQGOHDGVWRLQIXVLRQVHW
UHSODFHPHQW ;    ;      
,QVWUXFWVXEMHFWVDQGWKHLU
SDUHQWVFDUHJLYHUVLIDSSOLFDEOHWR
FRQVLGHUDYRLGLQJWKHXVHRISURGXFWV
FRQWDLQLQJDFHWDPLQRSKHQ
,IPHGLFDWLRQVFRQWDLQLQJ
DFHWDPLQRSKHQDUHWDNHQ
x :DLWXQWLOXVHRIWKH
PHGLFDWLRQLVVWRSSHGEHIRUHXVLQJ6*WRPDNHWUHDWPHQW
GHFLVLRQV
x 8VHDGGLWLRQDO%*PHWHU
UHDGLQJVWRYHULI\JOXFRVH
OHYHOV
x :KLOHWKH6PDUW*XDUGIHDWXUH
LVDFWLYHLQVWUXFWVXEMHFWVWR
XVHWKHWHPSWDUJHWIHDWXUH
ZKHQXVHG$XWR&RUUHFWLRQLV
QRWDYDLODEOH ; ;  ; ;  ; ; ; ;  ; ; 
CIP335 Clinical Investigation Plan 
 Form 
D00409632 Version E Page 65 of 106 
0HGWURQLF%XVLQHVV5HVWULFWHG
CONFIDENTIAL )5HY(&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Form
  Run-In Period Study Period 
Visit 1 
(Office)Visit 2 
(Office) Visit 3** 
and 4** 
(Phone) Visit 5 
(Phone) Visit 6 
(Office or 
Virtual 
Office) Visit 7 
(Office) Visit 
8** 
(Phone) Visit 9, 10 
& 11 
(Phone) Visit 12 
(Office) Visit 13 
(Office) Visit 14 
(Office) Visit 15* 
(Office) 
Visit Window  Enrollment   Day 1 
and Day 
3 after 
Visit 2  Day 7 
(Â±2 
days) 
after 
Visit 2 Day 14 
(Â±3 
days) 
after 
Visit 2  Day 7  
(-7 
days) 
after 
Visit 6 Day 2 
after 
Visit 7 Day 7 (Â±2 
days),  
Day 14 (Â±3 
days), and 
Day 21 (Â±3 
days) after 
Visit 7 Day 28 
(+7 
days) 
after 
Visit 7 Day 44 
(Â±3 
days) 
after 
Visit 7 Day 60 
(+7 
days) 
after 
Visit 7 Day 90 
(+7 
days) 
after 
Visit 7 
EOS 
x ,QVWUXFWVXEMHFWVWKDWLQFDVHRI
SURORQJHGXVHRI
DFHWDPLQRSKHQWKHWHPS
WDUJHWIHDWXUHFDQEHXVHGUHSHDWHGO\DQGLQVXFFHVVLRQ
5HPLQGVXEMHFWDQGWKHLUSDUHQWVFDUHJLYHUVLIDSSOLFDEOHWR
EULQJLQERWK$FFX&KHN*XLGH/LQN
VWXG\PHWHUDQGNHWRQHPHWHUDWHDFK
UHTXLUHGRIILFHYLVLW ; ; ;  ;  ; ; ; 
5HPLQGVXEMHFWDQGWKHLU
SDUHQWVFDUHJLYHUVLIDSSOLFDEOHWR
NHHSWKHLUGHYLFHVFKDUJHGDV
DSSOLFDEOH ; ;  ; ;  ; ; ; ;  ; ; 
,QVWUXFWVXEMHFWVDQGWKHLU
SDUHQWVFDUHJLYHUVLIDSSOLFDEOH
UHJDUGLQJWKHXVHRIWKH$FFX&KHN
*XLGH/LQNVWXG\PHWHUWRPDNH
WUHDWPHQWGHFLVLRQV
x :KHQD%*UHTXLUHGDOHUWLV
UHFHLYHGo &OHDUWKHDOHUWDQGHQWHU
D%*PHWHUUHDGLQJ
EHIRUHXVLQJWKH6*WRPDNHWUHDWPHQWGHFLVLRQV
x :KHQV\PSWRPVDUHSUHVHQW
o ,I6*UHDGLQJVDUHQRW
DOLJQHGZLWKV\PSWRPVHJLIDVWXG\VXEMHFW
LVIHHOLQJORZZKLOHWKH
6*UHDGLQJLVQRWORZ
XVHWKHPHWHUWR
FRQILUP%*
o ,I6*UHDGLQJVFRQWLQXH
WREHGLIIHUHQWIURP
V\PSWRPVFDOOWKH
VWXG\GRFWRU ; ;  ; ;  ; ; ; ;  ; ; 
CIP335 Clinical Investigation Plan 
 Form 
D00409632 Version E Page 66 of 106 
0HGWURQLF%XVLQHVV5HVWULFWHG
CONFIDENTIAL )5HY(&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Form
  Run-In Period Study Period 
Visit 1 
(Office)Visit 2 
(Office) Visit 3** 
and 4** 
(Phone) Visit 5 
(Phone) Visit 6 
(Office or 
Virtual 
Office) Visit 7 
(Office) Visit 
8** 
(Phone) Visit 9, 10 
& 11 
(Phone) Visit 12 
(Office) Visit 13 
(Office) Visit 14 
(Office) Visit 15* 
(Office) 
Visit Window  Enrollment   Day 1 
and Day 
3 after 
Visit 2  Day 7 
(Â±2 
days) 
after 
Visit 2 Day 14 
(Â±3 
days) 
after 
Visit 2  Day 7  
(-7 
days) 
after 
Visit 6 Day 2 
after 
Visit 7 Day 7 (Â±2 
days),  
Day 14 (Â±3 
days), and 
Day 21 (Â±3 
days) after 
Visit 7 Day 28 
(+7 
days) 
after 
Visit 7 Day 44 
(Â±3 
days) 
after 
Visit 7 Day 60 
(+7 
days) 
after 
Visit 7 Day 90 
(+7 
days) 
after 
Visit 7 
EOS 
,QVWUXFWVXEMHFWVDQGWKHLU
SDUHQWVFDUHJLYHUVLIDSSOLFDEOHWR
UHIHUSULPDU\KHDOWKFDUHSURYLGHUVWR
WKHLQYHVWLJDWLRQDOFHQWHUVWDIILIWKH\
KDYHDQ\TXHVWLRQVDERXWVWXG\
GHYLFHVDQGWKHLUIXQFWLRQV ; ; ; ; ; ;  ;  ; ; ; ; 
,QVWUXFWVXEMHFWVDQGWKHLU
SDUHQWVFDUHJLYHUVLIDSSOLFDEOHWKDW
WKH\VKRXOGQRWDVVXPHWKDW6PDUW*XDUGLVDEOHWRSUHYHQWDOO
K\SRJO\FHPLDRUDOOK\SHUJO\FHPLD
LQFOXGLQJGLDEHWLFNHWRDFLGRVLV ;   
; ;  
; ; ; 
,QVWUXFWVWXG\VXEMHFWVDQGWKHLU
SDUHQWVFDUHJLYHUVLIDSSOLFDEOHWKDW
UHJXODUZHHNO\XSORDGVRIWKHVWXG\
SXPSLVUHTXLUHG:LWK%OXHWRRWK
FRQQHFWLRQDQGWKH0LQL0HG&OLQLFDO
DSSVFKHGXOHGXSORDGVDUHQRW
UHTXLUHGIRUVXEMHFWVZLWKFRPSDWLEOH
VPDUWSKRQHVDVWKH\DUHGHVLJQHGWR
RFFXUFRQWLQXRXVO\6XEMHFWVWKDWGRQRWKDYHFRPSDWLEOHVPDUWSKRQHVZLOO
EHUHTXLUHGWRXVHWKH%OXH$GDSWHUWR
IDFLOLWDWHXSORDGVWRWKHLUFRPSXWHUV ; ; ; ; ;  ; ; ;  ; ; 
,QVWUXFWVXEMHFWVDQGWKHLU
SDUHQWVFDUHJLYHUVLIDSSOLFDEOHWR
JLYHPHDOEROXVRILQVXOLQ
PLQXWHVSULRUWRPHDOVGXULQJWKHUXQLQSHULRG ; ;  ; ;   
  
,QVWUXFWVXEMHFWVDQGWKHLU
SDUHQWVFDUHJLYHUVLIDSSOLFDEOHWR
JLYHPHDOEROXVRILQVXOLQPLQXWHV
SULRUWRPHDOVGXULQJWKHVWXG\SHULRG 
;  ; ;  ; ; ;  

1RWH:KHQVXEMHFWVH[LWWKHVWXG\HDUO\DOOUHTXLUHPHQWVWKD WDUHOLVWHGIRUWKHILQDOYLVLWDSSO\


1RWH5HTXLUHGIRUVXEMHFWVZLWKRXW&*0RUFORVHGORRSH[SHUL HQFHDVQHHGHGIRUDOORWKHUV
CIP335 Clinical Investigation Plan 
 Form 
D00409632 Version E Page 67 of 106 
0HGWURQLF%XVLQHVV5HVWULFWHG
CONFIDENTIAL )5HY(&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Form
9.2 Data Collection 
$OOGDWDFROOHFWLRQDQGVWXG\SURF HGXUHUHTXLUHPHQWVDUHGHVFUL EHGDWWKHVXEMHFWYLVLWVLQ Section 9.1 
9.3 Subject Consent 
,QIRUPHG&RQVHQWDQGD VVHQWLIDSSOLFDEOH ZLOOEHREWDLQHGLQDFFRUGDQFH ZLWKWKH&RGHRI)HGHUDO
5HJXODWLRQV&)57LWOH3DUW3ULRUWRHQWU\LQWRWKHVW XG\WKH&DOLIRUQLD([SH ULPHQWDO6XEMHFWÂ¶V%LOO
RI5LJKWVLIDSSOLFDEOHWKH,Q VWLWXWLRQDO5HYLHZ%RDUG,5% DQG0HGWURQLFDSSURYHG,&) IRUPDQG
DVVHQWIRUPLIDSSOLFDEOHDQG DQ$XWKRUL]DWLRQ)RUPUHTXLUHG E\WKH+HDOWK,QVXUDQFH3RUWDELOLW\DQG
$FFRXQWDELOLW\$FW+,3$$ZLOOEH SUHVHQWHGWRH DFKVXEMHFWWR UHYLHZDQGVLJQDVDSSOLFDEOH7KHVXEMHFW 
DQGWKHLUSDUHQWJXDUGLDQRUOH JDOO\DXWKRUL]HGUHSUHVHQWDWLY HDVDSSOLFDEOHZLOOEHJLYHQDPSOHWLPH
DQGRIIHUHGWKHRSSRUWXQLW\WRU HYLHZWKHVHGRFXPHQWVDZD\IURP WKHLQYHVWLJDWLRQDOFHQWHU
,IWKHVXEMHFWLVEHORZ\HDUVRIDJHKHVKHVKRXOGEHLQIRU PHGDERXWWKHVWXG\WRWKHH[WHQW
FRPSDWLEOHZLWKWKHVXEMHFWÂ¶VXQGHUVWDQGLQJ3HU,5%LIWKHVX EMHFWFRXOGJLYHFRQVH QWWRGHFLVLRQVDERXW
SDUWLFLSDWLRQLQUHVHDUFKWKHLQ YHVWLJDWRUPXVWREWDLQWKDWFR QVHQWLQDGGLWLRQWRWKHFRQVHQWRIWKHLU
OHJDOO\DXWKRUL]HGUHSUHVHQWDWLYH RUJXDUGLDQ&RQVHQWE\DOHJ DOJXDUGLDQRUDXWKRUL]HGUHSUHVHQWDWLYHLV
RQO\DOORZHGIRUVXEMHFWVZKRDUH\RXQJHUWKDQOHJDODJHDFFRUG LQJWRWKHLUVWDWHUHTXLUHPHQWV
7KHIROORZLQJZLOOEHSURYLGHGWR RUH[SODLQHGWRWKHVXEMHFWD QGWKHLUSDUHQWJXDUGLDQRUOHJDOO\
DXWKRUL]HGUHSUHVHQWDWLYHE\WKH LQYHVWLJDWRURUGHVLJQHHWKH SXUSRVHDQGGXUDWLRQRIWKHVWXG\WKH
UHTXLUHPHQWVH[SHFWHGWREHDGKHUHGWRE\WKHVXEMHFWGXULQJWK HVWXG\DQGWKHSRWHQWLDOULVNVSRWHQWLDO
EHQHILWVDVVRFLDWHGZLW KSDUWLFLSDWLRQLQW KHVWXG\(YHU\DWWH PSWZLOOEHPDGHWRDQ VZHUWKHVXEMHFWÂ¶V
DQGWKHLUSDUHQWÂ¶VJXDUGLDQÂ¶V RUOHJDOO\DXWKRUL]HGUHSUHVHQW DWLYHÂ¶VTXHVWLRQVGXULQJWKHLQIRUPHG
FRQVHQWDQGDVVHQWSURFHVV7KH ODQJXDJHXVHGVKDOOEHDVQRQW HFKQLFDODVSRVVLEOHDQGPXVWEH
XQGHUVWDQGDEOHWRWKHVXEMHFWRU WKHLUSDUHQWJXDUGLDQRUOHJ DOO\DXWKRUL]HGUHSUHVHQWDWLYH

1HLWKHUWKHLQYHVWLJDWRUQRUWK HLQYHVWLJDWLRQD OFHQWHUVWDII VKDOOFRHUFHRUXQGXO\LQIOXHQFHDVXEMHFWRU
WKHLUSDUHQWJXDUGLDQRUOHJDOO\ DXWKRUL]HGUHSUHVHQWDWLYHWR SDUWLFLSDWHRUWRFRQWLQXHWRSDUWLFLSDWHLQ
WKHFOLQLFDOVWXG\7KHLQIRUPH GFRQVHQWDVVHQWSURFHVVVKDOOQ RWZDLYHRUDSSHDUWR ZDLYHWKHVXEMHFWÂ¶V
ULJKWV7KHDVVHQWLIUHTXLUHG VKRXOGEHDGPLQLVWHUHGDFFRUGL QJWRWKHLQYHVWLJDWLRQDOFHQWHUÂ¶V6WDQGDUG
2SHUDWLQJ3URFHGXUHV623VDQGWKH,5%LQVWUXFWLRQVDVDSSOLF DEOH

6XEMHFWVZLOOFRPSOHWH&DOLIRUQL D([SHULPHQWDO6XEMHFWÂ¶V%LOOR I5LJKWVLIDSSOLFDEOHWKH+,3$$)RUPDQG
WKH,&)DVVHQWIRUP7KHFRQVHQWLQJSURFHVVPXVWEHGRFXPHQWHG LQWKHVXEMHFWÂ¶VVRXUFHGRFXPHQWV
7KHVXEMHFWDQGWKHLUSDUHQWJX DUGLDQRUOHJDOO\DXWKRUL]HGU HSUHVHQWDWLYHZLOOUHFHLYH FRSLHVRIWKHIXOO\
H[HFXWHGGRFXPHQWV$VXEMHFWÂ¶VSDUWLFLSDWLRQLQVWXG\SURFHGXU HVFDQQRWEHJLQEHIRUHWKHFRQVHQW
SURFHVVKDVEHHQSURSHUO\H[HFXWH G:KHQWKHVXEMHFWGHFLGHVWR SDUWLFLSDWHLQWKHVWXG\WKH,&)PXVW
EHVLJQHGDQGSHUVRQDOO\GDWHGE \WKHVXEMHFWDQGLQYHVWLJDWRU RUDXWKRUL]HGGHVLJQHHDVUHTXLUHGE\WKH
,&)$SDWLHQWFRQWDFWFDUGZ LOOEHSURYLGHGWRWKHVXEMHFW

0HGWURQLFZLOOLQIRUP WKHLQYHVWLJDWRUVZKH QHYHULQIRUPDWLRQEH
FRPHVDYDLODEOHWKDWP D\EHUHOHYDQWWR
WKHVXEMHFWÂ¶VFRQILUPHGSDUWLFL SDWLRQLQWKHFOLQLFDOVWXG\7K HLQYHVWLJDWRURUKLVKHUDXWKRUL]HGGHVLJQHH
VKRXOGLQIRUPWKHVXEMHFWDQGWK HLUSDUHQWJXDUGLDQRUOHJDOO \DXWKRUL]HGUHSUHVH QWDWLYHLQDWLPHO\
PDQQHU

0HGWURQLFZLOOUHYLVHW KHZULWWHQ,&)DVVHQW IRUPZKHQHYHUQHZ LQIRUPDWLRQEHFRPHVDYDLODEOHWKDWPD\
EHUHOHYDQWWRWKHVXEMHFWÂ¶VFRQ ILUPHGSDUWLFLSDWLRQLQWKHFOL QLFDOVWXG\7KHUHYLVH GLQIRUPDWLRQZLOOEH
VHQWWRWKHLQYHVWLJDW RUIRUDSSURYDOE\WKH,5%$IWHUDSSURYD OE\WKH,5%DFRS\RIWKLVLQIRUPDWLRQ
PXVWEHSURYLGHGWRWKHSDUWLFLS DWLQJVXEMHFWVDQGWKHLQIRUPH GFRQVHQWDVVHQWSURFHVVDVGHVFULEHG
DERYHQHHGVWREHUHSHDWHG
CIP335 Clinical Investigation Plan 
 Form 
D00409632 Version E Page 68 of 106 
0HGWURQLF%XVLQHVV5HVWULFWHG
CONFIDENTIAL )5HY(&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Form
,IWKH,&)DVVHQWIRUPLVDPHQGHG GXULQJWKHFRXUVHRIWKHVWXG \WKH,5%ZLOOGHWHUPLQH
x :KHWKHURUQRWDFWLYHVXEMHFWVD QGWKHLUSDUHQWJXDUGLDQRUO HJDOO\DXWKRUL]HGUHSUHVHQWDWLYH
VKRXOGEHUHFRQVHQWHGD WWKHLUQH[WYLVLWDQG
x :KHWKHURUQRWVXEMHFW VZKRKDYHFRPSOHWHGW KHVWXG\DWWKHWLP HRIWKHDPHQGPHQWVKRXOGEH
UHFRQVHQWHG

6XEMHFWVDQGWKHLUSDUHQWJXDUG LDQRUOHJDOO\DXWKRUL]HGUHSU HVHQWDWLYHZLOOEHLQIRUPHGWKDWTXDOLILHG
SHUVRQQHOIURPWKHLQYHVWLJDWLRQDOFHQWHUWKHVSRQVRU0HGWURQ LFUHJXODWRU\DXWKRULWLHVVXFKDVWKH
)'$DQGRUWKH,5%PD\KDYHDFFHVVWRWKHFOLQLFUHFRUGVWKDW UHYHDOWKHLULGHQWLW\DQGKHDOWKFDUH
LQIRUPDWLRQ

7KHLQYHVWLJDWLRQDOFHQWHUPXVW UHSRUWWKHIROORZLQJLQIRUPHGF RQVHQWDVVHQWYLRODWLRQVWRWKHLU,5%DQG
VSRQVRU
Âƒ )DLOXUHWRREWDLQLQIRUPHGFRQVHQWDVVHQWIURPVXEMHFWDQGWKHL USDUHQWJXDUGLDQRUOHJDOO\
DXWKRUL]HGUHSUHVHQWDWLYH
Âƒ )DLOXUHWRREWDLQLQIRUPHGFRQVHQWDVVHQWSULRUWRSHUIRUPLQJR QHRUPRUHVWXG\SURFHGXUHV
Âƒ )DLOXUHWRPDLQWDLQ,&)VDVVHQW IRUPVRQILOHIRUDOOVXEMHFWV ZKRKDYHSURYLGHGLQIRUPHG
FRQVHQW
Âƒ 8VHRIDQ,&)DVVHQWIRUPWKDWK DVQRWUHFHLYHGDSSURYDOIURPW KH,5%
Âƒ 8VHRIDQLQFRUUHFWYHUVLR QRIWKH,&)DVVHQWIRUP

9.4 Safety Monitoring/Risk Analysis 
9.4.1  Glucose Monitoring Risk 
x 6XEMHFWVZLOOEHLQVWUXFWHGWRPDNHVXUHWKH\KDYHFOHDQILQJHU VZKHQSHUIRUPLQJILQJHUVWLFN
JOXFRVHWHVWLQJ
x 6XEMHFWVZLOOKDYHWUDLQLQJRQGL DEHWHVVHOIPDQDJHPHQWSULQFLS OHV
9.4.2  Hypoglycemic/Hyperglycemic Risk 
,QWHUYHQWLRQDQGWUHDWPHQWIRUK\SRJO\FHPLDDQGK\SHUJO\FHPLDL VDGGUHVVHGLQ Section 10.1 
9.4.3  Calibration of CGM Risk 
:KHQDQHUURQHRXVEORRGJOXFRVH YDOXHLVXVHGWRFDOLEUDWHD&* 0WKLVFDQUHVXOWLQLQDFFXUDWH6*
YDOXHV6XEMHFWVZLOOEHWUDLQHGRQDSSURSULDWHFDOLEUDWLRQ
9.4.4  Reuse Risk 
$OOVWXG\GHYLFHVZLOOEHVLQJOHSDWLHQWXVH
9.4.5  Sterilization Risk 
7KHIROORZLQJGHYLFHVZLOOEHVXSSOLHGVWHULOL]HG
x ,QIXVLRQVHWV
x ,QVXOLQUHVHUYRLUV
x 6HQVRUV
CIP335 Clinical Investigation Plan 
 Form 
D00409632 Version E Page 69 of 106 
0HGWURQLF%XVLQHVV5HVWULFWHG
CONFIDENTIAL )5HY(&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Form
9.4.6  Misuse Risk 
&RPSUHKHQVLYHWUDLQLQJZLOOWDN HSODFHDWWKHLQLWLDWLRQYLVLW IRULQYHVWLJDWLRQDOFHQWH UVWDIIUHJDUGLQJWKH
RSHUDWLRQRIWKH0LQL0HG*V \VWHPWRLQFOXGHDOORILWVIXQ FWLRQDOFRPSRQHQWVDQGDOORWKHUVWXG\
GHYLFHVWREHXVHGGXULQJWKHVWXG\DWWKHLQYHVWLJDWLRQDOFHQW HU
9.4.7  Risk of Blood Sample Collection, Contamination from Sampling Te chniques 
'HWDLOHGPLWLJDWLRQVWREORRGVDPSOLQJULVNDUHSURYLGHGLQ Section 10.1 
9.4.8  HbA1c Risk 
$&HQWUDOODERUDWRU\ZLOOEHXVHGIRU+E$FWHVWLQJ
9.5 Glucose and Glycemia Measurements 
'XULQJWKHFRXUVHRIWKHVWXG\ WKHVXEMHFWVÂ¶%*OHYHOV6*OHY HOV+E$FDQGEORRGNHWRQHVZLOOEH
FROOHFWHGXVLQJWKHPHWKRGVRXWOLQHGLQWKLVVHFWLRQ
9.5.1  Daily Blood Glucose 
9DOXHVZLOOEHDVVHVVHGGXULQJW KHVWXG\E\DOOVXEMHFWVXVLQJ WKH$FFX&KHN*XLGH/LQN VWXG\PHWHU7KH
FRQWUROVROXWLRQWHVWZLOOEHSH UIRUPHGIROORZLQJWKHPDQXIDFWX UHUÂ¶VXVHUJXLGH6XE MHFWVZLOOEHWUDLQHG
RQWKHXVHRIWKH$FFX&KHN*XLGH/LQNVWXG\PHWHUSHUWKHPDQX IDFWXUHUÂ¶VLQVWUXFWLRQV
9.5.2  Blood Ketone Values 
6XEMHFWÂ¶VEORRGNHWRQHVZLOOEH PHDVXUHGE\DOOVXEMHFWVFRPSD QLRQVRUSDUHQWV FDUHJLYHUVLI
DSSOLFDEOHXVLQJWKHNHWRQHPHWHUZKHQFHUWDLQFRQGLWLRQVDUH PHW
x :KHQDVXEMHFWLVV\ PSWRPDWLFIRUKLJKEORRGJOXFRVHRU
x :KHQVHQVRUJOXFRVHGLVSOD\VDJOX FRVHYDOXH!PJG/%*VKRX OGEHFKHFNHGE\ILQJHUVWLFN
DQGLI%*LV!PJG/EORRGN HWRQHVVKRXOGEHFKHFNHG
7KHFRQWUROVROXWLRQWHVWZLOOE HSHUIRUPHGIROORZLQJWKHPDQXI DFWXUHUÂ¶VXVHUJXLGH 7KHLQYHVWLJDWLRQDO
FHQWHUVWDIIZLOOEHWUDLQHGRQWKHXVHRIWKHNHWRQHPHWHUSHU WKHPDQXIDFWXUHUÂ¶VLQVWUXFWLRQV$OONHWRQH
PHDVXUHPHQWVZLOOEHUHSRUWHGE\VWXG\VXEMHFWV  
9.5.3  Sensor Glucose Values 
6*GDWDZLOOEHFROOHFWHGE\VXEMHFWÂ¶VVWXG\SXPSDQGFDOLEUDWH GE\HDFKVXEMHFWÂ¶V$FFX&KHN*XLGH/LQN 
VWXG\PHWHU
9.5.4  HbA1c 
+E$FLVFROOHFWHGDWEDVHOLQHDQ GWKHHQGRIVXEMHFWVÂ¶SDUWLFL SDWLRQLIVXEMHFWVKD YHFRPSOHWHG9LVLW
DQGH[LWHDUO\D+E$FZLOOEHFROOHFWHG)RUVXEMHFWV\HDU VRIDJHDQGROGHU+E$FZLOODOVREH
FROOHFWHGDW9LVLWDQG
9.6 Recording Data 
'DWDH[FHSWTXHVWLRQQDLUHVHQWHUHGE\WKHLQYHVWLJDWLRQDOFHQ WHUVWDIIZLOOEHFDSWXUHGRQH&5)VXVLQJ
WKH(OHFWURQLF' DWD&DSWXUH('&V\VW HP2ULJLQDOH&5)VZLOOQ RWEHFRQVLGHUHGDVVRXUFHGDWDDQG
VXSSRUWLQJGRFXPHQWDWLRQZLOOEHUHTXLUHG ,QDGGLWLRQWKHVXEMHFWZLOOF RPSOHWHWKHTXHVWLRQQDLUHV
RQOLQHYLDGLUHFWHQWU\,QFDV HWKHRQOLQHOLQNLVXQDYDLODEOH VXEMHFWVZLOOFRPSOHW HWKHTXHVWLRQQDLUH
CIP335 Clinical Investigation Plan 
 Form 
D00409632 Version E Page 70 of 106 
0HGWURQLF%XVLQHVV5HVWULFWHG
CONFIDENTIAL )5HY(&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Form
XVLQJDSDSHUIRUPDWWKLVZLOOE HVRXUFHGDWDDQGVXEVHTXHQWO \WKHLQYHVWLJDWRURUGHVLJQDWHG
LQYHVWLJDWLRQDOFHQW HUVWDIIZLOOHQWHUWKH UHVSRQVHVRQOLQH, ISDSHUIRUPDWLVXVHG WKHLQYHVWLJDWRURU
GHVLJQDWHGLQYHVWLJDWLR QDOFHQWHUVWDIIVKRXOGPDLQWDLQWKHRUL JLQDOSDSHUVRXUFHLQWKHVXEMHFWÂ¶VVRXUFH
ILOH
(OHFWURQLFGHYLFHGDWDZLOOEHFR OOHFWHGIURPWKHVWXG\SXPSXV LQJ&DUH/LQN3HUVRQDO&DUH/LQNV\VWHP
VRIWZDUH7KHV\VWHPXVHV7/6WH FKQRORJ\ZKLFKHQFU\SWVDOOGD WDLWVWRUHV&)53 DUWFRPSOLDQW
&HUWDLQGDWDSRLQWVVWRUHGLQWKHGRZQORDGHGLQIRUPDWLRQPD\DO VREHFDSWXUHGRQWKHDSSURSULDWHH&5)
(OHFWURQLFGHYLFHGDWD FRXOGDOVREHFROOHFW HGE\WKH0LQL0HG& OLQLFDODSSDQGWKH&DUH/LQN&OLQLFDODSS
7KHLQYHVWLJDWRUZLOOH QVXUHWKDWDOOH&5)VDUHFRPSOHWHGSURPS WO\FRPSOHWHO\DQGDFFXUDWHO\0HGWURQLF
ZLOOSURYLGHGHWDLOHGLQVWUXFWLR QVWRDVVLVWZLWKH&5)FRPSOHWL RQ,QWKHHYHQWRI GDWDGLVFUHSDQFLHV
LQYHVWLJDWLRQDOFHQW HUVZLOOEHDVNHGWRUH VROYHTXHULHVHOHFWU RQLFDOO\LQWKH('&V \VWHPRWKHUZLVH
LUUHVROYDEOHGDWDUHODWHGLVVXH VZLOOEHURXWHGWRWKHVSRQVRU IRUUHYLHZDQGILQDOGLVSRVLWLRQ$QDXGLWWUDLO
LVPDLQWDLQHGLQWKH('&V\VWHP WRFDSWXUHDQ\FRUUHFWLRQVRUF KDQJHVRIWKHH&5)V6\VWHPEDFNXSVIRU
GDWDVWRUHGLQWKH('&V\VWHPZ LOOEHFRQVLVWHQWZ LWK0HGWURQLF 623V
0HGWURQLFZLOORQO\FRQVLGHUH&5 )VWREHFRPSOHWHZKHQDOOGLVF UHSDQFLHVEHWZHHQVRXUFHGDWDDQGH&5)
KDYHEHHQUHVROYHGH&5)FRQWHQ WZLOOEHUHYLHZHGE\DVWXG\PR QLWRUDVGHVFULEHGLQWKH0RQLWRULQJ
3ODQ,QDGGLWLRQVSHFLILFH&5) VPXVWDOVREHUHYLHZHGDQGHOH FWURQLFDOO\VLJQHGE\ WKHLQYHVWLJDWRU
LQGLFDWLQJKLVKHUDJUHHPHQWZLWKWKHDFFXUDF\RIDOOUHFRUGHG GDWD,WLVH[SHFWHGWKDWWKHLQYHVWLJDWRU
DQGKLVKHUVWDIIZLOOFRRSHUDWH ZLWKWKHPRQLWRULQJWHDPDQGS URYLGHDQ\PLVVLQJGDWDLQDWLPHO\
PDQQHU
9.7 Deviation Handling
$GHYLDWLRQLVDQ\LQVWDQFHVRI IDLOXUHWRIROORZLQWHQWLRQD OO\RUXQLQWHQWLRQDOO\WK HUHTXLUHPHQWVRIWKH
&,3,WLVH[SHFWHGWKDWWKHLQYHV WLJDWRUZLOOFRQGXFWWKLVFOL QLFDOWULDOLQFRPSOLDQF HZLWKWKH&,3DQGDOO
DSSOLFDEOHUHJXODWLRQVJRYHUQLQJWKHFRQGXFWRIFOLQLFDOUHVHDU FKLQYROYLQJKXPDQVXEMHFWV)DLOXUHWRGR
VRFRXOGUHVXOWLQRQHRUDOORIWKHIROORZLQJ
x ,QYHVWLJDWLRQDOFHQWHUGLVTXDOLILFDWLRQ
x 1RWLILFDWLRQWRWKHUHJXODWRU\DXWKRULWLHV,5%GHSHQGLQJRQWKH VHYHULW\RIWKHGHYLDWLRQDQG
UHSRUWLQJUHTXLUHPHQWV
7KHLQYHVWLJDWRUVKRXOGQRWLPSO HPHQWDQ\GHYLDWLRQIURPRUFK DQJHVWRWKH&,3ZLWKRXWDJUHHPHQWE\
WKHVSRQVRUDQGSULRUUHYLHZDQG GRFXPHQWHGDSSURYDOIDYRUDEOH RSLQLRQIURPWKHUHJXODWRU\DXWKRULW\
LIDSSOLFDEOHRU,5%H[FHSWZKHUHQHFHVVDU\WRHOLPLQDWHDQ LPPHGLDWHKD]DUGVWRVXEMHFWV7KHXVH
RIZDLYHUVIURPWKH&,3DU HSURKLELWHGLQWKLVVWXG\

6XEMHFWV\HDUVRIDJHDQGROG HUDUHDVNHGIRU DQ+E$FWHVW DW9LVLW9LVLW9LVLW9LVLWDQG
9LVLW)DLOLQJWRWDNHWKHWH VWDW9LVLWVDQGZLOOUHVX OWLQDGHYLDWLRQ)DLOLQJW RWDNHWKHWHVWDWYLVLWV
DQGZLOOQRWEHVXEMHFWWRDGHYLDWLRQ
9.7.1  Documenting Requirements for Study Deviations 
9.7.1.1  Unplanned CIP Deviations 
7KHLQYHVWLJDWRUPD\HQFRXQWHUWKHQHHGWRGHYLDWHIURPWKH&,3 ZKHQQHFHVVDU\WRSURWHFWWKHVDIHW\
ULJKWVRUZHOOEHLQJRIDVXEMHFW LQDQHPHUJHQF\RULQXQIRUHV HHQVLWXDWLRQVEH\RQGWKHLQYHVWLJDWRUÂ¶V
CIP335 Clinical Investigation Plan 
 Form 
D00409632 Version E Page 71 of 106 
0HGWURQLF%XVLQHVV5HVWULFWHG
CONFIDENTIAL )5HY(&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Form
FRQWUROHJVXEMHFWIDLOXUHWRDWWHQGVFKHGXOHGIROORZXSYL VLWVLQDGYHUWHQWORVVRIGDWDGXHWR
FRPSXWHUPDOIXQFWLRQLQDELOLW\WR SHUIRUPUHTXLUHGSURFHGXUHV GXHWRVXEMHFWLOOQHVV
'HYLDWLRQVIURPWKH&,3UHJDUGOHVVRIWKHUHDVRQVKRXOGEHGRF XPHQWHGDVVRRQDVSRVVLEOHDIWHUWKH
GHYLDWLRQRFFXUVRULVLGHQWLILH G7KLVGRFXPHQWDWLRQVKRXOGLQ FOXGHGHYLDWLRQGDWHGHVFULSWLRQRIWKH
GHYLDWLRQWKHUHDVRQIRUGHYLDWLRQDQGWKHFRUUHFWLYHDFWLRQ 5HIHUWR Table 6IRUUHSRUWLQJWLPHOLQHVIRU
HPHUJHQF\GHYLDWLRQV

&,3GHYLDWLRQVVKRXOGEHUHSRUWHGDVIROORZV
D 7RWKH,5%IRUQRWLILFDW LRQDFNQRZOHGJHPHQW
E 7RWKHVSRQVRUDQG LIUHTXLUHG
F 7RWKHDSSOLFDEOHUHJXODWRU\DXWK RULW\UHSRUWHGE\VSRQVRU
9.7.2  Reporting Requirements for Study Deviations 
$OOVWXG\GHYLDWLRQVPXVWEHUHS RUWHGRQWKHH&5)UHJDUGOHVVRI ZKHWKHUPHGLFDOO\MXVWLILDEOHDQ
LQDGYHUWHQWRFFXUUHQFHRUWDNHQWRSURWHFWWKHVXEMHFWLQDQH PHUJHQF\7KHGDWHGHVFULSWLRQDQG
UHDVRQIRUHDFKGHYLDWLRQZLOO EHGRFXPHQWHG&)55H FRUGV

7KHIROORZLQJH[DPSOHVDUHGHYLD WLRQVWKDWFRXOGLPSDFWVXEMHFW VDIHW\DIIHFWWKHLQWHJULW\RIVWXG\GDWD
DQGRUDIIHFWVXEMHFWÂ¶VZLOOLQJQH VVWRSDUWLFLSDWHLQWKHVWXG\ 7KHVHGHYLDWLRQVDUHVLJQLILFDQWDQGUHTXLUH
LPPHGLDWHVSRQVRUQRWLILFDWLRQX SRQLQYHVWLJDWRUDZDUHQHVV

Âƒ )DLOXUHWRREWDLQLQIRUPHGFRQVHQ WDVVHQWLHWKHUHLVQRGR FXPHQWDWLRQRIFRQVHQWLQJ
Âƒ ,QIRUPHGFRQVHQWDVVHQWREWDLQHG DIWHULQLWLDWLRQRIVWXG\SURF HGXUHV
Âƒ &RQWLQXDWLRQRIDVXEMHFWZKRGLGQRWPHHWDOOLQFOXVLRQH[FOXV LRQFULWHULD
Âƒ 3HUIRUPLQJVWXG\SURFHGXUH QRWDSSURYHGE\WKH,5%
Âƒ )DLOXUHWRLQIRUP,5%DQGVSR QVRURIUHSRUWDEOH$(VVHH Section 11
Âƒ ,QYHVWLJDWLRQDOVWXG\ GHYLFHGLVSHQVHGZLWKRXWREWDLQLQJLQIRUP HGFRQVHQWDVVHQW

,QWKHHYHQWW KHGHYLDWLRQLQYROYHVDI DLOXUHWRREWDLQDVXEMH FWÂ¶VFRQVHQWRULVPDGH WRSURWHFWWKHOLIHRU
SK\VLFDOZHOOEHLQJRIDVXEMHFW LQDQHPHUJHQF\WKHGHYLDWLRQ PXVWEHUHSRUWHGWR WKH,5%DVZHOODV
0HGWURQLFZLWKLQILYHZRUNLQJGD\V

5HSRUWLQJRIDOORWKHUVWXG\GHYLDWLRQVVKRXOGFRPSO\ZLWK
x ,5%SROLFLHVDQGRU
x ORFDOODZVDQGRU
x UHJXODWRU\DXWKRUL W\UHTXLUHPHQWV

7KH\PXVWEHUHSRUWHGWR0HGWURQ LFDVVRRQDVSRVVLEOHXSRQWKH FHQWHUEHFRPLQJDZDUHRIWKH
GHYLDWLRQ5HIHUWR,QYHVWLJDWRU5HSRUWV Table 6IRUVSHFLILFGHYLDWLRQUHSRUWLQJUHTXLUHPHQWVDQG
WLPHIUDPHVIRUUHSRUWLQJWR0HGW URQLF,5%DQGUHJXODWRU\DXWK RULW\LIDSSOLFDEOH
9.7.3  Analyzing Deviations 
0HGWURQLFLVUHVSRQVLEOHIRUU HYLHZLQJGHYLDWLRQVDVVHVVLQJWK HLUVLJQLILFDQFHDQGLGHQWLI\LQJDQ\
DGGLWLRQDOFRUUHFWLYHDQGRUSUH YHQWLYHDFWLRQVHJDPHQGWK H&,3FRQGXFWDGGLWLRQDOWUDLQLQJ
WHUPLQDWHWKHLQYHVWLJDWLRQ5H SHWLWLYHRUVHULRXVLQYHVWLJDWR UFRPSOLDQFHLVVXHVPD\UHVXOWLQLQLWLDWLRQRI
DFRUUHFWLYHDFWLRQSODQZLWKWK HLQYHVWLJDWRUDQGLQYHVWLJDWLR QDOFHQWHUDQGLQVRPHFDVHVQHFHVVLWDWH
VXVSHQGLQJHQUROOPHQWXQWLOWKH SUREOHPLVUHVROYHGRUXOWLPDWH O\WHUPLQDWLQJWKHLQYHVWLJDWRU
V
SDUWLFLSDWLRQLQWKHVWXG\
CIP335 Clinical Investigation Plan 
 Form 
D00409632 Version E Page 72 of 106 
0HGWURQLF%XVLQHVV5HVWULFWHG
CONFIDENTIAL )5HY(&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Form
9.8 Subject Exit, Withdrawal or Discontinuation 
6XEMHFWVPD\FKRRVHWRZLWKGUDZIURPWKHVWXG\DWDQ\WLPHE\Q RWLI\LQJLQYHVWLJDWLRQDOFHQWHUVWDIIRI
WKHLULQWHQW

,IDVXEMHFWFKRRVHVWRHQGKLVRUKHUVWXG\SDUWLFLSDWLRQRUL IWKHVXEMHFWLVUHPRYHGIURPWKHVWXG\DW
WKH,QYHVWLJDWRUÂ¶VGLVFUHWLRQRU IRUIDLOXUHWRPHHWWKHVWXG\ UHTXLUHPHQWVWKHUHDVRQIRUZLWKGUDZDO
PXVWEHGRFXPHQWHG$OOVWXG\GHYLFHVDQGVXSSOLHVPXVWEHUHWX UQHGDVDSSOLFDEOH DQGGRFXPHQWHG
ERWKLQVRXUFHGRFXPHQWVDQGRQDQH&5))ROORZLQJVWXG\H[LW VXEMHFWVZLOOUHFHLYHVWDQGDUGPHGLFDO
FDUHIURPWKHLURZQSURYLGHUV

$VXEMHFWZLOOEHZLWKGU DZQIURPWKHVWXG\LI

Âƒ ,QWKHRSLQLRQRIWKHLQYHVWLJDW RUWKHVXEMHFWÂ¶VKHDOWKRUVDI HW\ZRXOGEHFRPSURPLVHGE\
FRQWLQXLQJLQWKHVWXG\HJLQIHFWLRQDWVNLQVLWHVHYHUHV NLQUHDFWLRQWRDGKHVLYH
Âƒ ,QWKHRSLQLRQRIWKHLQYHVWLJ DWRULWLVLQWKHV XEMHFWÂ¶VEHVW LQWHUHVWWRGLVFRQWLQX HSDUWLFLSDWLRQLQ
WKHVWXG\
Âƒ 'XULQJWKHFRXUVHRIWKHVWXG\VXEMHFWEHJLQVXVLQJK\GUR[\XUH D
Âƒ 'XULQJWKHFRXUVHRIWKHVWXG\ VXEMHFWEHJLQVSDUWLFLSDWLRQLQ DQRWKHULQYHVWLJDWLRQDOVWXG\GUXJ
RUGHYLFH
Âƒ $WWKHGLVFUHWLRQRIWK HLQYHVWLJDWRUGXUL QJWKHVWXG\LWEHFR PHVNQRZQWKDWVXEMHFWVDUH
UHSHDWHGO\XVLQJDQRQOLQNHG%* PHWHUIRU60%*RUDV\VWHPWKD WUHSODFHV60%*
Âƒ 'XULQJWKHFRXUVHRIW KHVWXG\VXEMHFWEHJLQV DEXVLQJLOOLFLWGUXJV
Âƒ 'XULQJWKHFRXUVHRIWKHVWXG\ VXEMHFWEHJLQVDEXVLQJPDULMXDQ D
Âƒ 'XULQJWKHFRXUVHRIWKHVWXG\ VXEMHFWEHJLQVDEXVLQJSUHVFULS WLRQGUXJV
Âƒ 'XULQJWKHFRXUVHRIWKHVWXG\ VXEMHFWEHJLQVDEXVLQJDOFRKRO 
Âƒ 'XULQJWKHFRXUVHRIWKHVWXG\ VXEMHFWEHJLQVXVLQJSUDPOLQWLG H6\POLQ'33LQKLELWRUV
OLUDJOXWLGH9LFWR]DRURWKHU*/3 DJRQLVWVPHWIRUPLQFDQDJ OLIOR]LQ,QYRNDQDRURWKHU6*/7
LQKLELWRUV
Âƒ 'XULQJWKHFRXUVHRIWKHVWXG\ VXEMHFWUHFHLYHVUHGEORRGFHOO WUDQVIXVLRQRUHU\WKURSRLHWLQ
Âƒ 'XULQJWKHFRXUVHRIWKHVWXG\WKHVXEMHFWGHPRQVWUDWHVWKDWK HVKHLVQRWDEOHWRFRPSUHKHQG
LQVWUXFWLRQVIRUVWXG\SURFHGXUHV DVHYDOXDWHGE\WKHDSSURSUL DWHUHVHDUFKVWDII
Âƒ 'XULQJWKHUXQLQSHULRGDVXEMHFWUHSHDWHGO\DFWLYDWHV6PDUW* XDUGIHDWXUHZKHQLQVWUXFWHG
RWKHUZLVHHJ6PDUW*XDUGIH DWXUHLVWXUQHGRQDVDSSOLFDEOH DWWKHGLVFUHWLRQRIWKH
LQYHVWLJDWRU
Âƒ 'XULQJWKHFRXUVHRIWKHVWXG\ VXEMHFWLVWDNLQJRUDOLQMHFWD EOHRU,9JOXFRFRUWLFRLGV
Âƒ 'XULQJWKHVWXG\IHPDOHVXEMHFWEHFRPHVSUHJQDQW
Âƒ 'XULQJWKHVWXG\WKHVXEMHFWH[SHULHQFHVRQHVHYHUHK\SRJO\FHP LFHSLVRGHLILWLVUHODWHGWRWKH
XVHRI*V\VWHP6PDUW*XDUGIHDWXUH
Âƒ 'XULQJWKHVWXG\WKHVXEMHFWH[SHULHQFHVRQHHSLVRGHRI'.$L ILWLVUHODWHGWRWKHXVHRI*
V\VWHP6PDUW*XDUGIHDWXUH
Âƒ 'XULQJWKHVWXG\VXEMHFWKDVDFDUGLRYDVFXODUHYHQWRUDQ\YDV FXODUHYHQWVXFKDVVWURNH 
Âƒ 'XULQJWKHFRXUVHRIWKHVWXG\ VXEMHFWKDVÂ•LQIXVLRQVLWHUH DFWLRQVWKDWPHHWFULWHULDIRU
DGYHUVHHYHQWUHSRUWLQJ 
'RFXPHQWDWLRQRIWKHUHDVRQVO HDGLQJWRVXEMHFWZLWKGUDZDOZL OOEHNHSWLQWKHVXEMHFWÂ¶VVRXUFH
GRFXPHQWDWLRQ

CIP335 Clinical Investigation Plan 
 Form 
D00409632 Version E Page 73 of 106 
0HGWURQLF%XVLQHVV5HVWULFWHG
CONFIDENTIAL )5HY(&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Form
9.8.1  End of Subject Participation in Study/Completion of Study  
$IWHUWKHVWXG\KDVEHHQFRPSOHWHGDW9LVLWRULQFDVHRIH DUO\WHUPLQDWLRQVXEM HFWVZLOOEHH[LWHG
IURPWKHVWXG\6XEMHFWVZLOOFR QWLQXHWRZRUNZLWKWKHLUSK\VL FLDQDIWHUVWXG\H[LWSHUQRUPDOVWDQGDUG
RIFDUH7KHFOLQLFDOLQYHVWLJDW LRQLVFRQVLGHUHGFRPSOHWHGRQF HWKHODVWVXEMHFWKD VH[LWHGWKHVWXG\

9.8.2  Lost to Follow-Up 
,IDVXEMHFWGRHVQRWUHWXUQWR WKHLQYHVWLJDWLRQDOFHQWHUIRUU HTXLUHGIROORZXSYLVLWVDQGFDQQRWEH
UHDFKHGWKHLQYHVWLJDWLRQDOFHQWHUSHUVRQQHOVKRXOGPDNHGRF XPHQWHGDWWHPSWVWRFRQWDFWWKHVXEMHFW
E\SKRQHWRYHULI\LIWKHVXEMHF WVKRXOGEHFRQVLGHUHGÂ³ORVWWR IROORZXSÂ´,QWKHHYHQWWKHVXEMHFWLVQRW
DEOHWRSHUIRUPIROORZXSYLVLW VDWWKHLQYHVWLJDWLRQDOFHQWHU VXEMHFWZLOOEHFRQVLGHUHGÂ³ORVWWRIROORZXSÂ´
DQGWKLVQHHGVWREHGRFXPHQWHG LQWKH6WXG\([LWH&5)$OOHII RUWVZLOOEHPDGHE\LQ YHVWLJDWLRQFHQWHU
SHUVRQQHOWRFROOHFWDOOVWXG\GH YLFHVDQGVXSSOLHVEDFNIURPV XEMHFWLIDSSOLFDEOH
9.9  Study Stopping Rules 
7KHVWXG\PD\EHVWRSSHGLIWKH' DWD0RQLWRULQJ&RPPLWWHH'0& GHWHUPLQHVWKDWWKHUHDUHVLJQLILFDQW
VDIHW\LVVXHVLQFOXGLQJWKHRFFXU UHQFHRIFHUWDLQW\SHVRILQG LYLGXDODGYHUVHHYHQWVLH8$'(GHYLFH
UHODWHG'.$DQGGHYLF HUHODWHG6HYHUH+\SRJO\FHPLDWKDWKDYH XQGHUJRQHH[SHGLWHGDGMXGLFDWLRQE\
WKH&OLQLFDO(YHQWV&RPPLWWHH&(&6HH&(& Section 12.1 DQG'0& Section 12.2 IRUPRUHGHWDLOV
UHJDUGLQJWKHH[SHGLWHGUHYLHZ UHVSRQVLELOLWLHVRIERWKFRPPLWW HHV
10. Risks and Benefits 
10.1  Potential Risks 
7KHSRWHQWLDOUHVLGXDOULVNVDQG PLWLJDWLRQVDVVRFLDWHGZLWKWK HGHYLFHVXVHGGXULQJ WKLVVWXG\DUHOLVWHG
LQTable 45LVNVDVVRFLDWHGZLWKWKHFR PPHUFLDOO\DYDLODEOHGHYLFHVXVHG LQWKHVWXG\DUHOLVWHGLQWKH
DVVRFLDWHGGHYLFHODEHOLQJXVHU JXLGHVLQVWUXFWLRQVIRUXVHRU UHSRUWRISULRULQYHVWLJDWLRQV

7KHFOLQLFDOLQYHVWLJDWLRQKDVE HHQGHVLJQHGWRLQYROYHDVOLWW OHSDLQGLVFRPIRUWIHDUDQGDQ\RWKHU
IRUHVHHDEOHULVNDVSRVVLEOHIRUW KHVXEMHFWVDQGERWKWKHULV NWKUHVKROGDQGWKH GHJUHHRIGLVWUHVVDUH
VSHFLILFDOO\GHILQHGLQWKH&, 3DQGFRQVWDQWO\PRQLWRUHG
 
CIP335 Clinical Investigation Plan 
 Form 
D00409632 Version E Page 74 of 106 
0HGWURQLF%XVLQHVV5HVWULFWHG
CONFIDENTIAL )5HY(&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Form
Table 4. Risks, Prevention and Mitigation 
Riskswith Infusion Sets Prevention and Miti gation 
5LVNVZLWKLQIXVLRQVHWVPD\LQFOXGH
x /RFDOL]HGLQIHFWLRQ
x 6NLQLUULWDWLRQUHGQHVV
x %UXLVLQJ
x 'LVFRPIRUWSDLQ
x %OHHGLQJ
x ,UULWDWLRQ
x 5DVK 
x +\SHUJO\FHPLDVHFRQGDU\WRLQIXVLRQVHW
RFFOXVLRQRULQIXVLRQVLWHIDLOXUHLQFOXGLQJ
'.$ 
x +\SHUJO\FHPLDVHFRQGDU\WRVLWHIDOOLQJRII
LQFOXGLQJ'.$  
x 8QH[SODLQHG+\SHUJO\FHPLD%*!PJG/
!KRXUVDIWHUDPHDOQRUHGXFWLRQLQ%*
E\PJG/LQKRXUDIWHULQVXOLQ
DGPLQLVWUDWLRQOHDG LQJWRLQIXVLRQVHW
UHSODFHPHQW
x $Q[LHW\DVVRFLDWHGZLWKLQVHUWLRQ  3UHYHQWLRQDQGPLWLJDWLRQLQFOXGH
x )ROORZWKHSURYLGHGXVHUJXLGHVIRULQVHUWLRQV
DQGFDUHRILQIXVLRQVHWV  
x ,IDQLQIXVLRQVLWHEHFRPHVLUULWDWHGRULQIODPHG
WKHLQIXVLRQVHWZLOOEHUHPRYHGDQGDQRWKHU
SODFHGLQDQHZORFDWLRQ  
x ,QFDVHRIK\SHUJO\FHPLDVHFRQGDU\WRLQIXVLRQ
VHWRFFOXVLRQUHPRYHFXUUHQWLQIXVLRQVHWDQG
UHSODFHZLWKQHZLQIXVLRQVHWDQGJLYHFRUUHFWLRQ
LQVXOLQLIQHHGHGZLWKV\ULQJH  
x )ROORZWKHSURYLGHGXVHUJXLGHVIRULQVXOLQSXPS
PDQDJHPHQW  
x 7UDLQSULRUWRVWXG\GHYLFHXVHRQDSSURSULDWH
GHYLFHXVHDQGGLDEHWHVPDQDJHPHQWSULQFLSOHV
DQGLQVWUXFWWRFDOOLQY HVWLJDWRUZLWKSUREOHPV  
Riskswith Insulin Administration and 
Pumps Prevention and Mitigation 
5LVNVZLWKWKHXVHRIDQLQVXOLQLQIXVLRQSXPSPD\
LQFOXGHWKHULVNRIPDOIXQFWLRQRIWKHFRPSRQHQWVRI
WKHV\VWHPSXPSVRIWZDUHLQIXVLRQVHWDQG
UHVHUYRLUDVZHOODVWKHULVNRIXVHHUURUGXULQJXVH
RIWKHV\VWHP''VRUXVHHUURUVFDQUHVXOWLQ
DGPLQLVWUDWLRQRIWRRPXFKRUWRROLWWOHLQVXOLQZKLFK
FDQOHDGWRWKHIROORZLQJFOLQLFDOFRQVHTXHQFHV

x +\SRJO\FHPLD
x +\SHUJO\FHPLD
x 'LDEHWLFNHWRDFLGRVLV
x 6HYHUHK\SRJO\FHPLDZLWKRUZLWKRXW
DVVRFLDWHGVHL]XUHFRPDRUGHDWK
x .LQNHGFDQQXODOHDGLQJWRK\SHUJO\FHPLD
x ,QIXVLRQVHWGLVFRQQHFWLRQIURPSXPS
OHDGLQJWRK\SHUJO\FHPLD
x 6XEMHFWUHPRYHVWKHUHVHUYRLUIURPWKH
SXPSEXWIRUJHWVWRGLVFRQQHFWWKHLQIXVLRQ
VHWIURPWKHERG\ZKLFKUHVXOWVLQ
K\SRJO\FHPLDRUVHYHUHK\SRJO\FHPLD
x 'LVORGJHGFDQQXODOHDGLQJWRK\SHUJO\FHPLD
x $SXPSHUURUPD\OHDGWRXQGHUGHOLYHU\RU
RYHUGHOLYHU\RILQVXOLQ
x %DWWHU\IDLOXUHÂ±QRLQVXOLQGHOLYHUHG3UHYHQWLRQDQGPLWLJDWLRQLQFOXGH
x )ROORZWKHSURYLGHGXVHUJXLGHV	LQVWUXFWLRQV
IRULQVXOLQDQGLQVXOLQSXPSPDQDJHPHQWZKLFK
LQFOXGHVLQIRUPDWLRQRQLQIXVLRQVHWFKDQJH
x 7UDLQSULRUWRVWXG\GHYLFHXVHRQDSSURSULDWH
GHYLFHXVHDQGGLDEHWHVPDQDJHPHQWSULQFLSOHV
DQGLQVWUXFWWRFDOOLQYHVW LJDWRUZLWKSUREOHPV
x ,QVWUXFWWRFKHFNWKHLUPHWHUJOXFRVHLIWKHLUKLJK
RUORZV\PSWRPVGRQRWPDWFKWKHLUVHQVRU
DOHUWVRU6*UHDGLQJVLQRUGHUWRPDNHGLDEHWHV
WUHDWPHQWGHFLVLRQV
x ,QVWUXFWWRFKHFNWKHLUPHWHUJOXFRVHLIWKHUHDUH
DQ\FRQFHUQVWKDWWKH6*YDOXHLVQRWDFFXUDWH
x ,QVWUXFWWRKDYHJOXFRVHDQGJOXFDJRQRQKDQG
IRUK\SRJO\FHPLD
x ,QVWUXFWWRFKDQJHLQIXVLRQVHWLIVXVSHFWHG
FDWKHWHURFFOXVLRQRUDGPLQLVWHULQVXOLQZLWK
V\ULQJHIRUSHUVLVWHQWK\SHUJO\FHPLDHVSHFLDOO\LI
NHWRQHVGHYHORS  
x 3DUHQWVJXDUGLDQVLIDSSOLFDEOHZLOOEH
WUDLQHGRQVWXG\GHYLFHDQGLQVWUXFWHGWRFDOO
LQYHVWLJDWRUZLWKSUREOHPV  
x 3DUHQWVJXDUGLDQVLIDSSOLFDEOHDQG
FRPSDQLRQV  VKRXOGEHSUHVHQWDWQLJKWZLWK
VXEMHFWVDQGZLOOEHWUDLQHGRQGLDEHWHV
PDQDJHPHQWSULQFLSOHVDQGLQVWUXFWHGWRFDOO
LQYHVWLJDWRUZLWKSUREOHPV  
CIP335 Clinical Investigation Plan 
 Form 
D00409632 Version E Page 75 of 106 
0HGWURQLF%XVLQHVV5HVWULFWHG
CONFIDENTIAL )5HY(&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Form
x ,QVXOLQGHWHULRUDWLRQOHDGLQJWR
K\SHUJO\FHPLD
x ,QFRPSOHWHSULPLQJIDLOVWRSULPHWXELQJ
DQGRUFDQQXODOHDGLQJWRK\SHUJO\FHPLD
x 5HPRYHDUHVHUYRLUZLWKRXWVXVSHQGLQJ
DQGUHFRQQHFWLQJDIWHUD ZKLOHUHVXOWLQJLQD
K\SRJO\FHPLD
x 3DWLHQWQRWILOOLQJSXPSUHVHUYRLUZKHQ
QHHGHGOHDGLQJWRK\SHUJO\FHPLD
x 0DJQHWLFUHVRQDQFHLPDJLQJUHVXOWLQJLQ
SXPSWUDQVPLWWHUPDOIXQFWLRQ
x ,QDFFXUDWHLQVXOLQGHOLYHU\GXHWRVXGGHQ
DOWLWXGHFKDQJHV
x +\SRJO\FHPLDRUK\SHUJO\FHPLDIURP
PDQXDOEROXV
x +\SRJO\FHPLDRUK\SHUJO\FHPLDIURPWKH
XVHRIWKH6PDUW*XDUGIHDWXUHZKHUH6*
YDOXHVPD\EHXVHGWRFDOFXODWHLQVXOLQ
EROXVDPRXQWV
x +\SRJO\FHPLDRUK\SHUJO\FHPLDIURP
FRPSXWHUKDFNLQJ
x 8QH[SODLQHG+\SHUJO\FHPLD%*!PJG/
!KRXUVDIWHUDPHDOQRUHGXFWLRQLQ%*E\PJG/LQKRXUDIWHULQVXOLQ
DGPLQLVWUDWLRQOHDGLQJWRLQIXVLRQVHW
UHSODFHPHQW

5LVNVZLWKXVHRI/\XPMHY
x +\SHUJO\FHPLDRUK\SRJO\FHPLD
x +\SRNDOHPLD
x +\SHUVHQVLWLYLW\UHDFWLRQV
x ,QMHFWLRQLQIXVLRQVLWHUHDFWLRQ
x $OOHUJLFUHDFWLRQ
x 5DVK
x 3UXULWXV
x /LSRG\VWURSK\
x :HL
JKW*DLQ
5LVNVZLWKK\SHUJO\FHPLDPD\LQFOXGH
x 'LDEHWLFNHWRDFLGRVLV
x 6\PSWRPDWLFNHWRVLV
x &DUGLRYDVFXODUHYHQW
x 'HK\GUDWLRQ
x 3RWDVVLXPDQGVRGLXPLPEDODQFH
x 6KRFN
x $OWHUHGPHQWDOVWDWXV
x &RPD
x $FLGRVLV  3UHYHQWLRQDQGPLWLJDWLRQLQFOXGH
x )ROORZWKHSURYLGHGXVHUJXLGHVIRULQVXOLQSXPS
PDQDJHPHQW
x 3DUHQWVJXDUGLDQVLIDSSOLFDEOHZLOOEH
WUDLQHGRQVWXG\GHYLFHDQGLQVWUXFWHGWRFDOO
LQYHVWLJDWRUZLWKSUREOHPV  
x 3DUHQWVJXDUGLDQVLIDSSOLFDEOHDQG
FRPSDQLRQV  VKRXOGEHSUHVHQWDWQLJKWZLWK
VXEMHFWVDQGZLOOEHWUDLQHGRQGLDEHWHV
PDQDJHPHQWSULQFLSOHVDQGLQVWUXFWHGWRFDOO
LQYHVWLJDWRUZLWKSUREOHPV  
x 7UDLQSULRUWRVWXG\GHYLFHXVHRQDSSURSULDWH
GHYLFHXVHDQGGLDEHWHVPDQDJHPHQWSULQFLSOHV
DQGLQVWUXFWWRFDOOLQY HVWLJDWRUZLWKSUREOHPV  
x ,QVWUXFWWRFKHFNWKHLUPHWHUJOXFRVHLIWKHLUKLJK
V\PSWRPVGRQRWPDWFKWKHLUVHQVRUDOHUWVRU6*
UHDGLQJVLQRUGHUWRPDNHGLDEHWHVWUHDWPHQW
GHFLVLRQV
CIP335 Clinical Investigation Plan 
 Form 
D00409632 Version E Page 76 of 106 
0HGWURQLF%XVLQHVV5HVWULFWHG
CONFIDENTIAL )5HY(&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Form
x ,QVWUXFWWRFKHFNWKHLUPHWHUJOXFRVHLIWKHUHDUH
DQ\FRQFHUQVWKDWWKH6*YDOXHLVQRWDFFXUDWH
x $OWHUQDWLYHPHWKRGRIPDQDJLQJJOXFRVHOHYHOV
ZLOOEHDYDLODEOHLQVX OLQDQGV\ULQJHIRU
H[DPSOH
5LVNVZLWKK\SRJO\FHPLDPD\LQFOXGH
x 6HL]XUH
x &RPD
x $OWHUHGPHQWDOVWDWXV
x /RVVRIFRQVFLRXVQHVV
x &DUGLRYDVFXODUHYHQW
x 'HDWK
x 5LVNRIUHERXQGK\SHUJO\FHPLDZLWKNHWRVLV  3UHYHQWLRQDQGPLWLJDWLRQLQFOXGH
x )ROORZWKHSURYLGHGXVHUJXLGHVIRULQVXOLQSXPS
PDQDJHPHQW
x 3DUHQWVJXDUGLDQVLIDSSOLFDEOHZLOOEH
WUDLQHGRQVWXG\GHYLFHDQGLQVWUXFWHGWRFDOO
LQYHVWLJDWRUZLWKSUREOHPV  
x 3DUHQWVJXDUGLDQVLIDSSOLFDEOHDQG
FRPSDQLRQV  VKRXOGEHSUHVHQWDWQLJKWZLWK
VXEMHFWVDQGZLOOEHWUDLQHGRQGLDEHWHV
PDQDJHPHQWSULQFLSOHVDQGLQVWUXFWHGWRFDOO
LQYHVWLJDWRUZLWKSUREOHPV7UDLQSULRUWRVWXG\
GHYLFHXVHRQDSSURSULDWHGHYLFHXVHDQG
GLDEHWHVPDQDJHPHQWSULQFLSOHVDQGLQVWUXFWWR
FDOOLQYHVWLJDWRUZLWKSUREOHPV  
x ,QVWUXFWWRFKHFNWKHLUPHWHUJOXFRVHLIWKHLUORZ
V\PSWRPVGRQRWPDWFKWKHLUVHQVRUDOHUWVRU6*
UHDGLQJVLQRUGHUWRPDNHGLDEHWHVWUHDWPHQW
GHFLVLRQV
x ,QVWUXFWWRFKHFNWKHLUPHWHUJOXFRVHLIWKHUHDUH
DQ\FRQFHUQVWKDWWKH6*YDOXHLVQRWDFFXUDWH
x ,QVWUXFWWRKDYHJOXFRVHDQGJOXFDJRQRQKDQG
IRUK\SRJO\FHPLD
Riskwith Sensors Prevention and Miti gation 
5LVNVZLWKVHQVRUVPD\LQFOXGH
x 6NLQLUULWDWLRQRUUHDFWLRQWRDGKHVLYHV
x %UXLVLQJ
x 'LVFRPIRUW
x 5HGQHVV
x %OHHGLQJ
x 3DLQ
x 5DVK
x ,QIHFWLRQ
x ,UULWDWLRQIURPWDSHVXVHGZLWKJOXFRVH
VHQVLQJSURGXFWV
x 5DLVHGEXPS
x $SSHDUDQFHRIDVPDOOIUHFNOHOLNHGRW
ZKHUHQHHGOHZDVLQVHUWHG
x $OOHUJLFUHDFWLRQ
x 6\QFRSDOHSLVRGHVHFRQGDU\WRQHHGOH
LQVHUWLRQ
x 6RUHQHVVRUWHQGHUQHVV
x 6ZHOOLQJDWLQVHUWLRQVLWH
x 6HQVRUIUDFWXUHEUHDNDJHRUGDPDJH
x 0LQLPDOEORRGVSODWWHUDVVRFLDWHGZLWK
VHQVRUQHHGOHUHPRYDO
x 5HVLGXDOUHGQHVVDVVRFLDWHGZLWKDGKHVLYH
DQGRUWDSHV
x 6FDUULQJ  
x 6FDE
x %OLVWHU3UHYHQWLRQDQGPLWLJDWLRQLQFOXGH
x )ROORZWKHSURYLGHGXVHUJXLGHVIRULQVHUWLRQV
DQGFDUHRIVHQVRUV  
x ,IDVHQVRUVLWHEHFRPHVLQIHFWHGRULQIODPHG
WKHVHQVRUZLOOEHUHPRYHGDQGDQRWKHUSODFHG
LQDQHZORFDWLRQ  
x ,QVWUXFWWRFKHFNWKHLUPHWHUJOXFRVHLIWKHLUKLJK
RUORZV\PSWRPVGRQRWPDWFKWKHLUVHQVRU
DOHUWVRU6*UHDGLQJVLQRUGHUWRPDNHGLDEHWHV
WUHDWPHQWGHFLVLRQV
x ,QVWUXFWWRFKHFNWKHLUPHWHUJOXFRVHLIWKHUHDUH
DQ\FRQFHUQVWKDWWKH6*YDOXHLVQRWDFFXUDWH
x ,QVWUXFWLIWKHUHDUHQRVHQVRUYDOXHVQR
WUHDWPHQWGHFLVLRQVZLOOEHPDGHXQWLOD%*LV
FRQILUPHG

CIP335 Clinical Investigation Plan 
 Form 
D00409632 Version E Page 77 of 106 
0HGWURQLF%XVLQHVV5HVWULFWHG
CONFIDENTIAL )5HY(&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Form
x ,WFKLQHVV
x ,QIODPPDWLRQ
x $Q[LHW\
x ,QFRUUHFW6*UHDGLQJUHVXOWVLQLQFRUUHFW
GLDEHWHVPDQDJHPHQW  
x 6XEMHFWRYHUWUHDWLQJVHFRQGDU\WRDODUPV
ZKLFKFDQUHVXOWLQK\SHUJO\FHPLDRU
K\SRJO\FHPLD  


Risks with Transmitter  Prevention and Miti gation
5LVNVZLWKWUDQVPLWWHUPD\LQFOXGH
x 6NLQLUULWDWLRQRUUHDFWLRQWRDGKHVLYHV
x %UXLVLQJ
x 'LVFRPIRUW
x 5HGQHVV
x 3DLQ
x 5DVK
x ,QIHFWLRQ
x ,UULWDWLRQIURPWDSHVXVHGZLWKJOXFRVH
VHQVLQJSURGXFWV
x 5DLVHGEXPS
x $OOHUJLFUHDFWLRQ
x 6RUHQHVVRUWHQGHUQHVV
x 5HVLGXDOUHGQHVVDVVRFLDWHGZLWKDGKHVLYH
DQGRUWDSHV
x 6FDUULQJ
x 6FDE
x %OLVWHU
x ,WFKLQHVV
x ,QIODPPDWLRQ
3UHYHQWLRQDQGPLWLJDWLRQLQFOXGH
x )ROORZWKHSURYLGHGXVHUJXLGHV  
x 7UDLQRQWKHSURSHUX VHRIWKHWUDQVPLWWHUV  
Risks with Inserter Prevention and Miti gation 
5LVNVZLWKLQVHUWHUVPD\LQFOXGH
x ,PSURSHULQVHUWLRQPD\OHDGWRGHYLFH
SHUIRUPDQFHLVVXH  3UHYHQWLRQDQGPLWLJDWLRQLQFOXGH
x )ROORZWKHSURYLGHGXVHUJXLGHVIRULQVHUWLRQV
DQGFDUHRIGHYLFH
x 7UDLQRQWKHSURSHUXVHRIWKHLQVHUWHUDQGVNLQ
SUHSDUDWLRQSULRUWRLQVHUWLRQ
Risks with Fin gersticks and Blood Draws Prevention and Miti gation 
5LVNVZLWKIUHTXHQWILQJHUVWLFNWHVWLQJDQGEORRG
GUDZVPD\LQFOXGH
x 3RWHQWLDOULVNVDVVRFLDWHGZLWKIUHTXHQW
PHWHUWHVWLQJRI%*DQGEORRGNHWRQHV
LQFOXGHGLVFRPIRUWDQGHFFK\PRVLVDWWLSVRI
ILQJHUV
x 3RWHQWLDOULVNVDVVRFLDWHGZLWKILQJHUVWLFN
WHVWLQJLQFOXGHGLVFRPIRUWDQGEUXLVLQJ
x 3RWHQWLDOULVNVDVVRFLDWHGZLWKGUDZLQJ
EORRGLQFOXGHGLVFRPIRUWEUXLVLQJDQG
KHPDWRPD3UHYHQWLRQDQGPLWLJDWLRQLQFOXGH
x )ROORZWKHSURYLGHGXVHUJXLGHVIRUXVHRIWKH
VWXG\PHWHUZLWKILQJHUVWLFNWHVWLQJ
x 7UDLQRQWKHSURSHUXVHRIWKHVWXG\PHWHUDQG
ILQJHUVWLFNWHVWLQJ
x %ORRGGUDZVZLOOEHSHUIRUPHGE\DWUDLQHG
KHDOWKFDUHSURIHVVLRQDO

Risk with Closed Loop Therapy  Prevention and Miti gation
5LVNVZLWK&ORVHG/RRSPD\LQFOXGH 3UHYHQWLRQDQGPLWLJDWLRQ LQFOXGH
x)ROORZWKHSURYLGHGXVHUJXLGHVIRULQVXOLQSXPS
PDQDJHPHQW  
CIP335 Clinical Investigation Plan 
 Form 
D00409632 Version E Page 78 of 106 
0HGWURQLF%XVLQHVV5HVWULFWHG
CONFIDENTIAL )5HY(&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Form
x +\SRJO\FHPLD
x 6HYHUHK\SRJO\FHPLD
x +\SHUJO\FHPLD
x 'LDEHWLFNHWRDFLGRVLV
x 8VHUHQWU\HUURU
o 3DWLHQWDGPLQLVWHULQJEROXVHVE\
HQWHULQJIDOVHFDUEGRVHVOHDGLQJWR
K\SRJO\FHPLDRUK\SHUJO\FHPLD
o 3DWLHQWHQWHULQJIDOVHJOXFRVHYDOXHVIRU
DQ\UHDVRQOHDGLQJWRK\SRJO\FHPLDDQG
K\SHUJO\FHPLD
o 3DWLHQWHQWHULQJIDOVH%*YDOXHVIRU
FDOLEUDWLRQOHDGLQJWRK\SRJO\FHPLDRU
K\SHUJO\FHPLD
x 6HQVRUIDLOXUHUHVXOWLQJIURPSDWLHQWIDLOXUH
WRFDOLEUDWHOHDGLQJWRK\SRJO\FHPLDRU
K\SHUJO\FHPLD
x 6HQVRURYHUUHDGLQJUHVXOWLQJLQ
K\SRJO\FHPLD
x 6HQVRUXQGHUUHDGLQJUHVXOWLQJLQ
K\SHUJO\FHPLD
x 6HQVRUPLVVHGWUDQVPLVVLRQRUDQ\RWKHU
IDXOWUHVXOWLQJLQQR6*YDOXHOHDGLQJWR
K\SHUJO\FHPLDRUK\SRJO\FHPLD
x 9ROXQWDU\LQVXOLQGHOLY HU\ZLWKWKHSXPSRU
ZLWKDV\ULQJHLPPHGLDWHO\SULRUWR
HQWHULQJ6PDUW*XDUGPD\UHVXOWLQVHYHUH
K\SRJO\FHPLDGHVSLWHVKXWWLQJGRZQLQVXOLQ
GHOLYHU\E\WKHDOJRULWKP
x +\SRJO\FHPLDUHODWHGWRSDWLHQWWDNLQJ
LQVXOLQYLDLQMHFWLRQZKLOHLQ&ORVHG/RRS
6PDUW*XDUG
x +\SRJO\FHPLDRUK\SHUJO\FHPLDUHODWHGWR
HQWHULQJRUH[LWLQJ&ORVHG/RRS
6PDUW*XDUG
x ,QVXOLQRYHUGHOLYHU\GXHWRSRWHQWLDO
LQWHUIHUHQFHIURPDFHWDPLQRSKHQ
x &\EHUVHFXULW\KDFNLQJLQWRSXPSx 7UDLQSULRUWRVWXG\GHYLFHXVHRQDSSURSULDWH
GHYLFHXVHDQGGLDEHWHVPDQDJHPHQWSULQFLSOHV
DQGLQVWUXFWWRFDOOLQY HVWLJDWRUZLWKSUREOHPV  
x ,QVWUXFWWRFKHFNWKHLUPHWHUJOXFRVHLIWKHLUKLJK
RUORZV\PSWRPVGRQRWPDWFKWKHLUVHQVRU
DOHUWVRU6*UHDGLQJVLQRUGHUWRPDNHGLDEHWHV
WUHDWPHQWGHFLVLRQV
x ,QVWUXFWWRFKHFNWKHLUPHWHUJOXFRVHLIWKHUHDUH
DQ\FRQFHUQVWKDWWKH6*YDOXHLVQRWDFFXUDWH
x ,QVWUXFWLIWKHUHDUHQRVHQVRUYDOXHVQR
WUHDWPHQWVGHFLVLRQZLOOEHPDGHXQWLOD%*LV
FRQILUPHG  
x ,QVWUXFWWRKDYHJOXFRVHDQGJOXFDJRQRQKDQG
IRUK\SRJO\FHPLD  
x ,QVWUXFWWRDYRLGWKHXVHRISURGXFWVFRQWDLQLQJ
DFHWDPLQRSKHQ
x ,IDFHWDPLQRSKHQLVWDNHQVXEMHFWVZLOOEH
LQVWUXFWHGWRXVHDGGLWLRQDO%*PHWHUUHDGLQJV
WRYHULI\WKHLUJOXFRVHOHYHOV
x ,IDFHWDPLQRSKHQLVWDNHQZKLOHWKH
6PDUW*XDUGIHDWXUHLVDFWLYHVXEMHFWVZLOOEH
LQVWUXFWHGWRXVHWKHWHPSWDUJHWIHDWXUHZKHQ
XVHG$XWR&RUUHFWLRQLVQRWDYDLODEOH
x ,QVWUXFWVXEMHFWVWKDWLQFDVHRISURORQJHGXVH
RIDFHWDPLQRSKHQWKHWHPSWDUJHWIHDWXUHFDQ
EHXVHGUHSHDWHGO\DQGLQVXFFHVVLRQ
x 3XPSKDVF\EHUVHFXULW\HQFU\SWLRQVWRSUHYHQW
KDFNLQJ


5LVNVZLWKK\SHUJO\FHPLDPD\LQFOXGH
x 'LDEHWLFNHWRDFLGRVLV
x 6\PSWRPDWLFNHWRVLV
x &DUGLRYDVFXODUHYHQW
x 'HK\GUDWLRQ
x 3RWDVVLXPDQGVRGLXPLPEDODQFH
x 6KRFN
x $OWHUHGPHQWDOVWDWXV
x &RPD
x $FLGRVLV3UHYHQWLRQDQGPLWLJDWLRQLQFOXGH
x )ROORZWKHSURYLGHGXVHUJXLGHVIRULQVXOLQSXPS
PDQDJHPHQW  
x 7UDLQSULRUWRVWXG\GHYLFHXVHRQDSSURSULDWH
GHYLFHXVHDQGGLDEHWHVPDQDJHPHQWSULQFLSOHV
DQGLQVWUXFWWRFDOOLQY HVWLJDWRUZLWKSUREOHPV  
x ,QVWUXFWWRFKHFNWKHLUPHWHUJOXFRVHLIWKHLUKLJK
V\PSWRPVGRQRWPDWFKWKHLUVHQVRUDOHUWVRU6*
UHDGLQJVLQRUGHUWRPDNHGLDEHWHVWUHDWPHQW
GHFLVLRQV
x ,QVWUXFWWRFKHFNWKHLUPHWHUJOXFRVHLIWKHUHDUH
DQ\FRQFHUQVWKDWWKH6*YDOXHLVQRWDFFXUDWH
x ,QVWUXFWLIWKHUHDUHQRVHQVRUYDOXHVQR
WUHDWPHQWVGHFLVLRQZLOOEHPDGHXQWLOD%*LV
FRQILUPHG
CIP335 Clinical Investigation Plan 
 Form 
D00409632 Version E Page 79 of 106 
0HGWURQLF%XVLQHVV5HVWULFWHG
CONFIDENTIAL )5HY(&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Form
5LVNVZLWKK\SRJO\FHPLDPD\LQFOXGH
x 6HL]XUH
x &RPD
x $OWHUHGPHQWDOVWDWXV
x /RVVRIFRQVFLRXVQHVV
x &DUGLRYDVFXODUHYHQW
x 'HDWK
x 5LVNRIUHERXQGK\SHUJO\FHPLDZLWK
NHWRVLV3UHYHQWLRQDQGPLWLJDWLRQLQFOXGH
x )ROORZWKHSURYLGHGXVHUJXLGHVIRULQVXOLQSXPS
PDQDJHPHQW  
x 7UDLQSULRUWRVWXG\GHYLFHXVHRQDSSURSULDWH
GHYLFHXVHDQGGLDEHWHVPDQDJHPHQWSULQFLSOHV
DQGLQVWUXFWWRFDOOLQY HVWLJDWRUZLWKSUREOHPV  
x ,QVWUXFWWRFKHFNWKHLUPHWHUJOXFRVHLIWKHLUORZ
V\PSWRPVGRQRWPDWFKWKHLUVHQVRUDOHUWVRU6*
UHDGLQJVLQRUGHUWRPDNHGLDEHWHVWUHDWPHQW
GHFLVLRQV
x ,QVWUXFWWRFKHFNWKHLUPHWHUJOXFRVHLIWKHUHDUH
DQ\FRQFHUQVWKDWWKH6*YDOXHLVQRWDFFXUDWH
x ,QVWUXFWLIWKHUHDUHQRVHQVRUYDOXHVQR
WUHDWPHQWGHFLVLRQVZLOOEHPDGHXQWLOD%*LV
FRQILUPHG
x ,QVWUXFWWRKDYHJOXFRVHDQGJOXFDJRQRQKDQG
IRUK\SRJO\FHPLD
Risk with Acetaminophen Use  Prevention and Miti gation
3RWHQWLDOULVNVZLWKDFHWDPLQRSKHQPD\LQFOXGH
x )DOVHHOHYDWLRQRI6*UHDGLQJV SRWHQWLDOO\
UHVXOWLQJLQDQRYHUGHOLYHU\RILQVXOLQZKLFK
PD\FDXVHK\SRJO\FHPLD7KHOHYHORI
LQDFFXUDF\GHSHQGVRQWKHDPRXQWRI
DFHWDPLQRSKHQDFWLYHLQVXEMHFWÂ¶VERG\DQG
PD\EHGLIIHUHQWIRUHDFKVXEMHFW
x /LYHUGDPDJHOLYHUIDLOXUHDQGRUUDUHEXW
IDWDOOLYHUIDLOXUHFDQRFFXU
x 6NLQUDVKDQGRUVHULRXVDQGSRWHQWLDOO\
IDWDOVNLQUHDFWLRQVKDYHEHHQUHSRUWHG
x $OOHUJLFUHDFWLRQVLQFOXGLQJWKRVHZKLFKDUH
VHULRXVDQGSRWHQWLDOO\IDWDOFDQRFFXU
x .LGQH\GLVHDVH
x /RZHUHGEORRGFRXQWVUHGFHOOVDQGZKLWH
FHOOV
3UHYHQWLRQDQGPLWLJDWLRQLQFOXGH
x )ROORZWKHXVHUJXLGH
x ,QVWUXFWWRDYRLGWKHXVHRISURGXFWVFRQWDLQLQJ
DFHWDPLQRSKHQ
x ,IDFHWDPLQRSKHQLVWDNHQVXEMHFWVZLOOEH
LQVWUXFWHGWRXVHDGGLWLRQDO%*PHWHUUHDGLQJV
WRYHULI\WKHLUJOXFRVHOHYHOV
x ,IDFHWDPLQRSKHQLVWDNHQZKLOHWKH
6PDUW*XDUGIHDWXUHLVDFWLYHVXEMHFWVZLOOEH
LQVWUXFWHGWRXVHWKHWHPSWDUJHWIHDWXUHZKHQ
XVHG$XWR&RUUHFWLRQLVQRWDYDLODEOH
x ,QVWUXFWVXEMHFWVWKDWLQFDVHRISURORQJHGXVH
RIDFHWDPLQRSKHQWKHWHPSWDUJHWIHDWXUHFDQEHXVHGUHSHDWHGO\DQGLQVXFFHVVLRQ

10.2  Risk Minimization 
5HIHUWRÂ³3UHYHQWLRQDQG0LWLJDWLRQÂ´FROXPQLQWKHWDEOHXQGHU Section 10.1 
10.3  Potential Benefits 
7KHPDLQEHQHILWRIWKLVVWXG\LVWKDWVXEMHFWVPD\H[SHULHQFH LPSURYHGJOXFRVHFRQWURO7KH\PD\JDLQ
LQFUHDVHGDZDUHQHVVRIHPHUJLQJW HFKQRORJLHVIRUGLDEHWHVPDQDJ HPHQWDVDUHVXOWRIWKHLUSDUWLFLSDWLRQ
10.4  Risk-Benefit Rationale 
7KHPDLQEHQHILWRIWKLVVWXG\ LVWKDWVXEMHFWVPD\H[SHULHQFH LPSURYHGJOXFRVHFRQ WURO6LQFH/\XPMHY
LQVXOLQKDVQRWEHHQSUHYLRXVO\ VWXGLHGZLWKWKH0LQL0HG*V \VWHPLQDOODJHJURXSVWKHUHLVD
WKHRUHWLFDOULVNWKDWWKH0LQL0HG *SXPSÂ¶VFORVHGORRSDOJRU LWKPPD\QRWPDLQWDLQWKHVDPHOHYHORI
JOXFRVHFRQWURODFKLHYHGZLWKRWKHULQVXOLQVDOWKRXJKPRGHOLQJ KDVLQGLFDWHGWKDWXVHRI/\XPMHY,QVXOLQ
ZLOOQRWUHVXOWLQDQ\FOLQLFDOO \VLJQLILFDQWFKDQJHLQFOLQLFD ORXWFRPHV$GGLWLRQDOO\ULVNUHODWHGWRWKH
CIP335 Clinical Investigation Plan 
 Form 
D00409632 Version E Page 80 of 106 
0HGWURQLF%XVLQHVV5HVWULFWHG
CONFIDENTIAL )5HY(&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Form
SXPSGHOLYHULQJWRRPXFKRUQRWHQRXJKLQVXOLQDUHIXUWKHUPLQL PL]HGWKURXJKDYDULHW\RIVDIHW\FKHFNV
WKDWDUHDQLQWHJUDOSDUWRIWKH 0LQL0HG*FORVHGORRSDOJRU LWKP
10.5  Risk Determination 
,QWKHRSLQLRQRIWKHVSRQVRUW KLVVWXG\LVFRQVLGHUHGWREHD VLJQLILFDQWULVN65VWXG\5HVXOWVRIDQ
HYDOXDWLRQRIWKHUHTXLUHPHQWVSHU&)53DUWOHGWRWK H65GHWHUPLQDWLRQDVIROORZV
x 7KHGHYLFHVSUHVHQWSRWHQWLDOI RUVHULRXVULVNWRVXEMHFWKHDOW KVDIHW\RUZHOIDUH
x 7KHGHYLFHVDUHIRUDXVHRIVX EVWDQWLDOLPSRUWDQFHLQWUHDWLQJ GLVHDVHDQGSUHVHQWVSRWHQWLDOIRU
VHULRXVULVNWRVXEMHFWKHD OWKVDIHW\RUZHOIDUH
7KHUHIRUHVXEPLVVLRQRIDQ,QYH VWLJDWLRQDO'HYLFH([HPSWLRQ, '(DSSOLFDWLRQWRWKH8QLWHG6WDWHV)'$
LVUHTXLUHG

11. Adverse Events  
11.1  Adverse Events 
7KURXJKRXWWKHFRXUVHRIWKHVW XG\LQYHVWLJDWLR QDOFHQWHUVZLO OPDNHDOOHIIRUWVW RUHPDLQDOHUWWR
SRVVLEOHUHSRUWDEOHDGYHUVHHYHQW V$(VRUXQWRZDUGILQGLQJV 7KHVWXG\SHUVRQQHOZ LOOHOLFLWUHSRUWVRI
$(VIURPWKHVXEMHFWDWHDFKYLVLWLQFOXGLQJSKRQHFDOOVVWDU WLQJDWWKHWLPHRIVLJQLQJWKHLQIRUPHG
FRQVHQWGRFXPHQWLQJWKHPHGLFDOGLDJQRVLVGDWHRIHYHQWVWDUW DQGHQGFDXVDOLW\UHODWLRQVKLSWRGHYLFH
RUSURFHGXUHWUHDWPHQWRXWFRP HDVVHVVPHQWRIVHULRXVQHVVD QGGHVFULSWLRQWKDWLQFOXGHVWKHGHWDLOV
RIWKHHYHQW

11.2  Definitions and Classification of Adverse Events 
0HGWURQLFXVHVWKHGHILQLWLRQVS URYLGHGLQ,62DQG &)5IRU$(GHILQLWLRQV:KHUHWKH
GHILQLWLRQLQGLFDWHVÂ³GHYLFHÂ´LW UHIHUVWRDQ\GHYLFHXVHGLQ WKHVWXG\7KLVPLJKWEHWKHGHYLFHXQGHU
LQYHVWLJDWLRQRUDQ\PDUNHWUHO HDVHGFRPSRQHQWRIWKHV\VWHP

Severe Hypoglycemia LVDQHYHQWUHTXLULQJDVVLVWDQFHR IDQRWKHUSHUVRQGXHWRDOWH UHGFRQVFLRXVQHVV
WRDFWLYHO\DGPLQLVWHUFDUERK\GUDWHJOXFDJRQRURWKHUUHVXVFL WDWLYHDFWLRQV
7KLVPHDQVWKDWWKHVXEMHFWZDV LPSDLUHGFRJQLWLYHO\WRWKHSRL QWWKDWKHVKHZDVXQDEOHWRWUHDWKLPVHOI
RUKHUVHOIZDVXQDEOHWRYHUED OL]HKLVRUKHUQHHGVDQGZDVL QFRKHUHQWGLVRULHQWHGDQGRUFRPEDWLYH
 
7KHVHHSLVRGHVPD\EHDVVRFLDWHGZ LWKVXIILFLHQWQHXURJO\FRSHQL DWRLQGXFHVHL]XUHRUFRPD3ODVPD
JOXFRVHPHDVXUHPHQWVPD\QRWEHDYDLODEOHGXULQJVXFKDQHYHQW EXWQHXURORJLFDOUHFRYHU\DWWULEXWDEOH
WRWKHUHVWRUDWLRQRISODVPDJ OXFRVHWRQRUPDOLVFRQVLGHUHGVX IILFLHQWHYLGHQFHWK DWWKHHYHQWZDV
LQGXFHGE\DORZSODVPDJOXFRVHFRQFHQWUDWLRQ 
 
Severe Hyperglycemia LVGHILQHGDVK\SHUJO\FHPLD %*JUHDWHUWKDQ>!@  PJG/  RUPPRO/  
ZLWK%*NHWRQHVJUHDWHUWKDQ! PPRO/DQGRUDFFRPSDQLHG E\V\PSWRPVRIQDXVHDYRPLWLQJRU
DEGRPLQDOSDLQ
7KHPHWHUDQGNHWRQHWHVWVWULSV DUHVXSSOLHGIRUWKHHYDOXDWLR QRINHWRQHPRQLWRULQJ2QO\EORRG
NHWRQHVZLOOEHUHFRJQL]HGQRWXU LQHNHWRQHVIRUDVVLVWLQJLQ GLDJQRVLVRIVHYHUHK\SHUJO\FHPLD7KH
CIP335 Clinical Investigation Plan 
 Form 
D00409632 Version E Page 81 of 106 
0HGWURQLF%XVLQHVV5HVWULFWHG
CONFIDENTIAL )5HY(&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Form
PRQLWRUVWHVWVWULSVDUHTXDOLW \FRQWUROOHGSULRUWRGLVSHQVLQJ WRVXEMHFWV%ORRGNHWRQHVSURYLGH
FRQWHPSRUDQHRXVXQGHUVWDQGLQJR INHWRQHOHYHOVDVVRFLDWHGZLWK HOHYDWLRQVLQJOXFRVH

Diabetic Ketoacidosis/DKA diagnostic criteria %*JUHDWHUWKDQ!PJG/RUJUHDWHUWKDQ!
PPRO/DUWHULDOS+OHVVWK DQELFDUERQDWHOHVVWK DQP(T/PRGHUDWHNHWRQXULDRU
NHWRQHPLDDQGUHTXLULQJWUHDWPHQ WZLWKLQDKHDOWKFDUHIDFLOLW\ 
+\SHUJO\FHPLFHYHQWVZLOOEHUHF RUGHGDV'.$LIWKHHYHQWLQFOX GHVWKHSUHVHQFHRIDOORIWKHIROORZLQJ
x $UWHULDOEORRGS+OHVVWKDQ RUVHUXPELFDUERQDWHOHVV WKDQP(T/
x %ORRGJOXFRVHJUHDWHUWKDQ!PJG/RUJUHDWHUWKDQ! PPRO/
x 6HUXPNHWRQHVRUODUJHPRGHUDWHXULQHNHWRQHV
x 6\PSWRPVVXFKDVSRO\XULDSRO\GLSVLDQDXVHDRUYRPLWLQJ
x 7UHDWPHQWSURYLGHGLQDKHDOWKFDUHIDFLOLW\

Insulin infusion site reaction: DQ\UHDFWLRQDWWKHVLWHRILQV XOLQLQIXVLRQDVVHVVHGDVPRGHU DWHRU
VHYHUHVKRXOGEHU HSRUWHGDVDQ$(  
x $PRGHUDWHLQVXOLQLQIXVLRQVLWH UHDFWLRQLVGHILQHGDVIROORZV 
o 3DLQ,ISDLQLQ WHUIHUHVZLWKGDLO\DFWLY LWLHVRUUHTXLUHVWUHD WPHQW
o (U\WKHPD,IWKHHU\WKHPDLV PPLQGLDPHWHUEULJKWUHGR UGDUNZLWKXOFHUDWLRQRU
QHFURVLVDWWKHLQIXVLRQVLWH
o 3UXULWLV,ISUXULWLVFDXVHVIUH TXHQWLWFKLQJDQGRFFDVLRQDOO\ LPSDLUVGDLO\DFWLYLWLHV
 
x $VHYHUHLQVXOLQLQIXVLRQVLWH UHDFWLRQLVGHILQHGDVIROORZV  
o 3DLQ,ISDLQOLPLWVGDLO\DFWLY LWLHVDQGUHTXLUHVWUHDWPHQW
o (U\WKHPD,IWKH(U\WK HPDLV!PPLQGLDPHWHUEULJKWUHGRU GDUNZLWKXOFHUDWLRQRU
QHFURVLVDWWKHLQIXVLRQVLWH
o 3UXULWLV,ISUXULWLVFDXVHVQHD UFRQVWDQWLWFKLQJDQGVHYHUHO\ LPSDLUVGDLO\DFWLYLWLHV
 Adverse Event (AE) (ISO 14155:2020) 
8QWRZDUGPHGLFDORFFXUUHQFHXQL QWHQGHGGLVHDVHRULQMXU\RUX QWRZDUGFOLQLFDOVLJQVLQFOXGLQJ
DEQRUPDOODERUDWRU\ILQGLQJVLQVXEMHFWVXVHUVRURWKHUSHUVR QVZKHWKHURUQRWUHODWHGWRWKH
LQYHVWLJDWLRQDOPHGLFDOGHYLFHDQ GZKHWKHUDQWLFLSDWHGRUXQDQW LFLSDWHG
Note 1 to entry:  7KLVGHILQLWLRQLQFOXGHVHYHQW VUHODWHGWRWKHLQYHVWLJDWLRQD OPHGLFDOGHYLFHRUWKH
FRPSDUDWRU
Note 2 to entry:  7KLVGHILQLWLRQLQFOXGHVHYHQW VUHODWHGWRWKHSURFHGXUHVLQY ROYHG
Note 3 to entry:  )RUXVHUVRURWKHUSHUVRQVWK LVGHILQLWLRQLVUHVWULFWHGWR HYHQWVUHODWHGWRWKH
XVHRILQYHVWLJDWLRQDOPHGLF DOGHYLFHVRUFRPSDUDWRUV

Adverse Device Effect (ADE) (ISO 14155:2020) 
$GYHUVHHYHQWUHODWHGWRWKHXVH RIDQLQYHVWLJDWLRQDOPHGLFDO
GHYLFH
Note 1 to entry: 7KLVGHILQLWLRQLQFOXGHVDGYHUVH HYHQWVUHVXOWLQ JIURPLQVXIILF LHQWRULQDGHTXDWH
LQVWUXFWLRQVIRUXVHGHSOR\PHQW LPSODQWDWLRQLQVWDOODWLRQR URSHUDWLRQRUDQ\PDOIXQFWLRQRIWKH
LQYHVWLJDWLRQDOPHGLFDOGHYLFHNote 2 to entry:  7KLVGHILQLWLRQLQFOXGHVDQ\HYHQWUHVXOWLQJIURPXVHHUURUR UIURPLQWHQWLRQDO
PLVXVHRIWKHLQYHVWLJDW LRQDOPHGLFDOGHYLFH
Note 3 to entry:  7KLVLQFOXGHVÂµFRPSDUDWRUÂ¶LIWKHFRPSDUDWRULVDPHGLFDOGHY LFH

Serious Adverse Event (SAE) (ISO 14155:2020) 
CIP335 Clinical Investigation Plan 
 Form 
D00409632 Version E Page 82 of 106 
0HGWURQLF%XVLQHVV5HVWULFWHG
CONFIDENTIAL )5HY(&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Form
$GYHUVHHYHQWWKDWOHGWRDQ\RIWKHIROORZLQJ
D GHDWK
E VHULRXVGHWHULRUDWLRQLQWKHKHD OWKRIWKHVXEMHFWXVHUVRUR WKHUSHUVRQVDVGHILQHGE\RQHRU
PRUHRIWKHIROORZLQJ
 DOLIHWKUHDWHQLQJLOOQHVVRULQMXU\RU
 DSHUPDQHQWLPSDLUPHQWRIDERG\ VWUXFWXUHRUDERG\IXQFWLRQL QFOXGLQJFKURQLFGLVHDVHVRU
 LQSDWLHQWRUSURORQJH GKRVSLWDOL]DWLRQRU
 PHGLFDORUVXUJLFDOLQWHUYHQWLRQ WRSUHYHQWOLIHWKUHDWHQLQJLO OQHVVRULQMXU\RUSHUPDQHQW
LPSDLUPHQWWRDERG\VWUXF WXUHRUDERG\IXQFWLRQ
F IRHWDOGLVWUHVVIRHWDOGHDWKRUD FRQJHQLWDODEQRUPDOLW\RUEL UWKGHIHFWLQFOXGLQJSK\VLFDORU
PHQWDOLPSDLUPHQW

Note 1 to entry: 3ODQQHGKRVSLWDOL]DWLRQIRUDSUHH[LVWLQJFRQGLWLRQRUDSURF HGXUHUHTXLUHGE\WKH
&,3ZLWKRXWVHULRXVGHWHULRUDWL RQLQKHDOWKLVQRWFRQVLGHUHG DVHULRXVDGYHUVHHYHQW
Serious Adverse Device Effect (SADE) (ISO 14155:2020) 
$GYHUVHGHYLFHHIIHFWWKDWKDVUHVXOWHGLQDQ\RIWKHFRQVHTXHQ FHVFKDUDFWHULVWLFRIDVHULRXVDGYHUVH
HYHQW

Unanticipated Adverse Device Effect (UADE) (21 CFR 812.3(s)) 
$Q\VHULRXVDGYHUVHHII HFWRQKHDOWKRUVDIHW\RUDQ\OLIHWKUH DWHQLQJSUREOHPRUGHDWKFDXVHGE\RU
DVVRFLDWHGZLWKDGHYLFHLIWKD WHIIHFWSUREOHPRUGHDWKZD VQRWSUHYLRXVO\LGHQWLILHGLQQDWXUH
VHYHULW\RUGHJUHHRILQFLGHQFH LQWKHLQYHVWLJDWLRQDOSODQRU DSSOLFDWLRQLQFOXGLQJDVXSSOHPHQWDU\SODQ
RUDSSOLFDWLRQRUDQ\RWKHUX QDQWLFLSDWHGVHULRXVSUREOHPDVV RFLDWHGZLWKDGHYLFHWKDWUHODWHVWRWKH
ULJKWVVDIHW\RUZHOIDUHRIVXEMHFWV

11.3  Recording of Adverse Events  
7KHLQYHVWLJDWRURUGHVLJQHHZ LOOUHFRUG$//$(VZKLOHWKHVXEM HFWLVHQUROOHGLQWKHFOLQLFDOVWXG\
(DFK$(QHHGVWREHDVVHVVHGIRULWVGHYLFHRUSURFHGXUHUHODWH GQHVV$GHYLFHUHOD WHG$(LVDVVRFLDWHG
ZLWKWKHXVHRIWKHVWXG\GHYLFH VHJLQIHFWLRQRIVHQVRUVL WHRULQIXVLRQVHWRFFOX VLRQUHVXOWLQJLQ'.$
$SURFHGXUHUHODWHG$(LVDVVRFLDW HGZLWKWHVWLQJUHODWHGWRWK HVWXG\SURFHGXUHVVSHFLILHGLQWKH&,3
HJQHHGOHEORRGGUDZLQVHUWLRQSDLQ
([DPSOHVRIGHYLFHRUSURFHGXUHUHODWHG$(VLQFOXGH
x 'HYLFHUHODWHG$'(LQVH UWLRQVLWHLQIHFWLRQ
x 6HULRXVDGYHUVH GHYLFHHIIHFWFHOOXOLWLVDWGHYLFHLQVHUWLRQ VLWHUHTXLULQJKRVSLWDOL]DWLRQ 
x 3URFHGXUHUHODWHG$(EUXLVLQJDWQHHGOH EORRGGUDZLQVHUWLRQVLWH
6XEMHFWVSDUWLFLSDWLQJLQWKHVW XG\KDYHGLDEHWHVDQGDUHH[SHF WHGWRH[SHULHQFHK\SRJO\FHPLDDQGRU
K\SHUJO\FHPLD7KHVHQRUPDOHYHQ WVDUHQRWH[SHFWHGWREHUHSRU WHGWRVSRQVRUDVWKLVLVQRWFRQVLGHUHG
DQXQWRZDUGHYHQWEXWUDWKHUDQH[SHFWHGRFFXUUHQFH$Q\JO\FH PLFH[FXUVLRQWKDWPHHWVWKHSURWRFRO
GHILQLWLRQRIVHYHUHK\SRJO\FHPL DVHYHUHK\SHUJO\FHPLDRU'.$ LVFRQVLGHUHGDQXQWRZDUGHYHQWDQGD
ZRUVHQLQJIURPWKHVXEMHFWÂ¶VEDV HOLQHDQGZRXOGEHUHSRUWHGWR VSRQVRURQDQ$(H&5)
%DVHOLQHPHGLFDOFRQGLWLRQVVKRX OGRQO\EHUHSRUWHGWRVSRQVRU RQDQ$(H&5)LIW KHUHLVDZRUVHQLQJ
IURPWKHVXEMHFW Â¶VEDVHOLQH)RUH[DPSOH DVXEMHFWSUHYLRXVO\ GLDJQRVHGZLWKDVWKPDLVKRVSLWDOL]HGIRU
VHYHUHDVWKPDDWWDFNZRXOGEHDUHSRUWDEOHHYHQW
CIP335 Clinical Investigation Plan 
 Form 
D00409632 Version E Page 83 of 106 
0HGWURQLF%XVLQHVV5HVWULFWHG
CONFIDENTIAL )5HY(&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Form
$GYHUVHHYHQWVZLOOEHGRFXPHQWHG LQWKHVXEMHFWVRXUFHILOHDQ GUHSRUWHGWRVSRQVRURQDQH&5)7KH
LQYHVWLJDWLRQDOFHQWHULVUHVSRQ VLEOHIRUGRFXPHQWDWLRQRI$(V LQFOXGLQJREWDLQLQJVRXUFHGRFXPHQWV
UHODWHGWRWKHHYHQWVXFKDVHPHUJHQF\PHGLFDOWHFKQLFLDQSDUD PHGLFUHSRUWVKRVSLWDOUHFRUGV
DGPLVVLRQVXPPDU\ODEUHVXOWVW HVWUHVXOWVGLVFKDUJHVXPPDU \RUGHYLFHXSORDGVWRVXSSRUWWKH
HYHQW6RXUFHGRFXPHQWVZLOOEHU HYLHZHGWRGHWHUPLQHLIDGGLWL RQDO$(VKDYHRFFX UUHGDQGUHTXLUH
UHSRUWLQJ

$GYHUVHHYHQWVWKDWKDYHQRWUHVROYHGDWWKHWLPHRIWKHVXEMHF WÂ¶VGLVFRQWLQXDWLRQRUFRPSOHWLRQRIWKH
VWXG\VKRXOGKDYHDQÂ³RXWFRPHÂ´R I1RW5HFRYHUHG1RW5HVROYHGDW VWXG\HQGLQVXEMHFWVRXUFHDQGRQ
DQH&5)7KHLQYHVWLJDWRUVKRXOGHQVXUHWKDWVXEMHFWLVDZDUHR IDQ\IROORZXSRUDGGLWLRQDOWUHDWPHQW
WKDWLVUHTXLUHGIRUDQ\RQJRLQJ$(DW(26SDUWLFLSDWLRQKRZHY HUWKHUHZLOOEHQRH&5)HQWU\IRUWKH
RQJRLQJIROORZXS

11.4 Notification of Adverse Events
6SRQVRU1RWLILFDWLRQ
7KHLQYHVWLJDWLRQDOFHQWHUVWDII PXVWUHSRUWDOO$(VWR0HGWURQ LFLQDWLPHO\PDQQHU$OO VHYHUH
K\SRJO\FHPLD'.$6$(DQG6$'(VKRXOGEHUHSRUWHGDVVRRQDV SRVVLEOHGHVLUHGZLWKLQKRXUV
RILQYHVWLJDWRURUVWXG\FRRUGLQD WRUDZDUHQHVVWR0HGWURQLF) RUWKHSUHYLRXVO\P HQWLRQHGHYHQWV
WKH$(H&5)ZLOOEHFRPSOHWHG ZLWKDOONQRZQGHWDLOVDVVRRQDV SRVVLEOHWKLVZLOOVHUYHDV
QRWLILFDWLRQWR0HGWURQLF,IWKH VWXG\GDWDEDVHFDQQRWEHDFFH VVHGGXHWRWHFKQLFDOSUREOHPV
FRQWDFWWKHVSRQVRUYLDHPDLODW GOGLDEHWHVFOLQLFDOUHVHDU FKVDIHW\#PHGWURQLFFRP DQGSURYLGHWKH
GHLGHQWLILHGNQRZQGHWDLOVRIWK HHYHQW2QFHWKHDFFHVVLVVXH KDVEHHQFRUUHFWHGWKHHYHQWVKRXOG
EHHQWHUHGRQWRDQ$(H&5)
6RXUFHGRFXPHQWVWKDWVXSSRUWWKHHYHQWHJFOLQLFQRWHVKR VSLWDODGPLVVLRQDQGGLVFKDUJH
UHFRUGVODEUHSRUWV(07UHSRUWV (58UJHQW&DUHVKRXOGEHSU RYLGHGWRWKHVSRQVRUYLD0HGWURQLFÂ¶V
VHFXUHXSORDGDSSOLFDWLRQ$OOV RXUFHGRFXPHQWVPHGLFDOUHFRUGV VKRXOGEHUHGDFWHGRISDWLHQW
LGHQWLILHUVIXOOQDPHDGGUHVVH WFSULRUWRSURYLGLQJWRWK HVSRQVRU(DFKVRXUFHSDJHVKRXOGEH
LGHQWLILHGZLWKWKHVXEMHFW,'
11.5  Expedited Safety Rep orting Requirements  
)RUGHYLFHVWXGLHVLQYHVWLJDWRU VDUHUHTXLUHGWRVXEPLWDUHSR UWRID8$'(WRWKHVSRQVRUDQGWKH
UHYLHZLQJ,5%DVVRRQDVSRVVLEOH EXWLQQRHYHQWODWHUWKDQ ZRUNLQJGD\VDIWHUWKHLQYHVWLJDWRUILUVW
OHDUQVRIWKHHYHQWD
7KHVSRQVRUZLOOQRWLI\WKHLQYHVWLJDWRUDQG,5% RIDQ\HYHQWWKDWUHVXOWVLQDVDIHW\UHSRUWSHU
UHJXODWLRQVWRWKH)'$'RFXPHQWDWLRQRI,5%QRWLILFDWLRQRIDQ \VDIHW\HYHQWPXVWEHNHSWDWWKH
LQYHVWLJDWLRQDOFHQWHUDQGDFRS\VHQWWRWKHVSRQVRU

,WLVWKHUHVSRQVLELOLW\RIWKHLQYHVWLJDWRUWRIROORZWKHLU,5%UHSRUWLQJUHTXLUHPHQWV
11.6  Causality Assessment
$Q$(LVQRWDXWRPDWLFDOO\UHODW HGWRWKHVWXG\GHYLFHRUSURFH GXUHVLPSO\EHFDXVHWKHVXEMHFWLVZHDULQJ
WKHGHYLFHDQGSDUWLFLSDWLQJLQ WKHVWXG\7KHHYHQWVKRXOGEH UHYLHZHGWRGHWHUPLQHLIWKHGHYLFHRU
VWXG\SURFHGXUHFRXOGKDYHSRVVLEO\FDXVHGWKHHYHQWDQGWKHUHI RUHLVUHODWHGWRWKHVWXG\GHYLFHRU
SURFHGXUH

CIP335 Clinical Investigation Plan 
 Form 
D00409632 Version E Page 84 of 106 
0HGWURQLF%XVLQHVV5HVWULFWHG
CONFIDENTIAL )5HY(&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Form
&DXVDOLW\DVVHVVPHQWLVWKHGHWHU PLQDWLRQRIWKHUHODWLRQVKLSE HWZHHQDQ$(DQGWKHGHYLFHEHLQJ
VWXGLHG,WLVH[SHFWHGWKDWWKH LQYHVWLJDWLRQDOFHQWHUZLOOUH YLHZDOOHOHPHQWVVXUU RXQGLQJWKH$(WR
SURSHUO\DVVHVVWKHFDXVDOLW\RIW KHHYHQWWRWKH VWXG\GHYLFH RUWRDVWXG\SURFHGXUH
7KLVUHYLHZZRXOGLQFOXGHWKHVXEM HFWVÂ¶GHVFULSWLRQRIWKHHYHQ WVWXG\GHYLFHXSORDGVDQGPHGLFDO
UHFRUGVLIDSSOLFDEOHIURPWK HWUHDWLQJIDFLOLW\7KHVHUHFRU GVZLOOEHPDGHDYDLODEOHWRVSRQVRU
,QYHVWLJDWRUVVKRXOGFODVVLI\WKH UHODWLRQVKLSEHWZHHQWKH$(D QGWKHVWXG\GHYLFHRUVWXG\SURFHGXUHV
XVLQJRQHRIWKHIRXUSRVVLEOH FDXVDOLW\FDWHJRULHVOLVWHGEHOR Z

x Not related: UHODWLRQVKLSWRWKHGHYLFHFRPSDUDWRURUSURFHGXUHVFDQEHH[ FOXGHGZKHQ
o WKHHYHQWKDVQRWHPSRUDOUHODWL RQVKLSZLWKWKHXVHRIWKHLQYH VWLJDWLRQDOGHYLFHRUWKH
SURFHGXUHVUHODWHGWRWKHDSSOLFDW LRQRIWKHLQYHVWLJDWLRQDOGH YLFH
o WKHHYHQWGRHVQRWIROORZDNQRZ QUHVSRQVHSDWWHUQWRWKHPHGLF DOGHYLFHLIWKH
UHVSRQVHSDWWHUQLVSUHYLRXVO\N QRZQDQGLVELRORJLFDOO\LPSOD XVLEOH
o WKHGLVFRQWLQXDWLRQRIPHGLFDOG HYLFHDSSOLFDWLRQRUWKHUHGXFW LRQRIWKHOHYHORI
DFWLYDWLRQH[SRVXUHZKHQFOLQLF DOO\IHDVLEOHÂ±DQGUHLQWURGXF WLRQRILWVXVHRULQFUHDVH
RIWKHOHYHORIDFWLYDWLRQH[SRV XUHGRQRWLPSDFWRQWKHHYHQ W
o WKHHYHQWLQYROYHVDERG\VLWHR UDQRUJDQQRWH[SHFWHGWREHD IIHFWHGE\WKHGHYLFHRU
SURFHGXUH
o WKHHYHQWFDQEHDWWULEXWHGWRDQRWKHUFDXVHHJDQXQGHUO\L QJRUFRQFXUUHQWLOOQHVV
FOLQLFDOFRQGLWLRQDQHIIHFWRI DQRWKHUGHYLFHGUXJWUHDWPHQ WRURWKHUULVNIDFWRUV
o WKHHYHQWGRHVQRWGHSHQGRQDI DOVHUHVXOWJLYHQE\WKHLQYHVW LJDWLRQDOGHYLFHXVHGIRU
GLDJQRVLVZKHQDSSOLFDEOH

,QRUGHUWRHVWDEOLVKWKHQRQUH ODWHGQHVVQRWDOOWKHFULWHULD OLVWHGDERYHPLJKWEHPHWDWWKH
VDPHWLPHGHSHQGLQJRQWKHW\SHRIGHYLFHSURFHGXUHVDQGWKHH YHQW
x Possible: WKHUHODWLRQVKLSZLWKWKHXVHRI WKHLQYHVWLJDWLRQDOGHYLFHFR PSDUDWRURUWKH
UHODWLRQVKLSZLWKSURFHGXUHVLVZ HDNEXWFDQQRWEHUXOHGRXWF RPSOHWHO\$OWHUQDWLYHFDXVHVDUH
DOVRSRVVLEOHHJDQXQGHUO\LQ JRUFRQFXUUHQWLOOQHVVFOLQLF DOFRQGLWLRQRUDQGDQHIIHFWRI
DQRWKHUGHYLFHGUXJRUWUHDWPHQW&DVHVZKHUHUHODWHGQHVVFDQ QRWEHDVVHVVHGRUQR
LQIRUPDWLRQKDVEHHQREWDLQHGVKRXOGDOVREHFODVVLILHGDVSRVV LEOH
x ProbableWKHUHODWLRQVKLSZLWKWKHXVH RIWKHLQYHVWLJDWLRQDOGHYLFH
FRPSDUDWRURUWKH
UHODWLRQVKLSZLWKSURFHGXUHVV HHPVUHOHYDQWDQGRUWKHHYHQWF DQQRWUHDVRQDEO\EHH[SODLQHGE\
DQRWKHUFDXVH

x Causal relationship: WKHHYHQWLVDVVRFLDWHGZLWKWKH LQYHVWLJDWLRQDOGHYLFHFRPSDU DWRURU
ZLWKSURFHGXUHVEH\RQGUHDVRQDEOHGRXEWZKHQ
o WKHHYHQWLVDNQRZQVLGHHIIHFW RIWKHSURGXFWFDWHJRU\WKHGH YLFHEHORQJVWRRURI
VLPLODUGHYLFHVDQGSURFHGXUHV
o WKHHYHQWKDVDWHPSRUDOUHODWLR QVKLSZLWKLQYHVWLJDWLRQDOGHYL FHXVHDSSOLFDWLRQRU
SURFHGXUHV
o WKHHYHQWLQYROYHVDERG\VLWHRURUJDQWKDW
Âƒ WKHLQYHVWLJDWLRQDOGHYLFHRU SURFHGXUHVDUHDSSOLHGWR
Âƒ WKHLQYHVWLJDWLRQDOGHYLFHRUS URFHGXUHVKDYHDQHIIHFWRQ
o WKHHYHQWIROORZVDNQRZQUHVSRQV HSDWWHUQWRWKHPHGLFDOGHYLF HLIWKHUHVSRQVH
SDWWHUQLVSUHYLRXVO\NQRZQ
o WKHGLVFRQWLQXDWLRQRIPHGLFDOG HYLFHDSSOLFDWLRQRUUHGXFWLRQ RIWKHOHYHORI
DFWLYDWLRQH[SRVXUHDQGUHLQWUR GXFWLRQRILWVXVHRULQFUHDVH RIWKHOHYHORI
DFWLYDWLRQH[SRVXUHLPSDFWRQ WKHHYHQWZKHQ FOLQLFDOO\IHDV LEOH
CIP335 Clinical Investigation Plan 
 Form 
D00409632 Version E Page 85 of 106 
0HGWURQLF%XVLQHVV5HVWULFWHG
CONFIDENTIAL )5HY(&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Form
o RWKHUSRVVLEOHFDXVHVHJDQXQGHUO\LQJRUFRQFXUUHQWLOOQHV VFOLQLFDOFRQGLWLRQRUDQG
DQHIIHFWRIDQRWKHUGHYLFHGUX JRUWUHDWPHQWKDYHEHHQDGHTX DWHO\UXOHGRXW
o KDUPWRWKHVXEMHFWLVGXHWRHUURULQXVH
o WKHHYHQWGHSHQGVRQDIDOVHUHVXOWJLYHQE\WKHLQYHVWLJDWLRQD OGHYLFHXVHGIRU
GLDJQRVLVZKHQDSSOLFDEOH
,QRUGHUWRHVWDEOLVKWKHUHOD WHGQHVVQRWDOOWKHFULWHULDOLV WHGDERYHPLJKWEHPHWDWWKHVDPH
WLPHGHSHQGLQJRQWKHW\SHRIGHYLFHSURFHGXUHVDQGWKHHYHQW 

Example: A severe hyperglycemia AE with the following event des cription would have the 
followin g causality assessment for device relatedness: 
,PSURYHGJOXFRVHZLWKRXWDQLQ IXVLRQVHWVLWHFKDQ JH  Not related 
&KDQJHGLQIXVLRQVHWZLWK JOXFRVHLPSURYHPHQW  P o s s i b l e 
,QIXVLRQVHWIHOORXWEHQWFDQQXODRFFOXVLRQDODUP Causal relationship 
11.7  Anticipated or Unanticipated  
,IDQ$(LVGHWHUPLQHGWREHUHO DWHGWRWKHVWXG\GHYLFHWKHVS RQVRUZLOOWKHQDV VHVVWKHHYHQWWR
GHWHUPLQHLILWLVDQWLFLSDW HGRUXQDQWLFLSDWHG
x Anticipated: WKHHYHQWLVLGH QWLILHGLQWKH&,3ODEH OLQJUHSRUWRISULRUV RUXVHUJXLGH
x Unanticipated: WKHHYHQWKDVQRWEHHQ SUHYLRXVO\LGHQWLILH GLQWKH&,3ODEHO LQJUHSRUWRISULRUV
RUXVHUJXLGH
12. Data Review Committees 
12.1  Clinical Events Committee  
$FOLQLFDOHYHQWVFRPPLWWHH&(& FRQVLVWLQJRIH[WHUQDOSK\VLF LDQVZLWKDQH[SHUWLVH LQHQGRFULQRORJ\DQG
WKHPDQDJHPHQWRIGLDEHWHVLQFOXGLQJLQVXOLQSXPSVDQG&*0ZLOO EHFRQYHQHG7KH&(&ZLOOUHYLHZ$(V
DVUHTXLUHGSHUSURWRFRO ZKLFKLQFOXGHUHSRUWVRI
x 6HULRXVDGYHUVHHYHQW
x 6HULRXVDGYHUVHGHYLFHHIIHFW
x 8QDQWLFLSDWHGDGYHUVHGHYLFHHIIHFW
x 6HYHUHK\SRJO\FHPLD
x 'LDEHWLFNHWRDFLGRVLV
x 6HYHUHK\SHUJO\FHPLD

&(&LVWRUHYLHZDQGDGM XGLFDWHXQDQWLFLSDWHGDGYHUVHGHYLFHHI IHFWV8$'(GHYLFHUHODWHG'.$DQG
GHYLFHUHODWHGVHYHUHK\SRJO\FHP LDZLWKLQGD\ VIURPWKHWLPH WKDWWKHVSRQVRULVQRWLILHG
7KH&(&ZLOODVVHVVHYHQWVWRGHWHU PLQHDJUHHPHQWRUGLVDJUHHPH QWZLWKWKHLQYHVWLJDW RUFODVVLILFDWLRQRI
DQHYHQW

,IWKH&(&GLVDJUHHVZ LWKWKHLQYHVWLJDWRUÂ¶VFODVVLILFDWLRQRI WKHHYHQWWKHUDWLRQD OHZLOOEHSURYLGHGWR
WKHLQYHVWLJDWRU,IW KHLQYHVWLJDWRUDJUHH VZLWKWKH&(&Â¶VDGM XGLFDWLRQWKH&5)GRF XPHQWLQJWKH$(ZLOO
EHXSGDWHGDFFRUGLQJO\

,IWKHLQYHVWLJDWRUGRH VQRWDJUHHZLWKWKH&(&Â¶VDGMXGLFDWLRQ FODVVLILFDWLRQERWKGHWHUPLQDWLRQVZLOOEH
SURYLGHGZLWKLQWKHILQDOUHSRUWKRZHYHUWKH&(&Â¶VDGMXGLFDWL RQZLOOEHXVHGIRUGDWDDQDO\VLV7KH
GLVDJUHHPHQWZLOODOVREHLQFOXGHG LQUHSRUWLQJWR,5%VDQGUHJ XODWRU\DXWKRULWLHVLIUHTXLUHG
CIP335 Clinical Investigation Plan 
 Form 
D00409632 Version E Page 86 of 106 
0HGWURQLF%XVLQHVV5HVWULFWHG
CONFIDENTIAL )5HY(&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Form
7KH&(&PD\UHYLHZDSSOLFDEOHLQIR UPDWLRQIRUGHYLFHUHODWHG$( VZKLFKPD\LQFOXGH

x :KHWKHURUQRWWKHHYHQWZDVXQDQWLFLSDWHG
x 5HYLHZRIVHQVRUGDWDIURP&DUH/ LQN3HUVRQDO&DU H/LQNV\VWHPVR IWZDUHUHSRUWZKHQDSSOLFDEOH
x 5HYLHZRISXPSGDWDIURP&DUH/LQN3HUVRQDO&DUH/LQNV\VWHPVRIW ZDUHUHSRUWZKHQDSSOLFDEOH
x 0LVXVHRIWKHGHYLFHE\WKHXVHU

5HYLHZRIHYHQWVPD\UHTXLUHWKH IROORZLQJLQIRUPDWLRQ)LQDOG LVSRVLWLRQPD\EHGHOD\HGEDVHGRQ
REWDLQLQJWKLVLQIRUPDWLRQ

x 0RQLWRULQJE\VSRQVRUDWLQYHVWLJDWLRQDOFHQWHU
x 'HYLFHUHWXUQDQGIDLOXUHDQDO\VLV
x &DUH/LQN3HUVRQDO&DUH/LQNV\VWHP VRIWZDUHXSORDGDQGUHYLHZRI VRIWZDUHUHSRUWV
x 6XEMHFWFODULILFDWLRQWRLQYHVWL JDWLRQDOFHQWHU UHJDUGLQJGHWDL OVDERXWWKHHYHQW
x 6RXUFHGRFXPHQWVWKDWVXSSRUWHYHQW3DUDPHGLFUHFRUGV(5UHFR UGV/DEUHFRUGV+RVSLWDO
DGPLVVLRQDQGGLVFKDUJHVXPPDU\

7KHIROORZLQJIDFWRUVVKRXOGEHFDUHIXOO\FRQVLGHUHGLQWKH&(& Â¶VUHFRPPHQGDWLRQWRVSRQVRU

 :DVWKHVHYHUHK\SRJO\FHPLDRU'.$UHODWHGWRWKH$+&/DOJRULWK PRUZDVLWUHODWHGWRDNQRZQ
LQVXOLQSXPSULVN")RUH[DPSOHDTXHVWLRQWKDWPD\EHFRQVLGHU HGLQ'.$ZRXOG EHZKHWKHUWKH
HYHQWZDVUHODWHGWRDQLQIXVLRQ VHWLVVXHRUFDXVHGE\WKH$+& /DOJRULWKP

 $QRWKHULPSRUWDQWFRQVLGHUDWLRQZRXOGEHLIWKHVHYHUHK\SRJO\F HPLDVHYHUHK\SHUJO\FHPLDRU
'.$HYHQWZDVUHODWHGWRDGHYLF HPDOIXQFWLRQYHUVXVSDWLHQWQR QFRPSOLDQFH)RUH[DPSOHLID
VRIWZDUHDQRPDO\OHDGLQJWRDQ XQGHUGHOLYHU\RILQVXOLQLVGLV FRYHUHGYHUVXVWKHVXEMHFW
UHSHDWHGO\LJQRULQJDODUPVSURPS WLQJWKHVXEMHFWWRWDNHDFWLRQ 

 6HYHUHK\SRJO\FHPLDVHYHUHK\SH UJO\FHPLDRU'.$FDXVHGGLUHFWO \E\DQLQIXVLRQVHWLVVXHZKHQ
WKHVWXG\SXPSLVIXQFWLRQLQJDVLQWHQGHGZRXOGOLNHO\UHVXOWL QDFFHSWDQFHWRSURFHHGZLWKWKH
VWXG\YHUVXVVHYHUHK\SRJO\FHPLDRU'.$WKDWDUHGLUHFWO\FDXVH GE\WKH$+&/DOJRULWKPRUD
GHYLFHPDOIXQFWLRQPLJKWVWRSVW XG\HQUROOPHQWRUHQWLUHVWXG\ DOWRJHWKHU

 ,WVKRXOGEHQRWHGWKDWWKHILQD OGHWHUPLQDWLRQRIFDXVDOLW\UH ODWHGWR*V\VWHPWKDWLVPDGH
E\WKH&(&PD\LQFOXGH DGGLWLRQDOIDFWRUVZKLFKWKHPHPEHUVFRQ VLGHUWREHFOLQLFDOO\UHOHYDQW
DQGLPSRUWDQW
12.2  Data Monitoring Committee 
$GDWDPRQLWRULQJFRPPLWWHH' 0&FRQVLVWLQJRIH[WHUQDOSK\VLF LDQVZLWKDQH[SHUWLVHLQ
(QGRFULQRORJ\DQGWKHPDQDJHPHQW RILQVXOLQUHTXLULQJGLDEHWHV LQFOXGLQJ&*0DORQJZLWKDQ
H[WHUQDOVWDWLVWLFLDQZLOOEHFRQY HQHGWRUHYLHZVWXG\SURJUHVV DQGVDIHW\7KH%RDUGZLOOFRQYHQH
DSSUR[LPDWHO\HYHU\GD\V7K H%RDUGZLOODOVRPHHWZKHQDGK RFUHYLHZLVUHTXLUHG
 The DMC will perform 4 main functions:  
 
First:'0&ZLOOWUDFNDQGWUH QGWKHRYHUDOOVDIHW\RIWKHVWXG\

CIP335 Clinical Investigation Plan 
 Form 
D00409632 Version E Page 87 of 106 
0HGWURQLF%XVLQHVV5HVWULFWHG
CONFIDENTIAL )5HY(&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Form
(YHQWUDWHGHILQHGDVQXPEHURIHYHQWVSHUSDWLHQW\HDUV ZLOOEHUHYLHZHGE\WKH'0&ZLWK
UHVSHFWWRWKHIROORZLQJ

x (YHQWUDWHRIDOO6$(V
x (YHQWUDWHRIVHYHUHK\SRJO\FHPLD
x (YHQWUDWHRIVHYHUHK\SHUJO\FHPLD
x (YHQWUDWHRI'.$
x (YHQWUDWHRIGHYLFHUHODWHG$(V

Second:%DVHGRQWKHLUPHHWLQJV'0&Z LOOUHFRPPHQGDGHFLVLRQWRWKH VSRQVRUUHJDUGLQJWKH
IROORZLQJ

x :KHWKHURUQRWHQUROOP HQWVKRXOGEHKDOWHG
x :KHWKHURUQRWWKHHQWLUHVWXG\ZLOOQHHGWREHVWRSSHGLQFOXGL QJIRUWKRVHVXE MHFWVZKRKDYH
UHFHLYHGVWXG\GHYLFHVDOUHDG\

1RWH,ILWLVGHFLGHGWRZLWKGUDZ VXEMHFWVIURPSDUWLFLSDWLRQ LQWKHVWXG\RULIW KHVWXG\LVVWRSSHG
VXEMHFWVZLOOEHIROORZHGXSLQD FFRUGDQFHZLWKVWDQGDUGSUDFWL FHE\WKHLURZQSURYLGHUV
Third:'XULQJWKHVWXG\WKHIROORZLQJVWHSVZLOOEHWDNHQIRU
x 8QDQWLFLSDWHGDGYHUVHGHYLFHHIIHFWV8$'(
x 'HYLFHUHODWHG'.$
x 'HYLFHUHODWHGVHYHUHK\SRJO\FHPLD
'0&LVWRPHHWZLWKLQGD\VIURP WKHWLPHWKDWWKH&(&DGMXGL FDWHVDQHYHQWDVRQ HRIWKHDERYH,I
SRVVLEOHWKHLQYHVWLJDWRUVKRXO GEHDYDLODEOHWRDQVZHUTXHVWL RQVE\'0&
%DVHGRQWKHLUPHHWLQJV'0&Z LOOUHFRPPHQGDGHFLVLRQWRWKHV SRQVRUUHJDUGLQJWKHIROORZLQJ
x :KHWKHURUQRWHQUROOP HQWVKRXOGEHKDOWHG
x :KHWKHURUQRWWKHHQWLUHVWXG\ZLOOQHHGWREHVWRSSHGLQFOXGL QJIRUWKRVHVXE MHFWVZKRKDYH
UHFHLYHGVWXG\GHYLFHVDOUHDG\
1RWH,ILWLVGHFLGHGWRZLWKGUDZ VXEMHFWVIURPSDUWLFLSDWLRQ LQWKHVWXG\RULIW KHVWXG\LVVWRSSHG
VXEMHFWVZLOOEHIROORZHGXSLQD FFRUGDQFHZLWKVWDQGDUGSUDFWL FHE\WKHLURZQSURYLGHUV
 
Fourth:7KH'0&ZLOOUHYLHZ6DIHW\GDWD DQGSURYLGHDUHFRPPHQGDWLRQW RWKHVSRQVRUUHJDUGLQJ
VWDJHGHQUROOPHQWRI SHGLDWULFVXEMHFWV

7KH'0&ZLOOSURYLGHDUHFRPPHQG DWLRQWRSURFHHGZLWKWKHIROOR ZLQJVWDJHGHQUROOPHQW


(QUROOPHQWRISHGLDWULFVXEMHFWV \HDUVRIDJHLQWRWKHVWX G\PD\QRWSURFHHGXQWLO1 VXEMHFWV
\HDUVRIDJHRUROGHUKDYHFRPSOHWHGGD\VRIWKHVWXG\SHULR GDQGWKH'DWD0RQLWRULQJ&RPPLWWHH
'0&KDVGHWHUPLQHGLWLVVDIHIR UVXEMHFWV\HDUVRIDJH
WREHHQUROOHGLQWKHVWXG\ 
General guidance for DMCâ€™s recom mendations to sponsor should be  based on the following:  
,QJHQHUDOD'0&UHFRPPHQGDWLRQUHJDUGLQJVWXG\VWRSSDJHRUUH VXPSWLRQRIHQUROOPHQWVKRXOGEH
PDGHWRWKHVSRQVRUZLWKLQZHHNRIWKH'0&PHHWLQJZKHUHWKH GHWHUPLQDWLRQLVPDGH+RZHYHULI
CIP335 Clinical Investigation Plan 
 Form 
D00409632 Version E Page 88 of 106 
0HGWURQLF%XVLQHVV5HVWULFWHG
CONFIDENTIAL )5HY(&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Form
PRUHGDWDLVQHHGHGWKH'0&PD\PHHWDJDLQWRUHDVVHVVWKHLU GHFLVLRQZLWKLQZHHNVRUZKHQ
UHTXLUHGGDWDEHFRPHVDYDLODEOH
,QWKHLUUHFRPPHQGDWLRQWRWKHV SRQVRUWKH'0&PD\WDNHLQWRD FFRXQWWKHWKUHVKROG VOLVWHGEHORZIRU
WKHQXPEHURIVXEMHFWVH[SHULHQFLQJK\SRJO\FHPLDUHTXLULQJDVVL VWDQFHIURPDQRWKHUSHUVRQRU'.$WR
LGHQWLI\ZKHQWKHQXPEHURIVXEMHFWVH[SHULHQFLQJWKHVHHYHQWV H[FHHGVWKHQXPEHUWKDWZRXOGEH
DQWLFLSDWHGIRUWKHVWXG\SRSXOD WLRQRYHUWKHGXUDWLRQRIWKLV VWXG\7KHVHWKUHVKROGVVKRXOGEH
LQWHUSUHWHGZLWKFDXWLRQGXHWR SRWHQWLDOGLIIHUH QFHVLQVWXG\ SRSXODWLRQVDQGVWXG\GHVLJQ

D 5DWHVWDNHQIURPW\SHH[FKDQJH&HQJL]HW$ODQG:HLQVWRFN HW$ODUHKLJKHUWKDQ
WKHFOLQLFDOVWXGLHV67$5*DGXOWLQKRPHVWXG\&(3 DQG*3HGLDWULFLQ
KRPHVWXG\&(3

E 5HDVRQVIRUORZHUUDWH VRIVHYHUHK\SRJO\FH PLDDQG'.$LQWKHF OLQLFDOVWXGLHV
PHQWLRQHGFRXOGEHUHODWHGWRVH YHUDOIDFWRUVLQFOXGLQJEXWQRW OLPLWHGWRWKHH[FOXVLRQRI
WKRVHZLWK'.$RUVHYHUHK\SRJO\ FHPLDDGGLWLRQDODWWHQWLRQVHF RQGDU\WRPDQGDWRU\
VWXG\YLVLWVVHOHFWLRQELDVRI PRWLYDWHGSDWLHQWVZLOOLQJWRS HUIRUPVWXG\SURFHGXUHVDQG
DFFHVVWRIUHHVWXG\GHYLFHVGX ULQJWKHFRXUVHRIWKHVWXG\

F 7KH'0&VKRXOGFRQVLGHUVWRSSLQJ VWXG\LIUDWHVR IVHYHUHK\SRJ O\FHPLDDQG'.$DUH
VLJQLILFDQWO\ZRUVHH JKLJKHULQ$+&/WKDQUDWHVSURYLGHG E\FOLQLFDOWULDOVPHQWLRQHG
LQ Table 5

G $JHFRQVLGHUDWLRQPD\DOVREHIDFWRUHGLQE\WKH'0&)RUH[DPS OHVHYHUH
K\SRJO\FHPLDUDWHVLQWKRVH!\HDUVPD\EHKLJKHUWKDQWKRVH \HDUVDQGEHORZ
H 6KRXOG'.$DQGRUVHYHUHK\SRJO\FHPLDRFFXUHDUO\LQWKHVWXG\ WKH'0&VKRXOG
FRQVLGHUWKDWWKHKLJKHUHYHQWUDWHPD\QRWQHFHVVDULO\UHSUHVH QWDVLJQLILFDQWVDIHW\
FRQFHUQ
Table 5. Hypoglycemia/ Hyperglycemia/ DKA Threshold 
Adverse Event Reference Reference 
Rate > 25 
years old Reference 
Rate 
15-25 years 
old Reference 
Rate <15 
years old 
6HYHUH
+\SHUJO\FHPLD
HYHQWVSHU
SDWLHQW\HDUV&(5 1$ 1$ 
'.$HYHQWVSHU
SDWLHQW
\HDUV67$5
%HUJHQVWDOHWDO6$3DUP

&RQWURODUP6$3DUP

&RQWURODUP6$3DUP

&RQWURODUP

*$GXOWLQKRPHVWXG\
&(30'7RQILOH  1$
3HGLDWULFLQKRPHVWXG\&(3

0'7RQILOH1$ 1$ 
CIP335 Clinical Investigation Plan 
 Form 
D00409632 Version E Page 89 of 106 
0HGWURQLF%XVLQHVV5HVWULFWHG
CONFIDENTIAL )5HY(&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Form
Adverse Event Reference Reference 
Rate > 25 
years old Reference 
Rate 
15-25 years 
old Reference 
Rate <15 
years old 
7\SHH[FKDQJH:HLQVWRFN
HWDO 1$ 1$
7\SHH[FKDQJH&HQJL]HW
DO1$  

6HYHUH
K\SRJO\FHPLD
SHUSDWLHQW
\HDUV67$5
%HUJHQVWDOHWDO
6$3DUP

&RQWURODUP

6$3DUP

&RQWURODUP

6$3DUP
&RQWURODUP

*$GXOWLQKRPHVWXG\
&(3
0'7RQILOH  1$
*3HGLDWULFLQKRPHVWXG\
&(3
0'7RQILOH1$ 1$ 
7\SHH[FKDQJH:HLQVWRFN
HWDO 1$ 1$
7\SHH[FKDQJH&HQJL]HW
DO1$  
Severe hypoglycemia and DKA event rates were taken from the fol lowing: 
 5LFKDUG%HUJHQVWDOHWDO(IIHFW LYHQHVVRI6HQVRU$XJPHQWHG,QV XOLQ3XPS7KHUDS\LQ7\SH
'LDEHWHV1HZ(QJODQG-RXUQDO RI0HGLFLQH

 :HLQVWRFNHWDO6HYH UHK\SRJO\FHPLDDQGGLDEHWLFNHWRDFLGRVLV LQDGXOWVZLWKW\SHGLDEHWHV
UHVXOWVIURPWKH7'([FKDQJHF OLQLFUHJLVWU\-&OLQ(QGRFULQR O0HWDE$XJ

 &HQJL]HWDO6HYHUHK\SRJO\FHP LDDQGGLDEHWLFNHWRDFLGRVLVDP RQJ\RXWKZLWKW\SHGLDEHWHV
LQWKH7'([FKDQJHFOLQLFUHJLV WU\3HGLDWU'LDEHWHV6HS 
 0'7RQILOH6WDWLVWLFDO$QDO\VLV3 ODQ6$3IRU&(3) 

CIP335 Clinical Investigation Plan 
 Form 
D00409632 Version E Page 90 of 106 
0HGWURQLF%XVLQHVV5HVWULFWHG
CONFIDENTIAL )5HY(&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Form
13. Device Deficiencies and Troubleshooting 
7KH0HGWURQLF+RXU7HFKQLFDO 6XSSRUW76ZLOOEHFRQVXOWHG IRUGHYLFHWURXEOHVKRRWLQJ  HJ
DVVLVWDQFHLVQHHGHGE\VXEMHFWWR RSHUDWHWKHLUGHYLFH>V@:K HQVXEMHFWVFDOOWKH76WKH\DUHLQVWUXFWHG
WRQRWLI\WKH76RSHUDWRUWKDWWKH\DUHFXUUHQWO\SDUWLFLSDWLQJ LQDFOLQLFDOUHVHDUFKVWXG\$OOGHYLFH
GHILFLHQFLHVWKDWDUHUHSRUWHGW RWKH76ZLOOEHGRFXPHQWHGE\ WKH76VWDII
7KHLQYHVWLJDWLRQDOFHQWHUZLOOE HSURYLGHGZLWKDFRS\RIDOO 76FDOOVIRUWKHLUVXE MHFWV7KH76FDOO
UHSRUWVVKRXOGEHUHYLHZHGIRULQ YHVWLJDWLRQDOFHQWHUVWDIIDZD UHQHVVDQGDVVHVVPHQW IRUWKHSRVVLELOLW\
RIDQ$(,IDQ$(LVGHWHFWHGWK HLQYHVWLJDWLRQDOFHQWHUVWDII ZLOOFRPSOHWHWKHDSSURSULDWHH&5)V

$OOGHYLFHGHILFLHQFLHVUHSRUWHG GLUHFWO\WRWKHLQYHVWLJDWLRQD OFHQWHUVWDIIE\DVXEM HFWVKRXOGHLWKHUEH
UHSRUWHGWRWKH76E\WKHVXEMHF WRULQYHVWLJDWLRQDOFHQWHUVWD II$Q\GHYLFHGHILFLHQF \WKHLQYHVWLJDWLRQDO
FHQWHUPD\KDYHVKRXOGEHUHSRUWHGWRWKH76
Device Deficiency (ISO 14155:2020) 
$GHYLFHGHILFLHQF\LVDQ\LQDGHTXDF\RIDPHGLFDOGHYLFHZLWK UHVSHFWWRLWVLGHQWLW\TXDOLW\GXUDELOLW\
UHOLDELOLW\XVDELOLW\VDIH W\RUSHUIRUPDQFH
 
Note 1 to entry 'HYLFHGHILFLHQFLHVLQFOXGHPDOIXQFWLRQVXVHHUURUVDQGLQD GHTXDF\LQWKHLQIRUPDWLRQ
VXSSOLHGE\WKHPDQXIDFWX UHULQFOXGLQJODEHOLQJ
 
Note 2 to entry 7KLVGHILQLWLRQLQFOXGHVGHYLF HGHILFLHQFLHVUHODWHGWRWKHL QYHVWLJDWLRQDOPHGLFDOGHYLFH
RUWKHFRPSDUDWRU

7RUHWXUQDVWXG\GHYLFHDVSDUWRIDGHYLFHGHILFLHQF\WKHLQ YHVWLJDWLRQDOFHQWHUVWDIIDQGRUVXEMHFWDUH
UHTXLUHGWRFDOOWKH+RXU76 )ROORZLQJWKHFDOOWR76WKH LQYHVWLJDWLRQDOFHQW HUVWDIIVKRXOGWKHQ
IROORZWKHVWXG\SURFHGXUHVIRUU HWXUQLQJSURGXFW VZLWKGHYLFH GHILFLHQFLHV

,WLVWKHUHVSRQVLELOLW\RIWKHLQYHVWLJDWRUWRIROORZWKHLU,5%UHSRUWLQJUHTXLUHPHQWV
14. Statistical Design and Methods 
14.1  General Aspects of Analysis 
$OOGDWDFROOHFWHGIURPWKHWLPH RIVFUHHQLQJXQWLOWKHHQGRI WKHVWXG\ZLOOEHFROOHFW HGRQH&5)VVXEMHFW
TXHVWLRQQDLUHVDQGHO HFWURQLFDOO\E\XSORDGLQJWKHYDULRXVGHY LFHV'DWDDQGDQDO\VLVZLOOEHVXPPDUL]HG
LQD&OLQLFDO6WXG\5HSRUW$Q\G HYLDWLRQVIURPRULJLQDOVWDWLV WLFDOSODQDQGWKHUDWLRQDOHZLOOEHGHVFULEHG
LQWKH&OLQLFDO6WXG\5HSRUW
14.2  Subject Disposition 
7KHQXPEHURIVXEMHFWVHQUROOHG FRPSOHWHGDQGHDUO\WHUPLQDWHG LQWKHVWXG\ZLO OEHSUHVHQWHG 7KH
UHDVRQVIRUGLVFRQWLQXLQJSULRUW RVWXG\FRPSOHWLRQZLOOEHVXP PDUL]HG
14.3  Subject Demographics and B aseline Characteristics 
6XEMHFWFKDUDFWHULVWLFVLQFOXGL QJDJHJHQGHUUDFHHWKQLFLW\ PHGLFDOGLDJQRVLVKHL JKWZHLJKW%0,DQG
EDVHOLQH+E$FZLOOEHVXPPDUL]HG E\GHVFULSWLYHVWDWLVWLFVPH DQVWDQGDUGGHYLDWLRQPLQLPXPPHGLDQ
DQGPD[LPXPIRUFRQWLQXRXVYDULDEOHVDQGE\FRXQWVDQGSHUFHQW DJHVIRUFDWHJRULFDOYDULDEOHV
CIP335 Clinical Investigation Plan 
 Form 
D00409632 Version E Page 91 of 106 
0HGWURQLF%XVLQHVV5HVWULFWHG
CONFIDENTIAL )5HY(&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Form
14.4  Endpoints and Hypotheses 
14.4.1.1  Primary Safety Endpoint   
Age 18-80: 
x 7KHRYHUDOOPHDQFKDQJHLQ+E$FÂ¨Â— *IURPEDVHOLQHWRHQGRI PRQWKVWXG\SHULRGZLOOEH
HVWLPDWHGDQGFRPSDUHGWRWKHWKUHVKROGRIZLWKDPDUJLQ RI$VLJQLILFDQFHOHYHO
RIRQHVLGHGZLOOEHXVHG
7KHK\SRWKHVLVLVPDWKHPD WLFDOO\H[SUHVVHGDV 
+Â¨Â—*Â•
+DÂ¨Â—*

Age 7-17: 
x 7KHRYHUDOOPHDQFKDQJHLQ+E$FÂ¨Â— *IURPEDVHOLQHWRHQGRI PRQWKVWXG\SHULRGZLOOEH
HVWLPDWHGDQGFRPSDUHGWRWKHWK UHVKROGRIZLWKDPDUJLQ RI$VLJQLILFDQFHOHYHO
RIRQHVLGHGZLOOEHXVHG
7KHK\SRWKHVLVLVPDWKHPDW LFDOO\H[SUHVVHGDV 
+Â¨Â—*Â•
+DÂ¨Â—*
14.4.1.2  Primary Effectiveness Endpoint   
 
Age 18-80: 
x 7KHPHDQRIWLPHÂ— *LQUDQJH7,5PJG/ZLOO EHHVWLPDWHGDQGFRPSDUHGWR WKH
WKUHVKROGRIZLWKDPDUJLQ RI$VLJ QLILFDQFHOHYHO RIRQHVLGHGZLOOEH
XVHG
7KHK\SRWKHVLVLVPDWKHPD WLFDOO\H[SUHVVHGDV 
+Â—*Â”Â±
+DÂ—*!Â±
Age 7-17: 
x 7KHPHDQRIWLPHÂ— *LQUDQJH7,5PJG/ZLOO EHHVWLPDWHGDQGFRPSDUHGWR WKH
WKUHVKROGRIZLWKDPDUJLQRI$VLJQLILFDQFHOHYHO RIRQHVLGHGZLOOEH
XVHG
7KHK\SRWKHVLVLVPDWKHPD WLFDOO\H[SUHVVHGDV 
+Â—*Â”Â±
+DÂ—*!Â±
CIP335 Clinical Investigation Plan 
 Form 
D00409632 Version E Page 92 of 106 
0HGWURQLF%XVLQHVV5HVWULFWHG
CONFIDENTIAL )5HY(&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Form
14.4.1.3  Analysis of Secondary Effectiveness Endpoints  
Age 18-80: 
x 6HFRQGDU\(IIHFWLYHQHVV(Q GSRLQW7KHPHDQWLPH Â—*LQK\SRJO\FHPLDPJG/ZLOO
EHHVWLPDWHGDQGFRPSDUHGWRWKHWKUHVKROGRIZLWKDPDUJ LQRI$VLJQLILFDQFHOHYHO
RIRQHVLGHGZLOOEHXVHG
7KHK\SRWKHVLVLVPDWKHPD WLFDOO\H[SUHVVHGDV
+Â—*Â•
+DÂ—*

x 6HFRQGDU\(IIHFWLYHQHVV(QGSR LQW7KHPHDQRIWLPHÂ— *LQUDQJH7,5PJG/ZLOO
EHHVWLPDWHGDQGFRPSD UHGZLWKDVLJQLILFDQFHOHYHORIR QHVLGHG
7KHK\SRWKHVLVLVPDWKHPD WLFDOO\H[SUHVVHGDV
+Â—*Â” 
+DÂ—*!

Age 7-17:
x 6HFRQGDU\(IIHFWLYHQHVV(QGSRLQW7KHPHDQWLPH Â—*LQK\SRJO\FHPLDPJG/ZLOO
EHHVWLPDWHGDQGFRPSD UHGWRWKHWKUHVKROGRIZLWKDPDUJ LQRI$VLJQLILFDQFHOHYHO
RIRQHVLGHGZLOOEHXVHG
7KHK\SRWKHVLVLVPDWKHPD WLFDOO\H[SUHVVHGDV 
+Â—*Â•
+DÂ—*

x 6HFRQGDU\(IIHFWLYHQHVV(QGSR LQW7KHPHDQRIWLPHÂ— *LQUDQJH7,5PJG/ZLOO
EHHVWLPDWHGDQGFRPSD UHGZLWKDVLJQLILFDQFHOHYHORIR QHVLGHG
7KHK\SRWKHVLVLVPDWKHPD WLFDOO\H[SUHVVHGDV
+Â—*Â”
+DÂ—*!
14.4.2  Descriptive Endpoints 
x 7LPHVSHQWLQWKH6PDUW*XDUGIHD WXUHYHUVXVWLPHVSHQWLQ0DQXD O0RGH
x &KDQJHLQPHDQJOX FRVHYDOXHIURP EDVHOLQHWR(26
x 7LPHLQGLIIHUHQWUDQJHVRI 6*6*PJG/6*PJG /PJG/Â”6*Â”
PJG/6*!PJG/PJG/PJG/DQGPJG/
x 1XPEHURI(YHQWV$UHD8QGHU&XU YH$8&DQG7LP HLQWKHK\SHUJ O\FHPLFUDQJH6*!
PJG/PJG/PJG/DQGPJG/
x 1XPEHURI(YHQWV$8&DQG7LPHL QWKHK\SRJO\FHPLFUDQJH6* DQGPJG/
x &KDQJHLQ%*YDOXHVGXULQJPHDOH[HUFLVHFKDOOHQJH%*SULRUDQ G%*KRXUVDIWHU
PHDOH[HUFLVH
x &KDQJHLQRIWLPHLQHXJO\FHPLDPJG/GXULQJPHDOH[HU FLVHFKDOOHQJHSULRUDQG
KRXUVDIWHUPHDOH[HUFLVH
x 'LIIHUHQFHLQ$8&GXULQJPHDOFKDOOHQJHSULRUDQGKRXUVDIWHU PHDOH[HUFLVH
x &KDQJHRI7RWDO'DLO\'RVH7''RILQVXOLQIURPEDVHOLQHWR(2 63HULRG
x &KDQJHRIZHLJKWIURPED VHOLQHWR(263HULRG
x 6XEJURXSDQDO\VLVZLOOEHSHUIRUPHGIRU
o 6HWSRLQW
CIP335 Clinical Investigation Plan 
 Form 
D00409632 Version E Page 93 of 106 
0HGWURQLF%XVLQHVV5HVWULFWHG
CONFIDENTIAL )5HY(&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Form
Âƒ PJG/
Âƒ PJG/
Âƒ PJG/
Âƒ PJG/7HPS7DUJHW8VDJH 
14.4.3   Safety Data Summarized 
x 6HULRXV$GYHUVH(YHQWV6$(
x 6HULRXV$GYHUVH'HYLFH(IIHFWV6$'(
x 8QDQWLFLSDWHG$GYHUVH'HYLFH(IIHFWV
x ,QFLGHQFHRI6HYHUH+\SRJO\FHPLD
x ,QFLGHQFHRI6HYHUH+\SHUJO\FHPLD
x ,QFLGHQFHRI'.$

14.4.4   Device Deficiencies  
'HVFULSWLYHVXPPDU\ZLOOEHXVHGWRFKDUDFWHUL]HGHYLFHGHILFLH QFLHV
x $OOUHSRUWVRIGHYLFHLVVXHV
14.4.5   Subject Feedback 
'HVFULSWLYHVXPPDU\ZLOOEHXVHG WRFKDUDFWHUL]HVWXG\TXHVWLRQ QDLUHUHVXOWV5HIHUWR&,3/\XPMHY
4XHVWLRQQDLUH*XLGHIRUDGPLQLVWUDWLRQGHWDLOV
14.5  Sample Size Considerations/Sample Size Justification 
14.5.1   Age 18-80 

x6DPSOHVL]HIRUWKHSULPDU\VDIHW\HQGSRLQWWKHRYHUDOOPHDQFK DQJHLQ+E$FIURPEDVHOLQHWR
HQGRIPRQWKVWXG\SHULRG

7KHRYHUDOOPHDQFKDQJHLQ+E$F IURPEDVHOLQHWRHQGRIPRQW KVWXG\SHULRGIURP*
&(3+&/DJHWR1 VWXG\ZDV$VVXPLQJW KHPHDQFKDQJHLQ+E$F
IURPEDVHOLQHWRHQGRIPRQW KVWXG\SHULRGIURP*LVWKHV DPHDV*ZLWKDVWDQGDUG
GHYLDWLRQRI6$6SRZHUD QGVDPSOHVL]HFDOFXODWRUZLWKRQ HVDPSOH7WHVWVKRZVWKDWD
WRWDORIVXEMHFWVZLOOSURYLGH!SRZHUWRGHWHFWWKDWP HDQ+E$FLVOHVVWKDQ
ZLWKDPDUJLQRIDWDVLJQL ILFDQFHOHYHORIRQHVLG HG

x 6DPSOHVL]HIRUWKHSULPDU\HIIHFW LYHQHVVHQGSRLQWWKHPHDQ RIWLPHLQUDQJH7,5
PJG/
7KHPHDQRIWLPHLQWDUJHWIURP*&(3+&/DJHWR 1 VWXG\ZDV
$VVXPLQJWKHPHDQWLPHLQWDUJHWIURP*LVWKHVD PHDV*ZLWKDVWDQGDUG
GHYLDWLRQRI6$6SRZHUD QGVDPSOHVL]HFDOFXODWRUZLWKRQ HVDPSOH7WHVWVKRZVWKDWD
WRWDORIVXEMHFWVZLOOSURYLGH!SRZHUWRGHWHFWWKDWP HDQRIWLPHLQWDUJHWLVJUHDWHU
WKDQZLWKDPDUJLQRI DWDVLJQLILFDQFHOHYHORI RQHVLGHG
CIP335 Clinical Investigation Plan 
 Form 
D00409632 Version E Page 94 of 106 
0HGWURQLF%XVLQHVV5HVWULFWHG
CONFIDENTIAL )5HY(&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Form
x 6DPSOHVL]HIRUWKHVHFRQGDU\HIIHFWLYHQHVVHQGSRLQWWKHPHDQ RIWLPHEHORZUDQJH
PJG/

7KHPHDQRIWLPHEHORZUDQJHPJG/IURP*&(3+ &/DJHWR1 
VWXG\ZDV$VVXPLQJWKHPHD QWLPHEHORZWDUJHWIURP *LVWKHVDPHDV*
ZLWKDVWDQGDUGGHYLDWLRQRI6$6SRZHUDQGVDPSOHVL]HF DOFXODWRUZLWKRQHVDPSOH7
WHVWVKRZVWKDWDWRWDORIVX EMHFWVZLOOSURYLGH!SRZHU WRGHWHFWWKDWPHDQRIWLPH
EHORZUDQJHLVOHVVWKDQ ZLWKDPDUJLQRIDWDVLJQLIL FDQFHOHYHORIRQHVLGHG

6DPSOHVL]HIRUWKHVHFRQGDU\HIIHFWLYHQHVVHQGSRLQWWKHPHDQ RIWLPHLQUDQJH7,5
PJG/
7KHPHDQRIWLPHLQWDUJHWIURP*&(3+&/DJHWR 1 VWXG\ZDV
$VVXPLQJWKHPHDQWLPHLQ WDUJHWIURP*LVZ LWKDVWDQGDUGGHYLDWLRQRI
6$6SRZHUDQGVDPSOHVL]HFD OFXODWRUZLWKRQHVDPSOH7WH VWVKRZVWKDWDWRWDORI
VXEMHFWVZLOOSURYLGH!SRZHU WRGHWHFWWKDWPHDQRIWLP HLQWDUJHWLVJUHDWHUWKDQ
DWDVLJQLILFD QFHOHYHORIRQHVLGHG
14.5.2   Age 7-17 

x6DPSOHVL]HIRUWKHSULPDU\VDIHW\HQGSRLQWWKHRYHUDOOPHDQFK DQJHLQ+E$FIURPEDVHOLQHWR
HQGRIPRQWKVWXG\SHULRG
7KHRYHUDOOPHDQFKDQJHLQ+E$F IURPEDVHOLQHWRHQGRIPRQW KVWXG\SHULRGIURP*
&(3DQG&(3+&/DJHWR1 VWXG\ZDV $VVXPLQJWKHPHDQFKDQJH
LQ+E$FIURPEDVHOLQHWRHQGRI PRQWKVWXG\SHULRGIURP* LVWKHVDPHDV*ZLWKD
VWDQGDUGGHYLDWLRQRI6$6SRZHUDQGVDPSOHVL]HFDOFXODWR UZLWKRQHVDPSOH7WHVWVKRZV
WKDWDWRWDORIVXE MHFWVZLOOSURYLGH! SRZHUWRGHWHFW WKDWPHDQFKDQJHRI+E$FLV
OHVVWKDQZLWKD PDUJLQRIDWDVLJQLILFDQFHOHYHO RIRQHVLGHG
x 6DPSOHVL]HIRUWKHSULPDU\HIIHFWLYHQHVVHQGSRLQWWKHPHDQ RIWLPHLQUDQJH7,5
PJG/

7KHPHDQRIWLPHLQWDUJHWIURP*&(3DQG&(3+&/D JHWR1 VWXG\
ZDV$VVXPLQJWKHPHDQWLPHLQWDUJHWIURP*LVWK HVDPHDV*ZLWKD
VWDQGDUGGHYLDWLRQRI6$6SRZHUDQGVDPSOHVL]HFDOFXODWRU ZLWKRQHVDPSOH7WHVWVKRZV
WKDWDWRWDORIVXE MHFWVZLOOSURYLGH! SRZHUWRGHWHFW WKDWPHDQRIWLPHLQWDUJHWLV
JUHDWHUWKDQZLWKDPDUJLQRIDWDVLJQLILFDQFHOHY HORIRQHVLGHG

x 6DPSOHVL]HIRUWKHVHFRQGDU\HIIHFWLYHQHVVHQGSRLQWWKHPHDQ RIWLPHEHORZUDQJH
PJG/
7KHPHDQRIWLPHEHORZUDQJH PJG/IURP*&(3D QG&(3+&/DJHWR
1 VWXG\ZDV$V VXPLQJWKHPHDQWLPHEHORZWDUJ HWIURP*LVWKH
VDPHDV*ZLWKDVWDQGDUGGHYLDWLRQRI6$6SRZHUDQG VDPSOHVL]HFDOFXODWRUZLWK
RQHVDPSOH7WHVWVKRZVWKDWD WRWDORIVXEMHFWVZLOOSURYLG H!SRZHUWRGHWHFWWKDW
PHDQRIWLPHEHORZUDQJHLVOHVVW KDQZLWKDPDUJLQRI DWDVLJQLIL FDQFHOHYHORI
RQHVLGHG

CIP335 Clinical Investigation Plan 
 Form 
D00409632 Version E Page 95 of 106 
0HGWURQLF%XVLQHVV5HVWULFWHG
CONFIDENTIAL )5HY(&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Form
x 6DPSOHVL]HIRUWKHVHFRQGDU\HIIHFWLYHQHVVHQGSRLQWWKHPHDQ RIWLPHLQUDQJH7,5
PJG/

7KHPHDQRIWLPHLQWDUJHWIUR P*&(3DQG&(3+&/D JHWR1 VWXG\
ZDV$VVXPLQJWKHPHDQWLPHLQWDUJHWIURP*LV ZLWKDVWDQGDUG
GHYLDWLRQRI6$6SRZHUDQG VDPSOHVL]HFDOFXODWRUZLWKRQH VDPSOH7WHVWVKRZVWKDWDWRWDO
RIVXEMHFWVZLOOSURYLGH! SRZHUWRGHWHFWWKDWPHDQ RIWLPHLQWDUJHWLVJUHDWHUWKDQ
DWDVLJQLILFDQFHOHYH ORIRQHVLGHG

14.5.3   Expected Drop-out Rates 
,QFRUSRUDWLQJWKHH[SHFWHGGURS RXWUDWHVDWRWDORIXSWR VXEMHFWVZLOOEHHQUROOH GLQRUGHUWRKDYH
VXEMHFWVHQWHUWKHVWXG\SHULRG
14.6   Handling Missing Data 
)RUWKHSULPDU\VDIHW\DQDO\VLVFKDQJHRI+E$FLI+E$FDW HQGRIVWXG\LVQRWDYDLODEOHLQVXEMHFWV
PLVVLQJGDWDLQ+E$FPHDVXUHPH QWVZLOOEHKDQGOH GE\WKHPXOWL SOHLPSXWDWLRQDSSURDFKXVLQJ
LPSXWDWLRQUHJUHVVLRQPHWKRG7KH LQGHSHQGHQWYDULDEOHVLQWKH UHJUHVVLRQPRGHODUHDJHJHQGHU
EDVHOLQH+E$FGLDEHWHVGXUDWLR Q%0,7KHLPSXWDWLRQZLOOEH SHUIRUPHGILYHWLPH VDQGWKHDQDO\VLV
UHVXOWVZLOOEHFRPELQHGWRI RUPRQHLQIHUHQFHLQ6$6
1RLPSXWDWLRQIRU&*0UHODWHG HQGSRLQWVZLOOEHSHUIRUPHG  
14.7 Final Reports
7KHVWXG\UHVXOWVZLOOEHVXPPDUL]H GDQGSUHVHQWHGLQWKHILQDO UHSRUW
15. Ethics 
15.1 Statement(s) of Compliance
7KLVFOLQLFDOVWXG\ZLOOEHFRQGXFWH GLQFRPSOLDQFHZLWKWKH&, 3&OLQLFDO,QYHVWLJDWLRQ$JUHHPHQW86&)5
7LWOH3DUW(OHFWURQLF5HFRUGV(OHFWURQLF6LJQDWXUHV3 DUW,QIRUPHGFRQVHQWV3DUW
)LQDQFLDO'LVFORVXUHE\&OLQLFD O,QYHVWLJDWRUV3DUW,5%V 3DUW,QYHVWLJDWLRQDO'HYLFH
([HPSWLRQVDQGDOORWKHUDSSOLFDEOHIHGHUDODQGORFDOUHJXODW RU\UHTXLUHPHQWV
7KHVWXG\ZLOODOVREHFRQGXFWHG LQFRPSOLDQFHZLWKWKHSULQFLS OHVRIJRRGFOLQLFDOSU DFWLFH*&3PHDQLQJ
WKDWWKHVWXG\GHVLJQFRQGXFW SHUIRUPDQFHPRQLWRULQJDXGLWL QJUHFRUGLQJDQDO\VL VDQGUHSRUWLQJZLOO
DVVXUHWKDWWKHGDWDDQGUHVXOWVDUHFUHGLEOHDQGDFFXUDWHDQG WKDWWKHULJKWVVDIHW\DQGZHOOEHLQJRI
VXEMHFWVDUHSURWHFWHG*&3LQFO XGHVUHYLHZDQGDSSURYDOE\DQ LQGHSHQGHQWHWKLFFRPPLWWHH,(&,5%
EHIRUHLQLWLDWLQJWKHLQ YHVWLJDWLRQRQJRLQJ UHYLHZRIWKHLQYH VWLJDWLRQE\DQ,(&,5%DQGREWDLQLQJDQG
GRFXPHQWLQJWKHIUHHO\JLYHQLQIRUPHGFRQVHQWRIWKHVXEMHFWR UWKHVXEMHFWÂ¶VOHJDOO\DXWKRUL]HG
UHSUHVHQWDWLYHEHIRUHWKHLUSDU WLFLSDWLRQLQWKHLQYHVWLJDWLRQ 

7KHHWKLFDOSULQFLSOHVWKDWKDYHW KHLURULJLQLQWKH'HFODUDWLR QRI+HOVLQNL'R+KDYHEHHQLPSOHPHQWHG
LQWKLVFOLQLFDOVWXG\E\PHDQ VRIWKHLQIRUPHGFRQVHQWDVVHQW
SURFHVV,5%DSSURYD OVWXG\WUDLQLQJ
FOLQLFDOWULDOUHJLVWUDWLRQSUH FOLQLFDOWHVWLQJULVNEHQHILW DVVHVVPHQWSXEOLFDWLRQSROLF\HWF

CIP335 Clinical Investigation Plan 
 Form 
D00409632 Version E Page 96 of 106 
0HGWURQLF%XVLQHVV5HVWULFWHG
CONFIDENTIAL )5HY(&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Form
15.2  IRB Approval 
7KLV&,3DQ\VXEVHTXHQWDPHQGPH QWVWRWKLV&,3WKH,&)DVVHQW IRUPVXEMHFWPDWHULDOVDQGDQ\IRUP
RIVXEMHFWUHFUXLWPHQWLQIRUPDWL RQHJDGYHUWLVHPHQWVUHODW LQJWRWKLVVWXG\ZLOOEHDSSURYHGE\WKH
UHVSRQVLEOH,5%LQDFFRUGD QFHZLWK&)53DUW

7KHLQYHVWLJDWLRQDOFHQWHUZLOOQ RWLQLWLDWHDQ\V XEMHFWDFWLYLWLHVXQWLO,5%DSSURYDOKDVEHHQJUDQWHGWKH
VSRQVRUKDVFOHDUHGWKHLQYHVWLJ DWLRQDOFHQWHUWREHJLQWKHVWX G\DQGWKHLQYHVWLJDW LRQDOFHQWHUVWDIIKDV
EHHQDSSURSULDWHO\WUDLQHG WRFRQGXFWWKHVWXG\

15.3  Role of the Sponsorâ€™s Representatives 
6SRQVRUUHSUHVHQWDWLYHVPD\SURYLGHVXSSRUWDVUHTXLUHGIRUWKH VWXG\VXFKDVWHFKQLFDOVXSSRUWDW
LQYHVWLJDWLRQDOFHQWHU 6SRQVRUUHSUHVHQWDWLYHVPD\SURYLGHWHF KQLFDOVXSSRUWDVUHTXLUHGIRUWKHVWXG\
XQGHUVXSHUYLVLRQRIWKH3,LQFOXGLQJ
 3URYLGHVWXG\WUDLQLQJUHOHYDQW DQGSHUWLQHQWWRWKHLQYROYHPHQ WRISHUVRQQHOFRQGXFWLQJVWXG\
DFWLYLWLHVDQGLQYHVWLJDWRUUHVSRQVLELOLWLHV
 7HFKQLFDOVXSSRUWZLOOEHSURYLGHGGXULQJVWXG\SHULRG
 7HFKQLFDOVXSSRUWZLOOEHXQGHUWK HVXSHUYLVLRQRIDVWXG\LQYH VWLJDWRUEXWQRGDWDHQWU\RQWKH
H&5)VKDOOEHSHUIRUPHGE\0HGWUR QLFSHUVRQQHORUWKHLUUHSUHVH QWDWLYHVDWLQYHVWLJDWLRQDO
FHQWHUV
 7HFKQLFDOVXSSRUWWRFRQGXFWGHYLFHLQWHUURJDWLRQV
7KHVSRQVRUVKDOODYRLGLPSURSHU LQIOXHQFHRQRULQGXFHPHQWWR WKHVXEMHFWPRQLWRUDQ\
LQYHVWLJDWRUVRURWKHUSDUWLH VSDUWLFLSDWLQJLQRUFRQWULEXWL QJWRWKLVVWXG\

15.4  Investigatorâ€™s Responsibilities 
3HU&)5DQLQYHVWLJDWRUPHDQVÂ³DQLQGLYLGXDOZKRDFW XDOO\FRQGXFWVDFOLQLFDOLQYHVWLJDWLRQ
LHXQGHUZKRVHLPPHGLDWHGLUH FWLRQWKHWHVWDUWLFOHLVDGPL QLVWHUHGRUGLVSHQVHGWR RUXVHGLQYROYLQJ
DVXEMHFWRULQWKHHYHQWRIDQLQYHVWLJDWLRQFRQGXFWHGE\D WHDPRILQGLYLGXDOVLVWKHUHVSRQVLEOH
OHDGHURIWKDWWHDPÂ´(DFKLQYHV WLJDWLRQDOFHQWHUVKDOOGHVLJQD WHDSULPDU\LQYHVWLJDWRUZKRZLOOKDYH
RYHUDOOUHVSRQVLELOLW\IRUWKHFRQGXFWRIWKHLQYHVWLJDWLRQDW WKHLQYHVWLJDWLRQDOFHQWHU

7KHSULQFLSDOLQYHVWLJDWRUVDQG FRLQYHVWLJDWRUVLIDSSOLFDEOH DUHUHVSRQVLEOHIRUFRQ GXFWLQJWKHVWXG\LQ
DFFRUGDQFHZLWKWKLV&,3&7$DQG&)53DUWWKDWDSSO\W RVLJQLILFDQWULVN65GHYLFHVWXGLHV7KH
LQYHVWLJDWRUÂ¶VUHVSRQVLELOLWLHVUH TXLUHPHQWVLQFOXGHEXWDUHQ RWOLPLWHGWR

x &RQGXFWRILQYHVWLJDWLRQLQDFFR UGDQFHWRGUDIWJXLGDQFHIURP) '$Â³3URWHFWLQJWKH5LJKWV
6DIHW\DQG:HOIDUHRI6WXG\6XE MHFWV6XSHUYLVRU\5HVSRQVLELO LWLHVRI,QYHVWLJDWRUVÂ´WR
PHHWUHVSRQVLELOLWLHVZLWKUHVSHF WWRSURWHFWKXPDQVXEMHFWVDQ GHQVXULQJWKHLQWHJULW\RIWKH
GDWDIURPFOLQLFDOLQYHVWLJDWLR QV7KLVJXLGDQFHLVDOVRLQWHQG HGWRFODULI\)'$
VH[SHFWDWLRQV
FRQFHUQLQJWKHLQYHVWLJDW RU
VUHVSRQVLELOLW\
 WRVXSHUYLVHDFOLQLFDOVWXG\LQ ZKLFKVRPHVWXG\WDVNVDUHGHO HJDWHGWR
HPSOR\HHVRUFROOHDJXHVRIWKHLQ YHVWLJDWRURURWKHUWKLUGSDUW LHVDQG
 WRSURWHFWWKHULJKW VVDIHW\DQGZHOIDU HRIVWXG\VXEMHFWV
x 3URWHFWLQJWKHULJKWVVDIHW\DQ GZHOIDUHRIVXEMHFWVXQGHUWK HLQYHVWLJDWRUÂ¶VFDUH
o 3URYLGLQJUHDVRQDEOHPHGLFDOFDU HIRUVWXG\VXEMHFWVIRUPHGLFD OSUREOHPVWKDWDULVH
GXULQJSDUWLFLSDWLRQLQWKHWULDOWKDWDUHRUFRXOGEHUHODWH GWRWKHVWXG\LQWHUYHQWLRQ
CIP335 Clinical Investigation Plan 
 Form 
D00409632 Version E Page 97 of 106 
0HGWURQLF%XVLQHVV5HVWULFWHG
CONFIDENTIAL )5HY(&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Form
o 3URYLGLQJUHDVRQDEOHDFFHVVWRQ HHGHGPHGLFDOFDUHHLWKHUE\W KHLQYHVWLJDWRURUE\
DQRWKHULGHQWLILHGTXDOLILHGLQ GLYLGXDOHJZKHQWKHLQYHVW LJDWRULVXQDYDLODEOHZKHQ
VSHFLDOL]HGFDUHLVQHHGHG
o $GKHULQJWRWKH&,3VRWKDWVWXG \VXEMHFWVDUHQRWH[SRVHGWRX QUHDVRQDEOHULVNV
x &RQWUROOLQJGHYLFHVXQGHULQYHVWLJDWLRQ&)5
x 3URYLGLQJDGHTXDWHVXSHUYLVLRQRIWKRVHWRZKRPWDVNVKDYHEHHQ GHOHJDWHG7KH
LQYHVWLJDWRULVDFFRXQWDEOHIRUU HJXODWRU\YLRODWLRQVUHVXOWLQJ IURPIDLOXUHWRDGHTXDWHO\
VXSHUYLVHWKHFRQGXFWR IDFOLQLFDOVWXG\
x (QVXULQJWKDWWKHUHTXLUHPHQWVIRUREWDLQLQJLQIRUPHGFRQVHQWD VVHQWDUHPHWLQDFFRUGDQFH
ZLWK&)5
x 6XSHUYLVLQJWKHXVHRILQYHVWLJDW LRQDOGHYLFH$QLQYHVWLJDWRU VKDOOSHUPLWDQLQYHVWLJDWLRQDO
GHYLFHWREHXVHGRQO\ ZLWKVXEMHFWVXQGHU WKHLQYHVWLJDWRUÂ¶VV XSHUYLVLRQ$QLQYHVWLJDWRU
VKDOOQRWVXSSO\DQLQYHVWLJDWLRQDOGHYLFHWRDQ\SHUVRQQRWDX WKRUL]HGXQGHU&)53DUW
WRUHFHLYHLW
x 'LVSRVLQJRIGHYLFHSURSHUO\8SRQFRPSOHWLRQRUWHUPLQDWLRQRI DFOLQLFDOLQYHVWLJDWLRQRUWKH
LQYHVWLJDWRUÂ¶VSDUWRIDQLQYHVW LJDWLRQRUDWWKHVSRQVRUÂ¶VUH TXHVWDQLQYHVWLJDWRUVKDOOUHWXUQ
WRWKHVSRQVRUDQ\UHPDLQLQJVXSS O\RIWKHGHYLFHRURWKHUZLVH GLVSRVHRIWKHGHYLFHDVWKH
VSRQVRUGLUHFWV
x $OORZLQJVWXG\GHYLFHVW REHXVHGRQO\ZLWK VXEMHFWVXQGHUWKH LQYHVWLJDWRUÂ¶VVXSHUYLVLRQDQG
WRVXSSO\VWXG\GHYLFHVRQO\WRSHUVRQVDXWKRUL]HGWRUHFHLYHL W
x (QVXULQJWKDWLQYHVWLJDWLRQDOFHQ WHUVWDIIDUHDGHTXDWHO\WUDLQ HGWRSHUIRUPWKHLUDVVLJQHG
GXWLHV
x 0DLQWHQDQFHRIDFFXUDWHFRPSOHW HDQGFXUUHQWUHFRUGVUHODWLQJ WRWKHLQYHVWLJDWRUÂ¶VSDUWRI
DQLQYHVWLJDWLRQ&)5WRLQFOXGH
o DWWULEXWLRQOHJLELOLW\DQG WLPHOLQHVVRIVRXUFHGDWD
o DOOUHOHYDQWFRUUHVSRQGHQFHZLWK DQRWKHULQYHVWLJDWRUDQ,5% WKHVSRQVRUDPRQLWRURU
)'$LQFOXGLQJUHTXLUHGUHSRUWV
o UHFRUGVRIUHFHLSWXVHRUGL VSRVLWLRQRIVWXG\GHYLFHV
o UHFRUGVRIHDFKVXEMHFWÂ¶VFDVHK LVWRU\DQGH[SRVXUHWRWKHGHYL FHLQFOXGLQJLQIRUPDWLRQ
UHSRUWHGLQWKHH&5)VDQGLQD OORWKHUUHTXLUHGUHSRUWV
o WKH&,3ZLWKGRFXPHQWVVKRZLQJ WKHGDWHVRIDQGUHDVRQVIRUHD FKGHYLDWLRQIURPWKH
&,3
o DQ\RWKHUUHFRUGVWKH)'$UHTXLUH VWREHPDLQWDLQHGE\UHJXODWL RQVRUE\VSHFLILF
UHTXLUHPHQWIRUDFDWHJRU\RILQ YHVWLJDWLRQVRUDSDUWLFXODULQ YHVWLJDWLRQ
x 3UHSDUDWLRQDQGVXEPLVVLRQWR0HGWURQLFDQGZKHQUHTXLUHG)'$ DQGWKHUHYLHZLQJ,5%
WKHIROORZLQJFRPSOHWHDFFXUDWHDQGWLPHO\UHSRUWV
o DQ\UHSRUWDEOH$(VVHH Section 11) RFFXUULQJGXULQJDQLQYHVWLJDWLRQ
o SURJUHVVUHSRUWVRQWKHLQYHVWLJDW LRQDVUHTXLUHGE\WKH)'$DQ G,5%
o DQ\GHYLDWLRQIURPWKH&,3PDGH WRSURWHFWWKHOLIHRUSK\VLFDO ZHOOEHLQJRIDVXEMHFWLQ
DQHPHUJHQF\
o DQ\XVHRIWKHGHYLFHZLWKRXWRE WDLQLQJLQIRUPHGFRQVHQWDVVHQW 
o DQ\IXUWKHULQIRUPDWLRQUHTXHVWHGE\WKH)'$DQG,5%DERXWDQ\ DVSHFWRIWKH
LQYHVWLJDWLRQ
x 3HUPLWWLQJ)'$RURWKHUUHJXODWR U\DXWKRULWLHVWRLQVSHFWDQGF RS\DQ\UHFRUGVSHUWDLQLQJWR
WKHLQYHVWLJDWLRQLQFOXGLQJLQ FHUWDLQVLWXDWLRQVWKRVHZKLFK LGHQWLI\VXEMHFWV&)5

x 0HHWLQJZLWKWKHPRQLWRUWRG LVFXVVVWXG\SURJUHVVDQGILQGLQJV 
x (QVXULQJWKDWLQYHVWLJDWLRQDOFHQ WHUUHVRXUFHVDUHDGHTXDWHWR IXOILOOWKHREOLJDWLRQVRIWKH
VWXG\
CIP335 Clinical Investigation Plan 
 Form 
D00409632 Version E Page 98 of 106 
0HGWURQLF%XVLQHVV5HVWULFWHG
CONFIDENTIAL )5HY(&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Form
x (QVXULQJFRPSOHWLRQRIH&5)WRLQFOXGHHQWU\DQGDGGUHVVLQJGLV FUHSDQFLHVLQDWLPHO\
IDVKLRQDQGDSSURYLQJVHOHFWHGH&5)V

2QO\DXWKRUL]HGVWXG\SHUVRQQH ODVOLVWHGRQWKH'HOHJDWLRQRI $XWKRULW\/RJDUHSHUPLWWHGWRFRQVHQW
VXEMHFWVUHFHLYHGLVSHQVHGLVS RVHRIDQGUHWXUQLQYHVWLJDWLR QDOSURGXFWVFRQGXFWVX EMHFWYLVLWVLQVHUW
GHYLFHVDQGHQWHUGDW DRQH&5)V7KHVHWDVNVPD\EHGHOHJDWHG E\WKHLQYHVWLJDWRU+RZHYHUWKH
LQYHVWLJDWRULVXOWLPDWHO\UHVSRQ VLEOHWRHQVXUHLQYHVWLJDWLRQD OFHQWHUVWDIIDUHTXDOL ILHGDQGSHUIRUPWKH
WDVNVWKDWKDYHEHHQGHOHJDWHGWRWKHPFRUUHFWO\,QDGGLWLRQ WKHLQYHVWLJDWRULVUHVSRQVLEOHIRUWKH
FRQGXFWRILQYHVWLJDWLRQDOFHQWHU LQWKHH[HFXWLRQRIWKHFOLQL FDOWULDO
16. Study Administration 
16.1  Training of Clinical Staff 
7UDLQLQJRIWKHLQYHVWLJDWLRQDOF HQWHUVWDIIRQW KHFRQGXFWRI WKHVWXG\DQGV\VWHP EHLQJVWXGLHGZLOOEH
LQLWLDWHGEHIRUHWKH& ,3LVLPSOHPHQWHG$OOSDUWLFLSDWLQJSK\V LFLDQVDQGFRRUGLQDWRUVZLOOEHIDPLOLDUL]HG
ZLWKWKHV\VWHP2WKHUPHPEHUVRIWKHLQYHVWLJDWLRQDOFHQWHUVW DIIPD\UHTXLUHWUDLQLQJGHSHQGLQJRQ
WKHLUUROHOLVWLQJRQWKH'HOHJDW LRQRI$XWKRULW\/RJ7UDLQLQJ PD\FRQWDLQERWKOHFWXUHDQGKDQGVRQ
H[SHULHQFH
7KH3,LVUHVSRQVLEOHIRUHQVXULQ JWKDWLQYHVWLJDWLRQDOFHQWHU VWDIIDUHWUDLQHGWRS HUIRUPWKHLUDVVLJQHG
GXWLHVSHU'HOHJDWLRQRI$XWKRULW\/RJ,QGLYLGXDOLQYHVWLJDWLR QDOFHQWHUVWDIIPXVWEHDSSURSULDWHO\
WUDLQHGSULRUWRSHUIRUPLQJVWXG\UHODWHGWDVNV
16.2  Monitoring 
0RQLWRULQJYLVLWVPD\EHFRQGXFWHGDWWKHVWDUWGXULQJDQGDW WKHFORVXUHRIWKHFOLQLFDOVWXG\LQ
DFFRUGDQFHZLWK0HGWUR QLF623VDQGWKH0RQLW RULQJ3ODQ$WPLQL PXPLWZLOOEHYHULILHGZKHWKHUVLJQHG
DQGGDWHG,&)DVVHQWIRUPKDYHE HHQREWDLQHGIURPHDFKVXEMHFW DWWKHSRLQWRIHQUROOPHQWDQGWKDW$(V
GLVFXVVHGLQ Section 11ZHUHUHSRUWHGYLDFRPSOHWLRQRI WKH$(H&5)V0RUHGHWDLOVUHJ DUGLQJWKH
PRQLWRULQJDFWLYLWLHVIUHTXHQF\ RIPRQLWRULQJYLVLWVSODQQHG H[WHQWRIVRXUFHGDWDYHULILFDWLRQDUH
GHVFULEHGLQWKH0RQLWRULQJ3ODQ
16.2.1  Accessibility of Investigational  Center Staff and Study Materia ls 
7KH3,VKLVKHUGHOHJDWHVDQ GWKHVWXG\FRRUGLQDWRUVVKD OOEHDFFHVVLEOHWR0HGWURQLFILHOG
SHUVRQQHOPRQLWRUUH JXODWRU\DXWKRULW\SHU VRQQHODQGWKH&OL QLFDO6WXG\0DQDJHU7KLVDFFHVVLELOLW\LVRI
SDUWLFXODULPSRUWDQFHIRUUHYLHZL QJGDWDLQWKHH&5)$FFHVVWR VXEMHFWÂ¶VPHGLFDOI LOHVIRUVRXUFHGDWD
YHULILFDWLRQZLOOQHHGWREHJUDQ WHGSULRUWRDQ\PRQLWRULQJYL VLWV
16.2.2  Audits and Investigational Center Inspections 
,QDGGLWLRQWRUHJXODUPRQLWRULQJ YLVLWVWKHVSRQVRUPD\FRQGX FWDXGLWVDWSDUWLFLSDW LQJLQYHVWLJDWLRQDO
FHQWHUV7KHSXUSRVHRIDQDXGLWLVWRYHULI\WKHDGHTXDWHSHUI RUPDQFHRIWKHFOLQLFDOVWXG\UHODWHG
DFWLYLWLHVLQGHSHQGHQWRIWKHHPS OR\HHVLQYROYHGLQWKHFOLQLFD OVWXG\5HJXODWRU\DXWKRULWLHVPD\DOVR
SHUIRUPLQVSHFWLRQVDWSDUWLFLSDW LQJLQYHVWLJDWLRQDOFHQWHUV$ Q\UHJXODWRU\DXWKRULW\LQVSHFWLRQ
DQQRXQFHPHQWVVKDOOEHIRUZDUGHG LPPHGLDWHO\WRWKH&OLQLFDO6W XG\0DQDJHU

7KHLQYHVWLJDWRUDQGRULQVWLWXW LRQVKDOOSHUPLWVSRQVRUDQGUH JXODWRU\DXWKRULWLHVGLUHFWDFFHVVWRVRXUFH
GDWDDQGGRFXPHQWVWDNLQJLQWRD FFRXQWDQ\UHVWULFWLRQVGXHWR ORFDOODZWRSHUIRUPFOLQLFDOVWXG\
UHODWHGPRQLWRULQJDXGLWV,5% UHYLHZDQGUHJXODWRU\LQVSHFWL RQV
CIP335 Clinical Investigation Plan 
 Form 
D00409632 Version E Page 99 of 106 
0HGWURQLF%XVLQHVV5HVWULFWHG
CONFIDENTIAL )5HY(&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Form
16.2.3  Investigational Center Disqualification 
6SRQVRUDQGRUWKH,5%UHWDLQW KHULJKWWRGLVTXDOLI\DQLQYHVW LJDWLRQDOFHQWHUDQGUHPRYHDOOVWXG\
PDWHULDOVDWDQ\WLPH6SHFLILFLQVWDQFHVWKDWPD\SUHFLSLWDWH LQYHVWLJDWLRQDOFHQWH UGLVTXDOLILFDWLRQ
LQFOXGHEXWDUHQRWOLPLWHGWR
x 8QVDWLVIDFWRU\VXEMHFWHQUROOPHQWZLWKUHJDUGVWRTXDQWLW\
x 3HUVLVWHQWQRQFRPSOLDQFHWRSURWRFROSURFHGXUHVRQWKHSDUWRI DQ
LQYHVWLJDWRULQYHVWLJDWLRQDOFHQWHU
x ,QDFFXUDWHLQFRPSOHWHDQGRU XQWLPHO\GDWDUHFRUGLQJRQDUHF XUUHQWEDVLV
x 7KHLQFLGHQFHDQGRUVHYHULW\RI DGYHUVHH[SHULHQFHVLQWKLVRU RWKHUVWXGLHVLQGLFDWLQJD
SRWHQWLDOKHDOWKKD]DUGFDXVHGE\WKHGHYLFH
x 8QVDWLVIDFWRU\DFFRXQWDELOLW\RILQYHVWLJDWLRQDOGHYLFHV
$ZULWWHQVWDWHPHQWIXOO\GRFXPHQ WLQJWKHUHDVRQVIRUVXFKDWH UPLQDWLRQZLOOEHSURYLG HGWRVSRQVRUWKH
,5%LQYHVWLJDWLRQDOFHQWHUVDQGRWK HUUHJXODWRU\DXWKRULWLHVDV UHTXLUHG

16.3  Data Management 
16.3.1Electronic Case Report Forms (eCRFs)
7KHLQYHVWLJDWRUPXVWHQVXUHDFFX UDF\FRPSOHWHQHVVDQGWLPHOLQ HVVRIWKHGDWDUHSRUWHGLQWKHH&5)V
DQGLQDOORWKHUUHTXLUHGUHSRUWV 'DWDUHSRUWHGRQWKHH&5)V ZKLFKDUHGHULYHGIURPVRXUFHGRFXPHQWV
VXFKDVVXEMHFWPHGLFDOUHFRUGV PXVWEHFRQVLVWHQWZLWKWKHVR XUFHGRFXPHQWVDQGWKHGLVFUHSDQFLHV
QHHGWREHMXVWLILHGLQ DGRFXPHQWHGUDWLRQDOH
2QO\DXWKRUL]HGSHUVRQVFDQFR PSOHWHH&5)VH&5)VVKDOOEHVLJQ HGE\LQYHVWLJDWLRQDOFHQWHUVWDIIDV
VSHFLILHGRQWKH'HOHJDWLRQRI$ XWKRULW\/RJLQFOXGHGLQWKH,Q YHVWLJDWRU6LWH)LOH7KH('&V\VWHP
PDLQWDLQVDQDXGLWWUDLORQHQWULHVFKDQJHVDQGFRUUHFWLRQVL QWKHH&5)V

$FRS\RIWKHH&5)VWREHXVHG LQWKLVFOLQLFDOVWXG\LVDYDLOD EOHXQGHUDVHSDUDWHF RYHUXSRQUHTXHVWWR
WKHVSRQVRUDQGLQWKH,QYHVWLJDWRU6LWH)LOH
,QYHVWLJDWLRQDOFHQWH UVZLOOEHWUDLQHGWR WKHXVHRIWKHH&5)V $FFHVVWRILQDOH&5)VIRUVWXG\FRQGXFW
ZLOOEHJUDQWHGDIWHUWUDLQLQJLVSHUIRUPHGDQGSULRUWRSDWLHQ WÂ¶VHQUROOPHQW
16.3.2  CareLink Personal/CareLink System Software 
'XULQJWKHFRXUVHRIWKHVWXG\ VXEMHFWÂ¶V%*YDOXHVPD\EHDVVH VVHGIURPWKH$FFX &KHN*XLGH/LQN
VWXG\PHWHU7KH6*YDOXHVPD\E HDVVHVVHGIURPWKHVWXG\SXPS 7KHVWXG\SXPSZLOOEHXSORDGHGLQ
&DUH/LQN3HUVRQDO&DUH/LQNV\VWHP VRIWZDUHE\WKHLQYHVWLJDWRU RUGHVLJQDWHGLQYHVWLJ DWLRQDOFHQWHUVWDII
DQGVXEMHFWVDWKRPH7KHV\VWHP XVHV7/6WHFKQRORJ\ZKLFKHQF U\SWVDOOGDWDLWVWRUHV&)53DUW
FRPSOLDQW7KHGDWDLQWKHGLIIH UHQWGDWDEDVHVDUHOLQNHGWRH DFKRWKHUYLDWKHVXEMHFWÂ¶V,'
16.3.3   Subject Questionnaires 
,QWKLVVWXG\ZHDUHFROOHFWLQJ VXEMHFWIHHGEDFNUHJDUGLQJXVH UH[SHULHQFHDQGTXD OLW\RIOLIHWKURXJK
TXHVWLRQQDLUHV6XEMHFWVZLOOEHSURYLGHGDOLQNWRFRPSOHWHWK HTXHVWLRQQDLUHVWKDWZLOOEHNHSWRQOLQH
5HIHUWR&,34XHVWLRQQDLUH*X LGH,IWKHRQOLQHOLQNFDQQRW EHDFFHVVHGGXHWRWHFKQLFDOLVVXHV
VXEMHFWVZLOOFRPSOHWH WKHTXHVWLRQQDLUHXVLQJDSDSHUIRUPDW 7KHLQYHVWLJDWRURUGHVLJQDWHG
LQYHVWLJDWLRQDOFHQW HUVWDIIZLOOWKHQHQWHUWKHVXEMHFWÂ¶VUHV SRQVHVIURPWKHSDSHUTXHVWLRQQDLUHVWR
RQOLQHRQFHLWEHFRPHVDYDLODEOH ,ISDSHUIRUPDWLVXVHGWKH LQYHVWLJDWRURUGHVLJQD WHGLQYHVWLJDWLRQDO
FHQWHUVWDIIVKRXOGPDLQWDLQWKH RULJLQDOSDSHUVRXUFHLQWKHV XEMHFWÂ¶VVRXUFHILOH

CIP335 Clinical Investigation Plan 
 Form 
D00409632 Version E Page 100 of 106 
0HGWURQLF%XVLQHVV5HVWULFWHG
CONFIDENTIAL )5HY(&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Form
16.3.4  Time Windows for Completion and Submission of Case Report Forms  
,WLVH[SHFWHGWKDWH&5)VDUHFRPSOHWHGLQDWLPHO\PDQQHUZLWK WKHH[FHSWLRQRIWKHUHSRUWDEOH$(VVHH
Section 11$IWHUGDWDHQWU\H&5)VVKRXO GEHVXEPLWWHGLHVDYHGVR WKDWPRQLWRUVFDQSURFHHG
ZLWKGDWDYHULILFDWLRQZLWKRXWGHOD\
16.3.5  Data Review and Processing 
'DWDPDQDJHPHQWZLOOEHGRQHDFF RUGLQJWRVSRQVRU623VDQGWKH 'DWD0DQDJHPHQW3ODQIRUWKLVFOLQLFDO
VWXG\
&ROOHFWHGGDWDZLOOEHUHYLHZHGI RUFRPSOHWHQHVVFRUUHFWQHVV DQGFRQVLVWHQF\DVSHUWKHPRQLWRULQJ
SODQ,QFDVHRILVVXHVTXHULH VZLOOEHHQWHUHGRQWKHUHVSHFW LYHH&5)IRUWKHLQYHVWLJDWRUWRFRPSOHWH
FRUUHFWRUFRPPHQWRQWKHGDWD
16.4  Direct Access to Source Data/Documents 
7KHVXEMHFWÂ¶VFOLQLFILOH&DUH/L QN3HUVRQDO&DUH/LQNV\VWHPVR IWZDUHGDWDODERUDWRU\UHSRUWV
TXHVWLRQQDLUHVDQGVRXUFHGRFXPHQWVDUHKDQGOHGDVVRXUFHGDWD 

0HGWURQLFFOLQLFDOUHSUHVHQWDW LYHVRUGHOHJDWHVZLOOEHJUDQWHG DFFHVVE\WKHLQYHVWLJDWLRQDOFHQWHUWRDOO
VRXUFHGRFXPHQWVLQFOX GLQJHOHFWURQLFVRXUFH GRFXPHQWVRUFRSLH VRIHOHFWURQLFVRXU FHGRFXPHQWVLI
DSSOLFDEOHIRUWKHSXUSRVHVRIPRQLWRULQJDXGLWRULQVSHFWLR Q

16.5  Confidentiality 
7KHLQYHVWLJDWRUZLOOHQVXUHWK DWWKHVXEMHFWÂ¶VDQRQ\PLW\LVPD LQWDLQHG6XEMHFWVZLOOQ RWEHLGHQWLILHGLQ
DQ\SXEOLFO\UHOHDVHGUHSRUWVRIWKLVVWXG\$OOUHFRUGVZLOOE HNHSWFRQILGHQWLDOWRWKHH[WHQWSURYLGHGE\
IHGHUDOVWDWHD QGORFDOODZ7KHVWXG\P RQLWRUVDQGRWKHUDXWK RUL]HGUHSUHVHQWDWLYHVRIWKHVSRQVRUPD\
LQVSHFWDOOGRFXPHQWVDQGUHFRUG VUHTXLUHGWREHPDLQWDLQHGE\ WKHLQYHVWLJDWRULQFOXGLQJEXWQRWOLPLWHG
WRPHGLFDOUHFRUGV7KHLQYHVW LJDWRUZLOOLQIRUP WKHVXEMHFWV WKDWWKHDERYHQDPHG UHSUHVHQWDWLYHVZLOO
UHYLHZWKHLUVWXG \UHODWHGUHFRUGVZLWKRXW YLRODWLQJWKHFRQILG HQWLDOLW\RIWKHVXEMHFWV$OOODERUDWRU\
VSHFLPHQVHYDOXDWLRQIRUPVUHS RUWVDQGRWKHUUHFRUGVWKDWOH DYHWKHLQYHVWLJDWLRQDOFHQWHUZLOOEH
LGHQWLILHGRQO\E\WKHVXEMHFW,' FRGHLQRUGHUWRPDLQWDLQVXE MHFWFRQILGHQWLDOLW\$ OOUHFRUGVZLOOEHNHSW
ORFNHGDQGDOOFRPSXWHUHQWU\DQ GQHWZRUNLQJSURJUDPVZLOOEHG RQHZLWKFRGHGQXPEHUVRQO\
16.6  Liability and Subject Compensation 
6XEMHFWVZLOOEHSDLGIRUSDUWLFL SDWLRQ5HIHUWRWKH,&)IRUGH WDLOVRIWKHVXEMHFWÂ¶VFRPSHQVDWLRQ
16.7  CIP Amendments 
$QLQYHVWLJDWRURUVWXG\WHDPPHPEHUFDQSURSRVHDQ\DSSURSULDW HPRGLILFDWLRQVRIWKH&,3RUVWXG\
GHYLFHSURGXFWRUVWXG\GHYLFHS URGXFWXVH0HGW URQLFZLOOUHYL HZWKLVSURSRVDODQGGHFLGHZKHWKHUWKH
PRGLILFDWLRQVZLOOEHLPSOHPHQWHG
6SRQVRUFDQGHFLGHWRUHYLHZWKH &,3EDVHGRQQHZLQIRUPDWLRQ RUIRURWKHUUHDVRQVDQGZLOOVXEPLW
DQ\VLJQLILFDQWDPHQGPHQWWRWKH&,3LQFOXGLQJDMXVWLILFDWLRQ IRUWKLVDPHQGPHQW WRWKHDSSURSULDWH
UHJXODWRU\DXWKRULW\ LIDSSOLFDEOHIRUWKHLUDSSURYDODQGWR WKHLQYHVWLJDWRUVWRREWDLQDSSURYDOIURP
WKHLU,5%7KHLQYHVWLJDWRUZLOOR QO\LPSOHPHQWWKHDPHQGPHQWD IWHUWKHVSRQVRUKDVR EWDLQHGUHJXODWRU\
CIP335 Clinical Investigation Plan 
 Form 
D00409632 Version E Page 101 of 106 
0HGWURQLF%XVLQHVV5HVWULFWHG
CONFIDENTIAL )5HY(&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Form
DXWKRULW\LIDSSOLFDEOHDSSURY DODQGWKHDPHQGPHQWKDVEHHQD SSURYHGE\WKH,5%$GPLQLVWUDWLYH
DPHQGPHQWVWRWKH&,3ZLOOEHVXEPLWWHGWRWKH,5%IRUQRWLILFD WLRQ
16.8  Records and Reports 
16.8.1  Investigator Records 
$WDPLQLPXPWKHIROORZLQJUHFRU GVPXVWEHNHSWE\WKHLQYHVWL JDWRU
x $OOHVVHQWLDOVWXG\GRFXPHQWVDQGFRUUHVSRQGHQFHWKDWSHUWDLQV WRWKHFOLQLFDOVWXG\
x &,3DQGLIDSSOLFDEOHDQ\DPHQGPHQWV
x 5HSRUWRISULRULQYHVWLJDWLRQVDQGRUXVHUJXLGH
x 0HGWURQLFDQG,5%DSSURYHG 6XEMHFW,&)DVVHQWIRUP
x ,5%DQGUHJXODWRU\DXWKRULW\ DSSURYDORUQRWLILFDWLRQ
x )XOO\VLJQHGFOLQLFDOVWXG\DJUHHP HQWVLHLQFOXGLQJ,QYHVWL JDWRU6WDWHPHQWDQG6LJQDWXUH
3DJH&OLQLFDO7ULDO$JUHHPHQWDQG&RQILGHQWLDO'LVFORVXUH$JUH HPHQW
x &RPSOHWHG'HOHJDWLRQRI$XWKRULW\/RJ
x 7UDLQLQJGRFXPHQWDWLRQRIDOOLQYHVWLJDWLRQDOFHQWHUVWDII
x 6XEMHFW6FUHHQLQJORJDQGRUVXEMHFW,'ORJ
x 6LJQHGGDWHGDQGIXOO\H[HFXWHG6XEMHFW,&)DVVHQW IRUP
x 6RXUFHGRFXPHQWDWLRQ
x )XOO\H[HFXWHGH&5)VDQGFRUUHFWLRQV
x 5HSRUWRI$(VDQG''V
x 'HYLFHDFFRXQWDELOLW\UHFRUGV
x &,3'HYLDWLRQ&,31RQ &RPSOLDQFHLIDQ\
x &OLQLFDO%XOOHWLQVLI DSSOLFDEOH$EULHIRIILFLDOXSGDWHRU VXPPDU\RIFXUUHQWVWXG\QHZVRQD
PDWWHURILPPHGLDWHLQWHUHVWDQGK LJKLPSRUWDQFHWRLQYHVWLJDWL RQDOFHQWHUVXUURXQGLQJWKH
&,3
x &XUUHQWVLJQHGDQGGDWHG&9RI3, DQGNH\VWXG\WHDPPHPEHUVL IUHTXLUHGSHUORFDO
UHTXLUHPHQWV
x 6WXG\UHSRUWV

16.8.2  Investigator Reporting Responsibilities  
Table 6. Investigator Reporting Requirements 
Report Submit to Description/Constraints 
$(VDQG''V 6SRQVRU,5%DQG
UHJXODWRU\
DXWKRULW\ZKHUH
DSSOLFDEOH5HIHUWR Section 11DQG 13 IRUUHSRUWLQJUHTXLUHPHQWV
:LWKGUDZDORI,5%
DSSURYDOHLWKHU
VXVSHQVLRQRUWHUPLQDWLRQ6SRQVRU$QLQYHVWLJDWRUVKDOOUHSRUWWRW KHVSRQVRUZLWKLQZRUNLQJ
GD\VDZLWKGUDZDORIDSSURYDOE\WKHUHYLHZLQJ,5%RIWKH
LQYHVWLJDWRU
VSDUWRIDQLQYHVWLJDWLRQ

CIP335 Clinical Investigation Plan 
 Form 
D00409632 Version E Page 102 of 106 
0HGWURQLF%XVLQHVV5HVWULFWHG
CONFIDENTIAL )5HY(&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Form
Report Submit to Description/Constraints 
3URJUHVVUHSRUW6SRQVRUDQG
,5%7KHLQYHVWLJDWRUPXVWVXEPLWW KLVUHSRUWWRWKHVSRQVRUDQG
,5%DWUHJXODULQWHUYDOVEXWL QQRHYHQWOHVVWKDQ\HDUO\
6WXG\GHYLDWLRQV6SRQVRUDQG
,5%1RWLFHRIGHYLDWLRQVIURPWKH&,3WRSURWHFWWKHOLIHRU
SK\VLFDOZHOOEHLQJRIDVXEMHF WLQDQHPHUJHQF\VKDOOEH
JLYHQDVVRRQDVSRVVLEOHEXWQ RODWHUWKDQZRUNLQJGD\V
DIWHUWKHHPHUJHQF\RFFXUUHG
)DLOXUHWRREWDLQLQIRUPHG
FRQVHQWDVVHQWSULRUWRLQYHVWLJDWLRQDO
GHYLFHXVH6SRQVRUDQG
,5%V,IDQLQYHVWLJDWRUXVHVDGHYLF HZLWKRXWREWDLQLQJLQIRUPHG
FRQVHQWDVVHQW WKHLQYHVWLJDWRUVKDOOUHS RUWVXFKXVHZLWKLQ
ZRUNLQJGD\VDIWHUGHYLFHXVH
)LQDOUHSRUW6SRQVRU
,5%V
5HOHYDQW$XWKRULWLHV7KLVUHSRUWPXVWEHVXEPLWWHGZLWKLQPRQWKVRIVWXG\
FRPSOHWLRQRUWHUPLQDWLRQRIWKHLQYHVWLJDWLRQRUWKH
LQYHVWLJDWRUÂ¶VSDUWRI WKHLQYHVWLJDWLRQ
2WKHU6SRQVRU,5%DQG
)'$$QLQYHVWLJDWRUVKDOOXSRQUHTX HVWE\DUHYLHZLQJ,5%)'$
RUDQ\RWKHUUHJXODWRU\DX WKRULW\SURYLGHDFFXUDWH
FRPSOHWHDQGFXUUHQWLQIRUPDW LRQDERXWDQ\DVSHFWRIWKH
LQYHVWLJDWLRQ
16.9  Record Retention 
7KHVSRQVRUDQGLQYHVWLJDWRUZLOOUHWDLQDOOUHFRUGVDQGGRFXPH QWVSHUWDLQLQJWRWKLV VWXG\7KH\ZLOOEH
DYDLODEOHIRULQVSHFWLRQE\WKH DSSURSULDWHUHJXODWRU\DXWKRULW LHV,QDGGLWLRQWKHLQ YHVWLJDWRUZLOOUHWDLQ
WKHVRXUFHGRFXPHQWVIURPZKLFKWKHLQIRUPDWLRQHQWHUHGRQWKH H&5)ZDVGHULYHG7KHVHUHFRUGVDUHWR
EHUHWDLQHGLQDVHFXUHVWRUDJH IDFLOLW\PDLQWDLQHGE\WKHLQYH VWLJDWLRQDOFHQWHUXQWLO\HDUVRUORQJHULI
ORFDOODZVUHTXLUHDIWHUDSSURYDORIWKHDERYHOLVWHGVWXG\GH YLFHVRUWHUPLQDWLRQRIWKHVWXG\ZKLFKHYHU
LVORQJHU7KHLQYHVWLJDWRUVKRXOGQRWGLVSRVHRIWKHVHUHFRUGV ZLWKRXWWKHDSSURYDORIWKHVSRQVRU
16.10  Suspension or Early Termination 
6SRQVRURUDUHJXODWRU\DXWKRULW \PD\GHFLGHWRVXVSHQGRUSUHP DWXUHO\WHUPLQDWHWKHFOLQLFDOVWXG\
HJLILQIRUPDWLRQEHFRPHVD YDLODEOHWKDWWKHULVNWRVWXG\ VXEMHFWLVKLJKHUWKDQLQ LWLDOO\LQGLFDWHGODFN
RIHQUROOPHQWRUEHFDXVHRID EXVLQHVVGHFLVLRQ,IWKHFOLQLF DOVWXG\LVWHUPLQDWHGSUHPDWXUHO\RU
VXVSHQGHGVSRQVRUVKDOOSURPSWO \LQIRUPWKHLQYHVWLJDWRUVDQG UHJXODWRU\DXWKRULW\RIWKHWHUPLQDWLRQRU
VXVSHQVLRQDQGWKHUHDVRQVI RUWKLV7KHLQYHVWLJDWRUVKDOOW KHQSURPSWO\LQIRUPWKHUHYLHZLQJ,5%DQG
WKHVWXG\VXEMHFWV
CIP335 Clinical Investigation Plan 
 Form 
D00409632 Version E Page 103 of 106 
0HGWURQLF%XVLQHVV5HVWULFWHG
CONFIDENTIAL )5HY(&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Form
16.10.1   Early Investigational Center Suspension or Termination 
6SRQVRU,5%RUDUHJXODWRU\DXW KRULW\PD\GHFLGHWRVXVSHQGRU SUHPDWXUHO\WHUPLQDWH DQLQYHVWLJDWLRQDO
FHQWHUHJLQFDVHRIH[SLULQ JDSSURYDORIWKHUHYLHZLQJ,5% QRQFRPSOLDQFHWRWKH&,3RUODFNRI
HQUROOPHQW6XVSHQGHGFOLQLFD OVWXGLHVFDQQRWEHUHVXPHGZLWKR XWSHUPLVVLRQIURP,5%DQGUHJXODWRU\
DXWKRULW\LIDSSOLFDEOH,I DQLQYHVWLJDWLRQDOFHQWHULVVXVS HQGHGRUSUHPDWXUHO\ WHUPLQDWHGVSRQVRU
VKDOOSURPSWO\LQIRUPWKHLQYHVWL JDWRUVRIWKHWHUPLQDWLRQRU VXVSHQVLRQDQGWKHUHDVRQVIRUWKLV7KH
LQYHVWLJDWRUVKDOOWKH QSURPSWO\LQIRUPWKH UHYLHZLQJ,5%DQGW KHVWXG\VXEMHFWV

:KHQWKHULVNVDUHIRXQGWRRXWZ HLJKWKHSRWHQWLDOEHQHILWVRU ZKHQWKHUHLVFRQFOXVLYHSURRIRIGHILQLWH
RXWFRPHVLQYHVWLJDWRUVPXVWD VVHVVZKHWKHUWRFR QWLQXHPRGLI\ RULPPHGLDWHO\VWRS WKHFOLQLFDOVWXG\
LQWKHUHVSHFWLYHLQYH VWLJDWLRQDOFHQWHUDQGLPPHGLDWHO\LQIRUP WKHVSRQVRUDQG,5%LIDSSOLFDEOH
16.10.2  Subject Follow-Up In Case of Termination 
,QFDVHRIHDUO\LQYHVWLJDWLRQDOF HQWHUVXVSHQVLRQRUWHUPLQDWL RQDOOVXEMHFWVVKRXOGEHFRQWDFWHGWRSODQ
DQHDUO\WHUPLQDWLRQYLVLWDWWK HLQYHVWLJDWLRQDOFHQWHU$OOH IIRUWVZLOOEHPDGHWRF RPSOHWHDQGUHSRUWDOO
VWXG\REVHUYDWLRQVDWWKHWLPHR IWHUPLQDWLRQ7KHVXEMHFWZLOO UHWXUQWKHVWXG\GHYLFHVWRWKH
LQYHVWLJDWLRQDOFHQWHU)ROORZL QJVXVSHQVLRQRUHDUO\WHUPLQDWL RQVXEMHFWVZLOOUHFHLYHVWDQGDUGPHGLFDO
FDUHIURPWKHLURZQSURYLGHUV
16.11  Study Close-Out 
$WWKHWLPHRIDVWXG\FORVHR XWWKHLQYHVWLJDWRUVZLOOEHQRW LILHGE\VSRQVRU$SSURSULDWH
QRWLILFDWLRQUHSRUWWR,5%DQGUHJXODWRU\DXWKRULW\ZLOOEHSUR YLGHGLIUHTXLUHGSHUORFDOODZVDQG
UHJXODWLRQV
16.12  Publication and Use of Information 
3XEOLFDWLRQVIURPWKHVWXG\Z LOOEHKDQGOHGDFFRUGLQJWR0HGWUR QLF*OREDO6WDQGDUG2SHUDWLQJ3URFHGXUHV
DQGDVLQGLFDWHGLQWKH& OLQLFDO7ULDO$JUHHPHQW
7KHLGHQWLW\RIWKHVX EMHFWVPD\QRWEHGLVFORVHGXQOHVVUHTXL UHGE\ODZWRDQ\SHUVRQVQRWLPPHGLDWHO\
LQYROYHGLQWKHVWXG\RUWKHV WXG\SURFHGXUHV7KHVWXG\ZLOOE HSXEOLFO\UHJLVWHUHGRQ
KWWSZZZFOLQLFDOWULDOVJRYSULRUWRVXEMHFWHQUROOPHQW6WXG \UHVXOWVZKHQDYDLODEOHZLOOEHSRVWHGLQ
WKLVGDWDEDVH 
17. References 
 %HDWR9tERUD3,*DOOHJR*DPHUR)/i]DUR0DUWtQ/5RPHUR3 pUH]0'0$UUR\R'tH])-
3URVSHFWLYH$QDO\VLVRIWKH,PSDFW RI&RPPHUFLDOL]HG+\EULG&OR VHG/RRS6\VWHPRQ*O\FHPLF
&RQWURO*O\FHPLF9DULDELOLW\DQG 3DWLHQW5HODWHG2XWFRPHVLQ &KLOGUHQDQG$GXOWV$)RFXVRQ
6XSHULRULW\RYHU3UHGLFWLYH/RZ*OXFRVH6XVSHQG7HFKQRORJ\ 'LDEHWHV7HFKQRORJ\DQG
7KHUDSHXWLFV 
 &U\HU3('HILQLQJDQGUHSRUW LQJK\SRJO\FHPLDLQGLDEHWHV$ UHSRUWIURPWKH$PHULFDQGLDEHWHV
DVVRFLDWLRQZRUNJURXSRQK\SRJO\FHPLD 'LDEHWHV&DUH 
 +\SHUJO\FHPLF&ULVHVLQ'LDEHWHV 'LDEHWHV&DUH 6833/66

CIP335 Clinical Investigation Plan 
 Form 
D00409632 Version E Page 104 of 106 
0HGWURQLF%XVLQHVV5HVWULFWHG
CONFIDENTIAL )5HY(&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Form
18. Appendices 
18.1  Names and addresses 
18.1.1  Investigational Centers and IRB 
7KHQDPHVDQGDGGUHVVHVRILQYHVW LJDWRUVDQGSDUWLFLSDWLQJLQY HVWLJDWLRQDOFHQWHUVZLOOEHNHSWXQGHU
VHSDUDWHFRYHU
18.1.2  Monitor(s) Contact Information 
7KHVWXG\ZLOOEHPRQLWRUHGE\W KH0HGWURQLF&RUH&OLQLFDO6ROX WLRQV0&*OREDO0RQLWRULQJDQG
PRQLWRULQJGXWLHVWREHHQWUXVWHGXQGHU
 
&OLQLFDO0RQLWRULQJ0DQDJHU0&*OREDO0RQLWRULQJ
0HGWURQLF0HGWURQLF3DUNZD\
0LQQHDSROLV01
7KHQDPHVDQGDGGUHVVHVRIPRQLW RUVZLOOEHNHSWXQGHUVHSDUDWH FRYHU
18.2  Labeling of Devices 
7KHFXUUHQWODEHOVDQG,)8VIR UWKHVWXG\GHYLFHVZLOOEHSURYL GHGWRWKHLQYHVWLJDWRUVLQDVHSDUDWH
FRYHU
18.3  Sample Consent Materials 
6DPSOHVRIWKHIROORZLQJFRQVHQ WIRUPVPDWHULDOVZLOOEHSURYLG HGLQDVHSDUDWHFRYHU ZKLFKLQFOXGHVWKH
&DOLIRUQLD([SHULPHQWDO6XEMHFW Â¶V%LOORI5LJKWVLIDSSOLFDEOH ,&)DVVHQWIRUPDQGWKH+,3$$
$XWKRUL]DWLRQ3,
CIP335 Clinical Investigation Plan 
 Form 
D00409632 Version E Page 105 of 106 
0HGWURQLF%XVLQHVV5HVWULFWHG
CONFIDENTIAL )5HY(&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Form
19. Version History 
Version Summary of changes Author(s)/Title 
$ 1RW$SSOLFDEOH1HZ'RFXPHQW 

$)'$
$SSURYHGx 6HHÂ³$WWDFKPHQW&,3'HVF ULSWLRQRI3URWRFRO&KDQJHV
9HUVLRQ$WR$Â´IRUGHWDLOVRQFKDQJHV
x 8SGDWHGÂ³6WXG\'HVLJQÂ´VHFWLRQ
x 8SGDWHG6WXG\Â³9LVLW6FKHGXOH 	6FKHGXOHG)ROORZXS9LVLW
:LQGRZVÂ´VHFWLRQ
x 8SGDWHGÂ³7DEOH6WXG\9LVLW'HWDLOVÂ´
x 8SGDWHGÂ³6XEMHFW([LW:LWKGUDZDORU'LVFRQWLQXDWLRQÂ´VHFWLRQ
x 8SGDWHGÂ³'HILQLWLRQVDQG&ODVVLI LFDWLRQVRI$GYHUVH(YHQWVÂ´
VHFWLRQ
x $GPLQLVWUDWLYHFKDQ JHVWKURXJKRXW

$(TXLYDOHQW
WR9HUVLRQ
$x6HHÂ³$WWDFKPHQW&,3'HVFULSWLRQRI3URWRFRO&KDQJHV
9HUVLRQ$WR$Â´IRUGHWDLOVRQFKDQJHV
x 8SGDWHGVWXG\SURGXFW
x $GPLQLVWUDWLYHFKDQ JHVWKURXJKRXW
% x 6HHÂ³$WWDFKPHQW&,3'HVF ULSWLRQRI3URWRFRO&KDQJHV
9HUVLRQ$WR%Â´IRUGHWDLOVRQFKDQJHV
x 8SGDWHGVWXG\SURGXFW
x 8SGDWHGÂ³6WXG\'HVLJQÂ´VHFWLRQ
x 8SGDWHGÂ³([FOXVLRQ&ULWHULDÂ´
x 8SGDWHGÂ³9LVLW6FKHGXOH	6FKHGXOHG)ROORZXS9LVLW
:LQGRZVÂ´VHFWLRQ
x 8SGDWHGÂ³7DEOH3URGXFW$ FFRXQWDELOLW\5HTXLUHPHQWVÂ´
x 8SGDWHGÂ³7DEOH6WXG\9LVLW'HWDLOVÂ´
x 8SGDWHGÂ³6XEMHFW([LW:LWKGUDZDORU'LVFRQWLQXDWLRQÂ´VHFWLRQ
x 8SGDWHGÂ³6WXG\6WRSSLQJ5XOHVÂ´VHFWLRQ
x 8SGDWHGÂ³7DEOH5LVNV3 UHYHQWLRQDQG0LWLJDWLRQÂ´
x 8SGDWHGÂ³'DWD5HYLHZ&RPPLWWHHVÂ´VHFWLRQ
x $GPLQLVWUDWLYHFKDQ JHVWKURXJKRXW

%)'$
$SSURYHGx6HHÂ³$WWDFKPHQW&,3'HVFU LSWLRQRI3URWRFRO&KDQJHV
9HUVLRQ%WR%Â´IRUGHWDLOVRQFKDQJHV
x 8SGDWHGÂ³([FOXVLRQ&ULWHULDÂ´
x 8SGDWHGÂ³6XE MHFW([LW:LWKGUDZDORU'LVFRQWLQXDWLRQÂ´VHFWLRQ
%(TXLYDOHQW
WR9HUVLRQ
%x 6HHÂ³$WWDFKPHQW&,3'HVF ULSWLRQRI3URWRFRO&KDQJHV
9HUVLRQ$WR%Â´IRUGHWDLOVRQFKDQJHV
x $GPLQLVWUDWLYHFKDQ JHVWKURXJKRXW

& x 6HHÂ³$WWDFKPHQW&,3'HVF ULSWLRQRI3URWRFRO&KDQJHV
9HUVLRQ%WR&Â´IRUGHWDLOVRQFKDQJHV
x 8SGDWHGVWXG\WLWOH
x 8SGDWHGÂ³3XUSRVHÂ´
x 8SGDWHGÂ³2EMHFWLYHÂ´
x 8SGDWHGÂ³6WXG\'HVLJQÂ´
o 5HPRYHGHQUROOPHQWRIVXEMHFWV\HDUVRIDJH
WKURXJKRXWSURWRFRO
3,
3,
3,
3,
3,
3,
3,
CIP335 Clinical Investigation Plan 
 Form 
D00409632 Version E Page 106 of 106 
0HGWURQLF%XVLQHVV5HVWULFWHG
CONFIDENTIAL )5HY(&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH
Form
o &ODULILHGSXPSVHWWLQJVDW 5XQ,Q3HULRGDQG6WXG\
3HULRG
o 5HYLVHG)RRG3ULQWXVHODQJXDJH
x 8SGDWHGQXPEHURILQYHVWLJDWLRQDOFHQWHUV
x 8SGDWHGÂ³,QFOXVLRQ&ULWHULDÂ´
x $GGHGQHZYLVLWXQGHU6WXG\3HULRGÂ±'D\DIWHU9LVLW
WKURXJKRXWSURWRFRO
x 8SGDWHGHQGSRLQWVWRUHPRYH\HDUVRIDJHJURXS
x 8SGDWHGÂ³7DEOH6WXG\9LVLW'HWDLOVÂ´
x 8SGDWHGÂ³6WXG\6WRSSLQJ5XOHVÂ´VHFWLRQ
x 8SGDWHGÂ³'DWD0RQLWRUL QJ&RPPLWWHHÂ´VHFWLRQ
x $GGHGÂ³+DQGOLQJ0LVVLQJ'DWDÂ´VHFWLRQ
x 8SGDWHGÂ³,QYHVWLJDWLRQDO&HQWHUVDQG(&,5%Â´VHFWLRQ
x 8SGDWHGWRODWHVWYHUVLRQRI&,37HPSODWH
x $GPLQLVWUDWLYHFKDQ JHVWKURXJKRXW
&(TXLYDOHQW
WR)'$
9HUVLRQ&x 6HHÂ³$WWDFKPHQW&,3'HVF ULSWLRQRI3URWRFRO&KDQJHV
9HUVLRQ&WR&Â´IRUGHWDLOVRQFKDQJHV
x $GGHGÂ³$GPHORJÂ´LQVXOLQWKURXJKRXWSURWRFRO
x 8SGDWHGÂ³6WXG\'HVLJQÂ´
x ,QFUHDVHGQXPEHURISDUWLFLSDWLQ JVLWHVIURPWR

'(TXLYDOHQW
WR)'$
9HUVLRQ'x 6HHÂ³$WWDFKPHQW&,3'HVF ULSWLRQRI3URWRFRO&KDQJHV
9HUVLRQ&WR'Â´IRUGHWDLOVRQFKDQJHV
x8SGDWHG\HDULQFRS\ULJKWVWDWHPHQW
x 5HPRYHG/\XPMHYLQYHVWLJDWLRQD OVWDWXVIRU\HDUVRIDJH
x 8SGDWHGWKHIROORZLQJGHWDLOV XQGHU6WXG\'HVLJQVHFWLRQ
o UHJXODUVL]HGPHDOFKDOOHQJ HZLWKPLVVHGPHDOEROXV
o VXEMHFWVWRDYRLGDGGLWLRQDO H[HUFLVHDQGRUPHDOVXS
WRIRXUKRXUVDIWHUWKHVWDUWRIWKHFKDOOHQJH
o UHPRYHGWKHZRUG Â³OLYHÂ´WUDLQLQJ
x 8SGDWHGÂ³ZHHNVÂ´ZLWKDVVRFLDWHGVWXG\YLVLW
x +DUPRQL]HGVWDUWRI$XWR%DVDOWDUJHWDWPJG/
PJG/DQGLQYHVWLJDWRUÂ¶VGLVFU HWLRQDVVSHFLILHGXQGHU6WXG\
'HVLJQIRUWKHIROORZLQJ
o 6WXG\9LVLW6FKHGXOHVHFWLRQ
o 9LVLW'HWDLOV7DEOH
x $GGHG([FOXVLRQ&ULWHULDIRU*XVHUV
x 8SGDWHG6FKHGXOHRI(YHQWV6HF WLRQUHPRYHG7HOHPHGLFLQH
VLQFHZHDUHDOORZLQJYLUWXDOR IILFHYLVLWVZKHUH RIILFHYLVLW
RFFXUVDGGHGÂ³9LUWXDO2IILFHÂ´WRYLVLWV
x 8SGDWHG7DEOH
o 5HJXODWRU\FODVVLILFDWLRQIRU0HGWURQLF([WHQGHG
UHVHUYRLUXSGDWHGWRQ RQLQYHVWLJDWLRQDO
x 8SGDWHG3XEOLFDWLRQDQG8VHRI,QIRUPDWLRQVHFWLRQ
x 8SGDWHG0RQLWRUV&RQWDFW,QIRUPDWLRQVHFWLRQ

((TXLYDOHQW
WR)'$
9HUVLRQ(x 6HHÂ³$WWDFKPHQW&,3'HVF ULSWLRQRI3URWRFRO&KDQJHV
9HUVLRQ'WR(Â´IRUGHWDLOVRQFKDQJHV
x 8SGDWHG6WXG\'HVL JQVHFWLRQ
3,
3,
3,